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Summary
Ligation of the antigen reœptor (BCR) on B lymphocytes results in differential 
biological outcomes depending upon the maturation stage of the cell. Thus, 
mature B lymphocytes become activated and proliferate (clonal expansion) in 
response to antigen receptor cross-linking, whilst immature B cells either become 
unresponsive, alter the specificity of their BCR, or undergo apoptosis (clonal 
deletion). These biological responses to antigen are well defined, and many of 
the membrane proximal signalling events activated upon BCR ligation have been 
delineated and appear to be similar, despite their differential biological outcomes. 
The precise molecular events downstream of BCR signalling that are responsible 
for these distinct responses therefore remain to be established. This project has 
therefore centred upon identifying the important signalling mechanisms linking 
BCR ligation with regulation of the cell cycle and the induction of apoptosis in 
immature and mature B lymphocytes.
The murine B cell lymphoma cell line WEHI-231 is widely used as a model for 
clonal deletion of immature B lymphocytes. This is because it has the cell surface 
phenotype of an immature B lymphocyte, and as such responds to BCR ligation 
by undergoing growth arrest and apoptosis, mimicking the processes of clonal 
deletion. Moreover, WEHI-231 cells can be rescued from BCR-mediated 
apoptosis by co-stimulation via CD40, conditions mimicking T cell driven rescue 
of useful clonatypes. This cell line was therefore utilised to further examine the 
signalling events important for anti-lg induced growth arrest and apoptosis, and 
CD40~mediated rescue, in immature B lymphocytes. In particular, this 
investigation has explored the differential roles of the Ras/Erk-MAPKinase 
pathway and a number of specific PKC isoforms in the regulation of survival of 
immature B cells.
Initial studies examined the activation of the Erk-MAPKinase in both response to 
apoptotic signalling via the BCR and under conditions of CD40-mediated rescue. 
These studies indicated that Erk-MAPKinase plays a dual role in WEHI-231 cells, 
being required both for BCR induced growth arrest and apoptosis and CD40-
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mediated rescue. The outcome of Erk-MAPKinase activity is determined by the 
kinetics of activation, with an early, strong, yet transient signal required for BCR 
induced apoptosis, whilst CD40 signalling induces a more sustained, cycling 
pattern of Erk-MAPKinase activation. The role of Erk-MAPKinase was further 
addressed in these cells by expression of constitutively active mutants of the 
small GTPase, Ras, a key upstream regulator of Erk-MAPKinase as well as Pl-3- 
kinase. Interestingly, cells expressing a mutant form of Ras capable of directly 
coupling to the activation of PI-3-kinase, but not Erk-MAPKinase (RasV12-C40), 
was found to be better at rescuing the cells from growth arrest than the inverse 
mutant, which can couple to the Erk-MAPKinase, but not PI-3-kinase pathway 
(RasV12-S36). This appears to be due, at least in part, to the fact that in addition 
to activating Pl-3-kinase dependent cell survival pathways, RasV12-C40 
expressing cells can additionally activate Erk-MAPKinase, presumably 
downstream of PI-3-kinase activation. Cells expressing the RasV12-C40 
mutation additionally highlighted a role for PI-3-kinase in the CD40-mediated 
survival of WEHI-231 cells. This study also highlighted a key downstream role for 
p27 in the induction of growth arrest in immature B cells in response to BCR 
ligation, as the expression of p27 correlates with the induction of growth arrest.
One hypothesis for the different biological responses to antigen between 
immature and mature B cells is that immature B cells exhibit reduced PKC 
activity in response to antigen, compared to mature B cells. Indeed, stimulation of 
immature B cells with phorbol esters, which activate the conventional and novel 
PKC isozymes, can overcome anti-lg induced apoptosis. As PKC isoforms from 
all three subclasses have been implicated in the regulation of Erk-MAPKinase 
activity, the role of a variety of PKC family members in BCR signalling in 
immature B cells was investigated by transfection of either catalytically active or 
kinase dead mutants. Expression of the PKC isoforms PKCa, PKCô, PKCe, and 
PKC^ all appear capable of impairing BCR driven growth arrest to a certain 
extent. Indeed, the novel PKC, PKCe, appears to alter the response of WEHI-231 
cells to BCR ligation, as proliferation in these cells was slightly enhanced. PKCa 
also seems to enhance CD40-mediated rescue of anti-lg induced growth arrest
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and apoptosis, whilst the novel PKC, PKCô, seems to play a negative role in 
proliferation in response to stimulation via CD40, as WEHI-231 cells expressing a 
kinase dead form of PKCô appear to display enhanced proliferation in response 
to stimulation with anti-lg and anti-CD40. Examination of candidate downstream 
effector molecules failed to identity the mechanisms employed by these PKC 
isoforms to mediate their effects.
In contrast to immature B cells, mature B lymphocytes become activated and 
proliferate in response to antigen receptor cross-linking. Efficient B cell 
responses generally require interactions with helper T  cells (T h) that are specific 
for the same antigen, responses being modulated by both positive and negative 
co-receptors, which can lower the threshold of signalling required for a positive 
response, or down-modulate BCR signalling, respectively. As Erk-MAPKinase 
proved to play such key roles in both the BCR induced growth arrest and 
apoptosis, and CD40 mediated proliferation in immature B cells, the functions of 
Erk-MAPKinase in the response of mature B celts to BCR ligation was 
addressed. These studies highlighted a key role for the Erk-MAPKinase in the 
proliferative response of mature B cells to antigen, particularly sustained Erk- 
MAPKinase activity akin to that found in immature B cells undergoing CD40- 
mediated proliferation. A major negative regulator of BCR signalling in mature B 
cells is the FcyRllb receptor, which was observed to mediate its effects partly by 
inhibiting the sustained Erk-MAPKinase activity that is required for B cell 
proliferation. Other key targets of FcyRllb mediated inhibition of BCR driven 
proliferation in mature B cells appear to include the tumour suppressor proteins 
Rb and p53, as FcyRllb ligation leads to inhibition of phosphorylation of Rb, a 
process required for cells to enter the cell cycle, whilst the tumour suppressor 
protein p53 appears to be activated in response to FcyRllb ligation. The 
activation of p53 provides a mechanism by which FcyRllb ligation can lead to the 
apoptosis of mature B cells, as Bax, a pro-apoptotic member of the Bcl-2 family 
and a target of p53, is upregulated in response to co-ligation of the BCR with 
FcyRllb.
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Chapter 1 -  General Introduction
1.1 The immune system
The immune system is the defence mechanism that has evolved to protect the 
host from pathogens such as parasites, bacteria or viruses. The cells and 
molecules that comprise the immune system and mediate an immune response 
collaborate in a complex manner, through a finely balanced network of 
interactions. This network enables the host to detect the presence of the foreign 
agent, co-ordinate a specific attack, and finally, once the agent has been 
successfully removed, quench that specific response. The immune system also 
has a memory for agents that have been successfully cleared in the past, 
allowing a more rapid and effective response upon subsequent encounters. The 
immune system comprises two functionally distinct but interacting arms, the 
innate and the adaptive immune responses.
The innate immune response is the first line of defence a host has against 
infection, and as such is non-specific in nature as it functions regardless of the 
foreign substance or pathogen. The innate response is mainly driven by 
phagocytes, cells that engulf microorganisms before exposing them to an array 
of killing mechanisms. The phagocytic cells of innate immunity are derived from 
myeloid progenitor cells, and can be broadly divided into two families, monocytes 
and granulocytes, of which the latter can be further sub-divided into eosinophils, 
neutrophils and basophils. The internalisation process fundamental for innate 
immunity relies primarily upon cell surface receptors and secreted proteins 
produced by these cells that recognise conserved microbial structures such as 
carbohydrate, lipid, protein and DNA components. Upon internalisation these 
cells use a variety of mechanisms to destroy the ingested material, including the 
generation of reactive oxygen intermediates such as superoxide anions (O2 ), 
nitric oxide production, proteolytic enzymes such as lysozyme and acid
hydrolyases, cationic proteins or changes in intracellular pH. Other myeloid- 
derived cells are induced to release pro-inflammatory molecules, known as 
cytokines, which promote an immune response and assist in clearance of the 
pathogen. However, innate immunity relies on the infectious agent carrying 
common surface molecules that can be recognised by phagocytes, therefore 
many infectious agents have evolved mechanisms by which to evade detection 
by the innate immune system. As a result, the adaptive immune response 
evolved to provide an improved detection mechanism and a more versatile 
means of defence.
The adaptive immune response is comprised of cells derived from lymphoid 
progenitor cells, which give rise to two major types of lymphocytes, B 
lymphocytes (B cells) and T lymphocytes (T cells). Adaptive immunity relies upon 
the ability of lymphocytes to recognise antigens and respond in a highly specific 
and selective manner, as each lymphocyte will only recognise a unique antigen.
B cells generate and secrete antibodies, molecules that are specific for each 
unique antigen, and are important for combating infection by extracellular 
pathogens. These antibodies circulate in the bloodstream and permeate other 
body fluids. When an antibody molecule encounters its antigen and binds to it, it 
protects the host via one of three key processes, neutralisation, opsonisation or 
complement activation. Neutralisation is the process by which antigen-anti body 
complexes prevent antigen binding to receptors on host cells and causing 
pathology, for instance by preventing entry of viral particles or bacterial toxins 
into cells. Opsonisation is the process by which the antibody coating allows the 
antigen to be recognised as foreign by phagocytic cells, leading to its ingestion 
and destruction. The third mechanism involves the recruitment of a system of 
plasma proteins known as complement by antibody-antigen complexes, 
particularly when antibodies coat a bacterial cell. The antibodies form a receptor 
for the C1 component of complement, leading to activation of the system, which 
enhances opsonisation of the antigen, or can lead to direct lysis of some 
bacteria.
T cells are involved in a wide range of activities, and are required to combat 
infections by intracellular pathogens, which cannot be detected by antibodies. T 
cells are comprised of two main classes, CD8  ^T cells, and CD4^ T cells. CD8  ^T 
cells are capable of directly eliminating host cells that have become infected by 
viruses or other pathogens, therefore they are also known as cytotoxic T cells 
(Tc). Some CD4^ T cells are capable of modulating the functions of other immune 
cells, such as B cells, macrophages and cytotoxic T cells, hence they are also 
known as helper T cells (Th). Upon activation by antigen, Th cells can 
differentiate into either Th1 or Th2 effector T cells, and the outcome of this 
differentiation can be critical for determining whether the pathogen is eliminated 
or evades the host defence. This decision is influenced by the repertoire of 
cytokines present early in the immune response, and as such effector T cells can 
influence the adaptive immune response towards either a cellular (T h1) or 
humoral (T h2) response. There is also a small population (~ 10% ) of CD4" T cells 
that are CD25^, and these are associated with the suppression of harmful 
immunopathological responses to self or foreign antigens. These naturally 
occurring suppressor T cells, now regarded as regulatory T cells (Tr), are 
capable of inhibiting the proliferation of other I  cell populations both in vitro and 
in vivo. One interesting feature of the adaptive immune response is that, unlike 
the innate response, it improves with each successive encounter with the same 
pathogen. The adaptive immune response is therefore important for the 
generation of life-long immunity to a particular infection.
There is considerable interaction between the innate and adaptive arms of the 
immune system throughout the course of an immune response. T cells are only 
capable of recognising antigens presented to them in a particular way, and this is 
a key role of the phagocytes of the innate immune system. Cells such as 
dendritic cells display antigen via MHO molecules to T cells in a process known 
as antigen presentation, resulting in the activation of the T cell and the induction 
of a specific cell-mediated response.
The cells responsible for mediating the cellular and humoral responses have 
become major targets of biomedical research. This has resulted in the acquisition 
of a great deal of knowledge of both the development and effector functions of 
key cell types. However, much remains to be elucidated. One area that has 
received much interest, yet has still to yield much more information, is the 
molecular and biochemical mechanisms underlying B cell development and 
differentiation, and the differential responses that depend on maturation status. 
One receptor is responsible for the transduction of antigen encounter throughout 
B cell development, yet the biological response varies depending on the 
developmental stage. The study of these differential responses will further our 
understanding not only of normal B cell development, but also the role of B 
lymphocyte dysfunction in a number of disease states, including many 
autoimmune diseases.
1.2 The role of B cells in the adaptive immune response
1.2.1 Generation and selection of B cells
B cells are the principal cellular mediators of the specific humoral response to 
infection by bacteria, viruses and parasites as they produce antigen-specific 
antibodies. The processes controlling development of B cells are tightly regulated 
to ensure a constant supply of B cells expressing antigen receptors of distinct 
specificity, enabling identification of any encountered antigen, yet at the same 
time avoiding generation of autoreactive B cells that recognise ‘self antigens. 
This complex process involves the integration of numerous signals at a number 
of stages, including antigen, soluble mediators and accessory cells.
In mammals, B cell development begins with the commitment of haematopoietic 
stem cells (HSCs) to the B cell lineage, a process that occurs in the foetal liver, 
then after birth and into adult life in the bone marrow (Figure 1.1). Commitment 
of HSCs to the B cell lineage is dependent on the expression of the paired box
transcription factor Pax5 (Cory, 1999). Pax5 acts to promote the expression of B 
cell lineage genes whilst suppressing those genes responsible for T cell, 
erythroid or myeloid cell development, other lineages HSCs are capable of 
differentiating into. Once committed, the precursor B cells pass through a number 
of developmental stages marked by a series of changes in location and in the 
expression of genes, intracellular proteins and cell surface markers. Encounter 
with antigen in the bone marrow, however, leads to death by apoptosis, or 
anergy, a process by which the B cell becomes unresponsive to future 
encounters with its particular antigen. The B celts that emerge into the periphery 
are termed immature B cells, and these migrate to the secondary lymphoid 
organs, such as the spleen and lymph nodes. It is here, in association with 
specialised antigen-presenting cells and stromal cells, that B cell recognition of 
antigen can lead to one of several developmental pathways: (1) anergy and/or 
apoptosis, (2) activation, proliferation and differentiation into high rate antibody 
secreting plasma cells, or (3) differentiation into memory B cells (Tarlinton, 1994).
The stages of B cell development can be broadly divided into two quite distinct 
phases; antigen-independent and antigen-dependent (Rolink and Melchers, 
1991). The antigen-independent phase is completed in the bone marrow, and 
involves the production of a repertoire of immature B cells bearing functional 
antigen receptors (B cell receptor, BCR).
The production of a functional BCR relies on the completion of a complex pattern 
of immunoglobulin gene rearrangements to produce one functional heavy chain, 
followed by one functional light chain (Coleclough etal., 1981). This 
rearrangement is under the control of the protein products of the recombination- 
activating genes, RAG-1 and RAG-2 , which are highly expressed at the pro- and 
pre-B cell stages of differentiation and are essential for rearrangement 
(Spanopoulou etal., 1994). The immunoglobulin heavy chain variable region is 
encoded by V (variable) and J (joining) gene segments, with additional diversity 
provided by the D (diversity) gene segment. Rearrangement of the heavy chain
gene begins in the early pro-B stage with the joining of D h to Jh. Cells are allowed 
to progress to the next stage provided a productive rearrangement is achieved. 
Progression to the late pro-B cell stage is accompanied by the joining of a Vh 
gene to the pre-formed D Jh  complex. Although no functional immunoglobulin is 
expressed in late pro-B cells, recent studies have shown the expression of 
components of the mature BCR on their surface, namely the accessory Ig-a/lg- 
p heterodimers in association with cainexin (Nagata etal., 1997) (Figure 1.2). 
These accessory molecules have been shown to be essential for the continuing 
development of the pro-B cells to the pre-B cell stage (Gong and Nussenzweig, 
1996; Minegishi et al., 1999). Indeed, it has been shown that mice deficient in Ig- 
p exhibit a complete block in B cell development before Vh to DhJh 
rearrangement. It was therefore been suggested that signalling through the Ig- 
o/lg-p-calnexin receptor on pro-B cells may be required for successful initiation of 
Vh to DhJh gene rearrangement (Nagata etal., 1997). However, it has recently 
been shown that Vh to DhJh recombination can still take place in pro-B celts from 
mice lacking either Iga or Igp (Pelanda et al., 2002).
A successful first rearrangement results in the production and transient 
expression of intact p. heavy chains in an immunoglobulin-like "pre-BCR” complex 
with the surrogate light chains, X5 and VpreB (Karasuyama et al., 1994). X5 
bears close similarity to the known constant (C) X light-chain domains, whilst 
VpreB resembles a variable (V) domain but bears an extra N-terminal protein 
sequence. If this first rearrangement is unsuccessful, a second rearrangement is 
undertaken. Pro-B cells in which both rearrangements are unsuccessful are 
unable to produce a pre-B cell receptor. Surface expression of a pre-BCR is 
known to be important for instructing the cell to stop further Vh gene 
rearrangements (Neuberger, 1997) by inhibiting recombination at the heavy 
chain locus, a process described as allelic exclusion (Benschop and Cambier,
1999). Pre-B cell receptor expression also drives the transition to the large pre-B 
cell stage and induces proliferation in addition to signalling to the cell that gene 
rearrangements to the immunoglobulin light chain should begin. Thus, a lack of
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pre-B cell receptor expression results in a block in B cell development at the pre- 
B cell stage. This signalling to the cell is apparently in the absence of any specific 
ligand or cooperating cells, and indeed has recently been shown to be dependent 
upon the non-immunoglobulin portion of the surrogate light chain molecule, X5 
(Ohnishi and Melchers, 2003). This study showed that deletion or mutation of the 
N-terminal region of X5 resulted in a failure to initiate pre-BCR signalling, leading 
to the hypothesis that the pre-BCR might serve as its own ligand with oppositely 
charged amino acids in X5 and VpreB binding the two proteins together, resulting 
in autonomous self-cross-linking of neighbouring pre-BCRs.
Maturation of pre-B cells to immature B cells involves the rearrangement of 
immunoglobulin light chain genes to generate a conventional light chain (k or X), 
with appropriate constant and variable regions. Once a light chain gene has been 
rearranged successfully, a BCR consisting of p heavy chain, conventional light 
chains and accessory Ig-a/lg-p molecules is expressed by the immature B cells. 
This intact surface IgM is the first BCR to exhibit antigen specificity (Reth, 1992) 
and thus the B cell enters the antigen-dependent stage of development. It has 
been estimated that about 10® B lineage precursors are generated every day in 
the murine bone marrow, which in turn give rise to about 2x10^ sIgM-expressing 
immature B cells (Osmond, 1986). Thus, it is clear that the majority of B cells 
(80%) maturing in the bone marrow undergo a process of negative selection. 
Indeed, ligation of the antigen receptors on the vast majority of immature B cells 
leads ultimately to anergy, a state of non-responsiveness to antigen (Goodnow et 
ai, 1988) or deletion via apoptosis (programmed cell death) (Hartley etal., 1991; 
Hasbold and Klaus, 1990; Nemazee and Burki, 1989).
The inactivation of self-reactive B cell clones by deletion or inactivation (anergy) 
is important for the maintenance of self-tolerance by the immune system. 
Immature B cells that are capable of recognising self-antigens are eliminated or 
inactivated, preventing them from developing further and secreting antibodies 
that bind to host ceils or tissues. Self-reactive immature B cells may also be
rescued from deletion by undergoing receptor editing, where the autoreactive 
receptor is replaced with the product of a further rearrangement event (Radio et 
al., 1993). Immature B cells isolated from the bone marrow undergo apoptosis 
when cultured in vitro in the presence of anti-lg antibodies, but these cells are 
purified, therefore not in their physiological context (Norvell at a!., 1995). In 
contrast, when immature B cells are cocultured with whole syngeneic bone 
marrow they do not respond to anti-lg by undergoing apoptosis but by re­
expressing RAG-2, permitting receptor editing (Sandel and Monroe, 1999).
These studies suggest that the consequences of an immature B cell recognising 
its antigen are dictated by the site of antigen encounter, with the bone marrow 
microenvironment providing signals that promote receptor editing. If the immature 
B cell first encounters its antigen in the periphery, the absence of these signals 
results in commitment to apoptosis.
By maintaining high level expression of mIgM, transitional-immature (T1) B cells 
entering the periphery remain sensitive to antigen deletion for a number of days 
(Allman at a i, 1993). This is especially important for the development of 
tolerance, since not all self-antigens are expressed within the bone marrow 
(Monroe, 2000; Sandel and Monroe, 1999). To promote their survival and 
migration to the spleen, these cells require T cell-dependent help. Typically, of 
the 2x10^ slgM"  ^B cells that develop daily in murine bone marrow only 10% will 
reach the spleen and only 1-3% will survive and develop to the next stage of 
maturation (Allman at ai, 1993). The development into a transitional (T2) B cell is 
accompanied by the surface expression of IgD and requires constant BCR- 
derived signals for progression, resulting in a IgM*^ '^ *^  igD’^ '®'^  phenotype (Carsetti 
at ai, 1995; Neuberger, 1997; Sandel and Monroe, 1999). In addition, stimulation 
via cytokines or co-receptor ligation is thought to help shape the BCR repertoire 
and signalling thresholds (Craxton at a i, 1999). As the B cells migrate into the 
primary follicles of the spleen they are finally regarded as “mature” lgM'°'^ IgD'^ '®^
B cells.
In stark contrast to the immature B cell, antigen-receptor ligation leads to the 
activation of mature B cells. The activated B cell can develop into an IgM 
antibody-secreting plasma cell or undergo isotype switching and V region 
somatic mutation to become a memory B cell, in the presence of the correct T 
cell-derived cytokines and cell-cell contacts (Cushley and Harnett, 1993; Liu et 
al., 1992). Following re-exposure to the same antigen and affinity maturation, 
whereby the affinity of the cell for its particular antigen improves by a process of 
somatic hypermutation, the memory B cell can evolve into an IgG secreting 
plasma cell. The formation of memory is critical for mounting a rapid, specific 
secondary immune response and the ability of the immune system to generate 
these memory B cells forms the basis of effective vaccination.
The generation of memory B cells occurs in germinal centres (GCs), which are 
formed during primary immune responses to T cell-dependent antigens in 
lymphoid follicles (Figure 1.3). B cells activated by T cell-dependent antigens 
enter the primary lymphoid follicles where they undergo proliferation in areas rich 
in follicular dendritic cells (FDCs), which fix unprocessed antigen on their surface 
for presentation to newly-formed B cells. Following their expansion, the B cell 
blast population migrates from the centre of the follicle to form the dark zone of 
the GC, where they continue to proliferate and lose sig expression, becoming 
centroblasts. Centroblasts undergo somatic mutation of the immunoglobulin 
variable region genes and subsequently migrate to the light zone of the GC, 
which is rich in FDCs, and are now termed centrocytes, which express the 
mutated antigen receptors. In the light zone, centrocytes with the highest affinity 
antigen receptors are selected and return to the dark zone for further rounds of 
mutation and selection, whilst those with lower affinities undergo apoptosis. As 
centrocytes are intrinsically programmed to undergo apoptosis unless they are 
actively rescued, the level of B cell apoptosis in the light zone is very high. 
Rescue of centrocytes from apoptosis is driven by two signals. The first is 
generated by FDC-displayed antigen resulting in ligation of the high-affinity 
surface immunoglobulin, the second by CD40 ligation on the surface of
centrocytes, suggesting a role for helper T cell interactions in promoting 
centrocyte survival (Craxton et aL, 1999). This process results in the selection of 
high affinity B cell clones as redundant and low affinity receptors are selected 
against. Positively selected centrocytes then go on to establish the memory B 
cell pool in the apical light zone, providing the precursors for plasma cells that will 
produce antibodies of high affinity.
The developmental stages described in this section give rise to a population of 
“conventional” B cells. However a second population of B cells exists that appear 
to arise from distinct stem cells early on in development (Hayakawa and Hardy,
2000). These latter cells are known as B-1 B cells, to distinguish them from the 
conventional B-2 B cells described above. This subset of B cells was first 
distinguished from conventional B cells by the surface expression of CDS 
(Hayakawa et a/., 1983). Stem cells arising from the foetal liver give rise to B cell 
progenitors that have little or no terminal deoxynucleotidyl transferase (TdT), 
which in turn give rise to B-1 cells. A lack of TdT activity in these B-1 cells results 
in limited immunoglobulin heavy chain rearrangements and the expression of 
low-affinity antigen receptors for multivalent self-antigens. The restricted diversity 
of B-1 cell antigen-receptors includes broad specificities in antigen recognition, 
particularly to common bacterial polysaccharides such as lipopolysaccharide 
(LPS) and phosphorylcholine (PC), as well as phosphatidyl-choline, 
immunoglobulins and DNA. B-1 B cells are particularly important in newborns, as 
they are presumed to be responsible for natural immunity prior to the production 
of conventional B-2 B cells in adult life.
Predominantly located in the peritoneal cavity, the self-renewing population of 
mature B-1 cells express slgM with little or no surface expression of IgD. Little is 
known about the normal function of B-1 cells, however, the propensity of B-1 
cells to produce low-affinity auto reactive antibodies implicates a role for these 
cells in autoimmune disease. Indeed, B-1 B cell populations that produce
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autoantibodies are expanded in autoimmune disease models such as SHP-1^ 
(motheaten) and Lyn-deficient mice (Hayakawa and Hardy, 2000).
Another B cell subset is the naïve, marginal zone (MZ) B cell population, which is 
enriched primarily in the marginal zone of the spleen (Oliver etal., 1997). These 
cells are involved at an early stage of an immune response, and seem to have a 
lower threshold for activation, proliferation and differentiation into plasma cells. 
The MZ B cell population remains poorly characterised compared to the 
‘conventional’ B2 subset, however, it has been shown that MZ B cells are 
excellent antigen presenting cells, and are among the first cells to encounter 
blood-borne antigen in T cell dependent immune responses. This suggests that 
they may participate, along with lymphoid dendritic cells, in the early stages of T 
cell activation, though this remains to be seen.
1.2.2 BCR structure
The B cell antigen receptor (BCR) is a multiprotein structure, comprising a 
clonatypic antigen binding component (sIg) produced from the rearrangement of 
immunoglobulin heavy and light chain genes, which are non-covalently bonded 
with disulfide-linked Iga (CD79a) and Igp (CD79b) heterodimers (Pao etal.,
1997) (Figure 1.4). In contrast to the T cell receptor for antigen, which only 
recognises processed antigen associated with MHO molecules, the BCR 
recognises antigens in solution or on cell surfaces in a native conformation. B cell 
activation by antigen leads to antigen uptake by the BCR, processing and 
presentation to T cells. The BCR is essential for B cell development, the specific 
response to antigen, and B cell survival (reviewed by Niiro and Clark, 2002).
There are five classes of immunoglobulin, IgM, IgD, IgG, IgA and IgE, and all of 
these can be produced either in secreted or membrane-bound receptor form. 
However, only IgM and IgD are expressed on the surface of mature naive B cells. 
The ligand-binding unit of the BCR consists of Ig heavy chain homodimers, each
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linked by disulphide bonds to an Ig light chain, forming a symmetrical four chain 
structure with two antigen binding sites. A transmembrane region of 25 amino 
acids anchors it to the cell surface. The sig subunit lacks any intrinsic enzymatic 
activity within its cytoplasmic domains; thus it associates with accessory signal 
transducing molecules. Encoded by the mb1 and b29 genes respectively (Reth,
1995), Ig-a (34 kDa) and Ig-p (38 kDa) possess single, immunoglobulin 
extracellular domains and exist as disulphide linked heterodimers.
Like mIgM and mIgD, Iga and Igp do not contain any intrinsic catalytic activity. 
However, they do possess consensus sequence motifs responsible for the 
initiation of signal transduction. This motif originally designated as TAM, ARAM 
or RETH, is now termed the immunoreceptor tyrosine-based activation motif 
(ITAM) (Cambier, 1995a; Cambier, 1995b). This motif, spaced over 18 amino 
acids, is composed of a twice-repeated YxxL sequence flanking seven variable 
residues. Antigen-ligation of the BCR promotes the phosphorylation of the two 
tyrosine residues within each ITAM (four tandem motifs per BCR) by non­
receptor protein tyrosine kinases (PTKs) (Figure 1.4). Phosphorylation of the 
tyrosine residues is essential to the function of the motif and is deemed as being 
necessary and sufficient to initiate signal transduction (Cambier, 1995a). Many 
im mu noreceptors utilise this mechanism for initiation of cellular signalling events. 
Other ITAM containing membrane proteins include the CD3 and ^-chains of the T 
cell receptor (TCR) and several receptors for the Fc domain of immunoglobulin 
(FcRs).
1.2.3 BCR signalling
The downstream signalling pathways that couple surface Ig ligation to B cell 
activation and differentiation have become a major area of biomedical research 
with a view to understanding, and perhaps one day artificially modulating, the 
immune response. As such, the signalling pathways activated immediately 
following BCR ligation have been well elucidated. The first signalling event
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mediated by the BCR is the recruitment and concomitant activation of non- 
receptor protein tyrosine kinases (PTKs) (Campbell, 1999; Kurosaki, 1999). 
Recruitment and activation of three distinct types of PTKs are known, namely the 
Src- (Lyn, BIk, Fyn), Syk- and Tec- (Bruton’s tyrosine kinase, Btk) PTKs 
(Cambier, 1995a; Kurosaki, 1999) (Figure 1.4). Prior to BCR ligation, the Src 
family kinases are associated with the BCR in an inactive conformation, due to 
intramolecular interactions involving their SH2 domains. Following BCR ligation, 
these Src family PTKs become activated and phosphorylate the key tyrosine 
residues within the ITAMs of the Iga and Igp accessory molecules. The 
phosphorylated ITAMs create binding sites for the tandem SH2 domains of Syk, 
which, once recruited, itself becomes tyrosine phosphorylated and activated. One 
substrate of Syk is the adaptor protein BLNK (B cell linker protein), whose 
phosphorylation provides docking sites for Btk, allowing Btk to be brought into 
close proximity with, and subsequently become activated by phosphorylation by, 
Syk (Baba et a i, 2001). These kinases subsequently phosphorylate and activate 
downstream targets in various signalling cascades.
These early signalling events result in the aggregation and activation of a number 
of important downstream enzymes and adaptor proteins that, in turn, trigger three 
major signalling pathways (Figure 1.5) (Cushley and Harnett, 1993). The first 
pathway involves the hydrolysis of phosphatidylinositol-4,5-bisphosphate 
(Ptdlns(4 ,5)P2 or PIP2) to diacylglycerol (DAG) and inositol-1,4,5-trisphosphate 
(lns(1,4,5)Ps or IP3) by phospholipase C-y2 (PLC-y2). The second pathway 
results in the generation of phosphatidylinositol-3,4,5-trisphosphate 
(Ptdlns(3,4,5)Ps or PIP3) following phosphorylation of Ptdlns(4 ,5)P2 by 
phosphatidylinositol 3 kinase (PI-3-K). The third pathway is the classical 
Ras/Raf/Erk-MAPKinase pathway. These three pathways have recently been 
shown to interact at a variety of levels, increasing the complexity of BCR 
signalling.
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1.2.3.1 Activation of PLC-y
The PLC-y pathway was one of the first downstream pathways shown to be 
activated by the BCR (Bijsterbosch et a i, 1985). The PLC family comprises three 
homologous groups of enzymes (PLC-p, y and ô), all of which contain PH 
domains. In tyrosine kinase dependent signalling, including that initiated by most 
immune receptors, one or both of the two isoforms of PLC-y, PLC-y 1 and PLC-y2, 
are activated. In addition to the PH domain, PLC-y isoforms also contain two SH2 
domains and an SH3 domain (Lee and Rhee, 1995). The SH2 domain aids the 
recruitment and phosphorylation of PLC-y by the PTKs Btk and Syk, whilst the 
PH domain permits docking to the inner plasma membrane via a Ptdlns(3 ,4 ,5)P3 
dependent mechanism (Campbell, 1999).
The translocation of PLC-y to the cell membrane and its subsequent PTK- 
mediated tyrosine phosphorylation are essential for its activation. Indeed, a 
deficiency in either Btk or Syk results in ablation of PLC-y activation and 
lns(1,4 ,5)P3 production. Ptdlns(3,4 ,5)P3 plays a role in activating Btk by binding 
to its PH domain, allowing active Btk to proceed to phosphorylate and activate 
PLC-y. In addition, Ptdlns(3,4 ,5)P3 may directly activate PLC-y via PH domain 
binding interactions. Although the SH2 domain of PLC-y can bind to Syk in vitro, 
reconstitution experiments indicated that additional factors were required to 
initiate a BCR-mediated calcium response (Kelly and Chan, 2000). More 
recently, the B cell specific adaptor protein, BLNK (B cell linker protein), also 
termed SLP-65, has been identified as the additional factor required for coupling 
Syk to activation of PLC-y (Fu etal., 1998; Ishiai etal., 1999a). Indeed, studies 
using the chicken DT40 cell line have shown that BLNK gene disruption 
abolishes PLC-y phosphorylation (Ishiai et al., 1999b). BLNK is also thought to 
play a role in the recruitment and activation of Vav, Grb2 and Nek, serving to 
focus these signalling effectors at the plasma membrane for phosphorylation by 
Syk.
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PLC-y1 deficient mice are embryonic lethal and fail to mobilise calcium (Ji et a/., 
1997). Whilst PLC-y2 insufficiency is not lethal (Wang etal., 2000), PLC-y2 
deficient B cells have signalling defects similar to that seen in Btk knockouts 
(Khan etal., 1995) or the naturally occurring xid immunodeficient mice (Rawlings 
et ai, 1993), which possess a mutation in the PH domain of Btk preventing its 
recruitment and concomitant activation by Ptdlns(3 ,4 ,5)P3. The effects of PLC-y2 
deficiency have recently been shown to be due to a block in B cell maturation at 
the transitional 2 to follicular B cell transition. There is a dramatic increase in 
BCR-induced apoptosis in all subsets of splenic B cells from PLC-y2-deficient 
mice, due to a failure to increase the expression of the pro-survival proteins A1 
and Bcl-2 (Wen e ta i, 2003).
The generation of second messengers, DAG and lns(1,4 ,5)P3 , has been shown 
to be important for the activation of protein kinase 0  (PKC) isoforms, the release 
of intracellular calcium stores and the nuclear translocation of NF-kB (Berridge, 
1993; Berridge and Irvine, 1989; Lee and Rhee, 1995). DAG activates 
conventional and novel protein kinase C (PKC) isoforms at the plasma 
membrane (Parekh e ta i, 2000), whilst lns(1,4 ,5)P3 binds to receptors (InsPsR) 
in the endoplasmic reticulum. InsPsR activation leads to a process of capacitative 
calcium entry, by which the depletion of intracellular stores activates calcium 
influx across the plasma membrane (Parekh and Penner, 1997).
Members of the PKC superfamily are serine/threonine kinases, and to date 11 
PKC isoforms have been identified, which are subdivided into three groups 
depending on their structure and cofactor regulation (Mellor and Parker, 1998). 
Conventional PKCs (a, Pi, Pn and y) require both calcium and DAG for activation, 
novel PKCs (ô, 0) are calcium independent but require DAG whilst, atypical
PKCs (g, X/i) are calcium independent and are not activated by DAG. Several 
studies have highlighted the role for PKCs in modulating the BCR-mediated 
response in a maturation stage-dependent manner. Studies in knockout or 
depletion models of PKC isoforms have demonstrated that a lack of DAG-
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responsive PKC isoform activation, in particular PKCp, may be responsible for 
BCR-induced apoptosis in immature B cells (King etal., 1999; Leitges etal.,
1996). Thus, apoptosis can be overcome by stimulating immature B cells with 
phorbol esters (e.g. PMA), which bypass the BCR and activate the conventional 
and novel PKC isoenzymes directly (King etal., 1999; Nishizuka, 1992). in mast 
cells, stimulation via FceRI leads to phosphorylation of both PKCa and PKCPi by 
Syk, resulting in the generation of a binding site for the SH2 domain of Grb-2.
The concomitant recruitment of the Grb-2/Sos complex contributes to the full 
activation of Ras/Erk-MAPKinase cascade, demonstrating a link between PKC 
activation and the Ras/Erk-MAPKinase cascade (Kawakami et a l, 2003).
The recently isolated member of the CDC25 family of Ras guanyl nucleotide 
exchange factors (GEFs), RasGRP3, is preferentially expressed in B cells. It has 
a C l domain that binds DAG, suggesting it could be responsible for some of the 
DAG signalling events that have previously been attributed to PKC. Upon 
stimulation of Ramos B cells, RasGRP3 associates with the membrane, and is 
phosphorylated in a PKC-dependent manner. In vitro, PKC0 and PKCp, are 
capable of phosphorylating RasGRPS (Teixeira etal., 2003). The kinetics of 
RasGRPS phosphorylation correlate with the levels of both active Ras and Erk- 
MAPKinase, consistent with the idea that phosphorylation of RasGRPS is related 
to its functional activity, the activation of Ras by exchanging GDP for GTP. 
Interestingly, RasGRPS from stimulated cells does not react with phospho- 
ty rosi ne antibodies, suggesting that it contains phospho-th reoni ne or phospho- 
serine, supporting the idea it is a substrate for PKC.
1.2.3.2 Activation of PI-3-Kinase
Phosphatidylinositol 3-kinase (PI-3-Kinase) catalyses the phosphorylation of the 
inositol phospholipids Ptdlns, Ptdlns(4)P and Ptdlns(4,5)Pz on the 3' position of 
the inositol ring to produce Ptdlns(3)P, Ptdlns(3 ,4 )P2 and Ptdlns(3,4 ,5)P3, 
respectively (Fry, 1994). Three classes of PI-3-Kinase exist, which are classified
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according to their in vitro substrate specificities. Class I PI-3-Kinases are capable 
of phosphorylating all three forms of inositol phospholipid and can be further 
subdivided into Class lA and Class IB. Class lA comprise a p110 catalytic subunit 
(a, p or Ô) and a regulatory SH2/SH3-domain containing p85 family adaptor 
subunit. The Class lA isoforms are normally activated by PTK coupled receptors. 
Class IB isoforms consist of a p11 Gy catalytic subunit and a p101 adaptor subunit 
and are activated following signalling via G-protein coupled receptors. Class II 
isoforms phosphorylate PI and Ptdlns(4)P whilst Class III phosphorylates PI only.
PI-3-Kinase activity, and the concomitant generation of Ptdlns(3 ,4)P2 and 
Ptdlns(3 ,4 ,5)P3, are known to be important for BCR-mediated B cell proliferation, 
differentiation (Aagaard-Tillery and Jelinek, 1996) and survival (Campbell, 1999). 
Indeed, inhibition of PI-3-Kinase activity in actively cycling B cells results in 
apoptosis (Craxton et a/., 1999), However, a negative role for PI-3-Kinase has 
been shown in a human RL B cell line where BCR-induced growth-arrest can be 
blocked by inhibiting PI-3-Kinase activity (Craxton etaL, 1999). The interaction of 
Ptdlns(3 ,4)P2 and Ptdlns(3 ,4 ,5)P3 with SH2 and PH domain containing proteins, 
such as PLC-y, Btk, Vav, PDK1/2 and Akt/PKB permits their recruitment to the 
plasma membrane (Aagaard-Tillery and Jelinek, 1996; Alessi e ta i, 1997; 
Falasca e ta i, 1998; Franke and Cantley, 1997). Pl-3-Kinase activation following 
BCR ligation was thought to be solely dependent on PTK activity. However, 
studies have demonstrated the essential requirement for upstream activation of 
the GTPase Ras (Kodaki et ai, 1994), which then binds the p i 10 catalytic sub­
unit of the p85-dependent PI-3-Kinase (Genot and Cantrell, 2000). This 
mechanism establishes a link between the PI-3-Kinase pathway and the 
pathways driven by GTP binding proteins, such as the Ras/MAPK pathway.
Recently, it has been demonstrated that PI-3-Kinase activity is required for the 
BCR-induced phosphorylation and activation of Erk-MAPKinase. If murine 
splenic B cells are pretreated with the PI-3-Kinase inhibitors LY294002 or 
wortmannin, Erk-MAPKinase activation in response to BCR-ligation is greatly
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reduced (Jacob et a i, 2002). Such inhibition of PI-3-Kinase has no effect on Ras 
activity, but does block Raf and MEK activity, placing PI-3-Kinase between Ras 
and Raf in the pathway. This is somewhat surprising, as Ras is capable of 
directly interacting with Raf through its effector domain.
PI-3-Kinase activity is also required for B cell development, particularly of B1 
cells in the peritoneum and marginal zone (MZ) B cells. Mice deficient in the 
p85a regulatory subunit demonstrate a partial block in B cell development at the 
pro-B cell stage, and have a reduction in the number of B cells in the spleen, as 
well as a reduction in the number of B1 cells (Fruman e ta i, 1999) (Suzuki etal., 
1999). p i 100-deficient mice display a very similar phenotype, with B cell 
development blocked at the pro-B cell stage and a reduction in the number of 
splenic B cells (Okkenhaug et a i, 2002). Interestingly, these mice lack 81 and 
MZ B cells, as do mice lacking GDI 9, one of the key regulators of PI-3-Kinase 
activity in B cells (Martin and Kearney, 2000), suggesting GDI9 and PI-3-Kinase 
play important roles in the development or maintenance of MZ and B1 B cells.
1.2.3.3 Activation of the Ras/MAPKinase pathway
The mitogen-activated protein (MAP) kinases are a family of serine-threonine 
protein kinases that have been widely conserved throughout the evolution of 
eukaryotic cells. They are activated by a wide range of extracellular stimuli and 
are able to mediate a wide range of cellular functions ranging from proliferation 
and activation to growth arrest and cell death (Figure 1.6). The MAPKinase 
family is subdivided into three groups; the classical extracellular signal-regulated 
kinases (Erk-MAPKinase), the c-Jun N-terminal kinases, also known as the 
stress activated protein kinases (JNK/SAPK) and the p38 MAPKinases 
(Dhanasekaran and Premkumar Reddy, 1998; Elion, 1998). Activation of each 
group is determined by distinct upstream MAPKinase kinases (MEKs) and 
MAPKinase kinase kinases (MEKK). MAPKs are activated by dual 
phosphorylation on tyrosine and threonine residues, located in a T-X-Y motif,
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where X is different in each group. Following MAPKinase activation, activation of 
a number of downstream transcription factors occurs; Erk-MAPKinase activates 
Elk-1 and c-myc, JNK activates c-Jun and ATF-2 and p38 MAPKinase activates 
ATF-2 and MAX. The phosphorylation and activation of these transcriptional 
regulators enables the MAPKinase families to regulate gene expression and 
hence, cellular responses.
In B cells, coupling of the BCR to the Erk-MAPKinase pathway relies on the 
formation of adaptor protein scaffolds, which are recruited by activated protein 
tyrosine kinases. These complexes then facilitate the recruitment of downstream 
guanine nucleotide exchange factors (GEFs) and kinase cassettes of the Erk- 
MAPKinase pathway. Following BCR ligation, the adaptor protein She binds to 
the phosphorylated BCR ITAMs via its SH2 domain, and is in turn 
phosphorylated by the PTK Syk. Activated She then recruits Grb2-SoS 
complexes to the phosphorylated ITAMs (Harmer and DeFranco, 1997; Li e ta i,
1993). In conjunction with a GTPase activating protein (RasGAP), the GEF SoS 
(son of sevenless) regulates the activities of the guanine nucleotide binding 
protein Ras. Ras activation can also occur in a Shc-independent manner due to 
the utilisation of the linker protein BLNK (Kelly and Chan, 2000). Whilst already 
implicated as an intermediate adaptor in the membrane recruitment and 
activation of PLC-y by Syk, BLNK is known to associate with Grb2 and SoS to 
form a BLNK/Grb2/SoS complex, highlighting the ability of different adaptor 
molecules to mediate BCR-induced signalling.
Ras is a member of a family of small GTPases, which cycle between inactive 
GDP-bound and active GTP-bound states, functioning as signal relays linking 
membrane receptors to signal transduction pathways. They exist in their inactive 
GDP-bound state until they associate with GEFs, which promote their activation 
by inducing the exchange of GDP for GTP. Active, GTP-bound GTPases then 
interact with a variety of effector molecules, activating downstream signalling 
pathways. They are returned to their inactive GDP-bound state via their intrinsic
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GTPase activity, which is accelerated by association with GAPs (Henning and 
Cantrell, 1998). Thus, following BCR ligation the Grb2-SoS complex promotes 
the exchange of GDP for GTP on Ras to generate an active GTP-bound form. 
Ras is then able to regulate a wide range of downstream cellular processes, from 
cytoskeletal reorganisation through to modulation of transcription (Vojtekand 
Der, 1998). One effector of Ras is Raf, a serine/threonine kinase, which active 
Ras can bind and derepress, resulting in the activation of MAPKinase kinases 
(MEK) and the subsequent downstream activation of the Erk-MAPKinases 
(Kolch, 2000). Active Ras also promotes cell survival by direct interactions with 
PI-3-kinase, resulting in the production of the second messengers, Ptdlns(3 ,4)P2 
and Ptdlns(3,4 ,6)P3, and the activation of the serine/threonine protein kinase Akt, 
a key mediator of survival.
Ras is not the only small GTPase that can be activated in response to BCR- 
ligation. Co-recruitment of the GEF Vav by BLNK (Fu et al., 1998) can in turn 
activate the Rho-family of GTPases (Rac, RhoA and Cdc42) (Crespo et a!.,
1997). These GTPases provide a critical link for the activation of the other 
MAPKs, JNK/SAPK and p38 MAPK, by specific MEKKs (MEKK1-4). Rho- 
GTPases are also able to activate PI-6-kinase, which phosphorylates inositol 
phospholipids on the 5’ position of the inositol ring, leading to the activation of 
PLC-y and the generation of tns(3 ,4 ,5)P3 and calcium mobilisation (Campbell, 
1999).
Alternative pathways following GEF activation may also occur due to the 
structural similarities between the effector binding domains of the GTPases Ras 
and Rap-1. The Rap-1 GEF, C3G, interacts with Crk, a Grb2 like adaptor 
molecule, to form a C3G-Crk complex that associates with phosphorylated 
receptor tyrosine kinases. Activation of Rap-1 by C3G may lead to the 
sequestration of the downstream effector of Ras, Raf, resulting in the down- 
regulation of Erk-MAPKinase activation, as Rap-1 can bind Raf without activating 
it. However, in some cases, Rap-1 activation may actually occur in a Crk/C3G
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independent manner, as formation of a stable complex between Rap-1 and B-Raf 
promotes the activation of Erk-MAPKinase in nerve growth factor treated PC 12 
cells, suggesting that Rap-1 activity can positively regulate receptor-mediated 
responses in some cell types (York et al., 1998). Indeed, transient Ras- 
dependent Erk-MAPKinase activation in PCI2 cells results in proliferation, whilst 
sustained Rap-1-dependent MAPKinase activation induces differentiation (York 
et al., 1998). Utilisation of this alternative pathway may be facilitated by the 
different cellular localisation of these two GTPases; Ras is predominantly plasma 
membrane bound whilst Rap-1 is located in endocytic and lysosomal vesicles. It 
has recently been demonstrated that, in the WEHI-231 and A20 cell lines, Rap 
activation negatively regulates BCR-induced phosphorylation of Akt on key 
activating sites, but has no effect on Erk-MAPKinase activation (Christian etal., 
2003). This strongly suggests that BCR-induced Rap activation functions to limit 
the ability of the BCR to activate Akt. Indeed, blocking Rap activation in WEHI- 
231 cells enables them to survive prolonged treatment with anti-IgM antibodies, 
presumably as a result of increased Akt activation, as expression of a 
constitutively active Akt in WEHI-231 cells has been shown to reduce anti-IgM 
induced cell death (Banerji etal., 2001).
Another adaptor protein recruited to the plasma membrane upon BCR ligation is 
Bam32. Its recruitment requires the activity of Pl-3-Kinase, and it is a component 
in a novel pathway that leads from the BCR to the Erk-MAPKinase cascade, as 
well as JNK. A key initiator of this pathway is haematopoietic progenitor kinase 1 
(HPK1), a MAPKKKK activated downstream of both the BCR and TCR. HPK1 
interacts directly with Bam32, possibly allowing localisation of HPK1 to the 
plasma membrane where it can activate MEKK1. This novel pathway is required 
for normal BCR-mediated proliferation, but not for B cell survival (Han etal., 
2003). In humans, Bam32 expression is largely restricted to haematopoietic cells 
with the exception of T cells, and its expression is thought to be enhanced in 
germinal centre B cells (Marshall etal., 2000). In mice, the expression pattern is 
very similar, except there is no increase in germinal centre B cells, or activated
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splenic B cells, but rather a decrease. B cells develop normally in Bam32^' mice, 
except for B-1 B cells, which are slightly reduced. Bam32‘ "^ mice have normal T 
cell-dependent immune responses, but defective T cell-independent immune 
responses.
MAPKinase pathways ultimately regulate cell cycle machinery, thus controlling 
the fate of a cell and dictating whether it progresses through to rounds of 
proliferation or enters into growth arrest or apoptosis. One recently discovered 
target of Erk-MAPKinase is the RNA polymerase III machinery, whose output is 
tightly linked to growth (Larminie et a/., 1998) and subject to cell cycle regulation 
(White et a/., 1995). RNA pol ill is responsible for the synthesis of tRNAs, as well 
as other small RNAs including the 5S ribosomal RNA subunit. Erk-MAPKinase 
phosphorylates BRF1, a component of the RNA pol III transcription factor TFIIIB, 
resulting in Increased transcription of RNA pol III target genes (Felton-Edkins et 
al., 2003). Erk-MAPKinase also stimulates transcription of large ribosomal RNAs 
by RNA pol I (Stefanovsky et a i, 2001). As ribosomes require an equimolar ratio 
of rRNAs, it seems likely that Erk-MAPKinase plays a role in co-ordinating 
production of ribosomes, which are necessary for growth and cell cycle 
progression (Stefanovsky et al., 2001).
In B cells, the Erk-MAPKinase pathway has been shown to promote proliferation 
by inducing the expression of cyclin 01 (Lavoie et al., 1996). The cyclins are 
pivotal in controlling successful passage of cells through the cell cycle (see 
below). Phosphorylation of certain Ribosomal 86 Kinase isoforms (p90RSK1-3) 
by Erk-MAPKinase has also been postulated to be important for the regulation of 
translation (Frodin and Gammeltoft, 1999). In contrast, activation of the 
JNK/SAPK and p38 MAPKinases induces growth arrest and apoptosis in a 
human immature B cell line following BCR-ligation (Graves etal., 1996).
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1.2.5 Role of co-receptors in B cell signalling
A key feature of the immune response is the maintenance of equilibrium between 
antigen reactivity and cellular quiescence, as strict regulation and control over a 
potentially inappropriate response is vital. Recent studies into inhibitory cell 
surface receptors have highlighted the requirement for the balance of activatory 
and inhibitory pathways to maintain this control. Indeed, loss of suitable inhibitory 
signalling is frequently associated with the development of inflammatory 
responses and, in some cases, autoimmunity.
This balance of control is exemplified by the fine-tuning of B cell responses to 
antigen, resulting in different biological responses. A number of factors can alter 
BCR-mediated signalling, including the concentration of the antigen, the avidity 
with which it is bound, the timing and duration of antigen encounter and co­
stimulation by other cells, receptors or antigenic sources (Healy and Good now,
1998), Similarly, the differential expression of signalling molecules at different B 
cell maturation stages or the use of alternative signalling pathways by the 
recruitment of different adaptor molecules leads to the generation of a full 
repertoire of responses.
Another mechanism that regulates the BCR signalling threshold for B cell 
responses is the involvement of co-receptors. B cell co-receptors and their 
modulation of the cellular response have been widely studied in recent years 
(Tsubata, 1999). Molecules such as CD19, CD22, CD72 and the Fey receptor, 
FcyRllb, appear to associate with the BCR either constitutively or inducibly, thus 
altering the signalling threshold of the BCR either by facilitating positive signalling 
or by downmodulating BCR function.
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1.2.5.1 CD19
CD19 is a B cell restricted surface glycoprotein, which forms a non-covalent 
complex with CD21 (complement receptor type 2, CR2), CD81 (TAPA-1) and 
Leu-13. Co-ligation of this complex with the BCR results in a reduction of the 
signalling threshold required for B cell activation, such that CD 19-deficient mice 
are hyporesponsive to stimulation via the BCR (Engel et al., 1995). CD19-BCR 
co-ligation results in an increase in the release of intracellular calcium, DNA 
synthesis, Erk-MAPKinase activation and antibody production (Tedder et a!., 
1997). CD19 is expressed throughout B cell development, until plasma cell 
differentiation, with an increase in expression shown by mature B cells. Alteration 
in the levels of CD19 expression has little effect on B cell development until 
maturity, where an overexpression of CD19 by immature B cells results in a 
significant reduction of conventional B cells in the periphery (Engel eta!., 1995). 
This reduction is presumably as a result of hyper-responsiveness of immature B 
cells to antigen receptor ligation, leading to enhanced negative selection in the 
bone marrow. In some cases, CD 19-overexpression can lead to hyper- 
gammaglobulinema and autoimmune disease, which is believed to be due to 
CD19-mediated lowering of the threshold for BCR-mediated signalling. Thus, 
overexpression of GDI 9 may permit autoreactive B cells to overcome their 
anergic state. Consistent with this, CD 19-deficient mature B cells have also been 
reported to have reduced responses to T-cell dependent antigens and 
subsequent lack of germinal centre formation and decreased affinity maturation 
of serum antibodies (Fujimoto et a i, 1999b). This suggests that CD 19-signalling 
is important for T-cell dependent B cell responses.
Following BCR-ligation, the PTK Lyn phosphorylates the cytoplasmic tail of 
CD19, creating SH2 binding sites facilitating the recruitment and activation of 
various downstream signal-transducing molecules (Fujimoto et a i, 1999a). Src- 
family PTKs, PLC-y, PI-3-kinase, the GEF Vav and the adaptor molecule, She, 
have all been implicated in direct binding to activated GDI9 (Tuveson et ai,
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1993; Weng et a i, 1994). Studies into these complex associations have led to 
the belief that GDI 9 may be responsible for many of the initial early signalling 
events following BCR co-ligation, as absence of CD 19 leads to a reduction in the 
tyrosine phosphorylation of multiple effector molecules downstream of the BCR 
following BCR activation (Fujimoto ef a/., 1999b). The association of adaptor 
molecules with GDI9 has also helped to explain the ability of GDI9 to promote 
events normally associated with positive BCR signalling. Thus, GDI9 can 
regulate BCR coupling to PLC-y and sustained calcium influx via amplification of 
the Src-family PTK signal. The phosphorylation of GDI9 by Lyn initiates 
additional rounds of PTK activation including the activation of Syk and Btk, 
leading to the recruitment of the BLNK/PLC-y/calcium pathway. This amplification 
of PTK activity may be a key role of GDI 9, implying that loss of this amplification 
could be the main reason for the hypo-responsiveness of BCRs in CD19^ mice. 
GDI 9 can also interact with other regulators of BCR signalling such as CD22, 
which is a B cell specific protein that appears to be both a negative and a positive 
regulator of B cell activation (Sato ef a/., 1996).
1.2.5.2 CD22
CD22 is a cell surface glycoprotein restricted to the B cell lineage, whose ligand 
is a glycosylated sialic acid residue expressed at high levels on lymphocytes and 
inflamed endothelial cells. CD22 expression levels are low during the early 
stages of B cell development, but increase as B cells approach maturity in the 
periphery (Craxton et al., 1999). In contrast to GDI9, CD22 activation results in 
the specific suppression of Erk-MAPKinase and the modulation of JNK activity, 
increasing the threshold for BCR activation. Thus, CD22-deficient mice show 
enhanced B cell responses, including augmented intracellular calcium 
mobilisation. Following BCR ligation, CD22 is tyrosine phosphorylated via the 
PTK Lyn, permitting recruitment of multiple SH2 domain containing effector 
molecules to its cytoplasmic ITIM, including the tyrosine phosphatase SHP-1. 
SHP-1 dephosphorylates a number of proteins, including Syk, BLNK, and SH2
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domain-containing leukocyte protein 76 (SLP-76) (Maeda et ai, 1999) (Binstadt 
et ai, 1998). SHP-1 is a strong candidate for mediating the negative effects of 
CD22, as there are increased levels of SHP-1 recruited by CD22 following BCR 
ligation. Indeed, recent data suggests that CD22 may function as a molecular 
"scaffold" that specifically coordinates the docking of multiple effector molecules, 
in addition to SHP-1, in a context necessary for BCR-dependent JNK stimulation. 
(Poe et a i, 2000).
A role for CD22 in the induction of autoimmunity has also been suggested since 
the gene for CD22 maps within a region associated with the development of 
autoimmune disease in certain strains of mice. The CD22 protein expressed in 
these autoimmune mice is markedly underphosphorylated and binds very little 
SHP-1 (Cornall et a i, 1998). However, the disease phenotype displayed is milder 
than that of SHP-1 deficient mice, confirming that SHP-1 may also regulate B cell 
signalling by associating with other inhibitory receptors. The transmembrane 
protein tyrosine phosphatase CD45 has also been implicated in the regulation of 
CD22, since CD45 deficient mice display increased tyrosine phosphorylation of 
CD22, prior to BCR ligation. Not only that, they also exhibit enhanced recruitment 
of SHP-1 following BCR ligation. Consistent with this, cross-linking of CD45 leads 
to a decrease in tyrosine phosphorylation of CD22 and subsequent SHP-1 
recruitment (Greer and Justement, 1999).
1.2.5.3 CD72
CD72, a type II membrane protein, is also thought to negatively regulate B cell 
activation via the recruitment of SHP-1 (Parnes and Pan, 2000). However, the 
interaction of SHP-1 with CD72 is thought to have a different function than that 
displayed by other SHP-1 dependent inhibitory receptors, which recruit SHP-1 to 
dephosphorylate key mediators of BCR signalling. The tyrosine phosphorylation 
of CD72 in response to BCR ligation correlates strongly with BCR-induced 
growth arrest and/or apoptosis in B cell lines and primary B cells. Thus, CD72
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acts to send a signal resulting in cell death by decreasing the activation threshold 
level of the BCR in immature B cells. However, if CD72 is pre-ligated its tyrosine 
phosphorylation levels are decreased and B cell tolerance levels are increased, 
preventing BCR mediated apoptosis. Thus, SHP-1 acts to keep CD72 
dephosphorylated, thus preventing BCR signalling from causing cell death.
1.3 CD40
CD40 and its ligand, CD40L (CD154), are known to play crucial roles in the 
regulation of the humoral immune response, including cell activation, 
proliferation, immunoglobulin isotype switching, formation of germinal centres 
and induction of memory B cells (Durie etal., 1994). In addition to having roles in 
mediating B cell biology during normal development, recent studies have also 
suggested an important role for CD40 in antitumour strategies against B 
lymphocyte malignancies (Costello etal., 1999). These studies have indicated 
that CD40 stimulation leads to the up-regulation of adhesion and/or costimulatory 
molecules on the cell surface of tumour cells, which aids the recognition of such 
cells by the immune system. In addition, CD40 stimulation of tumour cells has 
also been shown to induce the release of anti-tumour cytokines by the tumour 
itself. However, the effectiveness of CD40 as a viable therapy against some B 
lymphocyte malignancies is in doubt, due to the anti-apoptotic/proliferative 
signals delivered by CD40-ligation in some low-grade B lymphocyte 
malignancies. Therefore, current research into CD40-mediated tumour therapy is 
focused on avoiding pro-tumourigenic effects of CD40 stimulation whilst 
understanding the role of CD40 in tumour recognition and the stimulation of the 
immune system.
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1.3.1 CD40 structure and expression
The CD40 receptor is a 48-kDa transmembrane glycoprotein and is a member of 
the TNF receptor (TNFR) superfamily (van Kooten and Banchereau, 1997) 
(Figure 1.7). Structurally, human CD40 consists of a 193 amino-acid 
extracellular domain, a 22 amino-acid transmembrane domain and a 62 amino- 
acid cytoplasmic domain. The extracellular domain consists of four homologous, 
repeating, cysteine-rich extracellular domains characteristic of TNFR family 
motifs (Kehry, 1996). It has been shown that murine CD40 shares approximately 
60% homology to human CD40, with the greatest homology (78%) to the human 
form in the cytoplasmic domain (Gray, 1997). This cytoplasmic domain contains 
no sequence of known protein tyrosine kinase activity. Indeed, the cytoplasmic 
tail of human CD40 contains no tyrosine residues, whilst only one exists in the 
murine form. Nevertheless, the cytoplasmic domain of CD40 is constitutively 
phosphorylated, presumably on serine and/or threonine residues, in which Thr- 
234 has been shown to be crucial for signal transduction (Gray, 1997).
Although CD40 was originally thought to be a B cell specific receptor, it has since 
been shown to be expressed on a variety of human and mouse cells, including 
dendritic cells, monocytes, macrophages, mouse fibroblasts and human smooth 
muscle cells (Grewal and Flavell, 1998). Although CD40 has been reported to be 
expressed on virtually all B cells, the level of CD40 expression varies depending 
on the maturation stage of the cell. Murine CD40 is expressed at low levels on 
30-40% of pre-B cells, at intermediate levels on 80% of immature B cells and on 
essentially all mature B cells, suggesting that CD40 expression may be more 
important in later stages of B cell maturation (Hasbold et a!., 1994).
1.3.2 CD40 signal transduction
Like both the p65 and p70 isoforms of the TNF receptor, CD40 has no 
intracellular kinase domain and no consensus sequence for binding kinases (van
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Kooten and Banchereau, 1997). However, CD40 ligation is known to rapidly 
activate the protein tyrosine kinases Lyn and Syk (Paris et al., 1994), whilst also 
inducing the tyrosine phosphorylation of PI-3-kinase and PLC-y2 (van Kooten 
and Banchereau, 1997) and activating serine/threonine kinases (Durie etal.,
1994). However, like all signalling mechanisms, it is important to be careful when 
comparing data from different cell types. Consequently, studies highlight quite 
distinct differences in proximal CD40 signalling events in B cells depending on 
whether the cells used were resting, activated or EBV-transformed (Paris et al., 
1994; Gray et ai, 1994). In addition, some studies suggest that instead of 
phosphorylating and activating a number of protein tyrosine kinases, CD40 
engagement de-phosphorylates the Src family PTKs or syk (Craxton et a i,
1999).
As well as regulating protein tyrosine kinase activity, CD40 is known to associate 
with intracellular proteins termed TNF receptor-associated proteins (TRAFs). 
TRAF2, TRAFS and TRAP 5 are known to associate with specific regions in the 
cytoplasmic domain of CD40 (Kehry, 1996) (Figure 1.7). TRAFS, or CD40 
receptor-associated factor (CRAF1), is specific to CD40 signal transduction and 
does not bind to other membrane proteins such as p70 TNFRII (Gray, 1997).
One fascinating feature of the TRAFs is their ability to bind both membrane 
elements (such as CD40) and also DNA. This latter function is due to the five 
zinc ring finger motifs encoded in the N-terminal domain of TRAP 2 and 3. In 
addition, TRAP proteins share homology in a C-terminal TRAP binding domain. 
This allows the various TRAFs to form homo- or hetero-dimers following CD40 
ligation (Kehry, 1996). These complexes (much like the STAT family of proteins) 
may then translocate to the nucleus to function as transcriptional activators. 
Indeed, TRAF2 is predicated to play a crucial role in CD40-mediated activation of 
the transcription factor NF-kB.
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1.4 The role of FcyRllb in B ceils
Fc receptors (FcRs) provide a critical link between the humoral and cellular arms 
of the immune system by binding the Fc domain of antibodies. A separate FcR 
exists for each of the five classes of immunoglobulin; FcaR (IgA), FcôR (IgD), 
FceR (IgE), FcyR (IgG), and FcfxR (IgM) (Ravetch and Kinet, 1991). The major 
function of most Fc receptors is the activation of the accessory cell they are 
found on, for example ligation of the FceRI receptor on mast cells activates a 
biochemical cascade leading to the secretion of inflammatory mediators.
The FcyRs are specific for the Fc domain of IgG, and comprise a family of 
structurally homologous, yet distinct, receptors. Three classes of FcyR exist, 
FcyRI, FcyRII, and FcyRill (Ravetch and Kinet, 1991). These three classes are 
defined by their cellular distribution, structure and affinity for the IgG subclasses 
(Hulett and Hogarth, 1994). FcyRI is a high affinity receptor, which is capable of 
binding monomeric IgG at physiological concentrations (Allen and Seed, 1989).
In contrast, FcyRII and FcyRIII are low affinity receptors that can only bind IgG 
that is complexed to multivalent soluble antigen as immune complexes (Hulett 
and Hogarth, 1994). The only FcyR found on B cells is the FcyRllb receptor 
(CD32), where it functions to inhibit signalling through the BCR upon cross- 
linking of the two receptors by IgG containing immune complexes, courtesy of a 
13 amino acid inhibitory ITIM motif in its cytoplasmic domain (Muta et al, 1994).
1.4.1 Mechanisms of FcyRllb-mediated negative regulation
Negative regulation of BCR-mediated activation was first recognised when 
passively administered antigen-specific IgG antibodies were shown to inhibit in 
vivo primary responses to that antigen (Chan and Sinclair, 1971). A molecular 
basis for this inhibition was revealed following the cloning of the genes for murine 
low-affinity IgG receptors, FcyRllb and FcyRIII (Ravetch etal., 1986). Inhibition
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by IgG-containing immune complexes required the co-ligation of the BCR with 
the Fc receptor, FcyRllb (van de Winkel and Capel, 1993). Although the 
mechanisms underlying the negative regulation of BCR signalling are poorly 
understood, several of the well characterised cellular responses of BCR 
stimulation; phosphoinositide hydrolysis, influx of extracellular calcium, cellular 
proliferation and immunoglobulin secretion are all inhibited following co­
engagement of FcyRllb.
Early in vitro studies on FcyRllb indicated that recruitment of the tyrosine 
phosphatases, SHP-1 and SHP-2, mediated the inhibitory effect of this receptor 
in B cells (D'Ambrosio eta!., 1996). However, SHP-1 was shown to be 
dispensable for FcyRllb-mediated inhibition of B cell antigen receptor activation 
(Nadler etal., 1997), Thus, in vivo, FcyRllb may not recruit SHP-1 or SHP-2 as 
the primary effectors, but rather the inositol 5' phosphatase, SHIP (Liu et a!.,
1998; Ono et a!., 1997). Studies with dominant negative SHIP mutants and 
knockout models have confirmed the inhibitory role of SHIP in mediating the 
FcyRllb negative signal (Gupta etal., 1997; Huber ef a/., 1998; Liu etal., 1998). 
Recruitment of SHIP to the tyrosine-phosphorylated ITIM of FcyRllb, following co­
ligation with the BCR, leads to a drastic reduction in levels of phosphoinositide 
hydrolysis, influx of extracellular calcium, cellular proliferation and 
immunoglobulin secretion. FcyRllb abrogation of BCR activation by the hydrolysis 
of Ptdlns(3 ,4 ,5)P3 disrupts PH domain phosphoinositol lipid interactions and 
prevents the association of Btk and PLC-y with the plasma membrane (Bolland et 
al., 1998). The deletion of SHIP increases Ptdlns(3 ,4 ,5)P3 levels, resulting in 
increased Btk membrane association and hyper-responsive BCR signalling. The 
negative effects of SHIP on Btk recruitment can also be overcome by the 
expression of Btk as a membrane-associated chimera. Thus, one key role of 
SHIP-1 is to inhibit the pathways leading to calcium mobilisation by interrupting 
PLC-y recruitment to the membrane.
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Overall, the recruitment and activation of SHIP by FcyRllb results in the inhibition 
of multiple B cell signalling pathways and the modulation of both BCR-induced B 
cell activation and antigen internalisation (Figure 1.8). In addition, ligation of 
FcyRllb alone on B cells has been found to be capable of generating an apoptotic 
signal (Ashman etal., 1996; Ono et a i, 1997). Studies in the B cell line, DT40, 
demonstrated that this response was independent of SHIP recruitment, 
suggesting that FcyRllb may directly couple to an apoptotic pathway in the 
absence of BCR-ligation. Additional work by Pearse and colleagues has shown 
that failure to recruit SHIP, either by deletion of SHIP or mutation of FcyRllb, 
resulted in enhanced FcyRI lb-triggered apoptosis (Pearse et a i, 1999). Further 
studies demonstrated that this SHIP-independent pathway lead to the Btk- 
dependent activation of JNK. Overall, these studies suggest that aggregation of 
FcyRllb in B cells results in a stress response that leads to apoptosis and that 
SHIP recruitment following co-ligation with the BCR ‘rescues' the cells from 
apoptosis. Interestingly, SHIP-1 may mediate this effect by recruiting the p85 
subunit of PI-3-kinase upon BCR-ligation and could act to regulate downstream 
events such as B cell activation-induced apoptosis (Gupta et a i, 1999).
1.5 Cell cycle and apoptosis
Signalling via the BCR plays a pivotal role in the activation of B cells, leading to 
various distinct cellular responses, including proliferation, differentiation, anergy 
and cell death. Despite numerous investigations, it is still not entirely clear how 
the biochemical signalling events can be translated into these responses. What is 
clear is that any cellular response is regulated by a number of enforced 
checkpoints. Checkpoints serve a critical role in the control of cell cycle 
progression and the damage response system, as they provide the cell with an 
opportunity to assess the situation and initiate an appropriate response.
Therefore a cellular response is the integration of biochemical signals that 
promote or inhibit the progression of the cell cycle.
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The cell cycle is the co-ordinated series of events required for cell growth and 
division. This complex process relies on the assembly of nuclear proteins that 
integrate signals and programme cell cycle progression (Figure 1.9) (O'Connor 
et a/., 2000). There are four main stages of the cycle, during which a cell must 
duplicate its contents and divide. Gi is characterised by gene expression and 
protein synthesis, resulting in an increase in cell size and production of all the 
proteins required for DNA synthesis. This is the main phase of the cell cycle that 
is regulated primarily by extracellular signals, as after a cell exits Gi it is generally 
committed to completing a full cycle. DNA duplication occurs in the S phase 
(synthesis). After chromosome replication a second growth period, Gz, allows the 
cell to monitor DNA integrity and cell growth prior to M phase (mitosis) when the 
cell finally divides. The resulting daughter cells either immediately enter Gi and 
may go through the full cycle again, or alternatively stop cycling temporarily and 
enter the Go phase (quiescence) (Planas-Silva and Weinberg, 1997). A number 
of checkpoints operate at various stages of the cell cycle to ensure events are 
completed properly and in the correct order.
Progression through the cell cycle is mainly driven by two essential cellular 
components, cyclin dependent kinases (CDKs) and their cyclin partners. Cyclins 
were first identified in sea urchin eggs as proteins whose levels oscillated with 
the cell cycle (Evans et al., 1983). It is now known that each cell contains many 
different cyclins, each expressed at different stages of the cell cycle. The kinases 
include CDK4 and CDK6, which associate with the D-type cyclins, and CDK2, 
which associates with cyclin E (Pavletich, 1999). At the Gi checkpoint cells have 
to decide whether or not to commit to DNA synthesis. Here, provided they 
receive the correct signals, D-type cyclins bind to CDKs 4 or 6 and the resulting 
complex promotes Gi/S transition by initiating the sequential phosphorylation of 
the retinoblastoma protein, pRb^^ ,^ with the cyclin E-GDK2 complex completing 
the phosphorylation, thus releasing the braking effect of Rb (Harbour et al.,
1999). Hypophosphorylated Rb actively blocks cycling by sequestering the
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transcription factor, E2F, thus blocking expression of necessary S-phase genes 
(Dyson, 1998). Once phosphorylated by the cyclin-CDK complexes, E2 F is 
released and S phase genes are transcribed (Figure 1.9).
In response to cellular stress or damage, various external signals and inhibitory 
proteins can halt the progression of the cycle at the Gi/S boundary and promote 
growth-arrest and/or apoptosis (see below). Extracellular regulators include the 
transforming growth factor-p (TGF-p) and interferon-a (IFN-a) (Sangfelt et al.,
2000). These pleiotropic factors act in part to suppress Rb phosphorylation, 
through the inhibition of CDKs and the recruitment of CDK inhibitors (Figure 
1.10) (Sherr and Roberts, 1999). The 1NK4 (p i5, p i6, p i8 and p i9) and the 
WAF1 (p21, p27 and p57) families of CDK inhibitors act to block CDK activity at 
various stages of the cell cycle, p i 6, p i and p27^'^ ^have all been 
demonstrated to inhibit the Cyclin D-CDK 4/6 complex in vitro, whilst p19^ "^^  and 
p2 iwafi thought to induce cell cycle arrest through interactions with the 
tumour suppressor gene, p53. However, the picture is not as simple as this, as 
some CKIs have been shown to be required for cycling by acting as cyclin-CDK 
assembly factors. Although p27 '^^  ^ can inhibit recombinant cyclin D-CDK 
complexes in vitro, it is a far more effective inhibitor of cyclin E-CDK complexes 
(Toyoshima and Hunter, 1994). Indeed, p27*^ “’  ^ immunoprecipitates contain a 
kinase activity with a strong preference for Rb, but not histone HI, a key indicator 
of cyclin D-CDK activity (Soos et al., 1996). Assembly of cyclin D-CDK 
complexes is impaired in mouse embryo fibroblasts from mice deficient in 
p21^^^ \^ or both (Cheng etal., 1999a).
Activation of the tumour suppressor gene, p53, in response to DNA damage from 
both endogenous and exogenous sources, results in cell cycle arrest in the Gi 
phase. This is presumably to allow an opportunity for DNA repair to occur before 
replication or mitosis (Hartwell and Kastan, 1994). However, in some cell types, 
including Immature B cells, p53 activation results in apoptosis. Anti-lg treatment 
of WEH1-231 cells increases the levels of p53 protein, as well as (Wu
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et a!., 1998). The Increase in protein levels of a downstream
transcriptional target of p63, was delayed relative to p53 induction, consistent 
with the notion that functionally active p53 induces expression. This
study also showed that ectopic expression of p53 in WEHI-231 cells leads to an 
induction of apoptosis, in the absence of any further stimulation.
The final outcome of p53 activation appears to depend on the action of a variety 
of downstream effector genes transactivated by p53. The protective role of p53 is 
highlighted by the fact that around 50% of all cancers possess an inactive form of 
p53, or have lost p53 all together. Indeed, the inactivation of various cell cycle 
proteins including Rb^° ,^ pie'^ *^"^  ^and p i5 has been implicated in the progression 
of human cancers, the overall effect of their loss being deregulation of the cell 
cycle and subsequent excessive proliferation of the cell.
The growth and proliferation of cells is tightly regulated to prevent the production 
of excessive cell numbers. Programmed cell death, or apoptosis, provides a 
mechanism for the disposal of “unwanted” cells in a co-ordinated manner 
(Hengartner, 2000). This mechanism also protects the organism by enabling the 
destruction of damaged or potentially harmful cells. The classical morphological 
features of apoptosis include the condensation of chromatin, protein and DNA 
fragmentation and the formation of apoptotic bodies. Thus, biologically activated 
apoptosis is quite distinct from necrosis, where cellular death arises due to 
chemical or physical injury. Most of the observed changes associated with 
apoptosis (i.e. DNA/protein cleavage, nuclear shrinking, loss of cell shape) are 
implemented by a set of cysteine proteases, caspases, which were at first 
thought to be specifically activated in apoptotic cells (Thornberry and Lazebnik, 
1998).
The caspases are a family of proteases that possess an active-site cysteine and 
cleave substrates after aspartic residues. The four residues amino-terminal to the 
cleavage site determines the distinct substrate specificity of different caspases
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(Thomberry et al., 1997). Proteolytic cleavage by caspases can lead to diverse 
results depending on the nature of the substrate and the exact cleavage site 
position. Thus, caspases are able to mediate both activation and inactivation of 
downstream target proteins. Most caspases are activated by proteolytic cleavage 
of an inactive pro-caspase form. Each pro-caspase contains in its prodomain a 
protein-protein interaction module, which allows it to bind and associate with 
upstream regulators. Initiator caspases-8 and -10 contain a death-effector 
domain (DED), permitting interaction with CD95 and the adaptor molecule FADD, 
whilst the effector caspases-2 and -9 contain a caspase activation and 
recruitment domain (CARD). Activation can occur simply by exposure to another 
previously activated caspase, resulting in a ‘caspase cascade’ of activation.
Many of the functions of the caspase cascade appear to converge on 
mitochondria, where the induction of apoptosis has been shown to result in a 
rapid loss of mitochondrial membrane potential and organelle swelling. However, 
the fate of a cell is often decided through the activity of the Bcl-2 family of 
apoptosis regulator proteins (Figure 1.11) (Jacobson, 1997). Homo- or 
heterodimers of pro- and anti-apoptotic Bcl-2 members act at the surface of the 
mitochondria and compete to regulate cytochrome c release, which, in 
association with the adaptor Apaf-1, has been implicated in the activation of 
caspase-9 in the cytosol. This complex results in the activation of caspase-3, 
another effector caspase, and can be antagonised by the expression of 
inhibitors-of-apoptosis proteins (lAPs). However, the Smac/DIABLO protein, also 
released from the mitochondria, negatively regulates lAP family members 
ensuring that they do not inhibit caspase activation once a cell is committed to 
apoptosis.
Cleavage of the pro-apoptotic Bcl-2 family member, Bid, by caspase-8 releases 
an active, truncated form (tBid) which translocates to the mitochondria and 
promotes the release of cytochrome c (Porter, 1999) (Figure 1.12). In addition, 
interaction of the pro-apoptotic regulator Bad with anti-apoptotic regulators Bcl-2
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or BcI-Xl at the mitochondrial surface promotes apoptosis. In contrast, 
phosphorylation of Bad by the survival protein Akt promotes the association of 
Bad with the phospho-serine binding protein, 14-3-3 and its removal from the 
mitochondria. The blocking of the interaction of Bad with other Bcl-2 family 
members thus promotes cell survival (Franke and Cantley, 1997).
The role of caspases and other, non-caspase, execution effector proteases has 
had to be reassessed recently with the observation that, in dense human tonsillar 
B cells, activation of caspase-8 and caspase-6 are required for proliferation in 
response to a number of stimuli, including anti-CD40. Indeed, inhibition of 
caspase-6 with specific inhibitors blocks the transcription of cyclin D and CDK4.
In contrast, the activation of caspase-3 is reduced upon stimulation of the cells 
with proliferative stimuli. These data strongly suggest that a distinct pattern of 
caspase activation, different from that involved in apoptosis, is induced by 
proliferative stimuli, with caspase-8 and caspase-6 playing positive roles in 
proliferation, while caspase-3 plays a negative role in proliferation (Olson et ai, 
2003).
Support for a negative role of caspase-3 in B cell proliferation comes from 
studies in caspase-3-deficient mice (Woo et al., 2003). B cells deficient in 
caspase-3 hyperproliferate, resulting in splenomegaly, though they display no 
defect in apoptosis. Hyperproliferation of caspase-3-deficient B cells depends 
upon the CDK inhibitor . This at first appears paradoxical, as it would
be assumed that an increase in the expression of a CDK inhibitor would lead to 
cell cycle inhibition. However, there is a concomitant increase in the levels of 
PCNA, which associates with p21 to promote mitosis. Interestingly, caspase-3 
cleaves p21 at its C-terminal PCNA binding site, abolishing the interaction 
between p21 and PCNA (Gervais et al., 1998). Thus, it is clear that apoptosis 
and proliferation are intimately coupled.
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1.6 The role of lipid rafts in immune cells
Immune receptors and components of their signalling cascades are spatially 
organised, and this spatial organisation plays a key role in the initiation and 
regulation of signalling. This spatial organisation is due to cholesterol- and 
sphingolipid-rich plasma membrane microdomains, or lipid rafts. Lipid rafts have 
been implicated in signal transduction, membrane trafficking and internalisation 
and other functions initiated at the plasma membrane through their ability to 
concentrate or exclude proteins and lipid mediators. Signalling molecules found 
in lipid rafts include dually acylated src family tyrosine kinases, heterotrimeric G 
protein subunits, adaptor proteins, PIP2 and lipid kinases and phosphatases.
Lipid rafts are estimated to represent a significant portion of immune cell 
membranes, greater than 40% by measurements of fluorescence anisotropy of 
the lipid order in plasma membranes and lipid rafts. In resting cells rafts appear 
to be highly dynamic, submicroscopic structures (50 nm in diameter) containing 
only thousands of lipids and a small number of proteins. Upon cross-linking of 
receptors associated with rafts, lipid rafts become larger, microscopic (100s of 
nm to jxm in diameter), and more stable structures, often attached to the actin 
cytoskeleton.
In resting B cells the BCR is excluded from lipid rafts. Following cross-linking 
either by Ig-specific antibodies or antigen, the BCR associates with lipid rafts, 
and a number of components of the BCR signalling pathways are recruited to 
rafts (Cheng et a/., 1999b). The association of the BCR with lipid rafts is 
dependent on membrane cholesterol, but it does not require a signalling 
competent receptor or active Src kinases and is not dependent on the actin 
cytoskeleton. Disruption of rafts by cholesterol sequestration blocks BCR 
redistribution but enhances BCR-mediated calcium mobilisation, which suggests 
that rafts play a role in both enhancing and suppressing B cell responses (Petrie 
et al., 2000). Indeed, the inositol phosphatase SHIP that inhibits BCR signalling
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has been shown to be transiently recruited to lipid rafts following BCR cross- 
linking (Petrie etal., 2000). The association of the BCR with rafts is transient; by 
15 to 30 minutes after cross-linking, the BCR is no longer isolated in rafts. The 
association of the BCR with rafts is even less stable and more transient when the 
BCR is unable to initiate signalling or to attach to the actin cytoskeleton, 
suggesting that signalling and clustering are necessary to stabilise the BCR in 
rafts (Cheng et a i, 2001). The maintenance of lipid rafts in B cells also requires a 
recently identified protein, Raftlin, the absence of which reduces the quantity of 
lipid rafts, resulting in an impairment of growth and signalling in Raftlin-deficient B 
cells (Saeki et a i, 2003).
In immature B cells, which respond to antigen by undergoing growth arrest 
and/or apoptosis, the BCR appears to be excluded from lipid rafts upon antigen 
ligation (Sprou! et a i, 2000) (Chung et a i, 2001). This is similar to anergic B 
cells, which also do not undergo proliferation in response to antigen, as the BCR 
fails to efficiently associate with lipid rafts upon antigen stimulation (Weintraub et 
ai, 2000). This strongly suggests that the failure of the BCR to associate with 
lipid rafts may contribute to the different biological outcomes of BCR ligation in 
immature and anergic B cells, compared to mature B cells.
The association of the BCR with rafts is one consequence of BCR ligation that 
can be regulated by both positive and negative co-receptors. The association of 
the BCR with lipid rafts is more stable and less transient when the CD19/CD21 
co-receptor complex is co-ligated to the BCR via the binding of C3d-tagged 
antigens (Cherukuri et a i, 2001). In contrast, when co-ligated in mature B cells 
both the BCR and FcyRllbl associate with lipid rafts, where FcyRllbl recruits the 
inositol phosphatase SHIP and blocks BCR signalling (Aman et a i, 2001). This 
results in a more transient association of the BCR with rafts.
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1.7 Aims and objectives of this study
The signalling events proximal to the BCR initiated in response to BCR ligation 
are becoming well established, with three key signalling pathways now known to 
be the major targets. The biological outcomes of BCR ligation at various stages 
of maturation have also been well established, with immature cells undergoing 
growth arrest or apoptosis, while mature B cells undergo proliferation and 
differentiation. The links between these proximal signalling events and the 
resulting biological response are less well known.
One of the key signalling pathways activated by the BCR is the Erk-MAPKinase 
pathway. This pathway is controlled by the small GTPase Ras, a key regulator of 
cell growth in all eukaryotic cells. This study aims to investigate the role of the 
Ras signalling pathway in the response of immature-transitional B cells to BCR 
ligation and CD40-mediated rescue of BCR-induced growth arrest and apoptosis. 
To achieve this, three constitutively active Ras mutants, along with a portion of 
p62^®‘^ , a negative regulator of Ras, and mutants of SHIP, a negative regulator of 
PI-3-Kinase, will be introduced into the WEH 1-231 cell line, and their effects on 
BCR-induced growth arrest and apoptosis investigated.
Another key signalling pathway initiated by the BCR is the PLCy pathway, which 
results in the production of the second messengers IP3 and DAG. Key 
downstream effectors of PLCy are the PKC family of kinases, two sub-groups of 
which are activated by DAG. A further aim of this study was to utilise mutants of 
PKC family members to elucidate the roles of individual PKC family members in 
immature B cell signalling.
Mature B cells respond to BCR ligation in a very different manner, by undergoing 
proliferation and differentiation as opposed to growth arrest and apoptosis. It was 
therefore planned to investigate the initiation and maintenance of proliferation in
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primary splenic B cells in response to a variety of signals, including mitogenic 
stimuli and T cell derived ‘help’ signals. The key pathways activated by these 
stimuli will also be examined, both by using specific inhibitors and by recruiting a 
physiologically relevant negative regulator of BCR signalling, FcyRllb. Finally, the 
elements important for BCR-mediated regulation of the cell cycle machinery and 
the recruitment of nuclear transcription components required for proliferation 
shall also be investigated.
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Figure 1.1 Summary of the development of conventional B cells
The stages of B ceil development are marked by a series of changes in location 
and in the expression of immunoglobulin heavy and light genes, intracellular 
proteins, and surface markers. B cell development starts in the bone marrow (or 
foetal liver) with the commitment of haematopoietic stem cells (HSCs) to the B 
cell lineage. Rearrangement of the heavy chain locus genes begins in the early 
pro-B stage. Cells are allowed to progress to the next stage if a productive 
rearrangement has been achieved. Although no functional immunoglobulin is 
expressed in late pro-B cells, expression of accessory Ig-a/lg-p heterodimers on 
the surface in association with calnexin has been demonstrated (Gong and 
Nussenzweig, 1996; Nagata etal., 1997). The antigen-independent stage 
continues within the bone marrow, where pre-B cells express a pre-BCR 
consisting of cytoplasmic ja chain in combination with a surrogate light chain,
VpreB and X5. Successful light-chain gene rearrangements result in the surface 
expression of a complete IgM molecule. The immature B cells then enter the 
antigen-dependent stage of B cell development where recognition of self-antigen 
can lead to clonal deletion, receptor editing or clonal inactivation (anergy). Once 
in the periphery, the mature B cells migrate to the lymphoid follicles and following 
further selection stages, enter the mature B cell pool until they encounter antigen. 
Upon interacting with their specific antigen in conjunction with co-stimulatory 
signals from Th cells, the B cell is activated. Depending on the nature of the 
signals, the mature B cell gives rise to antibody generating plasma cells or long- 
lived memory cells which contribute to lasting protective immunity
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Figure 1.2 The structure of the B cell receptor (BCR) throughout B cell 
development
The progression of B cells from the pro-B cell stage to the mature B cell is 
accompanied by changes in the surface expression of the BCR accessory 
molecules, Ig-o/lg-p, and associated molecules such as the chaperone molecule, 
calnexin, and the immunoglobulin heavy chain, ^m. Progression through the 
developmental stages is driven by incremental signalling through these Ig-ot/lg-p- 
containing receptors, therefore the expression of these molecules as part of 
receptor complexes is required for normal B cell development. Successful B cell 
development is dictated by (1) expression of Ig-a/lg-p in association with calnexin 
at the late pro-B cell stage. (2) Intact [x heavy chains expressed in an 
immunoglobulin-like “pre-BCR” complex with surrogate light chains, X5 and 
VpreB at the pre-B cell stage. (3) A mature BCR consisting of \i heavy chain, 
conventional light chains and accessory Ig-o/lg-p molecules from the immature B 
cell stage onwards.
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Figure 1.3 B cell activation and selection in germinal centres
Following T cell dependent activation (1) B cells migrate from the follicular mantle 
into the primary lymphoid follicles and form germinal centres. Here, B cells 
undergo proliferation (2) and differentiate into centroblasts (3) where they form 
the dark zone of the germinal centre. The rapidly dividing centroblasts undergo 
somatic hypermutation of their immunoglobulin variable-domain genes before 
differentiating into centrocytes (4). Within the light zone of the germinal centre, 
the small, non-dividing centrocytes are programmed to die unless they interact 
with follicular dendritic cells (FDC) that display complexed antigen on their cell 
surface. Positive selection of centrocytes Is dependent on the affinity of their 
mutated antigen receptors. Centrocytes with low affinity or autoreactive antigen 
receptors undergo spontaneous apoptosis. The positively selected centrocytes 
move to the outer edge of the light zone and interact with CD40 ligand 
expressing T cells (6). Here the centrocytes may undergo CD40-mediated 
isotype switching, become protected from Pas-induced apoptosis and finally 
differentiate into either memory B cells (6) or plasma cells (7).
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Figure 1.4 The mature B cell receptor
The mature B cell receptor for antigen (BCR) is functionally divided into the 
immunoglobulin molecule (sig), which is responsible for ligand binding, and the 
Ig-a (CD79a) and Ig-p (CD79b) accessory molecule heterodimers, which are 
responsible for signal transduction. Conserved immunoreceptor tyrosine-based 
activation motifs (ITAMs), present in the cytoplasmic domains of the accessory 
molecules, are essential for the signal transducing capacity of the receptor. The 
ITAMs aid the recruitment and activation of three distinct types of non-receptor 
protein tyrosine kinases (PTKs).
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Figure 1.5 Signai transduction pathways initiated by ligation of the BCR
A schematic representation of the parallel cascades initiated following ligation of 
the B cell receptor (BCR) on mature B cells. The tyrosine phosphorylation of 
conserved ITAMs, present in the cytoplasmic domains of the sIg accessory 
molecules Ig-a and Ig-p, results in the recruitment of sig associated PTKs. These 
include the Src-PTK family (Bik, Fyn, Lck, and Lyn), Syk, and Btk. Following 
activation of these kinases three parallel, but potentially cross-regulatory, 
pathways are recruited to the activated BCR complex. The phospholipase C-y 
(PLC-y) pathway results in the hydrolysis of phosphatidyl inositol 4,5 
bisphosphate (Ptdlns(4,5)P2), to produce diacylglycerol (DAG) and inositol 1,4,5- 
triphosphate (insPa). The phosphatidylinositol 3-kinase (PI-3-Kinase) pathway 
generates phosphatidylinositol 3,4,5 triphosphate (Ptdlns(3,4,5)Pa) whilst the 
classical Ras/MAPKinase cascade leads to the activation of Erk-MAPKinase. 
These pathways converge on the nucleus to initiate a cellular response.
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Figure 1.6 Mitogen-activated protein kinase (MAPKinase) signalling 
pathways
The mitogen-activated protein (MAP) kinases are a family of serine-threonine 
protein kinases that have been widely conserved throughout evolution. They are 
activated by a wide range of extracellular stimuli and are able to mediate a wide 
range of cellular functions ranging from proliferation and activation to growth 
arrest and cell death. The MAPKinase family is subdivided into three groups; the 
classical extracellular signal-regulated kinases (Erk-MAPKinase), the c-Jun N- 
terminai kinases, also known as the stress activated protein kinases (JNK/SAPK) 
and the p38 MAP Kinases. Activation of each group is determined by distinct 
upstream MAPKinase kinases (MEKs) and MAPKinase kinase kinases (MEKK). 
MAPKs are activated by dual phosphorylation on tyrosine and threonine 
residues, located in a T-X-Y motif, where X is different in each group. Following 
MAPKinase activation, activation of a number of downstream transcription factors 
occurs; Erk-MAPKinase activates Elk-1 and c-myc, JNK activates c-Jun and 
ATF-2 and p38 MAPKinase activates ATF-2 and MAX. The phosphorylation and 
activation of these transcriptional regulators enables the MAPKinase families to 
regulate gene expression and hence, cellular responses.
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Figure 1.7 Structure of CD40
The CD40 receptor is a 48-kDa transmembrane glycoprotein and is a member of 
the TNF receptor (TNFR) superfamily. Structurally, human CD40 consists of a 
193 amino-acid extracellular domain, a 22 amino-acid transmembrane domain 
and a 62 amino-acid cytoplasmic domain. The extracellular domain consists of 
four homologous, repeating, cysteine-rich extracellular domains characteristic of 
TNFR family motifs. CD40 is known to associate with intracellular proteins 
termed TNF receptor-associated proteins (TRAFs). TRAF2, TRAF3 and TRAF 5 
are known to associate with a specific region in the cytoplasmic domain of CD40.
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Figure 1.8 Molecular basis for the inhibitory activity of FcyRllb
PcyRIIb (CD32) Is a single chain, low affinity receptor for the Fc domain of IgG 
molecules, and as such can only interact with IgG In the form of immune 
complexes. It is the only Fey receptor found on B cells, and contains a 13 amino 
acid inhibitory ITIM motif in Its cytoplasmic domain that is responsible for its 
inhibitory effects on BCR signalling. Co-ligation of the BCR and FcyRllb by 
cognate antigen-anti body complexes leads to tyrosine phosphorylation of the 
ITIM by the Src-family kinase Lyn, and subsequent recruitment of the protein 
phosphatases SHP-1, SHP-2 and the inositol phosphatase SHIP. The overall 
outcome of the recruitment of these molecules is the abrogation of the 3 key 
signalling pathways activated upon BCR ligation.
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Figure 1.9 The cell cycle
The cell cycle is the co-ordinated series of events required for cell growth and 
division. There are four main stages of the cycle, during which a cell must 
duplicate its contents and divide. Gi is characterised by gene expression and 
protein synthesis, resulting in an Increase in cell size and production of all the 
proteins required for DNA synthesis. DNA duplication occurs in the S phase 
(synthesis). After chromosome replication a second growth period, G2, allows the 
cell to monitor DNA integrity and cell growth prior to M phase (mitosis) when the 
cell finally divides. The resulting daughter cells either immediately enter Gi and 
may go through the full cycle again, or alternatively stop cycling temporarily and 
enter the Go phase (quiescence). Cyclins and their activation of cyclin-dependent 
kinases (CDKs) are essential for the regulation of the cell cycle. At the Gi 
checkpoint cells have to decide whether to commit to DNA synthesis. Here, D- 
type cyclins bind to CDKs 4 or 6 and the resulting complex promotes Gi/S 
transition by initiating phosphorylation of the retinoblastoma protein, pRb^ ^®, 
before cyclin E and CDK2 catalyse further phosphorylation events, thus releasing 
the braking effect Rb applies. Hypophosphorylated Rb actively blocks cycling by 
sequestering the transcription factor, E2F, thus blocking expression of necessary 
S-phase genes. Once phosphorylated by the cyclin-CDK complexes, E2-F is 
released and S phase genes are transcribed.
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Figure 1.10 The role of cyclin-dependent kinase inhibitors
During Gi phase of the ceil cycle, D-type cyclins bind to CDKs 4 or 6 and the 
resulting complex phosphorylates key residues of the retinoblastoma protein, 
pRb °^®, allowing CDK2-cyclin E complexes to phosphorylate further key residues. 
Once Rb is phosphorylated by the cyclin-CDK complexes, E2-F is released and 
S phase genes are transcribed. The activity of the cyclin-CDK complexes can be 
inhibited by CDK inhibitory proteins of the INK4 (p15, p i 6, p i 8 and p19) and the 
WAF1 (p21, p27 and p57) families, blocking entry into S phase. These CDK 
inhibitors (CKIs) can be induced by a number of factors, one of which is the 
tumour suppressor protein, p53. Activation of p53, in response to DNA damage 
from both endogenous and exogenous sources, results in cell cycle arrest in the 
Gi phase as a consequence of the induction of the CKIs p21 and p27.
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Figure 1.11 The Bcl-2 family of apoptosis regulators
The Bcl-2 family of apoptotic regulators is comprised of over a dozen proteins, 
which have been classified into three functional groups. Bcl-2 family members 
are recognised due to the presence of one or more conserved Bcl-2 homology 
(BH) domains. Group I members all possess anti-apoptotic activity, thus protect 
cells from death, and contain one each of the four BH domains, as well as a 
transmembrane domain allowing their insertion into the mitochondrial membrane. 
Members of group II and ill promote cell death, hence are known as pro- 
apoptotic. Pro-apoptotic Bcl-2 family members have fewer BH domains, indeed 
some contain only a single BH3 domain. Many family members can 
homodimerise, but more importantly, pro- and anti-apoptotic members can form 
heterodimers to antagonise each other’s activity. For example, pro-apoptotic Bax 
can heterodimerise with the anti-apoptotic protein, Bcl-2. This interaction blocks 
the anti-apoptotic capabilities of the Bcl-2 protein and induces a pro-apoptotic 
response.
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Figure 1.12 The role of the mitochondria during apoptosis
Many cell death-inducing signals appear to converge on the mitochondria, which 
plays a pivotal role in the decision of a cell’s fate. The Bcl-2 family proteins form 
homo- or heterodimers and integrate competing pro- and anti-apoptotic signals at 
the surface of the mitochondria and other sites within the cell. The pro-apoptotic 
members of the Bcl-2 family have been proposed to act by inactivating dimers of 
anti-apoptotic Bcl-2 family members, which act to preserve mitochondrial 
integrity. For example, following apoptotic signals, the pro-apoptotic regulator 
Bax, is believed to heterodimerise with the anti-apoptotic regulator Bcl-2. This 
interaction blocks the anti-apoptotic capabilities of the Bcl-2-like proteins. 
Similarly, the pro-apoptotic regulator Bad is believed to interact with Bcl-2 or Bcl- 
X l , thus promoting apoptosis. Phosphorylation of Bad by the survival factor Akt 
promotes the association of Bad with the phospho-serine binding protein, 14-3-3 
and its removal from the mitochondria. The blocking of the interaction of Bad with 
its other family members thus promotes cell survival. Pro-apoptotic signals also 
result in the cleavage of Bid by caspase-8 , which releases an active, truncated 
form (tBid). tBid then translocates to the mitochondria, where it is involved in 
promoting the release of cytochrome c. The released cytochrome c associates 
with the adaptor Apaf-1 and together they activate caspase-9 in the cytosol. The 
death and mitochondrial pathways converge at the level of caspase-3 activation. 
Caspase 3 activation and activity is antagonised by the expression of inhibitors- 
of-apoptosis (lAPs), which in turn are inhibited by Smac/DIABLO proteins, also 
released from the mitochondria.
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Chapter 2 - Materials and Methods
2.1 Cell culture reagents and antibodies
All cell culture reagents were purchased from Invitrogen Life Technologies. All 
other reagents were obtained from Sigma-Aldrich, unless otherwise indicated, 
and were of the highest grade available. See Tables 2.1 and 2.2.
2.2 Animals
Male Balb/c mice, at least 7 weeks of age, were used unless otherwise stated. 
These mice were maintained at the Central Research Facility (CRF), University 
of Glasgow. Mice, arriving from Harlan UK Ltd, were quarantined for 7 days prior 
to commencing any experiment.
2.3 Purification of murine splenic B cells
Primary B cells were prepared from murine spleens using the CD43-magnetic 
bead negative-selection method of Miltenyi Biotec (Deehan et al., 2002). All 
procedures were performed at 4°G. A single cell suspension was prepared by 
mashing the spleens through a wire mesh (Sigma-Aldrich), in RPMI-1640 media. 
The resultant suspension was centrifuged (400 x g, 7 min, 4*C) and the pellet 
resuspended in 9 ml of red blood cell removal buffer (0.168 M NH4CI, pH 7.2). 
The suspension was carefully layered over 1 ml heat-inactivated foetal calf 
serum (FCS) and incubated on ice for 7 min to permit red blood cell lysis and 
lipid precipitation. The supernatant was removed, carefully layered over 1 ml 
FCS in a fresh tube and centrifuged again (400 x g, 7 min, 4“C).
54
The cell pellet was resuspended in 9 ml dead cell removal buffer (HEPES- 
buffered, mouse tonicity, balanced salt solution (BSS) supplemented with 0.12 M 
Sorbitol, 20 mM Glucose) (Shortman et a i, 1972; von Boehmer and Shortman, 
1973). The suspension was immediately filtered through two prepared dead cell 
removal columns (absorbent cotton wool plugged, short-form, glass pipettes, 
wetted with 1 ml RPMI/5% FCS). Cells were recovered from the column into a 15 
ml tube on ice containing 1 ml RPMI/5% FCS. The cells were centrifuged (400 x 
g, 7 min, 4 X ) and resuspended in 50 ml ice-cold MACS buffer (phosphate 
buffered saline (PBS), 0.5% BSA, 2 mM EDTA) counted by Trypan blue 
exclusion, and pelleted by centrifugation (400 xg, 7 min, 4"'C).
The cells were resuspended in ice-cold MACS buffer (2x10® cells/ml) and 
passed through gauze, to produce a single cell suspension for labelling. Cells 
were incubated for 25 min at 4°C with anti-CD43 (Ly-48) beads (100 \i\ CD43+ 
beads/2 x 10® cells). Labelled cells were passed through gauze again and 
applied to a CS-type negative selection magnetic column (Miltenyi Biotec) in a 
strong magnetic field. Purified mature B cells (CD43-) were eluted from the 
column by washing with 50 ml ice-cold MACS buffer. The cells were centrifuged 
(400 xg, 7 min, 4°C), resuspended in RPMI-1640 medium supplemented with 
5% FCS, 100 U/ml penicillin, 100 streptomycin, and 2 mM glutamine, 
counted and assessed for purity by FACS analysis. Typically, around 40 % of the 
mononuclear cells were B cells, with a purity >98 % B220 positivity after negative 
selection (as assessed by flow cytometry -  Figure 2.1 C and D).
2.4 Purification of anti-CD40 antibody from the FGK45 
hybridoma and anti-IgM antibody from the B7.6 hybridoma
Anti-CD40 antibody (rat anti-mouse) was purified from the FGK45 hybridoma, 
and anti-IgM antibody (rat anti-mouse) was purified from the B7.6 hybridoma, as 
described previously (Gilbert et a i, 1998). FGK45 and B7.6 hybridoma cells were
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maintained in RPMI-1640 medium containing 5 % foetal calf serum, L-glutamine 
(2 mM), penicillin (100 U/ml) and streptomycin (100 jig/ml), and 2- 
mercaptoethanol (50 p,M) (RPMI complete) at 37°C in 5 % COg. Culture 
supernatants were collected for purification of the appropriate antibody, and filter 
sterilised immediately prior to use. A protein G sepharose column was washed 
twice with binding buffer (0.2 M NaH2P04 , 0.2 M Na2HP04 , pH 7 at 25®C) and 
the appropriate antibody supernatant solution passed through the column 
overnight at 4®C to allow the immunoglobulin to bind to the column. The column 
was then washed twice with binding buffer, before eluting the bound antibody 
with elution buffer (0.1 M glycine, pH2.7). Eluted antibody was collected in 1.5 ml 
microcentrifuge tubes containing 0.5 ml 1 M Tris buffer, and the protein 
concentration of each aliquot assessed by spectrometry. Fractions whose protein 
concentration was greater than 0.1 mg/ml were pooled, and dialysed for 48 hours 
at 4®C against 1 x PBS. The purity of the antibody was assessed by SDS-PAGE, 
final protein concentration measured by spectroscopy and the antibody filter 
sterilised prior to being aliquoted and stored at -20°C.
2.5 Cell Culture
The murine B cell lymphoma WEHI-231 has the surface phenotype of an 
immature B lymphocyte (niemW^(m) IgM^, mlgD'^ '^ ,^ FcR'°'^ , Fas'®'^ , and MHC 
class ll'°^), and was obtained from the European Collection of Cell Cultures 
(ECACC; CAMR, Porton Down, U.K.). WEHI 231 cells were cultured in RPMI- 
1640 medium containing 5 % foetal calf serum, L-glutamine (2 mM), penicillin 
(100 U/ml) and streptomycin (100 ^g/ml), and 2-mercaptoethanol (50 p,M) (RPMI 
complete) at 37°C in 5 % COg. All cell culture reagents were obtained from 
Invitrogen Life Technologies.
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2.6 f  Hï-Thymidine DNA synthesis assay
Proliferation of WEHI-231 cells and primary cells was assessed by the tritiated 
thymidine uptake assay to evaluate DNA synthesis. Briefly, WEHI-231 cells (1 x 
10  ^cells/well) or purified B cells (2x10® cellsAvell) were cultured in triplicate in 
round bottomed microtitre plates in RPMI-1640 medium supplemented with 5% 
FCS, 100 U/ml penicillin, 100 fxg/ml streptomycin, 2 mM glutamine, 1% (v/v) non- 
essential amino acids, 1 mM sodium pyruvate and 50 p-M 2-Mercaptoethanol (2- 
Me). Cells were stimulated in the presence of the appropriate agonists in a final 
well volume of 200 Cells were cultured for 48 hours at 37°C in a 5% (v/v) CO2
atmosphere at 95% humidity,
DNA synthesis was assessed by pulsing with 0.5 ^xCi/well [6-®H]-thymidine 
(Amersham Pharmacia Biotech) for the last four hours of culture, to allow 
incorporation into cellular DNA. Cells were harvested onto glass fibre filter mats 
(Wallac) using a Betaplate 96-well harvester (Amersham Pharmacia Biotech). 
Incorporated label was assessed by liquid scintillation counting and results are 
expressed as counts per minute (c.p.m) incorporated ± SD.
2.7 Cell stimulation and preparation of cell lysates
WEHI-231 cells or splenic B cells (1 x 10 )^ were stimulated for the times 
indicated at 37°C. Control stimulations were carried out in the presence of 
medium alone (RPMI-1640 medium supplemented with 5% FCS, 100 U/ml 
penicillin, 100 \xg/m\ streptomycin, 2 mM glutamine, 1% (v/v) non-essential amino 
acids, 1 mM sodium pyruvate and 50 2-Mercaptoethanol (2-Me)). Following 
incubation, cells were lysed by the addition of ice-cold, modified RIPA buffer (50 
mM Tris, pH 7.4, 150 mM sodium chloride, 2% (v/v) NP-40, 0.25% (w/v) sodium 
deoxycholate, 1 mM EGTA, 10 mM sodium orthovanadate plus 0.6 mM
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phenylmethyisulfonyI fluoride, 10 p,g/mi chymostatin, 10 pig/ml leupeptin, 10 
^xg/ml antipain and 10 |xg/ml pepstatin). Whole cell lysates were incubated on ice 
for 30 min to permit protein extraction. Cellular debris was removed by 
centrifugation (20000 x g, 30 min, 4°C) and the supernatants transferred to fresh 
tubes, either for immediate use or stored at -20‘^ C until required.
2.8 Immunoprécipitation
A BCA Protein Assay kit (Pierce PerBio) was used to assess the protein 
concentration of whole cell lysates. Samples were normalised to 1 mg/ml with 2 x 
modified RIPA buffer and then pre-cleared with 10 1^ of a 50% protein-G- 
sepharose;RIPA slurry for 30 min at 4“C with constant rotation. Following 
centrifugation (13,000 xg, 15 niin, 4X ), the pre-cleared supernatant was 
transferred to a fresh tube and incubated with the appropriate 
immunoprecipitating antibody (1-2 (ig/sample) overnight at 4°C with constant 
rotation.
The protein-antibody complex was pulled down with 10 p-l of protein G-sepharose 
for 2 hours at 4"C with constant rotation. Protein-sepharose complexes were 
harvested by centrifugation (13,000 x g, 30 min, 4°C) and washed three times in 
ice-cold modified RIPA buffer. The samples were then dissociated from the 
sepharose beads by boiling in 50 p,l of 2 x sample loading buffer (100 mM Tris pH 
6.8, 4% (v/v) bromophenoi blue, 0.2% SDS and 20% v/v glycerol) containing 5% 
2-Me for 10 min at 100°C, followed by pulse centrifugation to pellet the 
sepharose beads. Supernatants were resolved by SDS-PAGE.
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2.9 SDS-Polyacrylamide gel electrophoresis
Cell lysates or immunoprecipitates were resolved by Tris-glycine, SDS-PAGE 
(Laemlli, 1970). Pre-cast NuPAGE® 10% bis-tris gels were purchased from 
Invitrogen Life Technologies and assembled into the gel apparatus according to 
the manufacturer’s instructions, and each well rinsed with 1 x MOPS (3-(N- 
morpholino) propane sulfonic acid) electrophoresis buffer (50 mM MOPS, 50 mM 
Tris, 3.5 mM SDS, 1 mM EDTA) prior to sample loading. Equal protein loadings 
of cell lysates or immunoprecipitates were resuspended in an appropriate volume 
of NuPAGE® LDS sample buffer (Invitrogen Life Technologies). Immediately prior 
to loading, NuPAGE® reducing agent was added to each sample (0.5 mM 
dithiothreitol, DTT) and samples denatured by heating to 70®C for 10 minutes. 
Samples were loaded into individual wells, along with the appropriate positive 
control proteins into one or two wells, and molecular weight markers into one well 
to elucidate the molecular weights of unknowns. The samples were 
electrophoresed into the stacking gel at 100V and then run at 200V through the 
resolving gel for approximately 60 minutes.
2.10 Western blotting
SDS-PAGE resolved proteins were transferred to nitrocellulose using the 
Invitrogen Life Technologies apparatus. The foot and the wells of the gel were 
removed and the gel transferred to two sheets of filter paper, pre-wetted with 
NuPAGE® transfer buffer (25 mM bicine, 25 mM bis-Tris, 1 mM EDTA, 50 
chlorobutanol) (Invitrogen Life Technologies), then placed on top of two sponges 
in the blotting module. The nitrocellulose (Amersham Pharmacia Biotech) was 
placed on top of the gel and a further two sheets of pre-wetted filter paper placed 
on top. Any air bubbles were rolled out before completing the gel/filter sandwich, 
and the blotting module sealed and placed in the running tank. The blotting
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module was topped up with transfer buffer and surrounded with distilled water to 
act as a coolant. The proteins were transferred at a constant voltage (30V) for 90 
minutes.
The nitrocellulose membranes were then incubated in modified TBS buffer I 
(TBS, pH 7.4, containing 5% non-fat milk and 0.1% Tween-20) for at least 1 hour 
at room temperature to block non-specific protein binding. Primary antibodies 
were diluted, at concentrations recommended by the manufacturer, in TBS buffer
1 or TBS buffer II (TBS, pH 7.4, containing 5% BSA and 0.1% Tween-20) 
according to the manufacturer’s instructions, and incubated with the membranes 
overnight at 4°C. Membranes were washed four times in TBS buffer (TBS, pH 
7.4, and 0.1% Tween-20) before incubating with the appropriate HRP-conjugated 
secondary antibody in modified TBS buffer I for 1 hour at room temperature. The 
membranes were then washed six times in TBS buffer and the immuno-reactive 
protein bands visualised using the Enhanced ChemiLuminescence (ECL)
Western Blotting Detection System (Amersham Pharmacia Biotech) and exposed 
to X-OMAT film (Kodak).
2.11 Flow cytometric analysis
2.11.1 Cell surface markers
Cells (0.5-1.0 x 10®) were washed twice in 5 ml tubes (Becton Dickinson) with
2 m I cold FACS buffer (PBS, 1 % BSA, 0.1 % sodium azide) at 400 x g for 5 min, 
4 X . Cells were resuspended in 50 ji! of an anti-Fc receptor blocking solution 
(supernatant from the 2.4G2 rat anti-mouse FcyRII/lll hybridoma, this is required 
as B cells express the FcyRII receptor which has affinity for the constant region of 
IgG molecules) or 50 fxl of FACS buffer for 10 min on ice. Cells were incubated 
with 50 \i\ of primary antibody, at a concentration previously determined by 
titration of optimum binding, for 20 min on ice. Cells were washed with 2 ml 
FACS buffer (400 xg, 5 min, 4^ ’C) and then resuspended in 300 1^ FACS buffer if
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the antibody was directly conjugated to a fluorescent molecule. For non-directly 
conjugated primary antibodies, the staining procedure was repeated with the 
addition of the secondary antibody. Immediately prior to data acquisition 50 p-g/ml 
propidium iodide (Calbiochem) was added to enable exclusion of dead cells from 
the analyses. Cellular fluorescence data was acquired using a Becton Dickinson 
FACSCalibar™ flow cytometer and analysed using Cell Quest software (Becton 
Dickinson) or FlowJo software (Tree Star, Inc.) (Figure 2.1).
2.11.2 Cell cycle analysis
To determine the percentage of cells at a particular stage of the cell cycle, 
propidium iodide (PI) staining of cells was undertaken. Propidium iodide 
intercalates into DNA in a stoichiometric fashion, enabling DNA content to be 
assessed as this will be proportional to fluorescence. Primary B cells (6 x10®) 
were washed twice in ice-cold FACS buffer then fixed with 100 pi ice-cold 70% 
ethanol for 16 min at 4°C. The cells were washed in FACS buffer and then 
incubated with propidium iodide (250 pg/ml) plus Ribonuclease A (50 pg/ml) for 
35 min at room temperature.
WEHI-231 cells (5 x 10®) were washed twice in ice-cold FACS buffer. Cells were 
resuspended in 200 pi ice cold PI hypotonic buffer (0.1% (w/v) sodium(tri) citrate, 
0.1% Triton X-100 (v/v), 50 pg/ml propidium iodide, and 50 pg/ml Ribonuclease 
A) and incubated for 45 minutes at room temperature. WEHI-231 cells were 
stained by a different method as it was found that they displayed a high level of 
auto-fluorescence after treatment with ethanol. The PI fluorescence of the 
stained cells was measured at an excitation wavelength of 488 nm. Cellular 
fluorescence data was acquired using a Becton Dickinson FACSCalibur'" flow 
cytometer and analysed using Cell Quest software.
To determine the percentage of cells in Gq/Gi phase, S phase, Gg/M phase of the 
cell cycle, or containing a sub-diploid DNA content, linear FL-3 voltage settings
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were used (Figure 2.2). The FL-3 voltage settings were altered until the Gi peak 
(2N DNA) was approximately 300 fluorescence units, and a marker was set at 
either side of the peak. The upper and lower 2N DNA peak values were then 
doubled to produce the upper and lower 4N DNA peak values and markers set. 
Sub-diploid DNA or apoptotic cells were determined by setting markers below the 
2N peak, whilst cells in the S phase were taken as those between the 2N and 4N 
peaks.
2.11.3 Mitochondrial membrane potential
Incorporation of the cationic lipophilic dye DiOCe(3) into the mitochondria is 
proportional to the mitochondrial transmembrane potential, Atjjm (Zamzami etaL, 
1995). Cells were stained for surface markers, as previously described, and then 
washed with FACS buffer. Cells were then incubated with 2.5 pM DiOCe(3) 
(Molecular Probes) for 30 min at room temperature, washed once with FACS 
buffer, and resuspended in 300 pi FACS buffer. Fluorescence data was acquired 
using a Becton Dickinson FACSCalibar™ flow cytometer and results were 
analysed using Cell Quest software (Figure 2.3).
2.12 Laser scanning cytometry
2.12.1 Cell cycle analysis by LSC
The laser scanning cytometer (LSC) is a microscope based cytofluorometer that 
combines advantages of flow cytometry and image analysis (Kamentsky et a/., 
1997a; Kamentsky etal., 1997b). Fluorescence of individual cells is measured 
rapidly, with high sensitivity and accuracy comparable to that of flow cytometry. 
Cell analysis on slides eliminates cell loss, which generally occurs during 
repeated centrifugations in sample preparation for flow cytometry. The data 
generated by LSC are equivalent to data generated by flow cytometers, however.
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LSC can measure more than just total fluorescence per cell. As LSC 
measurements are slide based, it is possible to measure each cell at a number of 
locations on the cell to generate additional low resolution morphologic features, 
and to record the position of each cell on the slide as a feature so that cells can 
be relocated after measurements are completed and re-examined visually or by 
image analysis with or without restaining. To distinguish cells from background, 
contours are drawn round each event by the LSC software using a threshold set 
by the user, and a number of parameters for each event recorded. Some key 
parameters recorded by the LSC are the integral (the sum of pixel values in the 
data contour), max pixel (the maximum pixel value within the data contour), and 
area (the area of the thresholding contour) (Figure 2.4).
One application of LSC is to determine the DNA content of cells using 
stoichiometric fluorescent DNA specific dyes, such as PI or 4% 6’-diamidino-2- 
phenylindole (DAPI). The parameters required for such analyses are the integral 
and the max pixel of the cells. In this instance, the integral value corresponds to 
the DNA content of the cell, whilst the max pixel gives and indication of the 
chromatin density of the cell. Cellular DNA is more concentrated in mitotic cells, 
so the max pixel value is brighter in these cells than other cells in interphase. 
Therefore, mitotic cells can be distinguished from other cells in Ga as they have a 
higher max pixel (Figure 2.5), and newly formed daughter cells have the same 
DNA content (integral) as other G q/G i cells, but they have higher max pixel 
values than the other G q/G i cells.
After stimulation by the desired agonists, cells were attached to microscope 
slides by cytocentrifugation at 600 rpm for 4 minutes in a Shandon Cytospin 
centrifuge (Shandon Co.), then fixed in 4% formaldehyde in PBS for 10 minutes 
at room temperature. The slides were washed with PBS, and the cells 
permeabilised with 2% FCS, 2mM EDTA pH 8.0, 0.01% w/v saponin for 5 
minutes at room temperature. The slides were then washed 3 x with PBS and 
incubated with blocking buffer (10% goat serum, 1% BSA, 0.02% sodium azide,
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and 1 X PBS) for 10 minutes. Subsequently, the cells were incubated for 30 
minutes with propidium iodide (5 |xg/m!) and RNase A (200 jig/ml). The slides 
were then washed 3 x 3  minutes with PBS/1 % BSA, allowed to dry, and mounted 
in Vectashield without DAPI (Vector Labs). Slides were stored at 4°C in the dark 
until required.
2.12.2 Analysis of intracellular staining by LSC
The LSC can also be used for analysis of intracellular proteins, for example in 
order to determine the activation status of proteins activated by phosphorylation, 
using phospho-specific proteins. Cells were stimulated as required, then attached 
to microscope slides by cytocentrifugation at 600 rpm for 4 minutes in a Shandon 
Cytospin centrifuge (Shandon Co.), then fixed in 4% formaldehyde in PBS for 10 
minutes at room temperature, washed with PBS, and permeabilised with 2%
FCS, 2mM EDTA pH 8.0, 0.01% w/v saponin for 5 minutes at room temperature. 
The slides were then washed 3 times with PBS and incubated with a blocking 
solution containing 10% goat serum, 1% BSA, and 0.02% sodium azide in PBS 
for 10 minutes. Subsequently, a 50^1 aliquot of a 1% BSA/PBS solution 
containing a 1:250 dilution of anti-phospho p44/42 MAPK antibody (Cell 
Signaling Technology) was placed atop the site with the attached cells on the 
microscope slide and incubated for 30 minutes. The sites were washed 3 x 3  
minutes with 1% BSA/PBS and incubated with a 50^1 aliquot of a 1% BSA/PBS 
solution containing a 1:100 dilution of anti-rabbit FITC conjugated secondary 
antibody in 5p,g/ml Propidium iodide containing RNase A (200p,g/ml) for 30 
minutes. Cells were washed a further 3 x 3  minutes in 1% BSA/PBS then allowed 
to dry in the dark before being mounted in Vectashield without DAPI and left in 
the dark at 4‘^ C until data acquisition on the LSC (CompuCyte Corp), and data 
analysed using WinCyte software (CompuCyte Corp).
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2.12.3 Image analysis using the LSC
The LSC also has image analysis capabilities, permitting localisation studies to 
be carried out. This was utilised to investigate the activity of Erk-MAPKinase, and 
co-localisation of activated Erk MAPK with lipid rafts in primary B cells. Activated 
Erk MAPK was detected via a commercially available monoclonal phospho- 
specific antibody, whilst cholera toxin B subunit was used to detect the location of 
lipid rafts. Cholera toxin B subunit attaches to cells by binding to ganglioside Gmi, 
a ubiquitous glycolipid cell surface receptor that is a component of lipid rafts.
Cells were stimulated as indicated, attached to slides by cytocentrifugation at 600 
rpm for 4 minutes in a Shandon Cytospin centrifuge (Shandon Co.), then fixed in 
4% formaldehyde in PBS for 10 minutes at room temperature. The slides were 
washed with PBS, then incubated in Blocking Reagent (Molecular Probes) for 30 
minutes. If required, biotin-labelled cholera toxin B subunit (Sigma) was added (1 
jig/ml) in TNB (50 mM Tris, 75 mM NaCI, 0.5% Blocking Reagent) to the cells 
and incubated for 30 minutes. The slides were washed 3 x 5  minutes with TNT 
wash buffer (10 mM Tris, 15 mM NaCI, 0.05% Tween 20), then Streptavidin- 
Alexa Fluor 647 (Molecular Probes) added, diluted 1:500 in TNB, and incubated 
for 30 minutes. Slides were washed a further 3 x 5  minutes with TNT wash 
buffer.
To facilitate intracellular staining following the surface staining, cells were 
incubated with permeabilisation buffer (2% FCS, 2 mM EDTA pH 8.0, 0.1% w/v 
saponin) for 10 minutes, then washed 3 x 5  minutes with PBS. Cells were 
incubated for 15 minutes with Blocking Reagent, then for 30 minutes with anti- 
phospho p44/42 MAPK monoclonal antibody (Cell Signaling Technology), diluted 
1:200 in 1% Blocking Reagent, 0.1% w/v saponin. Cells were washed 3 x 5  
minutes with TNT wash buffer, and anti-mouse IgG HRP conjugate (Amersham 
Pharmacia Biotech) added, diluted 1:100 in 1% Blocking Reagent, 0.1 % w/v 
saponin), and incubated with the cells for 30 minutes. Cells were washed a
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further 3 x 5  minutes with TNT wash buffer, and incubated with Alexa Fluor 488- 
labelled tyramide in Amplification Buffer (Molecular Probes) containing 0.015% 
H2O2 for 10 minutes. Following a further 3 x 5  minute washes, slides were 
allowed to dry and mounted with Vectashield containing DAPI (Vector Labs), 
permitting visualisation of the nuclei. Slides were stored a t4 ‘"C in the dark until 
image analysis took place.
2.13 Generation of WEHI-231 mutant cell lines by retroviral 
transfection
2.13.1 Constructs for retroviral transfection
The murine stem cell virus (MSCV)-based MIEV.CMV retroviral vector was 
constructed by replacing the phosphoglycerate kinase (PKG) promoter ( P pkg) in 
MIEV (Leung et a/., 1999) with the CMV promoter from the pcDNA3.1 (Invitrogen 
Life Technologies) backbone (Michie etal., 2001) (Figure 2.6). The key features 
of this vector are the ampicillin resistance gene to allow selection of the vector in 
bacterial culture, the 5’ and 3' long terminal repeats (LTR) that are required for 
integration into the host genome and initiate a full length viral transcript, the CMV 
promoter to drive translation of the gene of interest, the multiple cloning site 
(MGS) for insertion of the gene of interest, the internal ribosome entry site (1RES) 
allowing the bicistronic expression of the gene of interest and the enhanced 
green fluorescent protein (eGFP), and the eGFP gene itself. The green 
fluorescence protein allows for detection or sorting of infected cells, and should 
be expressed at around one tenth of the levels of the gene of interest. All genes 
of interest were inserted into the MGS, and all vectors were purified by maxi- 
prep, following the manufacturer’s instructions (Invitrogen Life Technologies).
66
2.13.2 Generation of stable retroviral packaging lines
The retroviral vector MIEV.CMV contains all the cis acting viral sequences 
necessary for transmission, but does not contain the structural genes required for 
production of an infectious virus particle (gag, pol, env). A cell line known as the 
packaging cell line must supply the products of these genes. To generate stable 
retroviral packaging lines, the vector is first transiently transfected into the PT67 
cell line (Clontech). The PT67 cell line is an NIH/3T3-based packaging line that 
expresses the 10A1 viral envelope. Virus packaged from PT67 cells can be used 
to infect a broad range of mammalian cells because the virus can enter cells via 
two different surface molecules, the amphotropic retrovirus receptor and the 
GALV receptor. Virus packaged by transfected PT67 cells was then used to 
infect the ecotropic packaging cell line, GP+E-86. The GP+E-86 cell line is an 
NIH/3T3-based packaging line produced by cotransfecting a plasmid containing 
the gag and pol genes and a plasmid containing the env gene of the Moloney 
murine leukaemia virus into NIH/3T3 cells (Markowitz etal., 1988).
PT67 cells were transiently transfected using the Effectene™ transfection 
reagent, according to the manufacturer’s instructions (Qiagen). Briefly, the cells 
were seeded at a density of 1 x 10® cells/well in RPMI complete in a 6 well plate 
and incubated overnight at 37°C. 0.4 p,g DNA was diluted with DNA- 
condensation buffer, buffer EC, to a final volume of 100 1^, 3.2 p,l enhancer 
added and the solution mixed by vortexing for 1 second. After incubation at room 
temperature for 5 minutes 10 fil effectene transfection reagent was added to the 
DNA-enhancer mixture, the solution mixed by vortexing for 10 seconds, and 
incubated at room temperature for 10 minutes. The cells were washed once with 
PBS and fresh RPMI complete added to the cells. Medium (600 pi) was added to 
the tube containing the transfection complexes, mixed, then added drop-wise to 
the cells. The cells were then incubated for 24 hours, an additional 0.5 ml media 
added and the cells incubated for a further 24 hours to permit production of virus 
particles.
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The GP+E-86 cell line was transfected using the supernatant of transiently 
transfected PT67 cells. Briefly, GP+E-86 cells were seeded at a density of 1 x 
10® cells/well in RPMI complete in a 6 well plate 24 hours prior to transfection 
and incubated overnight at 37°C. Polybrene™ (5 pg/ml) was added to the cells 
and incubated for 4 hours. Polybrene™ (Hexadimethrine Bromide) is a small, 
positively charged molecule that binds to cell surfaces and neutralises surface 
charge, apparently allowing the viral glycoproteins to bind more efficiently to their 
receptors, because it reduces the repulsion between sialic acid-containing 
molecules. After 4 hours the supernatant taken from PT67 cells transfected 48 
hours previously was filter sterilised to remove any cells, the media removed 
from the GP+E-86 cells, and 1.5 ml of the sterilised PT67 supernatant added to 
the GP+E-86 cells, along with 5 pg/ml polybrene™. The cells were then 
centrifuged, in the 6 well plate, at 550 x g for 45 minutes at room temperature, 
incubated overnight at 37°C, and 0.5 ml media supplemented with polybrene™ (5 
pg/ml) added. The cells were then incubated for a further 24 hours to allow 
expansion before selection of successful transfectants by cell sorting.
2.13.3 Selection of stable retroviral packaging lines
Stably transfected GP+E-86 cells were selected on the basis of expression of 
green fluorescent protein by means of a cell sorter. Briefly, 48 hours after 
transfection the cells were trypsinised, washed once in sterile sorting buffer 
(HBSS, 1% BSA) and resuspended in sterile sorting buffer. The cells were 
filtered through a 70 pm mesh, and incubated on ice for transportation to the cell 
sorter. GFP^ cells were sorted into 2 ml media with a FACSVantage™ SE cell 
sorter (Becton Dickinson), harvested by centrifugation (400 xg, 5 minutes, 4°C), 
resuspended in RPMI complete and incubated at 37°C until colonies were 
formed. After approximately 14 days, ceils were sorted once more to ensure 
there were no GFP" cells in the culture.
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2.13.4 Transfection of WEHI-231 cells using stable retroviral packaging
lines
Stably transfected GP+E-86 cells were used to infect WEHI-231 cells with the 
appropriate MIEV vector by co-culture. Stably transfected GP+E-86 cells that had 
been sorted twice to ensure GFP positivity were grown to 75% confluency in a 6 
well plate. WEHI-231 cells were pretreated for 4 hours with polybrene (5 pg/ml) 
prior to transfection. 3x10® WEHI-231 cells in media containing 5 pg/ml 
polybrene were added to the wells containing the appropriate stable GP+E-86 
transfectants, and incubated at 37°C for 16 hours. After this time, the WEHI-231 
cells were removed by careful aspiration and incubated for a further 4 hours, 
before a sample was removed for FACS analysis to assess the percentage of 
transfected cells by their green fluorescence.
2.14 Generation of WEHI-231 mutant ceil lines by electroporation
2.14.1 Feasibility of transfection of WEHI-231 celis by electroporation
Transfection of mammalian cells by electroporation relies upon transient 
membrane pore formation to allow passage of DNA molecules into the cell. A 
slight drawback with electroporation is that it requires large numbers of cells, due 
to the fact that a high proportion of cells do not survive. As such, optimisation is 
required to balance transfection efficiency against cell death, in order to optimise 
electroporation of WEHI-231 cells, pCMV-GFP was transfected at a constant 
capacitance (960 pFarads) with increasing voltages, 200 V, 250 V, 270 V, and 
300 V. Efficiency of electroporation was assessed by flow cytometry to detect the 
proportion of GFP^ cells, and the proportion of dead cells, 24 hours after 
transfection (Figure 2.7).
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Selection of WEHI-231 cells successfully transfected by electroporation with 
pcDNAS.I constructs was facilitated by resistance to the antibiotic G418, which is 
conferred by pcDNAS.I (Figure 2.8). The concentration of G418 used has to be 
sufficient to prevent any wild type cells from growing, but not at such a level that 
growth of transfected cells is inhibited in any way. In order to determine the 
concentration of G418 required to eliminate wild type WEHI-231 cells, cells were 
cultured in RPMI complete containing G418 at a variety of concentrations for up 
to 72 hours. The concentrations used were 0 pg/ml, 250 pg/ml, 500 pg/ml, 750 
pg/ml, 1 mg/ml, and 1.25 mg/ml. The minimum concentration required to kill all 
wild type cells was found to be 500 pg/ml, as assessed by microscopy and trypan 
blue exclusion (results not shown).
2.14.2 Constructs for transfection by electroporation
The pUC18 based vector pcDNA3.1 (Invitrogen Life Technologies) was used as 
the vector for the introduction of specific genes to WEHI-231 cells by 
electroporation. The key features of this vector are ampicillin resistance for 
selection in bacterial cultures, the CMV promoter to drive translation of the gene 
of interest, the multiple cloning site (MGS) for insertion of the gene of interest, the 
BGH polyadenylation sequence to ensure proper modification of the mRNA, and 
the neomycin resistance gene, to allow for selection of cells successfully 
transfected using G418 (Figure 2.8)
2.14.3 Preparation of vectors for transfection by electroporation
In order for DNA to be integrated into the genome of mammalian cells following 
transfection, it has to be linear before transfection takes place. For all of the 
constructs transfected into WEHI-231 cells by electroporation, this was achieved 
by digestion with Pvu I, as there is only one Pvu I site in pcDNA3.1 and none in 
any of the genes of interest. 10 pg of each of the vectors to be digested were 
incubated with 1 unit of Pvu I for 1 hour, with 0.5 units Pvu I added and incubated
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for a further 1 hour, at 37“C to ensure complete digestion. Following digestion, 
the fragments were separated by electrophoresis in a 0.8% agarose gel in TAE 
buffer (40 mM Tris-acetate, 2 mM EDTA) (Figure 2.9), and the appropriately 
sized fragment for each construct excised. Fragments were extracted from the 
agarose slice by means of the QIAquick™ gel extraction kit, following the 
manufacturer’s protocol (Qiagen). Briefly, the gel slices were weighed, 3 volumes 
of buffer QG added to 1 volume of gel and the gel dissolved by incubating at 
50*C for 10 minutes, with vortexing every 3 minutes. Once the gel was dissolved 
1 gel volume of isopropanol was added and the sample mixed. Samples were 
added to QIAquick spin columns and centrifuged for 1 minute at maximum speed 
in a microcentrifuge to allow binding of DNA to the columns. The flow through 
was discarded, and the column washed by adding 750 pi buffer PE and 
centrifuging for 1 minute, as before. The flow through was again discarded and 
the column centrifuged for a further 1 minute, before being placed in a fresh, 
clean 1.5 ml tube. DNA was eluted from the column by adding 20 pi dHgO to the 
centre of the membrane, standing for 1 minute, followed by centrifugation for 1 
minute. Purified DNA was transferred to ice and introduced to the cells by 
electroporation immediately.
2.14.4 Transfection of WEHI-231 cells by electroporation
24 hours prior to transfection cells were split to ensure they would be in log 
growth phase at the time of transfection to maximise efficiency. 5x10® cells per 
electroporation were washed in electroporation media (RPMI-1640 + 20%FCS) 
and resuspended in electroporation media at 2 x 10  ^cells/ml. Linearised DNA 
recovered from an agarose gel was added to a cuvette and cooled on ice for 5 
minutes. 5x10® cells were added and the cuvettes tapped lightly to mix, before 
being incubated on ice for a further 10 minutes. Cells were then electroporated at 
960 pFarads, 220 Volts (the optimum conditions for electroporation of WEHI-231 
cells, Figure 2.7), and incubated on ice for a further 10 minutes. After this time 
the cells were removed from the cuvettes by pipetting and placed into RPMI-
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complete media. The cells were incubated for 48 hours at 37®C in 5% CO2, 
before addition of the antibiotic G418 at 500 pg/ml (concentration high enough to 
kill wild type WEHI-231 cells -  see Section 2.14.1) to select for transfected cells. 
After 48 hours, cells were transferred to a 15 ml tube, underlaid with 1 ml FCS 
and centrifuged at 400 g for 7 minutes to remove debris. Cells were resuspended 
in RPMI complete supplemented with G418 (500 pg/ml) and incubated at 3 7 X  to 
allow for expansion of successfully transfected cells.
2.15 Total cellular RNA preparation
Total RNA was extracted using RNAzol™ B (Biogenesis) as described 
(Chomczynski and Sacchi, 1987). Briefly, cells (5 x 10®) were washed twice with 
ice-cold PBS (2000 xg, 5 min at 4°C) and the cellular pellet was resuspended in 
RNAzol™ B (0.2 ml/10® cells). Samples were extracted for 5 min on ice and the 
suspension was transferred to a fresh tube. Chloroform was added (0.1 ml /1 ml 
of RNAzol™) and the solution mixed by vigorous shaking for 15 seconds. The 
samples were incubated on ice for a further 5 min.
Following centrifugation (13,000 xg, 15 min, 4°C) the colourless upper phase 
was removed to a fresh tube (approximately 50% of the initial RNAzol™ volume) 
and an equal volume of isopropanol was added. RNA was precipitated by 
incubation on ice for 30 min and separated by centrifugation (13,000 xg, 15 min, 
4®C). The RNA pellet was washed with ice-cold 75% ethanol (1 m l /1 ml 
RNAzol™ volume), briefly dried for 10 min at room temperature and finally 
resuspended in 20-50pl of sterile, distilled water. RNA samples were incubated at 
68“C for 5 min in order to denature any double strands, prior to concentration 
assessment by UV spectroscopy. Absorbance readings of diluted samples (1:50) 
were taken at A260/280 and the concentration of RNA calculated (40 fxg/ml RNA = 
A26O of 1).
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2.16 Ribonuclease protection assay (RFA)
Expression levels of a group of genes involved in cell cycle control or apoptosis 
were examined by means of a RiboQuant™ ribonuclease protection assay 
(Pharmingen). The ribonuclease protection assay (RPA) is a highly sensitive and 
specific method for the detection and quantification of mRNA species. Radio­
labelled anti-sense RNA probes are generated from a cDNA fragment of interest, 
and hybridised with target RNA from samples of interest. Free probe and other 
single-stranded RNA are digested with RNases, the remaining RNase-protected 
probes are purified, resolved on denaturing polyacrylamide gels, and quantified 
by autoradiography or phosphorimaging (Figure 2.10). As undigested probes are 
resolved by electrophoresis, a number of RNA probes can be analysed provided 
they are of distinct length and each represents a unique sequence in a distinct 
mRNA species.
The protocol supplied with the ribonuclease protection assay kit was followed. 
Briefly, the RPA template set was incubated for one hour at 37°C with T7 RNA 
polymerase in the presence of ribonucleotides, including [a-®^P]-UTP (Amersham 
Pharmacia Biotech). The reaction was terminated by the addition of DNase, to 
remove the template, with a further 30 minute incubation at 37‘^ C. The RNA 
probe was extracted by phenol;chloroform extraction, then precipitated by 
incubation with 100% ethanol for 30 minutes at -70°C. Following centrifugation at 
13000g for 15 minutes at 4°0 the RNA pellet was washed with ice-cold 90% 
ethanol then allowed to dry briefly. The pellet was resuspended in hybridisation 
buffer, then the labelling assessed by scintillation counting. Probes had a typical 
yield of -2  x 10® Cherenkov counts/p.1 (measurement of cpm/p.1 without the 
presence of scintillation fluid).
RNA samples to be hybridised with the probe were prepared using RNAzol™ B 
as above, and 10^g of each sample was dried in a vacuum evaporator
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centrifuge. Each sample was solubilised by the addition of hybridisation buffer, to 
which was added the probe at the optimal probe concentration, according to the 
data sheet. The samples were placed in a heat block pre-heated to 90*C and the 
temperature was immediately turned down to 56°C to allow for annealing of 
complimentary strands, and allowed to incubate for 16 hours. Samples were then 
incubated with RNase at 30°C for 45 minutes to digest single stranded RNA. 
RNase was inactivated by incubation with proteinase K at 37°C for 15 minutes. 
RNA was extracted by phenol [chloroform extraction and precipitated with 
ethanol, as before. Protected probes were resolved on a 5% acrylamide gel at 50 
watts for around 3 hours in 0.5 x TBE (45 mM Tris, 45 mM boric acid, 1 mM 
EDTA pH 8.3). The gel was dried on a vacuum drier and the levels of 
radioactivity of protected probes quantified by phosphorimaging using a Storm 
phosphorimager.
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2.17 Suppliers addresses
Amersham Pharmacia Biotech
Amersham Place 
Little Chalfont 
Buckinghamshire HP7 SNA
BD Biosciences
21 Between Towns Road 
Cowley
Oxford 0X4 3LY
Biogenesis
Technology Road 
Poole BH17 7DA
Cell Signalling Technology 
New England Biolabs (UK) Ltd
73 Know! Piece, Wilbury Way 
Hitchin
Hertfordshire SG4 OTY
European Collection of Celt 
Cultures (ECACC), c/o CAMR
Porton Down 
Salisbury 
Wiltshire SP4 OJG
Invitrogen Life Technologies
3 Fountain Drive 
Inchinnan Business Park 
Paisley PA4 9RF
Calbiochem 
c/o CN Biosciences
Boulevard Industrial Park 
Padge Road 
Beeston
Nottingham NG9 2JR
CompuCyte Corp, c/o
Genetic Research Instrumentation
Gene House 
Queenborough Lane 
Rayne, Braintree 
Essex CM77 6TZ
Harlan UK Ltd
Shaw’s Farm, Blackthorne 
Bicester
Oxon 0X25 1TP
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Jackson Immunoresearch
Laboratories
c/o Stratech Scientific
61-63 Dudley Street 
Luton
Bedfordshire LU2 ONP
Kodak Ltd
Kodak House 
Station Road 
Hemel Hempstead 
Hertfordshire HP 1 1JU
Miitenyi Biotec
Almac House 
Church Lane 
Bisley
Surrey GU24 9DR
Molecular Probes
c/o Cambridge Bioscience
24-25 Signet Court 
Newmarket Road 
Cambridge CB5 8LA
Perbio Science UK Ltd
Centruy House 
High Street, Tattenhall 
Cheshire CH3 9RJ
Pharmingen 
c/o BD Biosciences
see above
QiAGEN Ltd
Boundary Court 
Gatwick Road, Crawley 
West Sussex RH10 9AX
Sigma-Aldrich Company Ltd
Fancy Road 
Poole
Dorset BH12 4QH
Shandon Inc
93-96 Chadwick Road 
Astmoor, Runcorn, 
Cheshire WAY 1 PR
Tree Star Inc
340 A Street Bd. 1#203
Ashland
OR 97520, USA
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Vector Laboratories Ltd Wallac
3 Accent Park c/o PE Life Sciences
Bakewell Road (Applera UK)
Orton Southgate Kelvin Close
Peterborough Birchwood Science Park North
PE2 6XS Warrington
Cheshire WAS 7PB
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Table 2.1 Other Reagents
2-mercaptoethanol 2-Me Invitrogen
3.3’-dlhexytoxacarbocyanine iodide DiOCe (3) Mol. Probes
5-/6-carboxyfluorescindiacetate, CFSE Calbiochem
succinimidyl ester
[a-®^P]-urldine tri phosphate [a-^2p]-UTP
Effectene transfection reagent Qiagen
Enhanced ChemiLuminescence Kit ECL Amersham
Foetal Calf Serum FCS Invitrogen
Geneticin antibiotic G418
Glutamine Glutamine Invitrogen
Hexadimethrine Bromide Polybrene Sigma
MEM Non-essential amino acids Amino acids Invitrogen
MicroBGA or Coomassie Protein Assay Protein Assay Pierce
NuPage pre-cast gels Invitrogen
Penicillin/Streptomycin Pen/Strep Invitrogen
Propidium Iodide PI Calbiochem
Pvu\ restriction enzyme Roche
Ribonuclease A RNase A Sigma
RPM 1-1640 culture media RPMI-1640 Invitrogen
Sodium Pyruvate Sodium Pyruvate Invitrogen
[6-^H]-thymidine (6 Ci/mmo!) [3H]- thymidine Amersham
Vectashield VectorLabs
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Table 2.2 Antibodies
anti-mouse IgG + 
IgM F(ab’)2
G, R S Jackson 
Immunoresearch Labs
anti-mouse IgG + 
IgM Intact
G, R S Jackson 
Immunoresearch Labs
anti-mouse IgM (n 
Chain) F(ab’)2
G S Jackson 
Immunoresearch Labs
anti-lgG Mouse, 
Rabbit
HRP V W Cell Signalling 
Technology
anti-lgG Goat HRP V W Jackson 
Immunoresearch Labs
8220 PE F Pharmingen
CD3 FITC F in House
CD4 APC F Pharmingen
CD8 APC F Pharmingen
CD19 Biotin F Pharmingen
FcyRII/ll (2.4G2) FITC Ra In House
phospho-cdc2 
(Tyr 15)
R W Cell Signalling 
Technology
Cyclin D1/D2 M W Upstate
p27 R W Pharmingen
P44/42 Erk-MAPK R W Cell Signalling 
Technology
phospho-p44/42
Erk-MAPK
M W Cell Signalling 
Technology
phospho-p44/42
Erk-MAPK
R W Cell Signalling 
Technology
p53 R W. IP Santa Cruz
phospho-p53 
(ser 15)
R W Cell Signalling 
Technology
Retinoblastoma (Rb) M W Pharmingen
phospho-Rb
(Ser807/811)
R W Cell Signalling 
Technology
CD43 Magnetic
beads
Ra Pure Miitenyi Biotech
^Host: R = Rabbit, G = Goat, Ra = Rat, M = Meuse, V = Various. 
^Use: WB = Western Blotting, IP = Immunoprécipitation, F = FACS, 
S = Stimulation {in vitro), PD = Pull Down, Pure = Purification
79
Figure 2.1 FACS analysis of cell surface marker staining
A A dot plot of forward scatter versus side scatter, showing the population of 
cells deemed healthy by their position in this plot. Forward scatter gives a 
measure of the size of the cells, whilst side scatter gives a measure of their 
granularity.
B A dot plot of forward scatter versus propidium iodide (PI) staining, showing the 
population of cells deemed viable by their lack of PI fluorescence. PI is excluded 
from viable cells, but can enter cells with porous membranes, such as dead cells, 
whereupon it binds the cellular DNA in a stoichiometric manner.
0  Dot plots of murine splenic mononuclear cells stained with anti-B220-PE, anti- 
CD4-APC, anti-CD8-APC, and anti-CD19-biotin-streptavidin-FITC. Dead cells 
were excluded from analysis by adding propidium iodide (50 p.g/ml) immediately 
prior to data collection, as healthy cells should not accumulate PI. The positions 
of gates were decided by including unstained cells and cells stained for single 
surface markers, then examining their fluorescence on a histogram. This allows a 
marker to be positioned between positively stained cells, and unstained cells, 
typically between 20 and 50 fluorescence units.
D Dot plots of murine splenic B cells, after purification with with anti-CD43 (Ly- 
48) magnetic beads, stained with anti-B220-PE, anti-CD4-APC, anti-CD8-APC, 
and anti-CD19-biotin-streptavidin-FITC. Analysis was carried out as above.
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Figure 2.2 FACS histogram of DNA content analysis
A histogram plot of cells stained with propidium iodide (50 ^g/ml for WEHI-231 
cells, 250 \iQ/m\ for primary splenic B cells). Histogram markers determine the 
percentage of cells in each stage of the cell cycle. The Gi peak (2N DNA) is set 
around 300 fluorescence units on the FL-3 x-axis and the G2/M peak (4N DNA) 
calculated accordingly. Cells exhibiting sub-diploid DNA content (representing 
apoptotic cells) are marked as those below the 2N peak, whilst cells in S phase 
are determined as those between the 2N and 4N peaks.
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File: 27-7-01-48hr.003 
Sample ID: 48 Mrs Control 
Acquisition Date: 27-Jul-1 
Total Events: 10000
Log Data Units: Linear Valui 
Patient ID: a-lg + aCD40 
Gated Events: 10000 
X Parameter: FL3-H PI (Line
Marker Left, Right Events % Total Mean Median
All 0, 1023 10000 100.00 225.02 243.00
Sub-diploid 9, 181 1022 10.22 66.56 55.00
GO/Gl 181, 284 2466 24.66 243.69 246.00
S phase 284, 372 1454 14.54 324.82 323.00
G2/M 372, 581 1931 19.31 446.80 439.00
Figure 2.3 FACS histogram of the mitochondrial membrane potential of 
ceils
A histogram of ceils stained with the cationic lipophilic dye DiOC6(3) (2.5 |xM) for 
analysis of mitochondrial membrane potential. Histogram markers determine the 
proportion of cells with low or high DiOCeCS) fluorescence on the FL-1 x-axis. 
Cells with low DiOCeCS) fluorescence are judged to represent the population 
that are committed to apoptosis, having decreased their mitochondrial membrane 
potential. Anti-lgM induces apoptosis in WEHI-231 cells, therefore the histogram 
pertaining to cells treated with anti-IgM displays a far greater proportion of cells 
with low mitochondrial membrane potential.
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Figure 2.4 The detection of ceils by the laser scanning cytometer (LSC)
To distinguish cells from background, contours are drawn round each event by 
the LSC software using a threshold set by the user on data from one sensor, 
typically the particular nuclear stain used. These contours are the threshold 
contour, integration contour, peripheral contours, and the background contours. 
The same contour locations are used when acquiring data for each event from all 
other sensor data.
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Figure 2.5 Cell cycle analysis by laser scanning cytometry (LSC)
Analysis of the cell cycle by LSC. Cells are stained with a stoichiometric 
fluorescent DMA specific dye {eg PI or DARI), and data acquired by means of the 
LSC. Max pixel versus Integral plot visualises cells at various cell cycle stages, 
with varying DNA content (Integral) and varying chromatin concentration (Max 
pixel) permitting assignment of cell cycle stage to cell populations.
84
<MitosisInterphase
U)
i! Red Max Pixel
Increasinq chromatin concentration
G1a - newly formed daughter cells 
G1b - resting cells 
G2 - cells in S-phase 
Mitosis - Dividing cells
Figure 2.6 Map of the MIEV.CMV retroviral vector
The MIEV.CMV vector was used to introduce various RasV12 mutants into 
WEHI-231 cells. This vector was constructed by replacing the phosphoglycerate 
kinase (P K G )  promoter (P pkg ) in MIEV (Leung et a/., 1 9 9 9 )  with the GMV 
promoter from the pcDNAS.I (Invitrogen Life Technologies) backbone (Michie et 
a/., 2001).
Amp^: ampicillin resistance
5’ and 3’ LTR: long terminal repeats
PcMv: cytomegalovirus promoter
MGS: multiple cloning site
1RES; internal ribosome entry site
eGFP; enhanced green fluorescent protein
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Figure 2.7 Analysis of efficiency of transfection of WEHI-231 cells by 
electroporation
In order to optimise electroporation of WEHI-231 cells, pCMV-GFP was 
transfected into cells at a constant capacitance (960 (iFarads) with increasing 
voltages, 200 V, 250 V, 270 V, and 300 V. 24 hours after transfection, cells were 
harvested, washed twice in FACS buffer, and immediately prior to acquisition 
propidium iodide was added to each tube (50 \ig/m\) to enable the proportion of 
dead cells to be assessed. Viable cells were selected from the dot plot on the 
basis that propidium iodide is excluded from viable cells, whilst successful 
transfectants were visualised on the basis that they should express the enhanced 
green fluorescent protein (eGFP), therefore display fluorescence in the FL-1 
channel.
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Figure 2.8 Map of the pcDNA3.1 vector
The pcDNA3.1 (+) vector (Invitrogen Life Technologies) was used to introduce a 
variety of mutant PKC isotypes into the WEHI-231 cell line.
Ampicillin: ampicillin resistance gene {bla)
PcMv: cytomegalovirus promoter 
BGH pA; BGH polyadenylation sequence 
f1 oh: origin of replication from the f1 phage 
SV40 ori: SV40 early promoter and origin 
Neomycin: neomycin resistance gene 
SV40 pA: SV40 polyadenylation sequence 
pUC ori: pUC origin
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Figure 2.9 Agarose gel electrophoresis of iinearised vectors
Constructs comprising pcDNA3.1 containing various PKC isotypes were 
completely digested with Pvu I. Following digestion, the fragments were 
separated by electrophoresis in a 0.8% agarose gel. Contents of the lanes are as 
follows, along with the expected size of the linearised vector:
1: 1 kb DNA ladder
2: PKC-Ô KR 7.9 kb
3: PKC-Ô CAT 6.4 kb
4: PKC-e KR 7.6 kb
5: PKC-e CAT 6.4 kb
6: PKC-Ç KR 7.17 kb
7: PKC-^ CAT 6.4 kb
8: pcDNA3.1 5.4 kb
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Figure 2.10 Rîbonuclease protection assay
A An overview of the rîbonuclease protection assay (RFA) protocol (adapted 
from the RiboQuant™ instruction manual).
B Sample data for mouse cell cycle regulator multiprobe template set (taken from 
RiboQuant^*^ instruction manual). The protected probes of the various genes vary 
in size by at least 10 nucleotides from each other, allowing them to be separated 
in a denaturing polyacrylamide gel. The housekeeping gene probes, L32 and 
GAPDH, are included for normalising samples to permit comparison of individual 
mRNA species between samples. Undigested probes are run on the gel as 
markers, though protected probes are approximately 29 nucleotides shorter due 
to the fact that the unprotected probe includes flanking sequences derived from 
the multiple cloning site of the vector.
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Chapter 3 -  The role of the Ras/Erk-MAPKinase pathway 
in the survival and proliferation of WEHI-231 cells
3.1 Introduction
During the generation of a functional B lymphocyte repertoire it is necessary to 
regulate the maturation of immature B cells to prevent the emergence of cells 
that bind self-antigen and which are therefore potentially auto-reactive. This 
major checkpoint in B lymphocyte development not only occurs in the bone 
marrow, but also in the periphery in cells termed transitional immature B cells 
(Monroe, 2000). These cells arise as a result of immature B cells maintaining 
their immature phenotype for several days after their exit into the periphery 
(Allman etal., 1992). In contrast to mature B lymphocytes which generally 
undergo a process of activation following antigen encounter, transitional and 
immature B lymphocytes undergo a process of negative selection that may 
involve deletion, anergy or replacement of the self-reactive receptor with a non­
self-reactive BCR (Choi et ai., 1995). The fate of the immature B cell upon 
antigen encounter is dependent upon a number of factors, including the affinity of 
the antigen and which additional, external signals they receive. One signal that 
has been shown to play an important role in immature B lymphocyte fate is that 
via CD40, which has been implicated in the rescue of these cells from apoptosis 
due to T-cell dependent interactions (Monroe, 1997). This would enable such 
cells to be recruited to an ongoing immune response in which T cell help has 
already been triggered.
3.1.1 The WEHI-231 B cell lymphoma: a cell line model for immature B cell 
selection.
The murine B cell lymphoma cell line WEHI-231 is widely used as a model for 
immature B lymphocyte clonal deletion. This is because it has a cell surface 
phenotype of an immature B lymphocyte (membrane (m) IgM"", mlgD'^'T FcR'°'^ ,
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Fas’°" and MHC class ll'°' )^, and as such responds to BCR ligation by 
undergoing growth arrest and apoptosis (Choi etal., 1995; Wiesner etal., 1997) 
and can be rescued from BCR-mediated growth arrest and apoptosis by 
costimulation via CD40. The signalling mechanisms responsible for such growth 
arrest, apoptosis and rescue remain to be precisely defined.
As stated in Chapter 1, the first signalling event mediated by the BCR is the 
recruitment and concomitant activation of non-receptor protein tyrosine kinases 
(PTKs) (Campbell, 1999; Kurosaki, 1999). Recruitment and activation of three 
distinct types of PTKs are known, namely the Src- (Lyn, BIk, Fyn), Syk- and Tec- 
(Bruton’s tyrosine kinase, Btk) PTKs (Cambier, 1995; Kurosaki, 1999) (Figure 
1.4). Following BCR ligation, the Src family PTKs become activated and 
phosphorylate the key tyrosine residues within the ITAMs of the Iga and Igp 
accessory molecules. The phosphorylated ITAMs create binding sites for the 
tandem SH2 domains of Syk, which, once recruited, itself becomes tyrosine 
phosphorylated and activated. One substrate of Syk is the adaptor protein BLNK 
(B cell linker protein), whose phosphorylation provides docking sites for Btk, 
allowing Btk to be brought into close proximity with, and subsequently become 
activated by phosphorylation by, Syk (Baba etal., 2001). These kinases 
subsequently phosphorylate and activate downstream targets in various 
signalling cascades.
These early signalling events result in the aggregation and activation of a number 
of important downstream enzymes and adaptor proteins that, in turn, trigger three 
major signalling pathways (Cushley and Harnett, 1993). The first pathway 
involves the hydrolysis of phosphatidylinositol-4,5-bisphosphate (Ptdlns(4 ,5)P2 or 
PIP2) to diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (Ins(1,4 ,5)p3 or 
IPs) by phospholipase C-y2 (PLC-y2). The second pathway results in the 
generation of phosphatidylinositol-3,4,5-trisphosphate (Ptdlns(3,4,5)Ps or PIP3) 
by phosphorylation of PIP2 by phosphatidylinositol 3 kinase (PI-3-K). The third 
pathway is the classical Ras/Raf/Erk-MAPKinase pathway. These seemingly
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independent pathways have recently been shown to interact at a variety of levels, 
increasing the complexity of BCR signalling. It is not clear how these three 
pathways interact to induce proliferation in mature B ceils, butgrowth arrest and 
apoptosis in WEHI-231 cells.
BCR-induced apoptosis in the WEHI-231 cell line has been shown to involve the 
regulation of the c-myc oncogene, as well as the tumour suppressor p53 and one 
of its transcriptional targets, the cydin-dependent-kinase inhibitor In
certain cell types, overexpression of c-myc can induce apoptosis (Evan ef a/., 
1992), however, inhibition of c-myc expression induces apoptosis in WEHI-231 
cells (Wu etal., 1996). Indeed, during BCR-mediated apoptosis in WEHI-231 
cells there is a marked decrease in c-myc at both the mRNA and protein level, 
following an initial, rapid elevation (Schauer et al., 1996). This down-regulation is 
a consequence of decreases in the binding of Rel/NF-KB to DNA, activity vital for 
maintaining c-myc levels and promoting cell survival (Wu etal., 1998). The 
transcription factor NF-kB has been shown to be important for B lymphocyte 
activation and development, and its inhibition using protease inhibitors (which 
prevent receptor-mediated degradation of the NF-kB inhibitor, IkB) has been 
shown to induce apoptosis in a number of B lymphocyte cell lines (Baichwal and 
Baeuerle, 1997). It has also been found that anti-CD40 stimulation is able to 
rescue WEHI-231 cells from anti-1 g mediated apoptosis by inducing NF-kB 
activity, consequentially elevating and maintaining c-myc RNA levels (Schauer et 
al., 1996). Anti-lg stimulation of WEHI-231 cells enhances the stability of kB-a, 
leading to accumulation of IkB-œ in both the cytosol and nucleus, and a 
concomitant decrease in the nuclear expression of the Rel/NF-KB family member 
c-Rel (Ku ef 2000).
As stated above, the tumour suppressor protein p53 has also been implicated in 
WEHI-231 cell death, with anti-lg treatment of WEHI-231 cells increasing the 
levels of p53 protein, as well as (Wu et al., 1998). The increase in
protein levels of pgi^AFi/cipi^ a downstream transcriptional target of p53, was
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delayed relative to p53 induction, consistent with the notion that functionally 
active p53 induces expression. This study also showed that ectopic
expression of p53 in WEHI-231 cells leads to an induction of apoptosis, in the 
absence of any further stimulation.
The same group have also demonstrated that the induction of the cyclin 
dependent kinase inhibitor p27*^ '^  ^ following anti-lg treatment promotes apoptosis, 
as well as cell cycle arrest (Wu et a/., 1999). Microinjection of an antisense c-myc 
expression vector induces apoptosis in WEHI-231 cells, and this can be rescued 
by co-microinjection of an antisense p27 expression vector, or an anti-p27 
antibody to ablate p27 levels. This c-myc pathway is independent of the p53/p21 
pathway as inhibition of the p53 pathway has no effect on the anti-lg mediated 
drop in c-myc levels or the elevation of p27 levels (Wu et al., 1999). WEHI-231 
cells are not the only cell type in which the induction of p27 induces apoptosis, 
this phenomenon has also been shown in lung fibroblasts and HeLa cells 
(Katayose etal., 1997; Wang etal., 1997).
3.1.2 Ras signalling
As stated above, the membrane proximal signalling events initiated in response 
to BCR ligation are becoming fairly well elucidated, with 3 key signalling 
pathways now known to be the major targets, one of these pathways being the 
Erk-MAPKinase pathway. A key regulator of the Erk-MAPKinase pathway is the 
small GTPase, Ras, which regulates cell growth in all eukaryotic cells. When 
serum-starved NIH-3T3 cells that are arrested in Go are exposed to serum, they 
undergo a period of intense signalling lasting 30-60 minutes, and this starts to 
decline as receptors are internalised and degraded. Serum or growth factors are 
required for a further 8-10 hours however, if the cells are to enter the cell cycle.
In cells continuously exposed to growth factors in this manner, Ras signalling is 
required in at least two phases of the Go to S phase transition, and these two 
phases of Ras signalling require different effector molecules. ERK is activated in
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the early stages of Ras activation, but its activity is not detected at later stages of 
Gi progression, even though Ras is still active. PI-3-Kinase is another effector 
molecule of Ras signalling important for Go to S phase progression. Pl-3-Kinase 
is active during the G0/G1 transition and in mid to late Gi phase (Jones et al., 
1999). Inhibition of PI-3-Kinase activity during the G0/G1 transition has no effect 
on cell cycle progression of HepG2 cells, however inhibiting the mid to late Gi 
phase PI-3-Kinase activity prevented cells from entering S phase (Jones et al., 
1999). In WEHI-231 cells, short term inhibition of PI-3-Kinase activity has no 
effect on spontaneous proliferation, anti-lg induced growth arrest or CD40- 
mediated rescue. However, prolonged inhibition (up to 30 hours) of P 1-3-Kinase 
results in growth inhibition of unstimulated cells, suggesting that PI-3-Kinase 
activity may be important for the basal proliferation of WEHI-231 cells. Prolonged 
inhibition also abrogated CD40-mediated rescue of anti-lg induced growth arrest, 
but this may be due to the fact that PI-3-Kinase inhibition blocks basal 
proliferation of these cells (Gauld, 2001).
RasV12 is a constitutively active form of Ras, the consequence of a point 
mutation that results in the substitution of valine for glycine at position 12. This 
mutation disables the intrinsic GTPase activity of Ras, therefore once Ras binds 
GTP and becomes active it is unable to deactivate itself by hydrolysing GTP to 
GDP. RasV12-S35 contains a further point mutation in the effector domain of the 
protein, resulting in the substitution of serine for threonine. This mutation 
prevents Ras from binding the pi 10a subunit of PI-3-Kinase, an interaction that 
is known to lead to the activation of PI-3-Kinase (Rodriguez-Viciana et al., 1994; 
Rodriguez-Viciana etal., 1996). By contrast, RasV12-C40 contains a point 
mutation in the effector domain resulting in the substitution of cysteine for 
tyrosine. This mutation abrogates the interaction between Ras and Raf, 
preventing Ras from activating the Erk-MAPKinase pathway.
Another tool for investigating the role of Ras is the p62'^“‘^  protein, a negative 
regulator of Ras activity. The Dok proteins are a family of adaptor proteins that
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are phosphorylated by a wide range of protein tyrosine kinases. The first Dok 
protein to be isolated was p62'*°*^ , originally identified as a 62 kD tyrosine- 
phosphorylated protein associated with Ras-GAP (Carpino etal., 1997; 
Yamanashi and Baltimore, 1997), a negative regulator of Ras (Bollag and 
McCormick, 1991). p62^ '^ '^  is rapidly tyrosine phosphorylated in response to a 
wide range of stimuli, including ligation of the BCR (Gold etal., 1993) and 
FcyRIIBI ligation (Vuica etal., 1997), and once phosphorylated interacts with a 
number of signalling molecules including Ras-GAP (Carpino etal., 1997; 
Yamanashi and Baltimore, 1997), Nek (Tang etal., 1997), and Csk (Vuica etal., 
1997) via their SH2 domains. In addition to SH2 domain-binding sites, p62‘^ °^  also 
contains a pleckstrin homology (PH) domain, a phosphotyrosine binding (PTB) 
domain, and potential SH3 domain-binding sites. Initially, p62^ °*^  was suspected 
of playing a positive role in mitogenic signalling as it was first identified as a 
substrate for the p210^ '^"'^ '^ oncoprotein (Carpino et al., 1997), as well as a target 
of v-AbI in v-AbI transformed B cells (Yamanashi and Baltimore, 1997). However, 
evidence is accumulating that suggests p62^ °"^  actually plays a negative role in 
Erk-MAPKinase activation and proliferation. Cells from mice deficient in p62^ ®'^  
demonstrate increased proliferation in response to growth factors, and such cells 
exhibit prolonged Erk-MAPKinase and Ras activation in response to growth 
factors (Di Cristofano et al., 2001). Inactivation of p62^ °"^  also enhances the 
transforming ability of p210*’‘^ ''"®'^ ', accelerating the onset of the chronic 
myelogenous leukaemia (CML)-iike disease triggered by expression of the 
chimeric protein (Di Cristofano et al., 2001). Réintroduction of p62^°’^  into mouse 
embryo fibroblast (MEF) cells from p62^ °"^ '^ " mice results in a return to a normal 
level of proliferation in response to PDGF, rather than the enhanced proliferative 
response seen in p62^ °"^ "^ ' MEFs, and this was concomitant with an abrogation of 
the sustained Ras and Erk-MAPKinase activation seen in p62^ °'^ "^ ' cells (Zhao et 
al., 2001). In B cells, p62^ °"^  negatively regulates Erk-MAPKinase activation and 
cell proliferation mediated by the BCR, by abrogating Ras activation (Yamanashi 
et al., 2000), and is phosphorylated in response to BCR-FcyRIIB co-ligation, 
enhancing its binding of Ras-GAP, implicating p62^°  ^as a key mediator of
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FcyRIIB inhibition of BCR-mediated Ras activation (Tamir et al., 2000). The 
phosphorylation of p62^ °"^ , and subsequent association with Ras-GAP, is 
dependent on phosphorylation of the ITIM of FcyRIIB, and the concomitant 
recruitment of SHIP to the ITIM, as p62 °^'  ^does not have a domain with which to 
interact with the ITIM, and has been shown to interact directly with SHIP (Tamir 
et al., 2000).
3.1.3 CD40 mediated rescue of apoptosis
As mentioned above, not all immature B lymphocytes undergo apoptosis in 
response to antigen. This reflects the importance of extrinsic signals upon the 
fate of B lymphocytes, and one such key signal is generated through CD40. The 
ability of CD40 to rescue both immature B lymphocytes from BCR-mediated 
apoptosis and prevent the spontaneous death of mature B cells is well 
documented (Choi etal., 1995; Monroe, 2000). However, the signalling 
mechanisms utilised by CD40 to achieve these outcomes are only just coming to 
light, particularly the downstream events. The initial signalling mechanisms, 
however, have been partially elucidated in recent years. For example, it has been 
shown that CD40 ligation results in the activation of the Erk-MAPKinase, JNK, 
and p38 stress-activated kinases, depending on the maturation stage of the cell, 
making dissection of the signalling mechanisms downstream of CD40 
complicated (Berberich eta!., 1996; Purkerson and Parker, 1998; Sutherland et 
al., 1996).
Studies in our laboratory have shown no evidence of Erk-MAPKinase activation 
in WEHI-231 cells in response to CD40 stimulation alone, however, anti-CD40 
co-stimulation was shown to alter the kinetics of ERK-MAPKinase activation in 
anti-lg treated WEHI-231 cells (Gauld, 2001). In contrast. p38 is activated in 
response to either anti-lg or anti-CD40 stimulation alone in WEHI-231 cells, with 
slightly different kinetics, though maximal activation is seen within 15 minutes in 
both cases (Craxton etal., 1998).
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3.2 Aims and objectives
The membrane proximal signalling events initiated in response to BCR ligation 
are becoming fairly well elucidated, with 3 key signalling pathways now known to 
be the major targets. The biological responses that are a consequence of BCR 
ligation have also been well established, with immature B cells undergoing 
growth arrest and/or apoptosis, while mature B cells undergo proliferation and 
differentiation. Some major effector molecules of these events have also been 
well characterised, with NF-kB and c-myc known to be major players in B cell 
response to antigen. However, the links between the activation of the 3 major 
signalling pathways and the key effector molecules are less well known. The 
aims of this research project are to further elucidate the downstream signalling 
pathways involved in linking BCR ligation with regulation of the cell cycle and 
induction of apoptosis in immature B lymphocytes. This study aims to investigate 
the role of Erk-MAPKinase in cell cycle progression of immature B lymphocytes, 
using the WEHI-231 cell line as a model. In particular, it aims to address:
1. The role of the small GTPase Ras in BCR-mediated signalling, using the 
constitutively active Ras mutant, RasV12.
2. The role of the effector molecules that Ras interacts with, using mutant 
forms of RasV12 that are unable to interact with key effector molecules.
3. The use of negative regulators of Ras (the p62'^ °'^  protein) and PI-3-Kinase 
(the inositol phosphatase SHIP) to corroborate Ras effector mutant data.
4. How these pathways link with the cell cycle machinery.
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3.3 Results
3.3.1 Anti-lg induces growth arrest of WEHI-231 cells, and this is rescued 
by co-stimulation with anti-CD40
It is well established that treatment of WEHI-231 immature B lymphocytes with 
anti-lg antibodies inhibits DNA synthesis and induces apoptosis (Hasbold and 
Klaus, 1990). Thus, as shown in Figure 3.1, treatment of WEHI-231 cells with 
anti-lg (B7.6) causes a dose-dependent increase in growth arrest, as assessed 
by the [^H]-thymidine uptake assay. In addition, co-stimulation of WEHI-231 cells 
through CD40 is known to protect the cells from such anti-lg induced growth 
arrest (Choi et al., 1995). Thus, Figure 3.1 also shows that co-stimulation with 
anti-CD40 (10 }xg/mi) restores DNA synthesis, as measured by pH]-thymidine 
uptake, back to the levels observed in unstimulated cells.
3.3.2 Anti-lg induces apoptosis in WEHI-231 cells, and this is rescued by 
co-stimulation with antl-CD40
The above experiments confirmed that BCR-ligation induces growth arrest in 
WEHI-231 cells, and that this growth arrest can be abrogated by co-stimulation 
with anti-CD40. BCR-ligation is also known to induce apoptosis in WEHI-231 
cells (Hasbold and Klaus, 1990), but thymidine uptake experiments give no 
indication as to the levels of apoptosis. To investigate the levels of apoptosis 
induced by anti-lg stimulation, and the protection from apoptosis afforded by co­
stimulation with anti-CD40, the number of cells in a population displaying sub­
diploid DNA content, as measured by flow cytometry following staining with the 
DNA intercalating dye propidium iodide, was measured. Figure 3.2 shows the 
effect of BCR-ligation on the DNA content profile of WEHI-231 cells, and the 
effect co-stimulation with anti-CD40 has on anti-lg-mediated apoptosis. The 
results confirm the ability of BCR-ligation to induce apoptosis in WEHI-231 cells, 
and the ability of stimulation via CD40 to protect WEHI-231 cells from anti-lg
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induced apoptosis. Anti-lg also induces a substantial increase in the proportion of 
cells in Gi phase of the cell cycle, with a concomitant decrease in the proportion 
of cells in both S phase and G2/M. Co-stimulation with anti-lg and antl-CD40 
leads to restoration of the proportion of cells in S phase and G2/M, corroborating 
the data from the previous section that stimulation via CD40 overcomes anti-lg 
induced growth arrest (Figure 3.1). By 72 hours, unstimulated cells, as well as 
cells stimulated with the combination of anti-lg and anti-CD40, begin to 
accumulate in Gi. This is most likely due to depletion of essential nutrients in the 
culture, as the cells are not dying, just ceasing to proliferate.
3.3.3 Anti-lg treatment of WEHI-231 cells results in the long term down 
regulation of Erk-MAPKinase activity, and this is restored during CD40- 
mediated rescue
Studies to investigate the signalling mechanisms underlying the growth arrest 
and apoptosis induced by anti-lg treatment of WEHI-231 cells, and the CD40- 
mediated rescue of anti-lg mediated effects, initiated in this laboratory by Gauld 
and Harnett identified potential dual roles for Erk-MAPKinase signalling in 
apoptosis and cellular proliferation in these cells. For example, in untreated 
WEHI-231 cells, there is a cyclical activation of Erk-MAPKinase over a 48 hour 
period (Figure 3.3) Stimulation with anti-lg, however, enhances the early 
activation of Erk-MAPKinase, particularly at 2 hours post stimulation, but 
completely abolishes the sustained Erk-MAPKinase activity exhibited by 
unstimulated cells beyond 4 hours (Figure 3.3). Treatment of cells with the 
combination of anti-lg and anti-CD40 prevents this down-regulation of Erk- 
MAPKinase activity, and indeed re-establishes and strengthens the cyclical 
pattern of Erk-MAPKinase activitation in WEHI-231 cells (Figure 3.3). Whilst anti- 
CD40 alone does not stimulate Erk-MAPKinase activity at early time points, the 
cyclical pattern of Erk-MAPKinase activation is still observed, with the levels 
peaking at 8 and 48 hours, with a lower level at 24 hours post stimulation. These 
findings suggest a key role for Erk-MAPKinase activity in the spontaneous
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proliferation of WEHI-231 cells, and that the abrogation of this activity, due to 
BCR ligation, may be sufficient to induce growth arrest and apoptosis. The 
restoration of Erk-MAPKinase activity induced by anti-CD40 treatment further 
underscores the potential significance of Erk-MAPKinase activity in the 
proliferation of WEHI-231 cells.
3.3.4 Erk-MAPKinase activity contributes to spontaneous proliferation and 
CD40-mediated rescue of growth arrest in WEHI-231 cells
Due to the sustained, but cyclical, activity of Erk-MAPKinase in untreated WEHI- 
231 cells and the ability of CD40 stimulation to restore Erk-MAPKinase activity in 
BCR stimulated cells, it was decided to study more closely the role Erk- 
MAPKinase plays in WEHI-231 B cell responses. Thus, MEK inhibitors were 
used to dissect the role Erk-MAPKinase plays in the proliferation of WEHI-231 
cells. To ensure maximal inhibition of Erk-MAPKinase, two MEK inhibitors, 
PD98059 and U0126, were tested in combination. These two inhibitors have 
different mechanisms for inhibiting MEK, suggesting they might work 
synergistically. For example, PD98059 inhibits MEK by binding to it and 
preventing its phosphorylation and concomitant activation by Raf, whereas 
U0126 directly inhibits the catalytic activity of MEK.
WEHI-231 cells were pre-treated with the MEK1/2 inhibitors PD98059 and U0126 
(both at 1 jxM), or no inhibitor, and stimulated with anti-lg, either alone or in 
combination with anti-CD40. Control cells received no stimulating antibodies. 
Cells treated with the MEK inhibitors were treated with an additional dose (1 j^M) 
every 4 hours for a total of 32 hours due to the inherent instability of these 
inhibitors in WEHI-231 cells (Gauld etal., 2002). Proliferation was assessed after 
48 hours by means of the fH]-thymidine incorporation assay (Figure 3.4). 
Following a stimulation time of 48 hours, the inhibition of MEK in this manner was 
effective at inducing growth arrest of spontaneously proliferating cells, as well as 
enhancing anti-lg induced growth arrest. Inhibition of MEK was also effective at
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abrogating CD40-nnediated rescue from growth arrest. These results suggest a 
key role for Erk-MAPKInase in both the spontaneous proliferation of WEHI-231 
cells and in the rescue of WEHI-231 cells from anti-lg mediated growth arrest by 
CD40, reinforcing earlier observations.
3.3.5 Effect of cell cycle Inhibitors on WEHI-231 cells
The observations outlined above strongly suggest that Erk-MAPKinase plays a 
major role in the proliferation of WEHI-231 cells. To further investigate how Erk- 
MAPKinase promotes WEHI-231 cell proliferation, we decided to examine the 
role Erk-MAPKinase plays at various stages of the cell cycle. In order to achieve 
this, cell cycle inhibitors were utilised to arrest WEHI-231 cells at various stages 
of the cell cycle, with the intention of synchronising the cells at a particular stage 
then releasing them from the inhibition. As we intended to study the function of 
Erk-MAPKinase at various cell cycle stages, a number of cell cycle inhibitors 
were assessed for their suitability at arresting the cell cycle at either Gq/Gi, S 
phase, or G2/M.
Olomoucine (2-(2-hydroxyethylamino)”6-benzylamino-9-methylpurine) is a purine 
derivative that acts as a competitive inhibitor of cyclin dependent kinases (CDKs) 
and induces Gi arrest (see Figure 1.9) (Abraham etal., 1995). In contrast, 
aphidicolin inhibits DNA synthesis by binding to DNA polymerase a, therefore 
inducing arrest in S phase (Mutomba and Wang, 1996). Nocodazole is an 
antimitotic agent that disrupts microtubules by binding to p-tubulin, inhibiting 
microtubule dynamics, disrupting mitotic spindle function and fragmenting the 
Golgi apparatus, reportedly resulting in G2/M arrest in a number of cell types.
To determine the efficiency of the cell cycle inhibitors olomoucine, aphidicolin, 
and nocodazole at inducing cell cycle arrest in WEHI-231 cells, cells were treated 
with each inhibitor over a period of 48 hours, and the cell cycle position of the cell
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populations determined at various time points by DNA content analysis by flow 
cytometry after staining with propidium iodide (50 }ig/ml).
As Figure 3.5 shows, olomoucine and aphidicolin induce arrest in WEHI-231 
cells in the appropriate phase of the cell cycle. Olomoucine results in a dramatic 
increase in the proportion of cells in Go/Gi compared to control cells, whilst 
aphidicolin greatly increases the proportion of cells in S phase, as would be 
expected. Nocodazole, however, appeared to be less efficient than the other two, 
as the proportion of cells in G2/M is very similar to that of the control cells. This 
failure could be explained by the accompanying increase in the proportion of sub­
diploid cells, which is perhaps unsurprising as nocodazole is known to induce 
apoptosis in a number of normal and tumour cell lines.
Using these inhibitors, it was only possible to attain enriched populations of each 
phase, as opposed to fully synchronised populations. As olomoucine inhibits the 
cdc2 (also known as CDK1) and CDK2 kinases, this is possibly due to the fact 
that the G2/M transition will be blocked slightly as well as the Gi/S transition (see 
Figure 1.9), resulting in most cells arresting in Gi, but a small percentage also 
arresting in G2. Too high a concentration, or treatment for an extended period of 
time, resulted in a vast increase in the percentage of WEHI-231 cells undergoing 
apoptosis, particularly following treatment with aphidicolin and nocodazole. The 
optimum conditions to induce reversible arrest in WEHI-231 cells were found to 
be 50 fxM olomoucine for 40 hours, and 5 (xg/ml aphidicolin for 24 hours. As 
nocodazole failed to significantly enrich the G2/M population without causing an 
increase in apoptosis, it was decided not to pursue use of this inhibitor in further 
studies.
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3.3.6 A role for cyclical Erk-MAPKinase activation in cell cycle progression 
of WEHI-231 cells
To investigate how cycling Erk activation correlates with cell cycle progression, 
the activity of Erk in WEHI-231 cells was analysed after release of cells from 
either Gi or S phase arrest, induced by olomoucine and aphidicolin respectively. 
WEHI-231 cells were therefore incubated with either 50 \iM olomoucine for 40 
hours, or 5 jxg/ml aphidicolin for 24 hours to induce arrest, then washed twice 
with fresh media to remove the cell cycle blockers. Arrested cells were then 
stimulated with anti-lg, a combination of anti-lg and anti-CD40, or left 
unstimulated in media for up to 48 hours, and whole cell lysates made at the 
appropriate time points. Erk activity was examined by western blotting of cell 
lysates with an anti-phospho-Erk antibody (Figure 3.6).
As with asynchronous cells, treatment with anti-lg alone induces inhibition of Erk 
activity by 16-24 hours, following an earlier, transient increase. Co-stimulation 
with anti-CD40 induces strong cycling Erk activation during this later time period, 
particularly in cells released from olomoucine-induced growth arrest (Gi). This 
supports the hypothesis that anti-lg induces growth arrest in WEHI-231 cells by 
suppressing sustained Erk activity associated with cell cycle progression, and 
that anti-CD40 rescues cells by reinstating such Erk activity, promoting cell cycle 
progression. The pattern of Erk activation in response to anti-lg and anti-CD40 
co-stimulation is slightly different between the cells arrested at different phases, 
most strikingly at 16 hours. The cells released from olomoucine arrest appear to 
demonstrate a strong Erk signal at this time. This time point could correlate with 
the Gi/S phase transition as these cells were previously arrested in Gi, 
suggesting a key role for Erk-MAPKinase activity somewhere around the Gi/S 
phase boundary. Overall, it appears that Erk activity follows a cyclical pattern 
regardless of where in the cell cycle the cells are at the outset, and that BCR 
ligation is capable of inhibiting Erk activity at any cell cycle stage, suggesting that 
it is unlikely to be associated with a single phase of the cell cycle. To address
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more directly the role of Erk-MAPKinase in driving cell cycle progression, 
intracellular staining of phospho-Erk was analysed at distinct cell cycle phases 
using the Laser Scanning Cytometer (LSC).
WEHI-231 cells were incubated in the presence of olomoucine (50 \iM) for 40 
hours, or aphidicolin (5 ^g/ml) for 24 hours, then washed to remove the cell cycle 
blocker. Arrested cells were then stimulated with anti-lg, a combination of anti-lg 
and anti-CD40, or left unstimulated in media for up to 48 hours. Cells were 
attached to slides at the appropriate time points, fixed and permeabilised, then 
stained for phospho-Erk and the DNA content assessed by staining with 
propidium iodide, as described in Section 2.12.2. Following staining, cells were 
scanned by LSC.
The majority of cells transiting the cell cycle were found to exhibit phospho-Erk 
staining, whereas fewer than 50% of newly formed daughter cells demonstrate 
phospho-Erk staining (Figure 3.7). Growth arrest-inducing treatments 
(olomoucine or anti-lg) reduced the percentage of cells expressing phospho Erk, 
indicating a strong link between Erk activity and cell cycle progression. This 
suggests that a late Erk signal is required by WEHI-231 cells to transit from Gi to 
S phase, indeed, in each cell cycle phase a high proportion of the cells display 
phospho-Erk staining, strongly suggesting that Erk-MAPKinase activity is 
required by WEHI-231 cells at every stage of the cell cycle.
3.3.7 Transfection of WEHI-231 ceils with RasV12 constructs
The above results suggest that Erk-MAPKinase plays an important role in the 
spontaneous proliferation of WEHI-231 cells, as well as in CD40-mediated 
rescue of anti-lg induced growth arrest. One of the key upstream regulators of 
Erk-MAPKinase activity is the small GTPase Ras, a key regulator of growth in all 
eukaryotic cells. To complement the above studies, we wished to see if over-
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expression of a constitutively active Ras mutant, RasV12, could rescue WEHI- 
231 cells from anti-lg induced growth arrest and/or apoptosis.
The first system for transfection we utilised was retroviral transfection, whereby 
the DNA of interest is packaged into a retroviral particle, which enters the cells 
via a specific receptor. DNA encoding RasV12 was inserted into the MIEV vector 
(Figure 2.7) using the Eco RI restriction enzyme sites present in the vector. This 
vector contains an internal ribosome entry site between the gene of interest and 
an enhanced green fluorescent protein gene (eGFP). This permits the 
identification of transfected cells on the basis that the eGFP is expressed along 
with the protein of interest, therefore transfected cells can be identified by flow 
cytometry and selected using a fluorescence activated cell sorter. The vector 
containing the RasV12 gene was first transiently transfected, as described in 
Section 2.13.2, into the PT67 cell line, an NlH/3T3-based packaging cell line that 
expresses the 10A1 viral envelope, permitting the vector DNA to be packaged 
into a form that is capable of transfecting cells expressing either the amphotropic 
retrovirus receptor or the GALV receptor. The supernatant from PT67 cells 
transiently transfected with MIEV.RasV12 was then used to transfect the GP+E- 
86 cell line, another NIH/STS-based packaging cell line that contains the gag, pal, 
and env genes of MMLV, and generates viral particles capable of infecting rat or 
murine cells (ecotropic). The gag, pal, and env genes are required for production 
of virus particles as the MIEV vector has had the structural genes removed to 
allow for insertion of the gene of interest. Successfully transfected GP+E-86 cells 
were selected on the basis of their green fluorescence using a FACSVantage™ 
cell sorter (Becton Dickinson) as described in Section 2.13.3.
Stably transfected GP+E-86 cells were then used to infect WEHI-231 cells with 
the MIEV.RasV12 vector by co-culture, as described in Section 2.13.4. After co­
culture with the stably-transfected GP+E-86.MIEV.RasV12 retroviral packaging 
line, Figure 3.8 shows that at least 80% of the WEHI-231 population were 
transfected, as measured by green fluorescence. The MIEV vector alone was
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also transfected into WEHI-231 cells in the same manner, and Figure 3.8 also 
shows that approximately 60% of cells were transfected with empty vector.
To complement the retroviral transfection studies, we decided to introduce the 
RasV12 coding sequence into WEHI-231 cells via electroporation also. To 
facilitate this, the RasV12 coding sequence was also inserted into the pcDNA3.1 
vector (Figure 2.9), again using the Eco RI restriction enzyme sites. This vector 
was introduced to WEHI-231 cells by electroporation, as described in Section 
2.14. Successfully transfected cells were selected by the addition of G418 (500 
fxg/ml) 48 hours after electroporation, as pcDNA3.1 confers resistance to G418 
upon WEHI-231 cells.
3.3.8 Effect of RasV12 transfection on response to anti-lg mediated growth 
arrest in WEHI-231 cells
Wild type WEHI-231 cells exhibit a pronounced growth arrest in the Gi phase of 
the cell cycle in response to anti-lg stimulation, as demonstrated in Figure 3.1. 
To investigate the effects of the constitutively active Ras mutant, RasV12, on 
anti-lg mediated growth arrest in WEHI-231 cells, WEHI-231 cells transfected 
with this form of Ras, either retrovirally or by electroporation, were stimulated 
with various concentrations of anti-lg for 48 hours, and proliferation assessed by 
the [^H]-thymidine uptake assay. When WEHI-231 cells retrovirally transfected 
with the constitutively active Ras mutant, RasV12, are stimulated with anti-lg the 
resulting growth arrest is less pronounced than that exhibited by wild type cells, 
particularly with 10 pg/ml anti-lg (Figure 3.9A).
WEHI-231 cells that have been transfected with pcDNA3.1.RasV12 by 
electroporation demonstrate an even more pronounced abrogation of anti-lg 
induced growth arrest (Figure 3.9B). In neither case is the alteration in anti-lg 
induced growth arrest a result of the vector, as WEHI-231 cells transfected with 
either empty vector behave in the same manner as wild type WEHI-231 cells,
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when stimulated with anti-lg (Figure 3.9A and 3.9B). As the RasV12 mutant is 
constitutively active these results suggest that activation of Ras is sufficient to 
prevent, or at least inhibit, anti-lg mediated growth arrest, resulting in promotion 
of proliferation. Indeed, in most cell types, RasV12 is capable of inducing 
transformation by circumventing the requirement for growth factor signals.
3.3.9 Effect of RasV12 transfection on response to anti-lg mediated 
apoptosis in WEHI-231 cells
To investigate whether the effect of RasV12 transfection on anti-lg induced 
growth arrest was a result of a concomitant decrease in anti-lg mediated 
apoptosis, DNA content analysis by flow cytometry following staining with 
propidium iodide was performed, following anti-lg stimulation. Retroviral 
transfection of WEHI-231 cells with RasV12 inhibits anti-lg-induced apoptosis, as 
there are far fewer WEHI-231 cells expressing RasVI2 with sub-diploid DNA 
content than wild type cells (Figure 3.10A). This decrease in the proportion of 
cells with a sub-diploid DNA content in response to anti-lg is accompanied by an 
increase in the proportion of cells in both S phase and G2/M, which is rather 
surprising as the [^H]-thymidine uptake assay suggested that these cells were 
still susceptible to anti-lg induced growth arrest, though not to quite the same 
extent as those containing the empty vector (Figure 3.9A) As before, this effect 
is not a direct consequence of the introduction of the MIEV vector to the cells, as 
WEHI-231 cells transfected with the MIEV empty vector respond in the same 
manner as wild type cells to anti-lg, with the levels of apoptosis doubling when 
cells are treated with anti-lg (Figure 3.10A).
WEHI-231 cells that have been transfected with pcDNA3.1.RasV12 by 
electroporation do not display the same inhibition of anti-lg induced apoptosis, 
but rather have a higher percentage of cells with a sub-diploid DNA content 
compared to those transfected with the empty pcDNAS.I vector (Figure 3.10B). 
This is accompanied by an increase in the percentage of cells in G0/G1, and a
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decrease in the percentage of cells in S phase and Gg/IVI, in response to anti-lg. 
This is surprising as the [^H]-thymidine assay suggested that these cells were 
protected from anti-lg induced growth arrest (Figure 3.9B), yet when the DNA 
content is analysed it appears as though anti-lg induced growth arrest is not 
affected.
3.3.10 Effect of RasV12 transfection on CD40-mediated rescue of anti-lg 
induced growth arrest and apoptosis in WEHI-231 cells
To investigate the effects that RasV12 has on CD40-mediated rescue of anti-lg 
induced growth arrest and apoptosis, transfected cells were stimulated with anti- 
lg alone, or a combination of anti-lg and anti-CD40. Following stimulation for 48 
hours, proliferation was assessed by the [^H]-thymidine incorporation assay 
(Figure 3.11), and apoptosis was assessed by DNA content analysis by flow 
cytometry following staining with propidium iodide (Figure 3.10). The effect of 
RasV12 on CD40-mediated rescue of anti-lg induced growth arrest appears to 
vary greatly depending on the transfection method (Figure 3.11). Retrovirally 
transfected RasV12 appears to completely abrogate CD40-mediated rescue of 
anti-lg induced growth arrest, as the levels of proliferation are similar to that of 
cells stimulated with anti-lg alone. In contrast, cells transfected by electroporation 
with RasV12 exhibit greater proliferation in response to anti-lg and anti-CD40 
stimulation than cells transfected with the vector alone. As RasV12 induces 
growth and transformation of most cell types, increased CD40-mediated 
proliferation is not an unexpected phenomenon. What is unexpected, however, is 
the difference in consequences depending on the transformation method.
DNA content analysis of WEHI-231 cells retrovirally transfected with RasV12 
suggests that CD40-mediated rescue of anti-lg induce growth arrest and 
apoptosis is slightly enhanced by the expression of RasVI2, particularly as there 
are over twice as many cells in G2/M compared to cells transfected with the 
empty vector alone (Figure 3.10A). This appears to contradict the [^H]~thymidine
108
assay data, where anti-CD40 did not appear to overcome anti-lg induced growth 
arrest (Figure 3.11). However, the [^H]-thymidine assay specifically measures 
cells in S phase of the cell cycle, therefore as there are a large percentage in 
Ga/M these would not be detected in that assay. In contrast, DNA content 
analysis of WEHI-231 cells containing the pcDNA3.1.RasV12 vector corroborates 
the [^H]-thymidine results, with cells exhibiting a strong rescue from anti-lg 
induced apoptosis, as there is a decrease in the proportion of apoptotic cells and 
a concomitant increase in the proportion of cells in S phase or Ga/M phases upon 
anti-lg and anti-CD40 co-stimulation, compared to cells stimulated with anti-lg 
alone (Figure 3.1 OB).
3.3.11 Effect of the p62°‘^ ’‘ PH-PTB domain on anti-lg mediated growth 
arrest and apoptosis in WEHI-231 cells
The Dok proteins are a family of adaptor proteins that are phosphorylated by a 
wide range of protein tyrosine kinases. The first Dok protein to be isolated was 
p62^ °"^ , originally identified as a 62 kD tyrosine-phosphorylated protein associated 
with Ras-GAP (Carpino etal., 1997; Yamanashi and Baltimore, 1997), a negative 
regulator of Ras (Bollag and McCormick, 1991). In B cells, p62^°“^ negatively 
regulates Erk-MAPKinase activation and cell proliferation mediated by the BCR, 
by abrogating Ras activation (Yamanashi etal., 2000). To complement the above 
studies, we decided to use the amino terminal portion of Dok, which contains 
pleckstrin homology (PH) and phosphotyrosine binding domains (PTB). This 
portion of the protein should not be able to abrogate Ras, and concomitant Erk- 
MAPKinase, activation, as these domains are not involved in Ras-GAP binding, 
therefore will not be able to induce the GTPase activity of Ras. WEHI-231 cells 
overexpressing the first 258 amino acids of Dok (Dok-PH/PTB a kind gift, along 
with cells expressing the empty retroviral vector, pMXI, of Stephen Gauld, Idan 
Tamir and John Cambier, Denver, CO, USA) were used to determine the role 
p62 °^'  ^plays, if any, in the anti-lg mediated growth arrest and apoptosis of WEHI- 
231 cells.
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To investigate the effects this portion of p62^ °"^  has on anti-lg induced growth 
arrest, cells expressing this domain were stimulated with anti-lg and proliferation 
assessed after 48 hours by the [3H]-thymidine uptake assay, and apoptosis 
assessed by DNA content analysis following staining with propidium iodide. 
WEHI-231 cells expressing Dok-PH/PTB exhibit no significant difference in 
growth arrest induced by anti-lg, or in anti-CD40-mediated rescue when 
compared to cells transfected with the empty vector alone (Figure 3.12A). The 
DNA content analysis following propidium iodide staining further demonstrates 
this, with 80% of Dok-PH/PTB expressing cells arrested in G0/G1 in response to 
anti-lg stimulation, compared to 75% of those cells containing the empty vector 
(Figure 3.12B). Interestingly, despite the proliferation assay suggesting GD40- 
mediated rescue occurs as normal, there appears to be slightly fewer cells in S 
and G2/M phases upon stimulation of these cells with anti-lg and anti-CD40, and 
a greater proportion displaying a sub-diploid DNA content. This is not what would 
be anticipated, as cells lacking p62‘^ °'^  demonstrate sustained Ras activation 
(Zhao et ai, 2001), and as the Dok-PH/PTB domain is thought to act in a 
dominant negative fashion, it would be expected that Ras would be activated and 
the cells more prone to proliferation. However, recent studies in our laboratory 
have suggested that BCR ligation in WEHI-231 cells increases the association of 
the Erk-MAPKinase specific phosphatase, Pac-1, with Erk-MAPKinase (Gauld, 
2001). This could result in BCR-induced Erk-MAPKinase activity being switched 
off downstream from Ras and MEK, so perhaps this overrides any effects p62‘^ ®‘^  
may have had on Erk-MAPKinase activity upon BCR ligation.
3.3.12 Transfection of the WEHI-231 cell line with RasV12 effector mutants
Ras has a number of effector pathways involved in an array of biological 
outcomes, two of the most important being the ERK-MAPK pathway and the Pl- 
3-K pathway. To address the question of whether these two pathways are 
involved in the inhibition of anti-lg-induced growth arrest, two RasVI2 effector
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mutants were transfected into the WEHI-231 cell line. These two mutants were 
RasV12-S35 and RasVI 2-C40, both of which contain the V I2 point mutation, 
along with one further point mutation each. RasV12-S35 contains a point 
mutation that results in a substitution of serine for threonine at position 35, in the 
heart of the domain of Ras responsible for interacting with its effector molecules. 
This mutation renders Ras incapable of interacting with the p i 10a subunit of PI- 
3-Kinase, or Ral.GDS, but it is still capable of interacting with Raf-1, therefore 
this Ras mutant can only activate the ERK-MAPK pathway (Rodriguez-Viciana et 
al., 1997). RasVI2-C40 is the consequence of a point mutation that results in the 
substitution of cysteine for tyrosine at position 40. This substitution abrogates the 
interaction between Ras and its effectors Raf-1 and Ral.GDS, but not PI-3- 
Kinase, resulting in a form of active Ras that can only activate the PI-3-Kinase 
pathway (Rodriguez-Viciana etal., 1997).
As with the RasVI 2 mutant, the effector mutants were introduced to the cells via 
two different methods, retroviral transfection and electroporation. To facilitate 
retroviral transfection, DNA encoding each effector mutant was inserted into the 
MIEV vector (Figure 2.7), and these vectors were used to generate stably 
transfected GP+E-86 retroviral packaging lines, as above. These packaging lines 
were then used to infect WEHI-231 cells in the same manner as the 
MIEV.RasVI2 vector. Figure 3.13 shows that approximately 65% of the 
population of WEHI-231 cells were successfully transfected with the RasVI 2-S35 
construct, whilst approximately 61% were successfully transfected with the 
RasVI 2-C40 construct, as determined by green fluorescence. The coding 
sequences for RasVI 2-S35 and RasVI2-C40 were also inserted into the 
pcDNA3.1 vector, and introduced to cells by electroporation, as described above. 
Successful transfectants were selected using the antibiotic G418.
11
3.3.13 Effect of the RasVI 2 effector mutant RasVI 2-S35 on WEHI-231 
response to anti-lg mediated growth arrest
To determine the effect that the RasVI 2-S35 mutant has on the response of 
WEHI-231 cells to anti-lg and anti-CD40 stimulation, transfected cells were 
stimulated as before and their biological responses assessed. WEHI-231 cells 
retrovirally transfected with the RasVI2-S35 construct (WEHI-231 M!EV.RasV12- 
S35) exhibit no great difference in their response to anti-lg compared to cells 
transfected with the empty vector (Figure 3.14A). This is not the case when 
RasVI 2-S35 is introduced to the cells by electroporation, as the growth arrest in 
response to anti-lg in these cells is not as great as those transfected with the 
empty vector alone, and is not significantly different from cells expressing 
RasVI2 (Figure 3.14B). CD40-mediated rescue from anti-lg induced growth 
arrest is not affected by RasVI2-S35, as cells transfected by both methods 
exhibit a robust proliferative response upon stimulation by anti-lg and anti-CD40 
(Figure 3.14A and B). This is in contrast to cells retrovirally transfected with 
RasVI 2, which are not refractive to CD40-mediated rescue of anti-lg induced 
growth arrest (Figure 3.14A).
3.3.14 Effect of the RasVI 2-S35 effector mutant on anti-lg mediated 
apoptosis in WEHI-231 cells
To determine the effects of the RasVI 2-S35 effector mutant on BCR-mediated 
apoptosis, the percentage of sub-diploid cells was investigated as before, by 
DNA content analysis following staining with propidium iodide, after stimulation 
with anti-lg alone, or in combination with anti-CD40. WEHI-231 MIEV.RasVI2- 
S35 cells have a similar proportion of cells displaying a sub-diploid DNA content 
in response to anti-lg, when compared to cells transfected with the empty vector 
(Figure 3.ISA) These cells show an alteration in their response to co-stimulation 
with anti-lg and anti-GD40, as anti-GD40 does not afford the same level of 
protection from apoptosis, as there are a similar proportion of sub-diploid cells
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after co-stimulation with anti-lg and anti-CD40 as there are when the cells were 
stimulated with anti-lg alone (Figure 3.15A). This is in stark contrast to cells 
transfected with MIEV.RasVI 2, as a very low percentage of these cells display a 
sub-diploid DNA content when they are treated with anti-lg and anti-CD40. These 
results suggest that Ras activation of the PI-3-Kinase pathway may play a role in 
the CD40-mediated reversal of anti-lg induced cell death in WEHI-231 cells, as 
the RasVI2-S35 mutant is unable to activate PI-3-Kinase. The reversal of growth 
arrest is not affected as measured by the f  H]-thymidine assay (Figure 3.14A), 
and the DNA content analysis appears to corroborate this as the proportion of 
RasVI 2-S36 expressing cells in S phase and G2/M in response to anti-lg and 
anti-CD40 costimulation is similar to that of cells expressing the empty vector 
alone (Figure 3.15A). This suggests that Ras induced PI-3-Kinase activity is 
required for CD40-mediated protection from anti-lg induced apoptosis, but not 
anti-lg induced growth arrest. As PI-3-Kinase has been widely suggested to play 
a role in cell survival, a role for it in the CD40-mediated protection from apoptosis 
and not growth arrest is plausible.
Cells expressing the RasVI2-S35 mutant from the pcDNA3.1 vector (WEHI-231 
pcDNA3.1.RasVI 2-S35) behave in a slightly different fashion. The percentage of 
sub-diploid cells is quite low in response to anti-lg in these experiments, though 
the FACS data correlates with the proliferation data in that there is an increase in 
the number of cells in G0/G1 upon anti-lg stimulation, compared to unstimulated 
cells, hence cell cycle arrest is still taking place in response to anti-lg (Figure 
3.15B). The proportion of sub-diploid cells decreases upon co-stimulation with 
anti-CD40, in stark contrast to the retrovirally transfected cells, where it appeared 
as though CD40-mediated inhibition of anti-lg induced apoptosis was abrogated.
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3.3.15 Effect of the RasVI2-C40 effector mutant on anti-lg mediated growth
arrest in WEHI-231 cells
To determine the effect that the RasVI 2-C40 mutant has on the response of 
WEHI-231 cells to anti-lg and anti-CD40 stimulation, transfected cells were 
stimulated as before and their proliferation assessed by the [3H]-thymidine 
uptake assay. WEHI-231 cells transfected with MIEV.RasVI2-C40 exhibit a 
similar extent of anti-lg mediated growth arrest to cells transfected with the empty 
vector alone, and cells transfected with RasVI 2, when 10 [xg/ml anti-lg is used, 
however, at lower concentrations anti-lg has little effect (Figure 3.16A). CD40- 
mediated rescue from anti-lg induced growth arrest does not appear to be altered 
by expression of RasVI 2-C40, as these cells exhibit a robust proliferative 
response to anti-lg and anti-CD40 stimulation, particularly compared to cells 
expressing the RasVI 2 mutant (Figure 3.16A).
Cells that have been transfected with RasVI 2-C40 by electroporation 
demonstrate a low level of growth arrest in response to a wide range of 
concentrations of anti-lg, from 0.1 to 10 \ig/m\ (Figure 3.16B). This strongly 
suggests that RasVI 2-C40 affords some level of protection against anti-lg 
induced growth arrest in WEHI-231 cells, as cells expressing RasVI2-C40 
display around 80% of the proliferation of untreated cells when stimulated with 10 
^g/ml anti-lg. Cells transfected with the empty vector alone on the other hand, 
display only around 40% of the proliferation of untreated cells when stimulated 
with anti-lg, ruling out the vector as a possible explanation for this observation 
(Figure 3.16B). Co-stimulation of cells expressing RasVI 2-C40 with anti-lg and 
anti-CD40 results in proliferation levels higher than untreated cells, but as the 
growth arrest was much less in response to anti-lg, this is a less than surprising 
observation (Figure 3.16B). Indeed, the levels of proliferation of RasVI2-C40 
expressing cells appear to be greater than those of cells containing the empty 
vector by a consistent amount when cells are stimulated with anti-lg alone or in 
combination with anti-CD40.
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3.3.16 Effect of the RasVI 2-C40 effector mutant on anti-lg mediated
apoptosis in WEHI-231 cells
To determine the effects of the RasVI 2-C40 effector mutant on BCR-mediated 
apoptosis, the percentage of sub-diploid cells was investigated as before by DNA 
content analysis following propidium iodide staining. WEHI-231 MIEV.RasV12- 
C40 cells have a reduced apoptotic response to anti-lg, demonstrating a lower 
proportion of cells with a sub-diploid DNA content compared to cells transfected 
with the empty vector, though still higher than cells transfected with RasVI 2 
(Figure 3.17A). The reasons for this are undoubtedly manifold. We have recently 
shown that anti-lg induced apoptosis requires an early (:S 2 hours) Erk signal, 
which activates a phospholipase A2 pathway that mediates arachidonic acid- 
mediated collapse of Atpm and depletion of cellular ATP, resulting in cathepsin B 
execution of apoptosis. When the activation of Erk-MAPKinase is inhibited by 
specific MEK1/2 inhibitors, anti-lg induced apoptosis is significantly decreased, 
almost to basal levels (Gauld et al., 2002). As this Ras mutant is unable to 
interact with and activate the Erk-MAPKinase pathway, this could provide one 
explanation for the decrease in anti-lg induced apoptosis, though endogenous 
Ras should still be able to activate Erk-MAPKinase. Another possible explanation 
is that the PI-3-Kinase pathway is increasing the activity of PKB/Akt, a powerful 
mediator of pro-survival signals capable of suppressing apoptosis induced by a 
wide range of stimuli (Datta et al., 1997). As there was a decrease in anti-lg 
induced apoptosis. It is difficult to draw any conclusions concerning the effect of 
RasVI 2-C40 upon anti-CD40-mediated rescue of apoptosis, though the levels of 
apoptosis are very similar when cells are stimulated with anti-lg in the presence 
or absence of anti-CD40 (Figure 3.17A)
By contrast, WEHI-231 cells containing the pcDNA3.1.RasVI2-C40 vector exhibit 
a greater proportion of cells with a sub-diploid DNA content in response to anti- 
lg, compared to unstimulated cells, though the percentage of unstimulated cells 
displaying a sub-diploid DNA content is very low to begin with (Figure 3.17B).
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Co-stimulation with anti-CD40 inhibits anti-lg induced apoptosis, as the 
proportion of cells with a sub-diploid DNA content drops. This is accompanied by 
an increase in the proportion of cells displaying an S phase or G2/M DNA 
content, supporting the [^H]-thymidine data that showed these cells demonstrate 
increased proliferation when co-stimulated with anti-lg and anti-CD40.
3.3.17 Effect of a catafytically inactive SHIP mutant and the SHIP SH2 
domain on anti-lg mediated growth arrest in WEHI-231 cells
To further investigate the role of PI-3-Kinase signalling, we decided to use cells 
expressing mutant versions of the 5’ inositol phosphatase SHIP, a negative 
regulator of PI-3-Kinase signalling. SHIP antagonises the functions of PI-3- 
Kinase by dephosphorylating the 5’ position of Ptdlns(3,4,5)Ps, a product of PI-3- 
Kinase that is important for the membrane localisation of many PH domain 
containing proteins. WEHI-231 cells retrovirally transfected so that they 
overexpress either a catalytically inactive mutant of SHIP (SHIP-CI) or the SH2 
domain atone (SHIP-SH2, both a kind gift of Stephen Gauld, Idan Tamir, and 
John Cambier, Denver, CO, USA) were used to determine the role SHIP plays, if 
any, in the anti-lg mediated growth arrest and apoptosis of WEHI-231 cells. 
Overexpression of these mutants should elicit a dominant negative effect, by 
preventing endogenous SHIP interacting with the appropriate proteins, thus its 
activity. To investigate the effects expression of these SHIP mutants has on anti- 
lg induced growth arrest in WEHI-231 cells, cells expressing them were 
stimulated with anti-lg, either alone or in combination with ani-CD40, and 
proliferation assessed after 48 hours by the [3H]-thymidine uptake assay.
WEHI-231 cells expressing either of these SHIP mutants do not appear to exhibit 
any significant difference in anti-lg induced apoptosis when compared to cells 
containing the empty vector (Figure 3.18). CD40-mediated rescue does not 
appear to be affected by expression of either of these SHIP mutants either, as
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cells transfected with either of these mutants display similar levels of proliferation 
in response to anti-lg and anti-CD40 as cells containing the empty vector.
3.3.18 Effect of a catalytically inactive SHIP mutant and the SHIP SH2 
domain on anti-lg mediated apoptosis in WEHI-231 cells
To investigate the effects expression of these SHIP mutants has on anti-lg 
induced apoptosis in WEHI-231 cells, cells expressing them were stimulated with 
anti-lg, either alone or in combination with anti-CD40 for 48 hours. Apoptosis was 
assessed via DNA content analysis by flow cytometry, following staining with 
propidium iodide.
WEHI-231 cells expressing SHIP-CI appear to be more prone to anti-lg mediated 
apoptosis than cells containing the empty vector after 48 hours treatment, as 
over 20% of the cells exhibit a sub-diploid DNA content, as assessed by 
propidium iodide staining and FACS analysis, in response to anti-lg (Figure 
3.19). Upon anti-lg stimulation only around 1% of cells containing the empty 
vector exhibit sub-diploid DNA content, though a vast proportion (almost 80%) 
display a diploid (Gi phase) quantity of DNA. WEHI-231 SHIP-SH2 cells behave 
in a similar manner to the empty vector-containing cells, with the vast majority 
arrested in Gq/Gi. All 3 cell types display an increase in the proportion of cells in 
S phase and G2/M upon co-stimulation with anti-lg and anti-CD40, supporting the 
above results that demonstrated that these ceils all display CD40-mediated 
rescue from anti-lg induced growth arrest (Figure 3.18).
3.3.19 Effect of RasVI 2 mutants on expression of p27*^ ‘'*^  in response to 
anti-lg and anti-CD40 stimulation
The cell cycle is the co-ordinated series of events required for cell growth and 
division. This complex process relies on the assembly of nuclear proteins that 
integrate signals and programme cell cycle progression (see Section 1.5)
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(Figure 1.9). In order to elucidate the effects of the expression of the various 
mutant proteins at a molecular level, as opposed to a biological level, we decided 
to look at the expression profiles of key cell cycle proteins in response to anti-lg 
and anti-CD40 stimulation. One such key regulator of the cell cycle is the cyclin 
dependent kinase inhibitor (CKI) p27" '^P\ an inhibitor of the CDK2-cyclin E 
complex during Gi, whose accumulation is associated with Gi arrest (Figure 
1.9)
Whole cell lysates from WEHI-231 cells expressing the empty pcDNAS.I vector, 
pcDNAS.I RasVI2, pcDNAS.I RasVI 2-S35 or pcDNAS.I RasVI2-C40 were 
examined by western blotting following the appropriate stimulation. Anti-lg 
treatment of WEHI-231 cells transfected with the empty pcDNAS.i vector 
induces an increase in p27^ '*^  ^ levels over time (Figure 3.20). Stimulation via 
CD40, both on its own and in combination with anti-lg, induces a decrease in 
p27‘^ '*^  ^ levels after an initial, transient, increase. WEHI-231 cells expressing the 
constitutively active RasVI 2 mutant exhibit a similar profile of p27 '^^  ^ expression 
in response to anti-lg, with an increase over time. However, upon stimulation with 
anti-CD40 or the combination of anti-lg and anti-CD40 p27 expression drops to 
barely detectable levels.
Overexpression of the RasVI 2-835 mutant results in a dramatic increase in the 
level of expression of p27^ ''^  ^ in response to anti-lg stimulation, and this increase 
is particularly evident after 24 and 48 hours of stimulation (Figure 3.20). This 
increase is repressed by co-stimulation with anti-CD40. In response to anti-lg, 
cells overexpressing the RasVI 2-C40 mutant demonstrate a slight increase in 
p27Kipi expression but not to the same degree as cells expressing the RasVI 2- 
835 mutant (Figure 3.20). 8timulation with anti-CD40 alone induces a decrease 
in p27'^ ''^  ^ levels over time, whilst co-stimulation with anti-lg and anti-CD40 
induces a decrease after 8 hours, with a modest increase over 24 and 48 hours.
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These results correlate fairly well with the proliferation assay results (Figures 
3.14B and 3.16B), as RasVI 2-S35 expressing cells demonstrated a more 
pronounced anti-lg-induced growth arrest than the RasVI 2 or RasVI 2-C40 
expressing cells, or cells containing the empty vector alone, possibly explained 
by a greater induction of p27 in response to anti-lg.
3.3.20 Effect of RasVI2 mutants on Tyr15 phosphorylation of the cdc2 
protein in response to anti-lg and anti-CD40 stimulation
A key regulator of the G2/M phase transition is the cyclin dependent kinase cdc2, 
whose cyclin partner is cyclin B. Entry of all eukaryotic cells into M-phase of the 
cell cycle is regulated by activation of cdc2. Activation of cdc2 is controlled at 
several steps, including cyclin binding and phosphorylation at threonine 161. 
However, the critical regulatory step in activating cdc2 during progression into 
mitosis appears to be dephosphorylation at tyrosine 15 and threonine 14 
(Atherton-Fessler ef a/., 1993). Phosphorylation atTyrlS and inhibition of cdc2 is 
carried out by Weel and Mytl protein kinases, while Tyr15 dephosphorylation 
and activation of cdc2 is carried out by the cdc25 phosphatase.
To assess the effects of the RasVI 2 mutants on the activity of cdc2 under 
different conditions, whole cell lysates were subjected to western blot analysis 
using an anti-phospho-cdc2 (Tyr15) antibody. WEHI-231 cells transfected with 
the empty pcDNAS.i vector display relatively low levels of Tyr15 phosphorylated 
(inactive) cdc2, which increase from 1 to 8 hours, then decrease again between 
24 and 48 hours (Figure 3.21). Stimulation of these cells with anti-lg, which 
induces Gi arrest (Figure 3.9), leads to an increase in the levels of Tyr15 
phosphorylated cdc2 at 1 hour compared to unstimulated cells, followed by a 
marked decrease over the time course (Figure 3.21). This is rather surprising, as 
during Gi cdc2 would be expected to be inactive, hence TyrlS phosphorylated. It 
would be expected that under mitogenic conditions (treatment with anti-CD40, 
either alone or in combination with anti-lg) there would be a decrease in Tyri 5
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phosphorylation as cells progress through the cell cycle, yet there appears to be 
more Tyr15 phosphorylation under these conditions, particularly at 24 hours 
(Figure 3.21).
This is not the case with cells transfected with RasVI 2, as the levels of 
phosphorylated Tyr15 in response to anti-lg and anti-CD40 co-stimulation are 
barely detectable, particularly at the later time points, suggesting a large 
proportion of cells in mitosis. The levels are also low in response to anti-lg 
treatment alone, and as anti-lg failed to induce much growth arrest in WEHI-231 
pcDNAS.i.RasVI2 cells, this is perhaps hardly surprising. Cells expressing either 
RasVI 2-S35 or RasVI 2-040 exhibit a drop in phospho-cdc2 (Tyri 5) levels when 
treated with anti-lg and anti-CD40 in combination, compared to anti-CD40 alone 
(Figure 3.21). The levels displayed by cells treated with anti-lg alone are 
comparable to the co-stimulated cells for both types, and again anti-lg failed to 
induce growth arrest to the same levels as in cells containing the empty vector, 
so the low levels of phospho-cdc2 (Tyri 5) could indicate more cells passing 
through mitosis.
3.3.21 Effect of RasVI 2 mutants on phosphorylation of the retinoblastoma 
protein, Rb, in response to anti-lg and antl-CD40 stimulation
Another key regulator of the cell cycle is the retinoblastoma tumour suppressor 
protein (Rb). Rb inhibits progression from Gi to S phase of the cell cycle by 
binding to the E2F family of transcription factors and preventing transcription of 
key genes required for cell cycle progression (Dyson, 1998) (Figure 1.9). The 
interaction between Rb and E2F is abrogated by phosphorylation of Rb by CDKs 
at a number of sites in its C-terminai domain, allowing E2F to activate 
transcription of a number of genes. Therefore, Rb phosphorylation is a measure 
of cell cycle progression, from Gi to S phase. To investigate the phosphorylation 
state of Rb, an antibody against phosphorylated Rb (Ser®°  ^and Ser^^^) was used 
in western blot analysis. Surprisingly, this antibody failed to detect phospho-Rb in
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whole cell lysates from WEHI-231 cells containing the RasVI 2 mutant. However, 
phospho-Rb was detected in cells expressing both RasVI 2 effector mutants 
(Figure 3.22)
WEHI-231 cells containing the empty pcDNA3.1 vector exhibit low levels of Rb 
phosphorylation in the absence of any stimulation, and the levels drop to 
undetectable after 48 hours. Stimulation with anti-lg accelerates the 
disappearance of detectable Rb phosphorylation, with no detectable levels at 24 
hours, as opposed to 48 hours. This correlates very well with the anti-lg induced 
growth arrest of these cells (Figure 3.9)
Cells expressing RasVI 2-835 display a low level of Rb phosphorylation over the 
time period looked at when they are not stimulated. Stimulation with anti-lg 
results in a reduction in Rb phosphorylation, after 8 hours, with levels barely 
detectable after 24 and 48 hours. Stimulation with anti-CD40 alone sees a slight 
decrease in the level of Rb phosphorylation up to 24 hours, with levels at 48 
hours barely detectable. Co-stimulation with anti-CD40 sees a large amount of 
Rb phosphorylation at 8 hours, but this drops by 24 hours and remains low at 48 
hours. Cells expressing the RasVI 2-C40 mutant display a very high basal level 
of Rb phosphorylation prior to any stimulation, and anti-lg stimulation induces a 
decrease over time. Cells stimulated with anti-CD40 alone exhibit a basal level of 
Rb phosphorylation slightly lower than that displayed by unstimulated cells, 
however, the levels do remain constant up to 24 hours then appear to decrease 
at 48 hours. Co-stimulation with anti-lg and anti-CD40 results in a slight increase 
in Rb phosphorylation by 8 hours, followed by a decrease at 24 hours with the 
levels remaining low after 48 hours.
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3.3.22 Effect of Dok PH-PTB domain and SHIP mutants on expression of
p27*^ ''^  ^ in response to anti-lg and anti-CD40 stimulation
To assess the effect of the overexpression of the Dok PH-PTB domain and the 
expression of SHIP mutants in WEHI-231 cells on the protein levels of p2?' '^‘^ \ 
whole cell lysates of unstimulated, anti-lg stimulated, anti-CD40 stimulated and 
anti-lg plus anti-CD40 stimulated WEHI-231 cells expressing the appropriate 
constructs were probed by western blotting with an anti-p27^‘^  ^ antibody (Figure 
3.23) In cells containing the empty pMXI vector, anti-lg stimulation results in an 
increase in p27^ ''^  ^ expression compared to unstimulated cells, concomitant with 
anti-lg induced cell cycle arrest and apoptosis. Co-stimulation with anti-CD40 
causes a reduction in the expression of p27* '^^\ concomitant with the re­
instatement of proliferation induced in these cells by co-stimulation with anti-lg 
and anti-CD40. WEHI-231 cells expressing the Dok PH-PTB domain have a 
similar profile of p27 expression levels under these conditions, though at the later 
time points anti-CD40 appears less efficient at abrogating anti-lg induced up- 
regulation of p27 expression as the levels are slightly higher than those detected 
in cells containing the empty vector.
Expression of both SHIP-CI and SHIP-SH2 seems to decrease the upregulation 
of p27^ '*^  ^ induced by anti-lg stimulation compared to cells transfected with the 
empty vector alone (Figure 3.23). This is despite the fact that these cells 
demonstrate a similar level of growth arrest as cells expressing the empty vector 
in response to anti-lg treatment (Figure 3.18). Anti-CD40 stimulation of WEHI- 
231 SHIP-SH2 cells induces an increase in p27 levels after 1 and 8 hours, but 
the levels drop again at 24 and 48 hours. This increase is not as evident in cells 
expressing SHIP-CI, though they do seem to have a slightly increased level of 
p27 in response to anti-CD40 compared to unstimulated cells. Anti-lg and anti- 
CD40 co-stimulation in these cells does seem to result in a decrease in p27 '^^  ^
expression, compared to the unstimulated cells, and as the proliferation data
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suggests CD40 ligation can rescue anti-lg induced growth arrest, lower levels of 
p2YKipi bQ expected.
3.3.23 Effect of the Dok PH-PTB domain and SHIP mutants on Tyr15 
phosphorylation of the cdc2 protein in response to anti-lg and anti-CD40 
stimulation
To assess the effects of the Dok PH-PTB domain and the SHIP mutants on the 
activity of cdc2 under different conditions, whole cell lysates were subjected to 
western blot analysis using an anti-phospho~cdc2 (Tyr15) antibody. Unstimulated 
cells containing the empty vector seem to have fairly high levels of 
phosphorylated (inactive) cdc2, particularly at 8 and 24 hours, and anti-lg 
stimulation appears to decrease the Tyr15 phosphorylation of cdc2, suggesting 
they have more active cdc2 than unstimulated cells (Figure 3.24) Stimulation of 
these cells with antl-CD40 alone results in an increase in the Tyr15 
phosphorylation at 24 hours, though this drops again by 48 hours, whilst cells co­
stimulated with anti-lg and anti-CD40 have lower levels of phosphorylated cdc2 
than cells treated with anti-lg alone. The expression of the Dok PH-PTB domain 
does not alter the pattern of cdc2 phosphorylation under these conditions, as it is 
very similar to the pattern exhibited by empty vector containing cells.
This is also the case with cells transfected with either of the SHIP mutants, as 
again, the pattern does not change significantly. Anti-lg stimulation appears to 
decrease the amount of phosphorylation of cdc2 in both cell types, despite the 
fact that both demonstrate cell cycle arrest in response to anti-lg treatment. 
Again, the levels are highest after 24 hours treatment with anti-CD40, indicative 
of cells in Gi, 8 phase or early to mid G2. Perhaps the majority of these cells 
pass through mitosis between 8 and 20 hours, resulting in them containing 
inactive cdc2 at 24 hours.
123
3.3.24 Effect of Dok PH-PTB domain and SHIP mutants on expression of D-
type cyclins in response to anti-lg and anti-CD40 stimulation
A key cyclin responsible for Gi progression in B cells is cyclin D2 (Solvason et 
al., 2000), the cyclin partner for CDK 4 which is responsible for phosphorylation 
of the retinoblastoma protein and hence Gi to S phase progression. To 
investigate the effects of the Dok PH-PTB domain and the SHIP mutants on the 
levels of cyclin D2, whole cell lysates were subjected to western blot analysis 
using an anti-cyclin D1/2 antibody. Expression of this cyclin is low in WEHI-231 
cells containing the empty vector when they are not stimulated, and levels are 
barely detectable upon stimulation of these cells with anti-lg (Figure 3.25). 
Stimulation with anti-CD40 alone induces an increase in cyclin D expression, yet 
cells co-stimulated with anti-lg and anti-CD40 have barely detectable levels of 
cyclin DI/2 except at 1 hour. WEHI-231 cells expressing the Dok PH-PTB 
domain have similar expression of cyclin D2 compared to cells containing the 
empty vector, except upon co-stimulation with anti-lg and anti-CD40. Co­
stimulation induces an increase compared to unstimulated cells over the time 
period looked at, not seen in cells containing the empty vector. However, this 
increase is less than that induced by anti-CD40 treatment alone.
Both WEHI-231 SHIP-CI and SHIP-SH2 cells have a much higher basal level of 
cyclin D2 expression when un stimulated, compared to cells containing the empty 
vector. Stimulation of both WEHI-231 SHIP-CI and SHIP-SH2 cells with anti-lg 
induces a decrease in cyclin D2 expression to undetectable levels, as would be 
expected as anti-lg induces growth arrest very effectively in these cells (Figure 
3.25). Rather surprisingly, co-stimulation of either cell type with anti-lg and anti- 
CD40 does not induce much of an increase in cyclin D2 expression, though 
WEHI-231 SHIP-CI cells do exhibit some cyclin D2, unlike cells containing the 
empty vector. This is slightly surprising as co-stimulation restores proliferation 
very efficiently in cells expressing either SHIP construct.
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3.4 Discussion
Immature B cells generally respond to antigen by undergoing negative selection, 
though in vivo the presence of other, extrinsic signals can lead to alternative 
fates. One of these signals is mediated through CD40, and this can induce 
rescue from BCR-mediated growth arrest and apoptosis. This is most likely to 
occur in the periphery rather than the bone marrow, as B cells maintain the 
immature B cell phenotype for several days after exit into the periphery to ensure 
any B cells that are specific for self-antigens expressed in the periphery and not 
the bone marrow are negatively selected (Carsetti etal., 1995). The ability of 
CD40 to mediate rescue from BCR-induced growth arrest and apoptosis would 
allow for recruitment of antigen-specific immature B cells into an ongoing immune 
response where T cell help already exists (Monroe, 2000). The results obtained 
at the beginning of this chapter showing that WEHI-231 cells undergo BCR- 
mediated growth arrest and apoptosis, and that this is rescued by CD40- 
mediated signals, confirm the WEHI-231 cell line represents a good model for the 
study of BCR-mediated growth arrest and apoptosis, and CD40-mediated rescue 
from BCR-induced growth arrest and apoptosis.
The early signalling mechanisms activated upon ligation of the BCR under 
conditions leading to proliferation in mature B cells or growth arrest and 
apoptosis in immature B cells appear to be very similar, with phospholipase C, 
PI-3 kinase and Erk-MAPKinase all being activated under both circumstances. 
However, we have shown that although BCR ligation of WEHI-231 cells results in 
early stimulation of Erk-MAPKinase activity, in the long term it leads to down- 
regulation of the sustained, cycling Erk-MAPKinase activity observed in 
proliferating WEHI-231 cells. This is in contrast to what we see in mature B cells, 
where BCR ligation leads to sustained, cycling Erk-MAPKinase activity (see 
Section 6.3.6). Co-stimulation of WEHI-231 cells with anti-lg and anti-CD40 re­
establishes the sustained, cycling Erk activity, driving proliferation of these cells 
(Figure 3.26). This is evidenced by the fact that sustained inhibition of MEK, a
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key activator of Erk-MAPKinase, leads to growth arrest of unstimulated WEHI- 
231 cells, as well as abrogating CD40-mediated rescue of BCR-driven growth 
arrest of WEH1-231 cells. Cell cycle inhibitor studies suggested that the 
requirement for Erk-MAPKinase activity was not associated with a single cell 
cycle checkpoint. Indeed, the requirement for Erk-MAPKinase throughout cell 
cycle progression of WEH 1-231 cells is further demonstrated by the observation 
that, following release from olomoucine induced Gi arrest, Erk-MAPKinase 
activity is exhibited in a large proportion of cells that are traversing the cell cycle, 
whereas it is not found in the majority of newly formed daughter cells or those 
undergoing growth arrest. Taken together, these results strongly suggest that 
sustained, cycling Erk-MAPKinase activity is required for proliferation of WEHI- 
231 cells, and that the BCR abrogates this sustained activation to induce growth 
arrest, whilst signalling via CD40 restores this sustained, cycling Erk-MAPKinase 
activity, allowing the cells to proliferate.
The early, transient, activation of Erk-MAPKinase in response to BCR ligation in 
WEH I-231 cells is important for the induction of apoptosis, as is evidenced by the 
fact that inhibition of early Erk-MAPKinase activity by pharmacological inhibitors 
of MEKcan suppress BCR-induced apoptosis (Gauld etal., 2002). Therefore, 
Erk-MAPKinase activity in WEHI-231 cells is capable of mediating diverse 
outcomes depending upon the timing and duration of the Erk-MAPKinase activity, 
with strong early transient Erk-MAPKinase activity leading to apoptosis, whilst 
sustained, cycling activation leads to proliferation. A similar phenomenon of 
differential biological outcomes depending on the kinetics, amplitude and 
duration of Erk-MAPKinase activity has also been demonstrated in PC12 cells, 
where transient Erk-MAPKinase activation results in proliferation, whilst 
sustained Erk-MAPKinase activation causes the cells to differentiate (York et al.,
1998).
One of the key upstream regulators of Erk-MAPKinase activity Is the small 
GTPase Ras, a key regulator of growth in all eukaryotic cells. To further
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investigate the mechanisms involved in regulating the sustained Erk-MAPKinase 
activity in WEHI-231 cells, the role of Ras and its downstream effectors was 
explored, utilising constitutively active mutants of Ras with varying degrees of 
affinity for two of its key effectors, Raf and Pl-3-Kinase. Expression of these 
constitutively actively Ras mutants provided partial protection to WEHI-231 cells 
from anti-lg induced growth arrest and apoptosis, especially when transfected via 
electroporation. This was particularly evident with the RasV12-C40 mutant, which 
can only interact with PI-3-Kinase and not Raf, as anti-lg only reduced fH]-  
thymidine uptake by around 20%, compared to 60% in cells containing the empty 
vector (Figure 3.16). The converse mutant, RasV12-S35, which can only interact 
with Raf, not PI-3-Kinase, also protects WEHI-231 cells from anti-lg induced 
growth arrest, but not to quite the same extent as pH]-thymidine uptake is 
reduced by around 40%. Indeed, cells expressing the RasV12-C40 construct 
exhibited greater proliferation in response to co-stimulation with anti-lg and anti- 
CD40. Expression of constitutively active Ras mutants might be expected to 
result in the constitutive activation of Erk-MAPKinase, but this is not the case in 
WEHI-231 cells. In studies performed in collaboration with Catriona Ford, in 
un stimulated cells, there is no evidence to suggest that either RasV12 or 
RasV12-S35 constitutively activate Erk-MAPKinase as the activity of Erk- 
MAPKinase follows a cyclical pattern, although levels are higher than in cells 
containing the empty vector. Rather surprisingly, this is also true of those cells 
transfected with the RasV12-C40 vector, suggesting that Erk-MAPKinase can be 
additionally activated downstream of PI-3-Kinase as reported elsewhere for B 
cells and other systems (Han etal., 2003; Jacob etal., 2002; Li and Carter, 2000; 
Von Willebrand et al., 1996) or alternatively that PI-3-Kinase signalling can 
abrogate/antagonise the negative regulatory signals acting on Erk-MAPKinase. 
Upon ligation of the BCR, all of the Ras mutants, but particularly RasV12-C40 
prevent anti-lg induced inhibition of sustained, cyclical Erk-MAPKinase activity. 
However, because they do not induce constitutive Erk-MAPKinase signalling 
these results strongly suggest that BCR-induced suppression of Erk-MAPKinase 
activity involves Erk-dependent negative regulatory mechanisms that function
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downstream of Ras (Catriona Ford, personal communication). This proposal is 
consistent with studies in this laboratory that have demonstrated that ligation of 
the BCR in WEHI-231 cells leads to an abrogation in Erk-MAPKinase activity not 
by uncoupling the upstream regulators of Erk-MAPKinase (Ras, Raf, MEK), but 
rather by upregulating the expression of the protein phosphatase Pac-1 and 
promoting its interaction with Erk-MAPKinase (Gauld etaL, 2002).
Ras signalling has been shown to be required in at least two phases of the Go to 
S phase transition in fibroblasts, and these two periods of Ras signalling require 
different effector molecules, therefore this may explain the slightly different 
effects of the RasV12-S35 (which couples to Raf) and RasV12-C40 (which 
couples to PI-3-Kinase and indirectly to Erk) mutants on WEHI-231 cells. 
Fibroblasts that are continually exposed to growth factors exhibit Erk-MAPKinase 
activity in the early stages of Ras activation, but Its activity is not detected at later 
stages of Gi progression, despite the fact Ras is still active. PI-3-Kinase is active 
in mid to late Gi, and this activity is required for entry into S phase (Jones et a!.,
1999). In WEHI-231 cells, inhibition of PI-3-Kinase activity for a prolonged period 
(up to 30 hours) results in growth arrest of unstimulated cells, suggesting that Pl- 
3-Kinase plays an important role in proliferation of WEHI-231 cells (Gauld, 2001). 
Our results suggest that activation of both PI-3-Kinase and Erk-MAPKinase by 
RasV12 or RasV12-C40 is capable of overcoming anti-lg induced growth more 
efficiently than Ras induced Erk-MAPKinase activity alone (resulting from 
transfection with RasV12-S36).
The results of the experiments on cells expressing the constitutively active 
RasV12 mutant rather surprisingly varied slightly depending upon the 
transfection method. Cells transfected with pcDNA3.1.RasV12 exhibit an 
abrogation in their growth arrest in response to anti-lg, whilst cells transfected 
with MIEV.RasV12 also demonstrate reduced growth arrest, but to a lesser 
extent (Figure 3.9). These results suggest that the RasV12 mutant is capable of 
overcoming anti-lg induced growth arrest, which is unsurprising as RasV12
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induces transformation in a number of cell types (Figure 3.27) and we have 
shown sustained, cycling Erk-MAPKinase activity to be important for WEHI-231 B 
cell proliferation. The most intriguing difference between transfection methods 
involves the rescue of anti-lg induced growth arrest by CD40 ligation. The 
MIEV.RasV12 transfected cells do not exhibit a great deal of DMA synthesis in 
response to co-stimulation after 48 hours, whereas the pcDNA3.1 .RasV12 cells 
do. The reasons for this are unclear, however, one possibility may simply reflect 
a limitation of the [^H]~thymidine incorporation assay in that, if these cells are 
proliferating at a faster rate, the majority may have already passed through S 
phase by 48 hours. This idea is supported by the flow cytometry analysis, which 
shows that, after 48 hours, a greater proportion of MIEV.RasV12 transfected 
cells are in G2/M as opposed to S phase. If the cells are proliferating at a faster 
rate, it is also plausible that they may have exhausted the nutrients in the media 
by 48 hours, therefore they are unable to continue proliferation through additional 
rounds of cell division, hence the drop in [^H]-thymidine incorporation. It would be 
interesting to investigate the number of rounds of cell division RasV12 
expressing cells undergo compared to those containing the empty vector, by 
labelling the cells with carboxy-fIuorescein diacetate succinimidyl ester (CFSE) 
and measuring the successive halving of the fluorescence. Initial attempts to 
investigate this found that CFSE is highly toxic to B cells, therefore requires a 
great deal of optimisation.
Investigation of the downstream events regulating cell cycle progression did not 
provide clear-cut answers as to how the Ras mutants were able to reduce anti-lg- 
mediated growth arrest. Nevertheless, it was clear that when cells containing the 
empty vector are stimulated with anti-lg, an increase in the levels of the cyclin 
dependent kinase inhibitor p27 occurs, concomitant with growth arrest.
Consistent with this, the mechanism by which the RasV12-C40 mutant is able to 
inhibit anti-lg induced growth arrest appears, at least in part, to involve 
modulation p27 levels. Thus, cells expressing RasV12-C40, which show reduced 
anti-lg induced growth arrest, do not increase their expression levels of p27. This
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correlates well with recent observations that inhibition of PI-3-Kinase activity in 
mouse embryo fibroblasts results in Gi arrest, concomitant with p27 up- 
regulation (Collado et al., 2000). Other recent findings suggest that, rather than 
interfering with the transcription or translation of p27, Akt, a major effector of PI- 
3-Kinase, impairs nuclear import of p27, thus abrogating the ability of p27 to 
induce Gi arrest resulting from interactions with cyclin E/CDK2 complexes in the 
nucleus (Fujita etal., 2002; Liang etal., 2002; Shin etal., 2002). This finding 
underlines the important role p27 plays in anti-lg mediated growth arrest of 
WEHI-231 cells, as demonstrated previously (Ezhevsky et al., 1996), and that the 
effects of the RasV12-C40 mutant can be explained, at least in part, by the 
repression of p27 expression. The regulation of p27 expression is highly 
complex, and involves both translational control and regulation of the stability of 
the protein, with various mechanisms of degradation being described, such as 
ubiquitin-dependent degradation by the proteasome (Montagnoli etal., 1999) and 
degradation by caipain (Patel and Lane, 2000). The translation of p27 is 
negatively regulated by Rho, another small GTPase, as inhibition of Rho 
increases the translational efficiency of p27 mRNA. A dominant negative mutant 
of Rho, RhoA^^®, suppresses the transformation ability of RasV12, but not in cells 
deficient in p27 (Vidal et al., 2002), so it would be interesting to investigate 
whether co-expression of this Rho mutant with these Ras mutants in WEHI-231 
cells would alter the response to anti-lg. It might be expected that WEHI-231 
cells co-expressing RasV12-C40 and RhoA^^® would undergo growth arrest in 
response to anti-lg, as Rho would be inhibited, therefore p27 levels should 
increase.
By contrast, the increase in p27 levels in anti-lg stimulated cells expressing 
RasV12-S35, relative to empty vector control, is rather unexpected as these cells 
displayed reduced growth arrest. However, this apparent contradiction may be 
explained by recent findings that the role of p27 is not as simple as cyclin 
dependent kinase inhibitor. For example, although p27*^ '^  ^ can inhibit 
recombinant cyclin D-CDK complexes in vitro, it is a far more effective inhibitor of
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cyclin E-CDK complexes (Toyoshima and Hunter, 1994). Indeed, assembly of 
cyclin D-CDK complexes is impaired in mouse embryo fibroblasts from mice 
deficient in p2l'^®^\ p27‘^ '' \^ or both (Cheng et a i, 1999), implying a role for p27 
as an assembly factor for cyclin D-CDK complexes. The assembly functions and 
subsequent sequestration of p27 in cyclin D-CDK4 complexes can titrate the 
amount of p27 from cyclin E-CDK2, the key target for p27 inhibition, allowing 
cells to progress through G-t and enter S phase (Tsutsui et a i, 1999). It would be 
interesting to determine the subcellular localisation of p27 in these cells, as in the 
cytoplasm p27 interacts with cyclin D/CDK complexes and does not inhibit cell 
cycle progression, but when it is present in the nucleus it interacts with cyclin 
E/CDK2 complexes and induces Gi arrest (Shin et ai, 2002). The Western blots 
investigating p27 expression were performed on whole cell lysates, therefore any 
differences in subcellular localisation would not be detected. This could be 
achieved either with the imaging software attached to the laser scanning 
cytometer, or by confocal microscopy, or by subcellular fractionation, followed by 
western blotting of individual fractions.
The investigation of other key regulators of the cell cycle produced unusual 
results, particularly the phosphorylation at tyrosine 15 of cdc2, the key regulator 
of the Ga/M transition. The critical regulatory step in activating cdc2 during 
progression into mitosis appears to be dephosphorylation at tyrosine 15 
(Atherton-Fessler et ai, 1993), yet the mitogenically stimulated cells appeared to 
possess more cdc2 phosphorylated at tyrosine 15 than cells stimulated via the 
BCR, which induces growth arrest. The reasons for this are unclear, but perhaps 
as the cells were an asynchronous population the dephosphorylation of cdc2 
occurs at different times, resulting in the apparent absence of any effects. It is 
possible that synchronisation of the cells prior to stimulation would result in the 
majority of the population passing the G2/M transition around the same time, thus 
the dephosphorylation of cdc2 would become more evident.
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To corroborate these data on the role of Ras and its downstream effectors in 
regulating immature B cell apoptosis, survival and proliferation we also 
transfected WEHI-231 cells with mutants of p62°‘^ ‘^ , a negative regulator of Ras. 
The Dok proteins are a family of adaptor proteins that are phosphorylated by a 
wide range of protein tyrosine kinases. The first Dok protein to be isolated was 
p62 '^ °k originally identified as a 62 kD tyrosine-phosphorylated protein associated 
with Ras-GAP (Carpino et al., 1997; Yamanashi and Baltimore, 1997), which is a 
negative regulator of Ras (Botlag and McCormick, 1991). Indeed, in B cells, 
pQ2dok been shown to negatively regulate Erk-MAPK activation and cell 
proliferation mediated by the BCR, by abrogating Ras activation (Yamanashi et 
a/., 2000). The behaviour of the Dok-PH/PTB mutants in this study, however, 
appears at first to be rather odd, as the Dok-PH/PTB domain should act in a 
dominant negative fashion, leading to sustained activation of Ras, as 
demonstrated by cells lacking p62"^ '''^  (Zhao et a/., 2001). This might be expected 
to result in the same biological outcomes as transfection with the RasV12 
mutant, however, WEHI-231 cells transfected with the Dok-PH/PTB domain 
respond in much the same manner as wild type cells, undergoing BCR-induced 
growth arrest. Despite this apparent absence of an effect at the biological level, 
inhibition of Dok has an effect at the molecular level as Erk-MAPKinase activity in 
WEHI-231 cells expressing the Dok-PH/PTB domain is significantly enhanced 
and, perhaps rather surprisingly given the Ras mutant data, is constitutively 
active even upon stimulation of the cells with anti-lg (Catriona Ford, personal 
communication). Therefore, despite the fact that these cells demonstrate 
sustained Erk-MAPKinase activation in the presence of anti-lg, they still undergo 
anti-lg induced growth arrest and apoptosis, and do not exhibit enhanced 
proliferation, as might be expected. These data suggest that Dok may play a role 
in mediating the negative regulation of Erk-MAPKinase in response to BCR 
ligation, as inhibition of Dok abrogates anti-lg induced down regulation of Erk- 
MAPKinase activity. This implies that Dok utilises mechanisms other than the 
recruitment of RasGAP to regulate the activity of Erk-MAPKinase, as expression 
of a constitutively active Ras mutant did not have the same effect on Erk-
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MAPKinase activity, yet one of the expected consequences of inhibiting Dok 
would be that Ras would be more active, as Dok is a negative regulator of Ras 
via RasGAP. This is consistent with recent findings that Dok can exert its 
negative effect on Erk-MAPKinase activity independently of its ability to associate 
with RasGAP and another of its effectors. Nek (Zhao et a!., 2001). Given our 
findings that sustained Erk-MAPKinase activity is associated with proliferation of 
WEHI-231 cells, it was rather surprising that cells expressing the Dok-PH/PTB 
domain undergo anti-lg induced growth arrest. However, the fact that WEHI-231 
cells expressing the Dok-PH/PTB domain undergo anti-lg induced growth arrest 
is consistent with the observation that they upregulate the CDK inhibitor p27^^\ 
whose accumulation has been linked to anti-lg induced cell cycle arrest in WEHI- 
231 cells (Ezhevsky et a!., 1996).
Analysis of WEHI-231 cells expressing the RasV12-C40 construct, along with 
previous work undertaken in this laboratory, suggested a key role for PI-3-Kinase 
in the proliferation and survival of WEHI-231 cells. To further investigate this, we 
utilised mutants of an antagonist of PI-3-Kinase activity, the SH2-containing 5’- 
inositol phosphatase, SHIP. SHIP antagonises the functions of PI-3-Kinase by 
dephosphorylating the 5’ position of Ptdlns(3,4,6)P3, a product of PI-3-Kinase 
that is important for the membrane localisation of many PH domain containing 
proteins. However, our results using two distinct mutant forms of SHIP which 
interfere with SHIP activity by either competing for SH2 domain interactions 
(SHIP-SH2) or competing for SH2 interactions as well as substrate binding 
(SHIP-CI) suggest that SHIP does not play a significant role in the regulation of 
anti-lg induced growth arrest or apoptosis in WEHI-231 cells. In contrast, in 
mature B cells SHIP has been shown to play a major role in the FcyRlIb 
mediated inhibition of BCR-induced proliferative signalling (Liu etal., 1998). We 
have recently demonstrated a role for the 3’-inositol phosphatase, PTEN, in 
FcyRlIb mediated inhibition of BCR-induced proliferative signalling, suggesting 
that B cells are capable of antagonising Pl-3-Kinase activity via the recruitment of 
both 3'- and 5’-inositol phosphatases (Brown etal., 2004). Therefore, perhaps in
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WEHI-231 cells, inhibition of SHIP by the overexpression of a catalytically 
inactive mutant or its SH2 domain does not lead to an observable effect as the 
levels of PIP3 can still be reduced by the 3’-inositol phosphatase activity of 
PTEN. It would be very interesting to assess the activity of PTEN in WEHI-231 
cells under different conditions, and expressing different constructs, to determine 
whether or not it plays a role in regulating responses in WEHI-231 cells.
Overall, these results demonstrate that Erk-MAPKinase activity is required for 
anti-lg induced growth arrest and apoptosis in WEHI-231 cells, as well as for 
CD40-mediated rescue from anti-lg induced growth arrest and apoptosis (Figure 
3.26). The small GTPase, Ras, and its effector molecules, also appear to play a 
key role in BCR-mediated responses (Figure 3.27) The Ras/PI-3-Kinase 
pathway seems to play a role in CD40-mediated rescue of anti-lg induced 
apoptosis of WEHI-231 cells, as cells overexpressing a constitutively active Ras 
mutant unable to interact with PI-3-Kinase are refractory to CD-40 mediated 
rescue of anti-lg induced apoptosis. Anti-lg induced growth arrest in WEHI-231 
cells is accompanied by an increase in the expression of the cyclin dependent 
kinase inhibitor p27 "^^  ^ (Figure 3.28)
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Figure 3.1 Anti-lg treatment induces growth arrest in WEHI-231 ceils which
is overcome by co-treatment with anti-CD40 antibodies
WEHI-231 cells ( 1x10*  cells/well) were cultured in the presence of anti-lg (0.1, 
1,10 ^ig/ml), or a combination of anti-lg (10 fig/m!) and anti-CD40 (10 ^g/ml), for 
48 hours. Control cells were cultured in the presence of medium alone. Culture 
wells were pulsed with [^H]-thymidine (0.5 jxCi/wel!) 4 hours prior to harvesting 
and f  H]-thymidine incorporation was assessed by liquid scintillation counting. 
Data are the mean ± standard deviation of triplicate measurements from a single 
experiment, representative of at least 4 other independent experiments.
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Figure 3.2 Anti-lg treatment induces apoptosis in WEHI-231 cells which is
overcome by co-treatment with anti-CD40 antibodies
WEHI-231 cells (5x10® cells/ml) were cultured in the presence of anti-lg (10 
i^g/ml), with or without anti-CD40 (10 fxg/ml). Cells cultured in the presence of 
medium alone were included as a control. Levels of apoptosis and the proportion 
of cells in each cell cycle phase were determined by propidium iodide staining to 
assess DNA content, and FACS analysis after 24, 48 and 72 hours, as described 
in Materials and Methods.
A DNA profiles of WEHI-231 cells treated with the appropriate agonists, from a 
single experiment, representative of at least four other independent experiments.
B Data represents each cell cycle phase expressed as a percentage of the total 
cells analysed from a single experiment, representative of at least four other 
independent experiments.
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Figure 3.3 Differential phosphorylation of Erk-MAPKinase in response to 
anti-lg and anti-CD40 co-stimulation in WEHI-231 cells
WEHI-231 cells ( 1x10^ cells) were stimulated in the presence of 10 (xg/ml anti- 
lg, either alone or in combination with 10 (ig/ml anti-CD40, for the times 
indicated. Cells incubated in the presence of medium alone were included as a 
control. Whole cell lysates were prepared and subjected to Western blot analysis 
with phospho-specific Erk-MAPK antibody. Equal protein loading was confirmed 
with a whole Erk-MAPKinase antibody.
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Figure 3.4 Sustained Erk-MAPKinase inhibition prevents normal cell 
proliferation but also inhibits CD40-mediated rescue from anti-lg induced 
growth arrest
WEHI-231 cells (10^ cells/well) were pre-incubated for 3 hours with PD98059 and 
U0126 (both 1 ^M). Cells were then treated with lOpg/ml anti-lg, either alone or 
in combination with 10[ig/ml anti-CD40. Control cells received no stimulating 
antibody. Cells treated with PD98059 and U0126 were treated with an additional 
dose (both at 1 every 4 hours for a total of 32 hours. Culture wells were 
pulsed with [^H]-thymidine (0.5 fxCi/well) 4 hours prior to harvesting and [^H]- 
incorporation was assessed by liquid scintillation counting. Data are the mean ± 
standard deviation of quadruplicate measurements taken from a single 
experiment, representative of at least two other independent experiments.
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Figure 3.5 Effects of the cell cycle inhibitors olomoucine and aphidicolin on 
the WEHI-231 cell cycle
WEHI-231 cells (5x10® cells/ml) were treated with the cell cycle inhibitors 
olomoucine (50 iiM), aphidicolin (5 fxg/ml), or nocodazole (10 jig/ml) for 48 hours. 
Levels of apoptosis and the proportion of cells in each cell cycle phase were 
determined by propidium iodide staining to assess DNA content, followed by 
FACS analysis, as described in Materials and Methods. Data represents each 
cell cycle phase expressed as a percentage of the total cells analysed from a 
single experiment, representative of at least two other independent experiments.
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Figure 3.6 Effects of the cell cycle Inhibitors olomoucine and aphidicolin on 
the phosphorylation of Erk-MAPKInase In WEHI-231 cells In response to 
anti-lg and antl-CD40 co-stlmulatlon
A WEHI-231 cells were treated with olomoucine (50 \M ) for 40 hours to induce 
Gi arrest. Cells were washed twice in media to remove the olomoucine, then 
stimulated (1 x 10  ^cells) in the presence of anti-lg (10 ^ig/ml) either alone or in 
combination with antl-CD40 (10 [ng/ml) for the times indicated. Cells incubated In 
the presence of medium alone following removal of olomoucine were included as 
a control. Whole cell lysates were prepared and subjected to Western blot 
analysis with a phospho-specific Erk-MAPK antibody.
B WEHI-231 cells were treated with aphidicolin (5 ^g/ml) for 24 hours to induce S 
phase arrest. Cells were washed twice in media to remove the aphidicolin, then 
stimulated (1x10^ cells) in the presence of anti-lg (10 pg/ml) either alone or in 
combination with anti-CD40 (10 fig/ml) for the times indicated. Cells incubated in 
the presence of medium alone following removal of aphidicolin were included as 
a control. Whole cell lysates were prepared and subjected to Western blot 
analysis with a phospho-specific Erk-MAPK antibody.
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Figure 3.7 Effects of cell cycle inhibitors on Erk-MAPKinase activation
WEHI-231 cells were incubated in the presence of olomoucine (50 iiM) for 40 
hours, or left untreated, then washed twice in fresh media to remove the 
olomoucine. Arrested cells were then stimulated with anti-lg (10 [ig/ml), a 
combination of anti-lg and anti-CD40 (both 10 (ig/ml), or left unstimulated in 
media for up to 48 hours. Cells were attached to slides at the appropriate time 
points, fixed and permeabilised, then stained using an anti-phospho-Erk 
antibody, along with propidium iodide to assess DNA content. Following staining, 
cells were scanned using the LSC. The percentage of cells in each cell cycle 
phase is shown, along with the proportion of those cells that were positive for 
phospho-Erk.
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Figure 3.8 Retroviral transfection of WEHI-231 cells with the MIEV.RasV12 
vector
WEHI-231 cells were co-cultured in the presence of the retroviral packaging lines 
GP+E.86.MIEV (the empty vector) or GP+E.86.MIEV.RasV12 (the MIEV vector 
carrying the DNA encoding the RasV12 mutant). Stably transfected GP+E-86 
were grown to 75% confluency in a 6 well plate. WEHI-231 cells were pretreated 
for 4 hours with polybrene (5 fxg/ml) prior to transfection. 3x10® WEHI-231 cells 
in media containing 5 (xg/ml polybrene were added to the wells containing the 
appropriate stable GP+E-86 transfectants, and incubated at 37°C for 16 hours. 
After this time, the WEHI-231 cells were removed by careful aspiration and 
incubated for a further 4 hours. Efficiency of transfection was assessed by flow 
cytometry to detect green fluorescent protein.
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Figure 3.9 Effects of overexpression of the RasV12 mutant on anti-lg-
Induced growth arrest in WEHI-231 cells
A WEHl-231 cells (1 x10* cells/well) containing MIEV.RasV12 or the MIEV 
vector were cultured, in triplicate, in the presence of increasing concentrations of 
anti-lg (0.01, 0.1, 1, 10 |ng/ml), for 48 hours. Control cells were cultured in the 
presence of medium alone. Culture wells were pulsed with [^H]-thymidine (0.5 
fxCi/well) 4 hours prior to harvesting and [^H]-incorporation was assessed by 
liquid scintillation counting. Data from individual experiments were normalised by 
expressing the mean [^H]-thymidine uptake values of anti-lg treated cells as a 
percentage of those obtained with control cell cultures. The normalised values 
from at least 4 independent experiments were then pooled and expressed as 
means ± sem.
B WEHl-231 cells (1x10^ cells/well) containing pcDNA3.1.RasV12 or the 
pcDNA3.1 vector were cultured and proliferation assessed as in A Data from 
individual experiments were normalised by expressing the mean f  H]-thymidine 
uptake values of anti-lg treated cells as a percentage of those obtained with 
control cell cultures. The normalised values from at least 4 independent 
experiments were then pooled and expressed as means ± sem.
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Figure 3.10 Effects of overexpression of the RasV12 mutant on anti-lg-
induced apoptosis in WEHl-231 cells
WEHl-231 cells (5x10® cells/ml) containing MIEV.RasV12, the MIEV vector, 
pcDNA3.1.RasV12, or the pcDNA3.1 vector were cultured in the presence of 
anti-lg (10 pg/ml). Cells cultured in the presence of medium alone were included 
as a control. Levels of apoptosis were determined by propidium iodide staining 
followed by FACS analysis to assess DMA content after 48 hours, as described 
in Materials and Methods. Data represents each cell cycle phase expressed as a 
percentage of the total cells analysed from a single experiment, representative of 
at least three other independent experiments.
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Figure 3.11 Effect of overexpression of the RasV12 mutant on CD40-
mediated rescue of anti-lg induced growth arrest and apoptosis in WEHl-
231 cells
WEHl-231 cells (1 xIO* cells/well) containing MIEV.RasV12, the MIEV vector, 
pcDNA3.1.RasV12, or the pcDNA3.1 vector were cultured, in triplicate, in the 
presence of anti-lg (10 fig/m!) or a combination of anti-lg and anti-CD40 (both 10 
(.ig/ml), for 48 hours. Control cells were cultured in the presence of medium 
alone. Culture wells were pulsed with [^H]-thymidine (0.5 fxCi/well) 4 hours prior 
to harvesting and [®H]-incorporation was assessed by liquid scintillation counting. 
Data from individual experiments were normalised by expressing the mean [^H]- 
thymidine uptake values of treated cells as a percentage of those obtained with 
control cell cultures. The normalised values from at least 4 independent 
experiments were then pooled and expressed as means ± sem.
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Figure 3.12 Effect of overexpression of the Dok-PH/PTB domain on anti-lg
induced growth arrest and apoptosis in WEHl-231 cells
A WEHl-231 cells containing the pMXI.Dok-PH/PTB vector or the empty pMXI 
vector (1 xIO* cells/well) were cultured, in triplicate, in the presence of various 
concentrations of anti-lg (0.01, 0.1, 1, 10 |iig/ml), or a combination of anti-lg (10 
^g/mi) and anti-CD40 (10 fxg/ml), for 48 hours. Control cells were cultured in the 
presence of medium alone. Culture wells were pulsed with [®H]-thymidine (0.5 
pCi/well) 4 hours prior to harvesting and [^H]-incorporation was assessed by 
liquid scintillation counting. Data from individual experiments were normalised by 
expressing the mean [^H]-thymidine uptake values of anti-lg treated cells as a 
percentage of those obtained with control cell cultures. The normalised values 
from 7 independent experiments were then pooled and expressed as means ± 
sem.
B WEHl-231 cells containing the pMXI.Dok-PH/PTB vector or the empty pMXI 
vector (5x10® cells/ml) were cultured in the presence of anti-lg (10 p.g/ml), with 
or without anti-CD40 (10 fxg/ml). Cells cultured in the presence of medium alone 
were included as a control. Levels of apoptosis were determined by propidium 
iodide staining and FACS analysis to assess DMA content after 48 hours, as 
described in Materials and Methods. Data represents each cell cycle phase 
expressed as a percentage of the total cells analysed from a single experiment, 
representative of at least three other independent experiments.
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Figure 3.13 Retroviral transfection of WEHl-231 cells with the RasV12 
effector mutants RasV12-S35 and RasV12-C40
WEHl-231 cells were co-cultured in the presence of the retroviral packaging lines 
GP+E.86.M!EV.RasV12-S35 or GP+E.86.MIEV.RasV12-C40. Stably transfected 
GP+E-86 were grown to 75% confluency in a 6 well plate. WEHl-231 cells were 
pretreated for 4 hours with polybrene (5 p.g/ml) prior to transfection. 3x10® 
WEHl-231 cells in media containing 5 [xg/ml polybrene were added to the wells 
containing the appropriate stable GP+E-86 transfectants, and incubated at 37*C 
for 16 hours. After this time, the WEHl-231 cells were removed by careful 
aspiration and incubated for a further 4 hours. Efficiency of transfection was 
assessed by flow cytometry to detect green fluorescent protein.
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Figure 3.14 Effects of overexpression of the RasV12 effector mutant
RasV12-S35 on anti-lg-induced growth arrest in WEHl-231 cells
A WEHl-231 cells (1 xIO* cells/well) containing the MIEV, MIEV.RasV12, or 
MlEV.RasV12-S35 vectors were cultured, in triplicate, in the presence of 
increasing concentrations of anti-lg (0.01, 0.1, 1, 10 fxg/ml), ora  combination of 
anti-lg (10 p.g/ml) and anti-CD40 (10 p.g/ml), for 48 hours. Control cells were 
cultured in the presence of medium alone. Culture wells were pulsed with [^H] - 
thymidine (0.5 jiCi/well) 4 hours prior to harvesting and [^H]-incorporation was 
assessed by liquid scintillation counting. Data from individual experiments were 
normalised by expressing the mean [^H]-thymidine uptake values of treated cells 
as a percentage of those obtained with control cell cultures. The normalised 
values from 4 independent experiments were then pooled and expressed as 
means ± sem.
B WEHl-231 cells (1 x 10'* cells/well) containing the empty pcDNA3.1 vector, 
pcDNA3.1.RasV12, or pcDNAS.I.RasV12-S35 vectors were cultured and 
proliferation assessed as in A Data from individual experiments were normalised 
by expressing the mean [®H]-thymidine uptake values of treated cells as a 
percentage of those obtained with control cell cultures. The normalised values 
from 14 independent experiments were then pooled and expressed as means ± 
sem.
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Figure 3.15 Effects of overexpression of the RasV12 effector mutant
RasV12-S35 on anti-lg-induced apoptosis in WEHl-231 cells
A WEHl-231 cells (5x10® cells/ml) containing the MIEV, MIEV.RasV12, or 
MIEV.RasV12-S35 vectors were cultured in the presence of anti-lg (10 ^g/ml), or 
a combination of anti-lg (10 pig/ml) and anti-CD40 (10 pig/ml). Control cells were 
cultured in the presence of medium alone. Levels of apoptosis were determined 
by propidium iodide staining and FACS analysis to assess DMA content after 48 
hours, as described in Materials and Methods. Data represents each cell cycle 
phase expressed as a percentage of the total cells analysed from a single 
experiment, representative of at least three other independent experiments.
B WEHl-231 cells (5x10® cells/ml) containing the empty pcDNAS.I vector, 
pcDNA3.1.RasV12, or pcDNA3.1.RasVI2-835 vectors were cultured and 
apoptosis assessed as in A, Data represents each cell cycle phase expressed as 
a percentage of the total cells analysed from a single experiment, representative 
of at least three other independent experiments.
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Figure 3.16 Effects of overexpression of the RasV12 effector mutant
RasV12-C40 on anti-lg-induced growth arrest in WEHl-231 cells
A WEHl-231 cells (1 X 10"^  cells/well) containing the MIEV, MIEV.RasV12, or 
MIEV.RasV12-C40 vectors were cultured, in triplicate, in the presence of 
increasing concentrations of anti-lg (0.01, 0.1, 1, 10 ng/ml), or a combination of 
anti-lg (10 p.g/ml) and anti-CD40 (10 p.g/ml), for 48 hours. Control cells were 
cultured in the presence of medium alone. Culture wells were pulsed with [®H]- 
thymidine (0.5 (iCi/well) 4 hours prior to harvesting and [®H]-incorporation was 
assessed by liquid scintillation counting. Data from individual experiments were 
normalised by expressing the mean [®H]-thymidine uptake values of treated cells 
as a percentage of those obtained with control cell cultures. The normalised 
values from 4 independent experiments were then pooled and expressed as 
means ± sem.
B WEHl-231 cells (1 x lO'* cells/well) containing the empty pcDNA3.1 vector, 
pcDNA3.1.RasV12, or pcDNA3.1.RasVI 2-C40 vectors were cultured and 
proliferation assessed as in A. Data from individual experiments were normalised 
by expressing the mean [®H]-thymidine uptake values of treated cells as a 
percentage of those obtained with control cell cultures. The normalised values 
from 14 independent experiments were then pooled and expressed as means ± 
sem.
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Figure 3,17 Effects of overexpression of the RasVI 2 effector mutant
RasVI2-C40 on anti-lg-induced apoptosis in WEHl-231 cells
A WEHl-231 cells (5x10® cells/ml) containing the MIEV, MIEV.RasVI2, or 
MIEV.RasV12-C40 vectors were cultured in the presence of anti-lg (10 jxg/ml), or 
a combination of anti-lg (10 fxg/ml) and anti-CD40 (10 ^g/ml). Control cells were 
cultured in the presence of medium alone. Levels of apoptosis were determined 
by propidium iodide staining and FACS analysis to assess DNA content after 48 
hours, as described in Materials and Methods.
B WEHl-231 cells (5x10® cells/ml) containing the empty pcDNA3.1 vector, 
pcDNA3.1.RasV12, or pcDNA3.1.RasVI2-C40 vectors were cultured and 
apoptosis assessed as in A
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Figure 3.18 Effects of overexpression of a catalytically inactive SHIP
mutant and the SHIP-SH2 domain on anti-lg induced growth arrest and
CD40-mediated rescue in WEHl-231 cells
A WEHl-231 cells (1 X 10"^  cells/well) containing the empty pMXI, pMXI.SHIP-CI 
or pMX!.SHIP-SH2 vectors were cultured, in triplicate, in the presence of 
increasing concentrations of anti-lg antibodies (0.01, 0.1, 1, 10 |xg/ml), for 48 
hours. Control cells were cultured in the presence of medium alone. Culture wells 
were pulsed with [®H]-thymidine (0.5 ^Ci/well) 4 hours prior to harvesting and 
[®H]-incorporation was assessed by liquid scintillation counting. Data from 
individual experiments were normalised by expressing the mean [®H]-thymidine 
uptake values of anti-lg treated cells as a percentage of those obtained with 
control cell cultures. The normalised values from at least 7 independent 
experiments were then pooled and expressed as means ± sem.
B WEHl-231 cells (1 x 10"^  cells/well) containing the empty pMXI, pMXI.SHIP-CI 
or pMXI.SHIP-SH2 vectors were cultured in the presence of anti-lg (10 fAg/ml), 
either alone or in combination with anti-CD40 (10 ^g/ml), for 48 hours. Control 
cells were cultured in the presence of medium alone. Culture wells were pulsed 
with [®H]-thymidine (0.5 jxCi/well) 4 hours prior to harvesting and [®H]- 
incorporation was assessed by liquid scintillation counting. Data from individual 
experiments were normalised by expressing the mean [®Hj-thymidine uptake 
values of treated cells as a percentage of those obtained with control cell 
cultures. The normalised values from at least 7 independent experiments were 
then pooled and expressed as means ± sem.
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Figure 3.19 Effects of overexpression of a catalytically inactive SHIP
mutant and the SHIP-SH2 domain on anti-lg induced apoptosis in WEHl-231
cells
WEHl-231 cells (5x10^ cells/ml) containing the empty pMXI, pMXI.SHIP-CI or 
pMXI.SHIP-SH2 vectors were cultured in the presence of anti-lg (10 (ig/ml), with 
or without anti-GD40 (10 |.ig/ml). Cells cultured in the presence of medium alone 
were included as a control. Levels of apoptosis were determined by propidium 
iodide staining followed by FACS analysis to assess DNA content after 48 hours, 
as described in Materials and Methods.
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Figure 3.20 Effects of the overexpression of RasVI2, RasV12-S35 and
RasVI 2-C40 on the expression of p27'^ '*’  ^ in WEHl-231 cells
WEHl-231 ceils (1x10^ cells) containing the pcDNAS.I, pcDNAS.I.RasVI2, 
pcDNAS.I.RasVI2-S35 or pcDNAS.I.RasVI2-C40 vectors were stimulated in 
the presence of 10 p.g/ml anti-lg or 10 |xg/ml anti-CD40, alone and in 
combination, for the times indicated. Cells incubated in the presence of medium 
alone were included as a control. Whole cell lysates were prepared and 
subjected to Western blot analysis with anti-p27 '^P^ antibody.
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Figure 3.21 Effects of the overexpression of RasVI2, RasVI2-S35 and
RasVI2-C40 on the regulation of the cdc2 protein in WEHl-231 cells
WEHl-231 cells (1x10^ cells) containing the pcDNAS.I, pcDNAS.I.RasVI2, 
pcDNAS.1.RasVI 2-S35 or pcDNA3.1.RasVI 2-C40 vectors were stimulated in 
the presence of 10 p.g/ml anti-lg or 10 pig/ml anti-CD40, alone and in 
combination, for the times indicated. Cells incubated in the presence of medium 
alone were included as a control. Whole cell lysates were prepared and 
subjected to Western blot analysis with anti-phospho-cdc2 (Tyr^ ®) antibody.
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Figure 3.22 Effects of the overexpression of RasV12, RasV12-S35 and
RasV12-C40 on the regulation of the retinoblastoma protein in WEHI-231
cells
WEHI-231 cells (1x10^ cells) containing the pcDNAS.I, pcDNA3.1.RasV12, 
pcDNA3.1.RasV12-S35 or pcDNA3.1.RasV12-C40 vectors were stimulated in 
the presence of 10 |ng/ml anti-lg or 10 j:Ag/ml anti-CD40, alone and in 
combination, for the times indicated. Cells incubated in the presence of medium 
alone were included as a control. Whole cell lysates were prepared and 
subjected to Western blot analysis with anti-phospho-Rb (Ser®°^ ^®^ )^ antibody.
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Figure 3.23 Effects of the overexpression of Dok PH-PTB, SHIP-CI, and
SHIP-SH2 on the expression of p27‘^ '>’  ^ in WEHI-231 cells
WEHI-231 cells (1x10^ cells) containing the pMXI, pMXI Dok PH-PTB, pMXI 
SHIP-CI or pMXI SHIP-SH2 vectors were stimulated in the presence of 10 \ig/m\ 
anti-lg or 10 jjig/mi anti-CD40, alone and in combination, for the times indicated. 
Cells incubated in the presence of medium alone were included as a control. 
Whole cell lysates were prepared and subjected to Western blot analysis with 
anti-p27'^ *P^  antibody.
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Figure 3.24 Effects of the overexpression of Dok PH-PTB, SHIP-CI, and
SHIP-SH2 on the regulation of the cdc2 protein In WEHI-231 cells
WEHI-231 cells (1x10^ cells) containing the pMXI, pMXI Dok PH-PTB, pMXI 
SHIP-CI or pMXl SHIP-SH2 vectors were stimulated in the presence of 10 p,g/ml 
anti-lg or 10 |ig/ml anti-CD40, alone and in combination, for the times indicated. 
Cells incubated in the presence of medium alone were included as a control. 
Whole cell lysates were prepared and subjected to Western blot analysis with 
anti-phospho-cdc2 (Tyr^®) antibody.
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Figure 3.25 Effects of the overexpression of Dok PH-PTB, SHIP-CI, and
SHIP-SH2 on the expression of D type cyclins in WEHI-231 cells
WEHI-231 cells (1x10^ cells) containing the pMXI, pMXl Dok PH-PTB, pMXI 
SHIP-CI or pMXI SHIP-SH2 vectors were stimulated in the presence of 10 ^g/m! 
anti-lg or 10 ^g/ml anti-CD40, alone and in combination, for the times indicated. 
Cells incubated in the presence of medium alone were included as a control. 
Whole cell lysates were prepared and subjected to Western blot analysis with 
anti-cyclin DI/2 antibody.
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Figure 3.26 Erk-MAPKinase plays a dual role In WEHI-231 cells
Ligation of the BCR on the WEHI-231 immature B cell line leads to growth arrest 
and apoptosis. Growth arrest and apoptosis is preceded by an essential, but 
transient, activation of Erk-MAPKinase. WEHI-231 cells are responsive to T cell 
derived signals, permitting rescue of anti-lg induced growth arrest and apoptosis 
by T cell derived signals such as CD40 ligand (or anti-CD40 antibodies). CD40- 
mediated rescue from anti-lg induced growth arrest and apoptosis also requires 
Erk-MAPKinase activity, but in this instance It is a sustained, cyclical activity, as 
opposed to transient activity. This demonstrates a dual role for the Erk- 
MAPKinase in WEHI-231 cells, with the kinetics of the activation controlling the 
biological response.
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Figure 3.27 Role of the small GTPase, Ras, in anti-lg Induced growth arrest
and apoptosis, and CD40 mediated rescue, in WEHI-231 cells
Overexpression of the constitutively active Ras mutant, RasV12, in WEHI-231 
cells results in the cells being less susceptible to anti-lg induced growth arrest, 
though the effects on anti-lg induced apoptosis are unclear as this varies greatly 
depending upon the transfection method. The constitutively active mutant 
RasV12-C40, which can only activate the PI-3-Kinase pathway and not the Erk- 
MAPKinase pathway directly, though it does activate Erk-MAPKinase indirectly, 
provides a measure of protection from both anti-lg induced growth arrest and 
apoptosis, unsurprising as PI-3-Kinase signalling is widely held to promote 
survival of cells. This is further evidenced by the observation that RasV12-C40 
expressing cells display enhanced CD40-mediated protection from anti-lg 
induced apoptosis, whilst RasV12-S35 expressing cells are refractory to CD40- 
mediated rescue from anti-lg induced apoptosis, though, surprisingly, not anti-lg 
mediated growth arrest. RasV12-S35 expressing cells are protected from anti-lg 
induced growth arrest to a certain extent, but not as well as by the mutants that 
induce both PI-3-Kinase and Erk-MAPKinase.
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Figure 3.28 Role of the cyclin dependent kinase inhibitor in anti-lg
induced growth arrest of WEHI-231 cells
Anti-lg induced growth arrest of WEHI-231 cells is accompanied by an increase 
in the levels of expression of the cyclin dependent kinase inhibitor p27. This may 
be, at least in part, a consequence of Erk-MAPKinase activation, as cells 
expressing RasV12-C40 do not respond to anti-lg by undergoing growth arrest, 
nor by increasing expression of p27. This is in contrast to RasV12-S35 
expressing cells, as these cells increase the level of expression of p27 more than 
cells containing the empty vector, despite not demonstrating an increase in 
growth arrest compared to cells containing the empty vector.
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Chapter 4 -  The role of PKC isoforms in the reguiation 
of survivai and proiiferation ofWEHi-231 celis
4.1 Introduction
Protein kinase C (PKC) was initially identified and characterised as a 
proteolytically activated kinase and named protein kinase M in the late 1970s 
(Inoue et al., 1977; Takai et al., 1977). Members of the PKC superfamily are 
serine/threonine kinases and are downstream effectors of multiple signalling 
pathways. To date, 11 isoenzymes have been identified, and these can be 
subdivided into three groups on the basis of their enzymatic properties, though 
they all require association with acidic phospholipids such as phosphatidylserine 
(PS). The conventional (sometimes known as classical) PKCs (cPKCs; a, pi, pu,
Y) are Ca^^-dependent and are activated by diacylglycerol (DAG); the novel PKCs 
(nPKCs; Ô, e , q, 0) are Ca^^-independent but are also activated by DAG; the 
atypical PKCs (aPKCs; X/t -  X being the murine isoform, i the human isoform) 
are calcium-independent and are not activated by DAG. Each PKC isoform is 
likely to have different substrates and therefore unique functions.
Activation of the cPKCs depends primarily on activation of the phospholipase C 
(PLC) pathway that results in the generation of DAG as well as inositol 1,4,5- 
trisphosphate which causes increases in cytoplasmic Ca^  ^concentrations. The 
nPKCs can also be activated by the PLC pathway and presumably by other 
reactions that produce DAG including phosphatidylcholine hydrolysis and the 
dephosphorylation of phosphatidic acid to DAG. The full activation of nPKC 
isoforms also requires phosphorylation by other kinases such as PDK1 and 
PKCÇ which are downstream targets of phosphatidylinositol 3-kinase (Pl-3- 
kinase). The aPKCs are both downstream targets of Pl-3-kinase signalling, 
therefore, as BCR ligation leads to the activation of both the PLC and PI-3- 
Kinase pathways (Campbell, 1999), it seems highly likely that multiple PKC 
isoforms participate in BCR signalling.
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4.1.1 Expression of PKC isoforms in B lymphocytes
To elucidate the functions of PKCs in BCR signalling it is important to first 
determine which PKCs are activated following BCR ligation. Seven members of 
the PKC family have been detected in B cells; PKCa, PKCp, PKCÔ, PKCe, PKCÇ, 
PKCt), and PKC0 (Bras et a i, 1997; Krappmann et at., 2001; Mischak ef a/.,
1991; Morrow et at., 1999). Of the novel PKC isoforms, PKCô and PKCe are 
expressed at much higher levels in B cells than T cells, while PKC0 is expressed 
at higher levels in T cells (Krappmann et a/., 2001). Of these seven members that 
have been detected in B cells, most have shown to be involved in B cell 
signalling in some way or another.
4.1.2 PKCa
PKCa was the first member of the PKC family to be identified and cloned, being 
isolated from a brain cDNA library over 15 years ago (Parker et a!., 1986). It has 
since been found to have a wide tissue distribution, and as such has been 
implicated in the control of a number of major cellular functions, including 
proliferation, differentiation, apoptosis and mobility. In some cell types, 
overexpression of PKCa is sufficient to induce proliferation, and it has recently 
been shown that expression of constitutively active PKCa in NIH-3T3 cells 
results in increased expression of cyclins D1 and E, and increased proliferation 
rates (Soh and Weinstein, 2003).
As well as promoting proliferation, accumulating evidence suggests a role for 
PKCa in the inhibition of apoptosis. Reducing the level of PKCa results in 
apoptosis in a number of cell types, including U937 cells (Whelan and Parker,
1998) and glioma cells (Dooley et a/., 1998). PKCa has also been shown to 
phosphorylate the survival promoting protein Bcl-2 on a site that enhances the 
antiapoptotic properties of Bcl-2 (Ito eta!., 1997; Ruvolo eta!., 1998). 
Furthermore, the induction of apoptosis by ceramide involves the inhibition of
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PKCa by déphosphorylation {Lee et a i, 1996). Perhaps pertinently, PKCa has 
also been shown to play an essential role in the survival of the Ramos human B 
ceil line (Keenan et a i, 1999).
4.1.3 PKCp
The PKCp gene encodes two proteins, PKCp, and PKCpn, which are generated 
by alternative splicing of the C-terminal exons, resulting in two proteins differing 
in only the final 50 (PKCPi) or 52 (PKCpn) amino acids, the V5 region. PKCpi 
appears to play an important role in B cell survival, at least in WEHI-231 cells. 
WEHI-231 cells expressing the C-terminal half of leukocyte-specific protein 1 
(LSP1) display enhanced apoptosis in response to anti-IgM (Jongstra-Bilen et a i,
1999). This increase in anti-lgM-induced apoptosis correlates with failure to 
translocate PKCpi to the plasma membrane, but not PKCpn or PKCa, and a 
decrease in activation of ERK2 (Cao et a i, 2001).
Interestingly, PKCp“^“ mice have significantly fewer B1 lymphocytes as well as B- 
1a cells in the peritoneal cavity, compared to wild type mice. The proportion and 
absolute number of pre-B and mature B cells in the bone marrow of PKCp  ^ mice 
and wild type mice are essentially identical, and the proportion of mature B cells 
in the spleen and lymph nodes is also similar, suggesting that PKCp is not 
absolutely required for B cell maturation. However, the absolute number of 
splenic B cells is slightly reduced (Leitges et a i, 1996). The T cell compartment 
of PKCp ^  mice is comparable to that of wild type mice, with the thymus of PKCp 
'' mice being of normal size and containing CD4^CD8^ double-positive cells and 
CD4^ or CD8^ single-positive cells at normal ratios. PKCp  ^ mice have a reduced 
primary response to T cell-dependent antigens, as well as a decreased response 
to T cell-independent type II antigens (Leitges et ai, 1996). The phenotype of 
PKC(3'^ ' mice is very similar to that of xid mice, which exhibit a mild 
immunodeficiency and a slight reduction in the number of peripheral B cells, 
particularly mature B cells, as a result of a point mutation in the PH domain of Btk
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(Kurosaki, 1999). Further similarities between PKCP' '^ and xid mice are 
demonstrated by the in vitro responses to various stimuli. B cells from both types 
of mice exhibit significantly less proliferation in response to anti-IgM, anti-CD40 
or LPS. This reduction in antigen receptor-mediated proliferation in the absence 
of PKCp is restricted to B cells, as the in vitro response of splenic T cells and 
thymocytes to anti-CD3 antibody from PKCp ^  mice is unchanged.
PKCp  ^ transitional 2 and mature follicular B cells fail to activate N F-k B or up- 
regulate BcI-xl in response to BCR stimulation, resulting in increased apoptosis. 
This failure to activate N F-k B is a consequence of an inability to induce the 
degradation of Ik B as a result of IKK not being recruited to lipid rafts, and hence 
not becoming activated, as in wild type cells PKCp is rapidly recruited to lipid 
rafts upon BCR ligation (Su et al., 2002). This is reminiscent of PKCG '^ mice, 
where T cell stimulation fails to induce NFk B activation (Sun et a i, 2000). In wild 
type T cells, TCR signalling induces recruitment of PKC0 and IKK into lipid rafts 
(Khoshnan et a i, 2000).
Interestingly, and in marked contrast to this, PKCp activity is required for HLA- 
DR-mediated B cell death (Guo et ai, 2003). However, HLA-DR-induced PKCp 
activation does not require its translocation to lipid rafts, indeed, the majority of 
HLA-DR-activated PKCp exists outwith lipid rafts. Moreover, cell activation state 
plays a role in MHC class II signalling, as resting murine B cells undergo MHC 
class 11-mediated cell death, whereas activated cells are insensitive to MHC class 
ll-mediated cell death (Newell et a i, 1993). The opposite is true in human B cells, 
with resting human B cells insensitive to MHC class ll-mediated death, whilst 
activated cells are highly susceptible to HLA-DR-mediated death (Garban et ai, 
1998). interestingly, the signalling pathways regulating these distinct functional 
outcomes appear to be the same, as activated murine B cells and resting human 
B cells exhibit PTK activation and high Ca^^ flux, whereas resting murine B cells
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and activated human B cells demonstrate elevated cAMP levels and PKC 
activation.
Although PKCp ^ ' mice exhibit an immunodeficiency similar to that seen in xid 
mice (that arise from a point mutation in Btk) the overall tyrosine phosphorylation 
of Btk is significantly enhanced in PKCp-deficient B cells. It has recently been 
shown that PKCp actually acts as a negative feedback inhibitor of Btk by 
phosphorylating Btk. This results in a conformational change in the PH domain of 
Btk abrogating its interaction with PIP3, hence disrupting its membrane 
localisation, which is required for its activity. Mutation of the phosphorylation site 
creates a mutant Btk that is resistant to PKCp-mediated inhibition and enhances 
BCR-dependent calcium signalling. The inhibition of Btk by PKCp is likely to play 
a key role in setting and maintaining the BCR signalling threshold (Kang et ai,
2001).
4.1.4 PKCô
PKCô is expressed at high levels in B cells (Mischak et ai, 1991) and has been 
shown to become tyrosine phosphorylated in response to BCR ligation (Barbazuk 
and Gold, 1999), suggesting that PKCô could be an important mediator of BCR 
signalling. This phosphorylation in response to BCR ligation occurs in the WEHI- 
231 immature B cell line, the BALI 7 mature B cell line, and in small resting 
murine splenic B cells, suggesting that this process is not dependent on the 
developmental stage of the B cell. Tyrosine phosphorylation of PKCô in response 
to BCR ligation in WEHI-231 cells correlates with its translocation to the 
membrane, hence its activation, as PKCs must bind membrane lipids in order to 
become activated. Activation of PLC, and the subsequent production of DAG, Is 
both necessary and sufficient for this membrane recruitment of PKCô, and 
necessary but not sufficient for its BCR-induced phosphorylation.
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The consequences of PKCô activation appear to vary depending on cell type. 
Overexpression of PKCô in fibroblasts can induce activation of the Raf/MEK/ERK 
signalling cascade, resulting in activation of the transcription factor AP-1 (Hirai et 
a!., 1994; Ueda etal., 1996). However, PKCô is also thought to participate in 
apoptosis, as it is cleaved by caspases (Emoto et al., 1995), producing a 
constitutively active form of the enzyme that is sufficient to induce apoptosis 
when expressed in human myeloid leukaemia cells (Ghayur etal., 1996). This 
catalytic fragment inhibits DNA-dependent protein kinase and contributes to DNA 
damage-induced apoptosis. It has also been demonstrated that levels of PKCô 
expression decrease as cells progress through Gi and enter S phase of the cell 
cycle, and increase above initial levels as cells re-enter Gi (Srivastava et al.,
2002), suggesting that PKCô acts as an inhibitor of cell cycle progression.
PKCÔ knockout mice have a greater percentage of B lymphocytes in the spleen 
and lymph nodes compared to wild type mice, and indeed the absolute number 
of B lymphocytes in spleen and lymph nodes of PKCÔ ^  mice is greater than from 
wild type animals (Miyamoto etal., 2002). This expansion of the B cell population 
occurs in the periphery, as there are no significant differences in the bone 
marrow of PKCô" '^ mice compared to that of wild type mice. The proliferative 
response of PKCô-deficient B cells stimulated with anti-IgM and anti-CD40 in 
combination, or LPS alone was significantly greater than that of B cells from wild 
type mice, whilst the response of T cells was unchanged, indicating that the 
effect of loss of PKCô is B cell specific (Miyamoto et al., 2002). Another group 
generated PKCô-deficient mice independently at the same time (Mecklenbrauker 
et al., 2002), and they claim that loss of PKCô does not affect BCR-mediated B 
cell activation in vitro or in vivo. However, this paper does not assess proliferation 
of stimulated B cells by means of a DNA synthesis assay as Miyamoto, but by 
staining with CFSE. An alternative interpretation of the CFSE data is that B cells 
from PKCô' "^ mice undergo more than 1 cell division, whereas B cells from wild 
type mice only undergo 1 cell division, in concurrence with Miyamoto. It was also
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found that B cells from PKCô'^ ' are refractory to tolerance, permitting maturation 
and terminal differentiation of self-reactive B cells in the presence of the 
tolerance-inducing antigen. The serum of PKCô'^ ' mice also contained 
autoreactive anti-DNA and anti-nuclear antibodies (Mecklenbrauker ef a/., 2002) 
and PKCô ^  mice are prone to autoimmune disease (Miyamoto et a/., 2002), 
further demonstrating a likely role for PKCô in the induction of self antigen- 
induced B cell tolerance. Despite its proposed role as a tumour suppressor, due 
to its ability to inhibit cell cycle progression, there was no increase in cancer- 
induced death in the PKCô"^  animals compared to control animals, suggesting 
that the lack of functional PKCô does not lead to predisposition towards cancer. 
The phenotype seen in B cells of PKCô ^ " mice contrasts markedly with that seen 
in PKCp '^ mice, as PKCp' '^ animals develop an immunodeficiency as a result of 
decreased proliferation of B cells (Leitges et a/., 1996), suggesting that the 
activation of PKCp is required for the proliferation of stimulated B cells, whilst 
PKCô plays a role in negatively regulating the proliferation of stimulated B cells.
Overexpression of PKCô leads to a decrease in the expression of cyclin D1 in 
primary bovine smooth muscle cells, and overexpression of a dominant negative 
PKCô results in an increase in cyclin D1 expression (Page et a/., 2002). It has 
also recently been shown that expression of a constitutively active PKCô mutant 
inhibits expression from the cyclin D1 promoter in NIH3T3 cells, but there was no 
increase in activity of the cyclin D1 promoter in response to a PKCô dominant 
negative mutant (Soh and Weinstein, 2003).
4.1.5 PKCe
PKCe is thought to be a positive regulator of cell survival and proliferation. PKCe 
has been shown to activate the Raf-1/ERK pathway (Hamilton ef a/., 2001), thus 
promoting the activation of the two key survival factors NF-kB (Tojima ef a/.. 
2000) and Akt (Matsumoto etal., 2001). PKCe may also promote cell survival by
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contributing to the activation of Akt, a protein kinase that mediates PI-3-kinase 
survival signals, as expression of a catalytically inactive form of PKCe has been 
shown to inhibit the activation of Akt by insulin (Matsumoto et a/., 2001). PKCe 
appears to play a role in cell proliferation also, as it is activated in response to a 
variety of mitogens (Moriya etal., 1996; Olivier and Parker, 1994). In certain cell 
types, overexpression of PKCe results in transformation, a consequence of PKCe 
inducing the phosphorylation of Raf-1 and the resulting activation of the ERK- 
MAPKsignalling pathway (Cacace etal., 1996; Cai etal., 1997; Perletti etal., 
1998). More recently, it has been shown that expression of a constitutively active 
mutant of PKCe in NIH3T3 cells activates the cyclin D1 promoter (Soh and 
Weinstein, 2003). However, overexpression of PKCe in NIH-3T3 cells increases 
radiation-induced cell death, as a result of increased Erk1/2 activation (Lee et al,
2003). Overexpression of a constitutively active PKCe caused an even greater 
increase in radiation-induced cell death, whereas overexpression of a dominant 
negative PKCe returned cell death to control levels.
PKCe is highly expressed in B lineage cells, and ligation of the BCR of the A20 
murine B cell line induces its translocation from the cytoplasm to cellular 
membranes, and this translocation coincides with PI-3-Kinase-dependent 
phosphorylation of PKCe, the two steps required for maximal activation of PKCe 
(Ting et ai, 2002). Translocation of PKC enzymes from the cytoplasm to the 
membrane allows them to bind their lipid activators and is taken as a measure of 
PKC activation. The role of PKCe in BCR signalling remains to be elucidated, 
however, in other cell types activation of PKCe has been strongly linked to cell 
survival and proliferation. PKCe activation inhibits both TNF- and TRAIL-induced 
apoptosis (Mayne and Murray, 1998; Shinohara e ta i, 2001), so it would seem 
likely that PKCe activation contributes to BCR-induced survival signals. The 
BCR-induced survival signal is thought to involve, at least in part, N F-k B, and it 
has been shown that PKCe promotes the activation of N F-k B (Tojima et ai,
2000).
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Further support for the idea that PKCe activation could be involved in B cell 
proliferation comes from the fact that PKCe was found to be constitutively 
phosphorylated in a number of B lymphoma cell lines that are constitutively 
proliferating, but such phosphorylation was only induced in mature splenic B cells 
by BCR ligation (Ting etal., 2002).
4.1.6 PKC^
PKC^ has been implicated in the control of Erk-MAPKinase and NF-kB signalling 
pathways. In PKCC  ^ mice the composition of the B cell compartment in lymphoid 
tissue is abnormal. PKCC '^ mice have a higher percentage of immature B cells in 
Peyer's Patches at all ages examined, and in the lymph nodes at 2 weeks. The 
difference in percentage between wild type and knockout mice was less 
pronounced in lymph nodes at 7-8 weeks, though there was still a slightly higher 
percentage of immature cells in the PKC^-deficient mice, as assessed by B220 
and MHC expression. In PKCt ^  mice, proliferation of purified splenic B cells 
activated via the BCR is severely impaired, however, this is not the case when 
the cells are stimulated with LPS or anti-CD40 (Martin etal., 2002). This 
attenuation of proliferation in response to BCR stimulation correlates with a 
significant decrease in activation of MEK, and a concomitant decrease in 
activation of Erk-MAPKinase, as assessed by western blotting with anti-phospho- 
MEKand -ERKantibodies respectively (Martin etal., 2002).
4.2 Aims and Objectives
Many of the seemingly contradictory results whereby PKC activation led to 
apoptosis or survival in different cell types stems from the use of phorbol esters 
as activators of PKCs. Phorbol esters can stimulate both cPKC and nPKC 
isoforms, but prolonged treatment of cells with these agents results in PKC down 
regulation and cellular depletion. However, generally speaking, conventional and
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atypical PKCs are considered to be predominantly anti-apoptotic, being 
principally involved in promoting cell survival and proliferation. The novel PKCs, 
however, generally have a tumour suppressor function and are regarded as pro- 
apoptotic proteins. PKCa and PKCô are two of the most well characterised PKCs 
with respect to their roles in preventing and promoting apoptosis, respectively. It 
is interesting that these two have been demonstrated as having key roles in 
regulating apoptosis, as these isoforms are present in the majority of B cell 
stages.
To further elucidate the roles of individual PKC isoforms in signalling in immature 
B cells, mutant forms of four PKC isoforms were transfected into the WEHI-231 
immature B cell line. The isoforms were chosen on the basis that knockout 
studies imply that they have roles in B cells. This chapter aims to address:
1. The role of the conventional PKC, PKCa, in BCR-mediated signalling, 
using the constitutively active PKCa-CAT mutant and the kinase dead 
PKCa-KR mutant.
2. The role of the novel PKC, PKCô, in BCR-mediated signalling, using the 
constitutively active PKCÔ-CAT mutant and the kinase dead PKCô-KR 
mutant.
3. The role of the novel PKC, PKCs, in BCR-mediated signalling, using the 
constitutively active PKCe-CAT mutant and the kinase dead PKCs-KR 
mutant.
4. The role of the atypical PKC, PKCÇ, in BCR-mediated signalling, using the 
constitutively active PKC^-CAT mutant and the kinase dead PKC^-KR 
mutant.
6. The effects all of these mutants have on key regulators of the cell cycle in 
WEHI-231 cells.
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4.3 Results
4.3.1 Transfection of WEHI-231 cells with PKC mutants
To investigate the roles of the four PKC family members PKCa, PKGô, PKCe, 
and PKC^, two mutant forms of each were inserted into the pcDNA3.1 vector 
(Figure 2.9). The mutant forms used were either a constitutively active catalytic 
domain (CAT) or full-length kinase dead as the result of a lysine -  arginine 
substitution (KR) (Figure 4.1). All eight mutants were transfected into the WEHI- 
231 cell line by electroporation, as described in Section 2.14 Successfully 
transfected cells were selected by the addition of G418 (500 fxg/ml) 48 hours 
after electroporation and continued culture of the cells with 500 p.g/ml G418.
4.3.2 Effect of PKCa mutants on anti-lg mediated growth arrest in WEHI-231 
cells
Wild type WEHI-231 cells exhibit a pronounced growth arrest in Gi phase of the 
cell cycle in response to anti-lg, as shown in Figure 3.1. To investigate the 
effects of expression of a constitutively active PKCa (PKCa-CAT) or a kinase 
dead form of PKCa (PKCa-KR) on anti-lg mediated growth arrest in WEHI-231 
cells, transfected cells were stimulated with various concentrations of anti-lg, and 
proliferation assessed by the [^H]-thymidine uptake assay at 24 and 48 hours 
(Figure 4.2). Cells transfected with the empty vector were used as a control.
Even at 24 hours, WEHI-231 cells transfected with the empty pcDNA3.1 vector 
exhibit a pronounced growth arrest in response to anti-lg, with thymidine uptake 
levels only approximately 60% of those of unstimulated cells in response to 1 
[ig/ml anti-lg, and only about 50% in response to 10 ^g/ml anti-lg (Figure 4.2A) 
By 48 hours, both concentrations of anti-lg have reduced levels of thymidine 
uptake to around 40% of those of the unstimulated cells (Figure 4.2B). In 
contrast to this, cells transfected with the PKCa mutants do not show signs of
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growth inhibition in response to 10 (xg/ml anti-lg at 24 hours. If anything, PKCa- 
KR ceils actually exhibit slightly increased levels of proliferation after 24 hours 
stimulation with anti-lg, particularly 0.1 [ig/ml and 10 p,g/ml. Cells expressing 
PKCa-CAT demonstrate slightly lower levels of proliferation in response to low 
doses of anti-lg (0.1 and 1 p.g/ml), but the levels increase in response to 10 pig/ml 
(Figure 4.2A). After 48 hours treatment cells expressing either PKCa mutant do 
demonstrate growth arrest in response to anti-lg at 1 or 10 jxg/ml, but not quite to 
the same extent as cells containing the empty vector alone (Figure 4.2B). The 
most surprising thing about this result is the fact that both mutants confer the 
same properties upon WEHI-231 cells, despite the fact that one should be 
constitutively active and the other dominant negative.
4.3.3 Effect of PKCa mutants on anti-lg mediated apoptosis in WEHI-231 
cells
To investigate the effects of expression of PKCa-CAT and PKCa-KR on anti-lg 
mediated apoptosis in WEHI-231 cells, transfected cells were stimulated with 
anti-lg (10 ^g/ml) or a combination of anti-lg (10 p,g/ml) and anti-CD40 (10 (xg/ml) 
for up to 72 hours. Cells receiving no stimulating antibodies were used as a 
control. At 24, 48 and 72 hours the DNA content was assessed by flow cytometry 
following staining with propidium iodide, to determine the proportion of cells with 
a sub-diploid DNA content, as well as the proportion of cells in each cell cycle 
phase.
At each time point, cells containing the empty vector display an increase in the 
proportion of cells displaying a sub-diploid DNA content, along with an increase 
in cells in G0/G1 and a concomitant decrease in cells in S phase or G2/M in 
response to anti-lg stimulation (Figure 4.3). WEHI-231 cells expressing the 
PKCa-CAT mutant display a similar pattern, with an increase in sub-diploid cells 
and cells in G0/G1, and a decrease in cells in S phase and G2/M. The increase in 
apoptosis is much greater than that shown by cells containing the empty vector
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at 48 hours, with PKCa-CAT expressing cells demonstrating a 6-fold increase in 
apoptosis, compared to approximately 3-fold for the vector containing cells at the 
same time point. On the contrary, the PKCa-KR mutant does not appear to alter 
the apoptotic response of WEHI-231 cells to anti-lg, as the increase in apoptosis 
induced by anti-lg is of a similar magnitude to cells containing the empty vector.
4.3.4 Effect of PKCa mutants on CD40-mediated rescue from anti-lg 
mediated growth arrest and apoptosis in WEHI-231 cells
To investigate the effects of the PKCa mutants on CD40-mediated rescue from 
anti-lg induced growth arrest and apoptosis, cells were stimulated with anti-lg (10 
\xg/m\) or a combination of anti-lg (10 ^g/ml) and anti-CD40 (10 {xg/ml). Following 
stimulation for 48 hours, proliferation was assessed by the [^H]-thymidine 
incorporation assay. At 24, 48 and 72 hours the DNA content was assessed by 
flow cytometry following staining with propidium iodide, to determine the 
proportion of cells with a sub-diploid DNA content, as well as the proportion of 
cells in each cell cycle phase.
Expression of PKCa-CAT enhances CD40-mediated rescue of anti-lg induced 
growth arrest at 48 hours compared to cells carrying the empty vector (Figure 
4.4) This is not as evident when the proportion of cells in each cell cycle phase 
is assessed by flow cytometry, as the PKCa-CAT expressing cells have a 
proportion of cells in each cell cycle phase intermediate between that of 
unstimulated cells and those stimulated with anti-lg alone. However, there is a 
dramatic increase in the proportion of S phase cells at 48 hours compared to 
cells stimulated with anti-lg alone, though this does not reach the proportion of 
unstimulated cells in S phase (Figure 4.3). PKCa-KR expressing cells exhibit a 
very similar level of CD40-mediated rescue of anti-lg induced growth arrest and 
apoptosis as cells containing the empty vector.
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4.3.5 Effect of PKCô mutants on anti-lg mediated growth arrest in WEHI-231 
cells
To investigate the effects of expression of a constitutively active PKCô (PKCô- 
CAT) or a kinase dead form of PKCô (PKCô-KR) on anti-lg mediated growth 
arrest in WEHI-231 cells, transfected cells were stimulated with increasing 
concentrations of anti-lg, and proliferation assessed by the [^H]-thymidine uptake 
assay at 24 and 48 hours (Figure 4.5 and results not shown). Cells transfected 
with the empty vector were used as a control.
After 24 hours of stimulation with anti-lg, WEHI-231 cells expressing either PKCô 
mutant show no signs of growth arrest, even at the maximum concentration of 
anti-lg, whereas cells containing the empty vector exhibit only 50% of the [^H] 
thymidine uptake of unstimulated cells (Figure 4.5A) By 48 hours of treatment, 
10 pg/ml has induced growth arrest of a similar magnitude to cells containing the 
empty vector in cells expressing either PKCô mutant (Figure 4.5B).
4.3.6 Effect of PKCô mutants on anti-lg mediated apoptosis in WEHI-231 
cells
To investigate the effects of expression of PKCô-CAT and PKCô-KR on anti-lg 
mediated apoptosis in WEHI-231 cells, transfected cells were stimulated with 
anti-lg (10 ^g/ml) or a combination of anti-lg (10 jxg/ml) and anti-CD40 (10 |ig/mi) 
for up to 72 hours. Cells receiving no stimulating antibodies were used as a 
control. At 24, 48 and 72 hours the DNA content was assessed by flow cytometry 
following staining with propidium iodide, to determine the proportion of cells with 
a sub-diploid DNA content, as well as the proportion of cells in each cell cycle 
phase.
After 24 hours of treatment, WEHI-231 cells expressing PKCô-CAT or PKCô-KR 
do not exhibit an increase in apoptosis in response to anti-lg, nor do they appear
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to demonstrate any growth arrest as there is a high proportion of cells in S phase 
and G2/M (Figure 4.6), corroborating the [^H]-thymidine data (Figure 4.5A). By 
48 hours however, both mutants exhibit very similar patterns to cells carrying the 
empty vector, with anti-lg stimulation inducing an increase in the proportion of 
cells with sub-diploid DNA content and a huge increase in the proportion of cells 
in G0/G1. As expected there is a concomitant decrease in cells in S phase and 
G2/M. By 72 hours the proportion of apoptotic cells is still greater in cells 
stimulated with anti-lg compared to unstimulated cells, but unstimulated cells are 
starting to accumulate in Gq/Gi, probably as a result of exhaustion of essential 
nutrients in the culture.
4.3.7 Effect of PKCÔ mutants on CD40-mediated rescue from anti-lg 
mediated growth arrest and apoptosis in WEHI-231 cells
To investigate the effects of the PKCô mutants on CD40-mediated rescue from 
anti-lg induced growth arrest and apoptosis, cells were stimulated with anti-lg (10 
[ig/ml) or a combination of anti-lg (10 fAg/ml) and anti-CD40 (10 p,g/ml). Following 
stimulation for 48 hours, proliferation was assessed by the pH]-thymidine 
incorporation assay (Figure 4.7). Apoptosis was assessed at 24, 48 and 72 
hours by flow cytometry following propidium iodide staining, to determine the 
proportion of cells with sub-diploid DNA content as well as the proportion of cells 
in each cell cycle phase (Figure 4.6).
Expression of PKCÔ-CAT does not appear to affect CD40-mediated rescue of 
anti-lg induced growth arrest as [^H] thymidine incorporation is not significantly 
different from control cells in response to anti-lg alone or the combination of anti- 
lg and anti-CD40 (Figure 4.7). PKCô-KR appears to have a slight positive effect 
on CD40-mediated rescue, as cells expressing PKCô-KR appear to have 
enhanced growth in response to anti-lg and anti-CD40 treatment, compared to 
control cells (Figure 4.7). This is supported by the DNA content analysis as 
PKCô-KR expressing cells display a larger proportion of cycling cells (S phase or
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G2/M) upon co-stimulation than in the population of cells stimulated with anti-lg 
alone at 48 hours (Figure 4.6). Neither PKCô-CAT nor PKCÔ-KR appear to affect 
CD40-mediated rescue from anti-lg induced apoptosis as the proportion of ceils 
with sub-diploid DNA content is greatly reduced by co-stimulation with anti-lg and 
anti-CD40, compared to anti-lg treatment alone (Figure 4.6).
4.3.8 Effect of PKCe mutants on anti-lg mediated growth arrest in WEHI-231 
cells
To investigate the effects of expression of a constitutively active PKCe (PKCe- 
CAT) or a kinase dead form of PKCe (PKCe-KR) on anti-lg mediated growth 
arrest in WEHI-231 cells, transfected cells were stimulated with increasing 
concentrations of anti-lg over a period of 48 hours, and proliferation assessed by 
the [^H]-thymidine uptake assay at 24 and 48 hours (Figure 4.8) Cells 
transfected with the empty vector were used as a control.
WEHI-231 PKCe-CAT cells appear to increase their proliferation upon stimulation 
with anti-lg for 24 hours, in a dose-dependent manner (Figure 4.8A). WEHI-231 
PKCe-KR cells do not undergo growth arrest in response to anti-lg after 24 hours, 
but nor do they increase their proliferation. By 48 hours, however, anti-lg (1 and 
10 p,g/ml) has induced growth arrest in both these cell types, to the same level as 
the empty vector control (Figure 4.8B).
4.3.9 Effect of PKCe mutants on anti-lg mediated apoptosis in WEHI-231 
cells
To investigate the effects of expression of PKCe-CAT and PKCe-KR on anti-lg 
mediated apoptosis in WEHI-231 cells, transfected cells were stimulated with 
anti-lg (10 fxg/ml) or a combination of anti-lg (10 \xg/m\) and anti-CD40 (10 |iig/ml) 
for up to 72 hours. Cells receiving no stimulating antibodies were used as a 
control. At 24, 48 and 72 hours the DNA content was assessed by flow cytometry
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following staining with propidium iodide, to determine the proportion of cells with 
a sub-diploid DNA content, as well as the proportion of cells in each cell cycle 
phase.
WEHI-231 PKCe-CAT cells exhibit an abrogation of anti-lg induced growth arrest 
and apoptosis as there is only a slight Increase in the proportion of cells with sub­
diploid DNA content or in cells in Go/Gi, whereas there is no great decrease in 
cells in S phase or G2/M (Figure 4.9). This corroborates the [^H] thymidine data, 
which suggested that PKCe-CAT confers a level of resistance to anti-lg mediated 
growth arrest at 24 hours. However, by 48 and 72 hours, anti-lg induces a 
substantial increase (6-fold at 48, 5-fold at 72) in the proportion of WEHI-231 
PKCe-CAT cells with sub-diploid DNA content relative to unstimulated cells. This 
is accompanied at 48 hours by an increase in cells arrested in G0/G1, and a 
decrease in cells in both S phase and G2/M. PKCe-KR also appears to confer 
resistance to anti-lg induced growth arrest and apoptosis at 24 hours, as there is 
very little increase in the proportion of cells with a sub-diploid DNA content and in 
Go/Gi, and no great decrease in the proportion of cells in S phase or G2/M, 
compared to cells containing the empty vector. This effect again is not sustained 
as by 48 hours there is a dramatic increase in the proportion of cells with a sub­
diploid DNA content and arrested in Gq/Gi, and this remains the case at 72 
hours.
4.3.10 Effect of PKCe mutants on CD40-mediated rescue from anti-lg 
mediated growth arrest and apoptosis In WEHI-231 cells
To investigate the effects of the PKCe mutants on CD40-mediated rescue from 
anti-lg induced growth arrest and apoptosis, cells were stimulated with anti-lg (10 
jxg/ml) ora combination of anti-lg (10 i^g/mt) and anti-CD40 (10 fxg/ml). Following 
stimulation for 48 hours, proliferation was assessed by the [^H] thymidine 
incorporation assay (Figure 4.10) At 24, 48 and 72 hours the DNA content was 
assessed by flow cytometry following staining with propidium iodide, to determine
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the proportion of cells with a sub-diploid DNA content, as well as the proportion 
of cells in each cell cycle phase (Figure 4.9).
Neither PKCe-CAT or PKCe-KR seem to affect CD40-mediated rescue of anti-lg 
induced growth arrest or apoptosis, as the results of the proliferation assay 
(Figure 4.10) and DNA content analysis (Figure 4.9) do not differ significantly 
from control cells. This is somewhat surprising, given the increase in anti-lg 
mediated apoptosis induced by expression of PKCe-CAT.
4.3.11 Effect of PKC^ mutants on anti-lg mediated growth arrest in WEHI- 
231 cells
To investigate the effects of expression of a constitutively active PKCC (PKC^- 
CAT) or a kinase dead form of PKCt (PKC^-KR) on anti-lg mediated growth 
arrest in WEHI-231 cells, transfected cells were stimulated with increasing 
concentrations of anti-lg, and proliferation assessed by means of the f n y  
thymidine uptake assay at 24 and 48 hours (Figure 4.11) Cells transfected with 
the empty vector were used as a control.
After 24 hours stimulation with 0.1 \ig/m\ anti-lg, WEHI-231 cells expressing 
either PKC^ construct display a decrease in proliferation compared to the empty 
vector, but when stimulated with 1 or 10 jxg/ml anti-lg WEHI-231 cells expressing 
these constructs exhibit a minimal decrease in proliferation (Figure 4.11 A). After 
48 hours stimulation, there is no great difference in the growth arrest induced by 
10 jxg/ml upon WEHI-231 cells expressing either PKCt mutant compared to cells 
containing the empty vector (Figure 4.1 IB). Similar to the PKCa mutants, the 
behaviour of the PKC^ mutants is fairly similar at the level of the biological 
response to anti-lg.
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4.3.12 Effect of PKC^ mutants on anti-lg mediated apoptosis in WEHI-231
cells
To investigate the effects of expression of PKC^-CAT and PKC^-KR on anti-lg 
mediated apoptosis in WEHI-231 cells, transfected cells were stimulated with 
anti-lg (10 ^ig/ml) or a combination of anti-lg (10 fxg/ml) and anti-CD40 (10 jig/ml) 
for up to 72 hours. Cells receiving no stimulating antibodies were used as a 
control. At 24, 48 and 72 hours the DNA content was assessed by flow cytometry 
following staining with propidium iodide, to determine the proportion of cells with 
a sub-diploid DNA content, as well as the proportion of cells in each cell cycle 
phase.
Interestingly, at 24 hours, cells transfected with either PKCt mutant display a 
modest increase in the proportion of sub-diploid cells upon stimulation with anti- 
lg compared to cells containing the empty vector (Figure 4.12). Indeed, they still 
display relatively large proportions of cells in S phase and G2/M, corroborating 
the [^H]-thymidine data, which suggested that these cells are refractory to anti-lg 
induced growth arrest at 24 hours (Figure 4.11). Transfection with the PKCt- 
CAT mutant results in a substantial increase in apoptosis upon 48 hours of 
treatment with anti-lg, with a 7-fold increase in the proportion of sub-diploid cells 
compared to unstimulated cells, whilst cells containing the empty vector display a 
more modest 3-fold increase (Figure 4.12). This is accompanied by a large 
decrease in the proportion of cells in either S phase or G2/M, corroborating the 
results yielded by the [^H]-thymidine incorporation assay (Figure 4.11). In 
contrast, PKC^-KR expressing cells exhibit only a 3-fold increase in apoptosis 
upon stimulation with anti-lg for 48 hours, compared to unstimulated cells. 
However, there is a substantial decrease in the proportion of cells in either S 
phase or G2/M, again corroborating the f  H]-thymidine data (Figure 4.11).
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4.3.13 Effect of PKCÇ mutants on CD40~mediated rescue from anti-lg 
mediated growth arrest and apoptosis in WEHI-231 cells
To investigate the effects of the PKCC mutants on CD40~mediated rescue from 
anti-lg induced growth arrest and apoptosis, cells were stimulated with anti-lg (10 
[xg/ml) or a combination of anti-lg (10 fxg/ml) and anti-CD40 (10 pg/ml). Following 
stimulation for 48 hours, proliferation was assessed by the [^H]-thymidine 
incorporation assay (Figure 4.13) At 24, 48 and 72 hours the DNA content was 
assessed by flow cytometry following staining with propidium iodide, to determine 
the proportion of cells with a sub-diploid DNA content, as well as the proportion 
of cells in each cell cycle phase (Figure 4.12)
Neither PKC^-CAT or PKC^-KR seem to affect CD40-mediated rescue of anti-lg 
induced growth arrest or apoptosis, as the results of the proliferation assay 
(Figure 4.13) and DNA content analysis (Figure 4.12) do not differ significantly 
from control cells.
4.3.14 Effect of PKC mutants on p27’^ '*’  ^expression levels in response to 
anti-lg and anti-CD40 stimulation
To assess the effects of the PKC mutants on the protein levels of key cell cycle 
regulators in response to anti-lg and anti-CD40 stimulation, whole cell lysates 
from WEHI-231 cells expressing each mutant were examined by Western blotting 
following the appropriate stimulation. One key regulator of the cell cycle is the 
cyclin dependent kinase inhibitor p27^'^^ An anti-p27 antibody was used to 
detect levels of p27^ '*^  ^ following Western blotting (Figure 4.14).
Un stimulated WEHI-231 cells containing the empty vector display very low levels 
of p27 throughout the 48 hour period. Stimulation with anti-lg antibodies leads to 
an increase in p27 levels overtime, concomitant with induction of growth arrest. 
Stimulation of these cells with anti-CD40 antibodies leads to a transient increase
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in the levels of p27, though they drop by 24 hours, before increasing again 
slightly at 48 hours. Co-stimulation with anti-lg and anti-CD40 antibodies also 
leads to a transient increase in p27 expression, though the levels fall quickly and 
remain low.
WEHI-231 PKCa-CAT cells display a very similar pattern of p27 expression to 
cells containing the empty vector, with anti-lg inducing a substantial increase 
overtime. The same is true of WEHI-231 PKCa-KR cells, though perhaps there 
is also a slight increase in p27 levels in unstimulated cells at 48 hours, probably 
as a result of exhaustion of the nutrients in the media.
WEHI-231 PKCô-CAT cells have a slightly different p27 expression profile from 
WEHI-231 pcDNA3.1 cells, as anti-lg fails to induce an increase in p27 levels in 
these cells. In contrast, anti-CD40 stimulation of WEHI-231 PKCô-CAT cells 
appears to induce an increase in p27 levels. WEHI-231 PKCô-KR cells also have 
a different pattern of p27 expression, almost exactly the opposite of WEHI-231 
PKCô-CAT cells. Unstimulated WEHI-231 PKCô-KR cells, and those stimulated 
with anti-lg, exhibit fairly high levels of p27 expression compared to WEHI-231 
pcDNA3.1 cells. Stimulation of these cells with anti-CD40, either alone or in 
combination with anti-lg, results in a decrease in p27 expression.
WEHI-231 PKCe-CAT cells display a largely similar pattern of p27 expression, 
with anti-lg inducing an increase over time, even though the basal levels appear 
to be slightly higher. Stimulation with anti-CD40, either alone or in combination 
with anti-lg, leads to a transient increase in levels, followed by a steady 
decrease. WEHI-231 PKCe-KR cells also have fairly high basal levels of p27 
expression, but anti-lg doesn’t appear to induce an increase. Stimulation with 
anti-CD40 does, however, lead to the expected decrease in p27 levels, following 
a transient increase.
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WEHI-231 PKC^-CAT cells and WEHI-231 PKC^KR cells exhibit a similar 
pattern of p27 expression to WEHI-231 pcDNA3.1 cells, albeit with a higher basal 
level in untreated cells. Stimulation with anti-lg leads to an increase in p27 
expression levels overtime, whilst stimulation with anti-CD40, either alone or in 
combination with anti-lg, leads to a decrease over time.
The PKC mutant that induces the greatest difference in p27*^ ^^  expression levels 
in response to anti-lg and anti-CD40 stimulation is PKCôCAT. In all the other cell 
types, anti-lg induces a vast increase in p27*^ *^  ^expression at 24 and 48 hours, 
but this is not evident in the WEHI-231 PKCô-CAT cells. These cells, however, 
did not exhibit anti-lg induced growth arrest at 24 hours, though by 48 hours they 
had succumbed to growth arrest (Figure 4.5). Surprisingly, stimulation with anti- 
CD40 alone, ora combination of anti-lg and anti-CD40 induces an increase in 
p27 *^ p^  levels, compared to unstimulated cells. This is entirely unexpected as 
p27^ ^^  ^ is a key inhibitor of the cell cycle, so upregulation of its expression would 
not be conducive to increased proliferation.
4.3.15 Effect of PKC mutants on D-type cyclin expression levels in 
response to anti-lg and anti-CD40 stimulation
A key cyclin responsible for Gi progression in B cells is cyclin D2 (Solvason et 
al., 2000), the cyclin partner for CDK4 which is responsible for phosphorylation 
of the retinoblastoma protein and hence Gi to S phase progression. To 
investigate the effects of the PKC mutants on cyclin D2, an anti-cyclin DI/2 
antibody was used (Figure 4.15). Cyclin D2 could not be detected in samples 
from PKCô or PKC^ expressing cells.
Unstimulated WEHI-231 pcDNA3.1 cells express a fairly constant level of cyclin 
D2 over the time points investigated, with perhaps a slight increase at 24 hours. 
Stimulation with anti-lg antibodies leads to a decrease in cyclin D2 levels over 
time, which would be expected as the cells are undergoing growth arrest. Cells
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stimulated with anti-CD40 alone also display a relatively constant level of cyclin 
D2 expression, and, somewhat surprisingly, co-stimulation with anti-lg and anti- 
CD40 induces a decrease in cyclin D2 protein levels over time, despite an 
increase in proliferation.
WEHI-231 PKCa-CAT and WEHI-231 PKCaKR cells demonstrate a largely 
similar profile of cyclin D2 expression to cells containing the empty vector, with 
anti-lg, either alone or in combination with anti-CD40, inducing a decrease in 
expression. WEHI-231 PKCe-CAT and WEHI-231 PKCeKR cells also exhibit a 
largely similar profile of cyclin D2 expression to cells containing the empty vector, 
with anti-lg, either alone or in combination with anti-CD40, inducing a decrease in 
expression. Therefore it appears as though none of these PKC mutants can 
prevent the anti-lg mediated down-regulation of expression of cyclin D2.
4.3.16 Effect of PKC mutants on phosphorylation of the retinoblastoma 
protein, Rb, in response to anti-lg and anti-CD40 stimulation
Another key regulator of the cell cycle is the retinoblastoma tumour suppressor 
protein (Rb). Rb inhibits progression from Gi to S phase of the cell cycle by 
binding to the E2F family of transcription factors and preventing transcription of 
key genes required for cell cycle progression (Dyson, 1998) (Figure 1.9). The 
interaction between Rb and E2F is abrogated by phosphorylation of Rb by CDKs 
at a number of sites in its C-termina! domain, allowing E2F to activate 
transcription of a number of genes. Therefore, Rb phosphorylation is a measure 
of cell cycle progression, from Gi to S phase. To investigate the effects of PKC 
mutants on the phosphorylation state of Rb, an antibody against phosphorylated 
Rb (Ser®°^  and Ser®^ )^ was used in western blot analysis (Figure 4.16).
The phosphorylation of Rb at Ser®®^ ®^^  ^ in WEHI-231 pcDNA3.1 cells does not 
appear to vary much between different stimulations. Unstimulated cells have a 
low level, which decreases by 24 hours and is undetectable at 48 hours.
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stimulation with anti-lg accelerates the decrease, with phospho-Ser®°^^®" 
undetectable by 24 hours. Cells stimulated with anti-CD40, either alone or in 
combination with anti-lg, only appear to have detectable Ser®®^ '®^  ^
phosphorylation at 8 hours.
WEHI-231 PKCa-CAT cells and WEHI-231 pcDNA3.1 cells display a generally 
similar pattern when unstimulated, but upon stimulation with anti-lg Ser®®^ '®^  ^
phosphorylation of Rb appears to increase in WEHI-231 PKCa-CAT cells. 
Stimulation with anti~CD40, alone or in combination with anti-lg, leads to a 
transient increase in phosphorylation that diminishes to undetectable levels by 48 
hours. Unstimulated WEHI-231 PKCa-KR cells increase their levels of phospho- 
ggj.807/811 with time, whilst cells stimulated with anti-lg have barely detectable 
levels except at 24 hours, where there is a substantial increase. WEHI-231 
PKCa-KR cells stimulated with anti-CD40, alone or in combination with anti-lg, 
have barely detectable levels throughout the time course.
WEHI-231 PKCô-CAT cells have a very similar pattern of Rb phosphorylation to 
WEHI-231 PKCa-CAT cells, particularly when co-stimulated with anti-lg and anti- 
CD40, though not when stimulated with anti-lg alone. WEHI-231 PKCô-KR cells 
also have a very similar pattern of Rb phosphorylation to WEHI-231 PKCa-CAT 
cells, this time particularly when stimulated with anti-lg alone, suggesting that 
PKCô-CAT provides some measure of protection against anti-lg mediated down 
regulation of phosphorylation of Rb.
Un stimulated WEHI-231 PKCe-CAT cells and those stimulated with anti-lg exhibit 
an increase in Rb phosphorylation levels compared to cells containing the empty 
vector. Phosphorylated Rb could not be detected in whole cell lysates from 
WEHI-231 PKCe-CAT cells stimulated with either anti-CD40 or a combination of 
anti-lg and anti-CD40. WEHI-231 PKCe-KR cells display greater levels of Rb 
phosphorylation at Ser®®^ ®^^  ^under all conditions, suggesting that these cells may 
demonstrate enhanced proliferation, as phosphorylated Rb is an indication of
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cells leaving Gi. In particular, these cells do not display the anti-lg induced down 
regulation of Rb phosphorylation displayed by the cels containing the empty 
vector.
Unstimulated WEHI-231 PKC^-CAT cells have high levels of Rb phosphorylation 
at 1 hour, but the levels drop to barely detectable at 8, 24 and 48 hours, slightly 
different from cells containing the empty vector. With all other treatments, WEHI- 
231 PKCt-CAT cells show a very similar pattern of Rb phosphorylation to cells 
containing the empty vector. WEHI-231 PKC^-KR cells do not exhibit any 
significant differences in terms of the pattern of Rb phosphorylation compared to 
that of cells containing the empty vector.
4.3.17 Effect of PKC mutants on Tyr15 phosphorylation of the cdc2 protein 
in response to anti-lg and anti-CD40 stimulation
Entry of all eukaryotic cells into M-phase of the cell cycle is regulated by 
activation of cdc2. Activation of cdc2 is controlled at several steps, including 
cyclin binding and phosphorylation of threonine 161. However, the critical 
regulatory step in activating cdc2 during progression into mitosis appears to be 
dephosphorylation of tyrosine 15 and threonine 14. Phosphorylation at Tyr15 and 
inhibition of cdc2 is carried out by Weel and Mytl protein kinases, while Tyr15 
dephosphorylation and activation of cdc2 is carried out by the cdc25 
phosphatase. The antibody used is specific for Phospho-Tyri 5 cdc2, the inactive 
form of the kinase (Figure 4.17)
All cell types tested exhibit a broadly similar pattern of cdc2 phosphorylation at 
Tyr^ ®, including ceils containing the empty vector. Unstimulated cells exhibit a 
fairly steady increase in levels to 24 hours, before dropping by 48 hours. Anti-lg 
appears to induce a decrease in cdc2 phosphorylation over time, which would 
not be expected as the un phosphorylated form of the protein is active, therefore 
capable of promoting entry to mitosis. Stimulation with anti-CD40, either alone or
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in combination with anti-lg, results in a similar pattern to unstimulated cells, with 
cdc2 phosphorylation increasing to 24 hours before dropping at 48 hours. As all 
the cell types display similar patterns, it appears as though none of the PKC 
mutants tested alter the role of cdc2 in WEHI-231 cells.
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4.4 Discussion
Upon ligation by antigen the B cell receptor activates a number of signalling 
pathways to mediate a response. One of the first pathways shown to be activated 
by the BCR was phospholipase C, which results in the generation of the second 
messenger DAG, a key regulator of both conventional PKCs and novel PKCs. 
This suggests a key role for PKC family members in BCR signalling. Indeed,
BCR cross-linking on mature B cells leads to strong activation of PKCs, whereas 
ligation of the BCR on immature B cells does not, providing a possible 
explanation for the differential responses to BCR cross-linking in mature and 
immature B cells (Sarthou et al., 1989). As a consequence, it has been proposed 
that BCR uncoupling from PKC activation may be a major factor in anti-lg 
induced growth arrest and apoptosis in immature B cells. Consistent with this, 
treatment of WEHI-231 cells with PMA, a potent activator of most PKC isoforms, 
protects them from anti-lg induced growth arrest and apoptosis (Gold and 
DeFranco, 1987). Moreover, PKC isoforms from all three subclasses have been 
implicated in the regulation of Erk-MAPKinase, which we have shown to be 
important for apoptosis and proliferation, through a number of mechanisms. For 
instance, PKCa and PKCe have both been implicated as directly activating Raf, 
an upstream regulator of Erk-MAPKinase, in NIH-3T3 and COS cells (Cai et ai, 
1997). Other studies have demonstrated that conventional and atypical PKCs, 
but not novel PKCs, can induce dissociation of Raf from RKIP (Raf Kinase 
Inhibitory Protein) by phosphorylation of RKIP at a key serine residue (Corbit et 
al., 2003). In addition, it has recently been demonstrated that RasGRPS, an 
activator of Ras selectively expressed in B cells, is phosphorylated in a PKC 
dependent fashion, and that this phosphorylation is required for its optimal 
activation (Teixeira et ai, 2003). Furthermore, a novel mechanism for PKC 
mediated activation of Erk-MAPKinase has recently been identified in mast cells 
where FceRl driven phosphorylation of PKCpl and PKCa by Syk generates 
binding sites for Grb2, thus recruiting Grb2/Sos to the plasma membrane and 
contributing to the full activation of Ras (Kawakami et a i, 2003). All these studies
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suggest that at least some of the key roles that PKCs play in a number of cellular 
processes may be due to the regulation of Erk-MAPKinase activity. As Erk- 
MAPKinase activity plays important roles in apoptotic and proliferative signalling 
via the BCR in immature B cells, we investigated the roles of key PKC isoforms 
that had previously been shown to be involved in B cell signalling in regulating 
these differential functions.
The conventional PKC, PKCa, has been proposed to play a positive role in 
proliferation and an anti-apoptotic role in a number of cell types. For instance, 
overexpression of a catalytically active PKCa in NIH-3T3 cells results in 
increased expression of cyclins D1 and E and a concomitant increase in 
proliferation (Soh and Weinstein, 2003). Consistent with this, expression of a 
catalytically active form of PKCa in WEHI-231 cells appears to protect cells from 
anti-lg induced growth arrest and apoptosis at 24 hours (Figure 4.2A and 4.3). 
However, at 48 hours, these cells do exhibit signs of growth arrest and apoptosis, 
suggesting that PKCa perhaps alters the kinetics of anti-lg induced growth arrest 
and apoptosis, perhaps by slowing the onset of apoptosis (Figure 4.2B and 4.3). 
It is also possible, however, that, if PKCa enhances proliferation then the cells 
may divide at a faster rate, resulting in the depletion of essential nutrients in the 
media, slowing growth and making cells more susceptible to apoptosis at later 
timepoints. Overexpression of PKCa-CAT also led to an enhancement of anti- 
CD40 mediated rescue from anti-lg induced growth arrest (Figure 4.4). 
Interestingly, previous, unpublished studies in this laboratory using anti-sense 
oligonucleotides generated results which corroborate these, as anti-sense PKCa 
oligonucleotides abrogated anti-CD40 mediated rescue of anti-lg induced growth 
arrest in WEHI-231 cells. However, expression of a kinase dead PKCa mutant 
does not lead to an enhancement of anti-lg induced growth arrest or apoptosis, 
nor a defect in CD40-mediated rescue. Indeed, the kinase dead PKCa mutant 
had a very similar effect on the cells as the PKCa-CAT mutant, protecting cells 
from anti-lg induced growth arrest and apoptosis. Taken together, these results 
suggest that PKCa may not play a significant role in the normal proliferation and
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anti”CD40 mediated rescue from anti-lg induced apoptosis in WEHI-231 cells, 
but that overexpression of a constitutively active form of PKCa can override anti- 
lg induced signals which induce growth arrest, at least for 24 hours. Consistent 
with this, PKCa-CAT cells display sustained, cycling Erk-MAPKinase activity in 
the presence of anti-lg, whilst PKCa-KR has no effect on Erk-MAPKinase activity 
(Catriona Ford, personal communication). PKCa-CAT expression also results in 
general up regulation of Bc1-Xl, even in the presence of anti-lg, unlike cells 
containing the empty vector. Again, PKCa-KR had no effect (Catriona Ford, 
personal communication). These findings strongly suggest that PKCa-CAT plays 
both proliferative and pro-survival roles in WEHI-231 cells.
WEHI-231 cells expressing either PKCô mutant do not exhibit anti-lg induced 
growth arrest after 24 hours, while cells containing the empty vector do. After 48 
hours cells expressing both PKCô mutants do display growth arrest, as assessed 
by the [®H]-thymidine incorporation assay. The propidium iodide data supports 
this, as after 24 hours there is still a high proportion of cells in S phase and Gg/M 
after anti-lg stimulation, and no increase in the proportion of cells with a sub­
diploid DNA content. Indeed, the proportion of cells with a sub-diploid DNA 
content is considerably less than that exhibited by cells containing the empty 
vector. The expression of the PKCô-CAT mutant appeared to have no effect on 
CD40-mediated rescue from growth arrest or apoptosis, though PKCÔ-KR cells 
appear to have an enhanced proliferative response to anti-lg and anti-CD40. This 
is in agreement with studies in PKCô ^ " mice where B cells exhibit a greater 
proliferative response upon stimulation with anti-lg and anti-CD40 (Miyamoto et 
af., 2002). This suggests that PKCÔ plays a negative role in proliferation of B 
cells, a hypothesis supported by the observation that PKCÔ ^  mice have an 
increased number of splenic and lymph node B cells (Miyamoto etaL, 2002).
This is also in accordance with the fact that levels of PKCô expression decrease 
as fibroblasts progress through Gi and enter S phase of the cell cycle, and 
increase above initial levels as cells re-enter Gi (Srivastava et a i, 2002),
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suggesting that PKCô acts as an inhibitor of cell cycle progression (Figure 4.18). 
Interestingly, expression of PKCô-CAT did not induce apoptosis in unstimulated 
cells, nor enhance anti-lg induced apoptosis, yet it has previously been shown 
that expression of a catalytically active fragment of PKCô induces apoptosis in a 
number of cell types, including human myeloid leukaemia cells (Emoto etaL, 
1995). Interestingly, expression of PKCÔ-CAT abrogates anti-lg induced down 
regulation of Erk-MAPKinase activity, as anti-lg stimulated cells display 
sustained, cycling Erk-MAPKinase activity, whilst PKCô-KR has no effect on Erk- 
MAPKinase activity, as these cells have a very similar pattern to wild type cells 
under all stimulatory conditions (Catriona Ford, personal communication).
Neither WEHI-231 PKCe-CAT nor WEHI-231 PKCe-KR cells demonstrate anti-lg 
induced growth arrest or apoptosis at 24 hours (Figures 4.8A and 4.9). 
Interestingly, WEHI-231 PKCe-CAT cells actually display increased proliferation, 
as assessed by [®H]-thymidine uptake, in response to anti-lg, in a dose 
dependent manner. This is supported by the DNA content analysis, which shows 
that a high proportion of these cells are in S phase and Ga/M in response to anti- 
lg at 24 hours. However, this protection form anti-lg induced growth arrest and 
apoptosis is lost by 48 hours, as both cell types exhibit anti-lg induced growth 
arrest and apoptosis after 48 hours stimulation (Figures 4.8B and 4.9). Indeed, 
PKCe-CAT expressing cells exhibit high levels of apoptosis in response to anti-lg 
at 48 and 72 hours, suggesting that the protective effects can be subverted by 
prolonged exposure to antigen. When PKCe is overexpressed in NIH-3T3 cells, 
these cells become more susceptible to radiation-induced cell death, 48 hours 
after exposure, as a result of increased Erk1/2 activation (Lee etaL, 2003). 
Perhaps in WEHI-231 cells PKCe-CAT is enhancing the extent of anti-lg induced 
apoptosis, though slowing the kinetics. It would be interesting to assess the 
number of divisions PKCe-CAT expressing cells undergo in response to anti-lg 
compared to cells containing the empty vector, as it might be expected that they 
have undergone more divisions as the [®H]-thymidine incorporation is much 
greater at 24 hours. Taken together, these results suggest that PKCe might play
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a role in anti-lg mediated apoptosis in WEHI-231 cells, though the kinetics are 
slowed compared to wild type cells (Figure 4.18). Interestingly, despite the fact 
that PKCe has been implicated as a direct activator of Raf in fibroblasts (Cai et 
a/., 1997), expression of PKCe-CAT or PKCe-KR did not lead to an overall 
increase in Erk-MAPKinase activity in WEHI-231 cells, and only led to a very 
slight increase in activity of Erk-MAPKinase in anti-lg treated cells (Catriona 
Ford, personal communication).
Overexpression of PKC^-CAT or PKC^-KR has a slight effect on anti-lg induced 
growth arrest of WEHI-231 cells, as cells expressing these constructs do not 
display the same level of anti-lg induced growth arrest at 24 hours as cells 
containing the empty vector. By 48 hours, however, cells expressing these 
constructs behave in a very similar manner to those containing the empty vector. 
This is slightly surprising, as PKC^-deficient mice have a higher percentage of 
immature B cells, suggesting that PKCÇ plays a role in negative selection of 
immature B cells (Leitges et al., 2001). This implies that PKC^ positively 
regulates apoptosis in immature B cells, and consistent with this PKCt has 
recently been suggested to play a role in negatively regulating the pro-survival 
kinase Akt (Doornbos et al., 1999). Indeed, B cells from PKC^ deficient mice 
display accelerated apoptosis in culture, strongly suggesting that PKC^ plays an 
important role in the survival of B cells (Martin et al., 2002). Interestingly, this is a 
similar phenotype to that observed in RelA and c-Rel deficient mice (Grossmann 
et al., 2000), and PKCC deficient mice also display impaired activation of 
transcription of NF-KB-dependent genes, though the nuclear translocation of NF- 
k B is not inhibited, placing PKC^ upstream of NF-kB in B cells (Martin etal.,
2002). It would be interesting to assess the ability of WEHI-231 cells expressing 
PKC^ mutants to activate NF-KB-mediated transcription, as anti-lg induced 
apoptosis involves down-regulation of NF-KB activity, whilst one mechanism by 
which CD40 mediates survival is through the induction of NF-kB activity (Schauer 
et al., 1996). Both PKCt isoforms inhibit anti-lg induced down regulation of Erk-
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MAPKinase activity as sustained, cycling Erk-MAPKinase phosphorylation is 
exhibited in these cells (Catriona Ford, personal communication).
The analysis of expression of key cell cycle regulators to determine the 
mechanisms underlying the effects PKC isoforms have on WEHI-231 cells did 
not always produce results apparently consistent with the biological data, given 
our current understanding. For example, most cell types exhibit a substantial 
increase in p27 expression in response to anti-lg at 24 hours, yet do not exhibit 
any growth arrest. The most interesting mutant with respect to p27 expression is 
the PKCô-CAT, as cells expressing this construct do not exhibit an increase in 
p27 levels in response to anti-lg, yet still display anti-lg induced growth arrest 
after 48 hours. Similarly, in all cells in which cyclin D2 was detected (PKCa CAT 
and KR, and PKCe CAT and KR), anti-lg induces a down regulation of cyclin D2, 
yet there was proliferation in all of these cells at 24 hours. This is somewhat 
surprising, as overexpression of PKCô has been shown to lead to a decrease in . 
cyclin D1 expression in bovine smooth muscle cells, whilst over expression of a 
dominant negative PKCô results in an increase in cyclin D1 expression (Page et 
al., 2002). Cyclins D2 and D3 have been detected in primary murine B cells, but 
not cyclin D1 (Solvason et al., 1996), yet no cyclin D expression was detected in 
cells expressing either PKCô mutant. The antibody used was specific for cyclins 
D1 and D2, so perhaps in immature B cells cyclin D3 plays an important role in 
the regulation of proliferation. This would be consistent with the observation that 
B cell development is not impaired in cyclin D2 "^ mice (Solvason etal., 2000).
One puzzling aspect to emerge from this study was the similarity in biological 
responses between the CAT and KR mutants, one supposedly catalytically 
active, the other dominant negative. One possible explanation comes from the 
structure of these mutants in relation to the structure of native PKCs (Figure 4.1). 
The regulatory domains of PKCs are responsible for the binding of receptors for 
activated C kinases (RACKs), a family of anchoring proteins that determine the 
ultimate sub-cellular locations of PKCs after activation (Schechtman and Mochly-
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Rosen, 2001). The CAT mutants used in this study lack their regulatory domains, 
therefore it is possible that they are not targeted to their correct sub-cellular 
locations. This could result in lack of phosphorylation of the appropriate targets, 
or even phosphorylation of inappropriate targets, as the constructs are not able 
to interact with the correct substrates, or are not targeted to the same area within 
the cell as their intended substrates. If the appropriate substrates are not 
phosphorylated, this could easily explain the absence of an effect. This highlights 
disadvantages of using overexpression methods and mutant constructs to 
investigate the roles of signalling molecules, as sometimes the regulation of 
pathways may be circumvented. To compliment these studies the use of 
inhibitors specific for individual PKC isoforms could be utilised, though this also 
raises issues of specificity of inhibitors.
Another possibility is that the PKC signalling events taking place here are 
independent of kinase activity. This is not without precedent, for example, in 
IFNy-primed U937 cells, PKCa assists the activation of PLD1 following ligation of 
FcyRI by directly binding to PLD1 in a PKCa kinase-independent manner.
Indeed, inhibition of PKCa kinase activity does not prevent FcyRI-mediated 
induction of PLD1 whereas downregulation of PKCa levels does impair PLD1 
activation. FcyRI-dependent induction of PLD1 thus requires the recruitment of 
PKCa but PKCa kinase activity is not necessary (Melendez et al., 2001), strongly 
suggesting that PKCa can perform important signalling functions independently 
of its kinase activity, possibly through protein-protein interactions via the 
regulatory domain. However, this is unlikely to be the case for all isoforms 
studied, indeed, PKCa-CAT and PKCa-KR did not have the same impact on 
either Erk-MAPKinase or Bc1-Xl expression in response to anti-lg. PKCa-CAT 
suppressed anti-lg mediated down-regulation of Erk-MAPKinase activity and 
induced a general increase in BcI-Xl expression, yet PKCa-KR had no effect on 
either (Catriona Ford, personal communication). To further explore the 
requirement for the kinase and regulatory domains of PKCs, it would be 
interesting to transfect WEHI-231 cells with PKC-CAT-KR constructs, which
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encode the catalytic domain of PKC only, but with a point mutation that abolishes 
kinase activity, and with full length constitutively active constructs, to compare 
the effects they have on WEHI-231 cell responses with the effects of the catalytic 
fragment only.
Another puzzling aspect is the differential responses to anti-lg observed at 24 
and 48 hours, particularly in the [®H]-thymidine incorporation assay. Thus, some 
cell types exhibit no growth arrest in response to anti-lg at 24 hours, indeed 
those expressing PKCe-CAT display enhanced proliferation in response to anti-lg 
at this time point, yet at 48 hours they exhibit a level of growth arrest at least 
equal to that of the cells containing the empty vector. The reasons for this are 
unclear at present, but merit further investigation. Perhaps the protection 
afforded by these mutants can be overcome by prolonged signalling via the BCR, 
resulting in delayed onset of growth arrest and apoptosis. It may also be that 
prolonged activity of these enzymes results in the induction of negative 
regulators of PKC activity, enabling the constitutively active mutants to be 
switched off. It would be interesting to assess [®H]-thymidine incorporation at time 
points between 24 and 48 hours, both in cells containing the empty vector and 
cells expressing PKC constructs, to further gauge the kinetics of growth arrest. It 
should be noted, however, that anti-lg induced growth arrest of WEHI-231 cells 
containing the empty vector is not as pronounced at 24 as 48 hours, and it has 
been reported that the negative signals generated following BCR-ligation in 
immature B lymphocytes progress in an ordered kinetic manner (Monroe, 2000). 
Perhaps the cells containing the PKC constructs take longer to pass through the 
cell cycle, therefore their kinetics of response to anti-lg are altered accordingly. It 
might be interesting to determine the number of divisions cells undergo in 48 
hours, utilising a dye like CFSE, which binds to cellular proteins and is then 
equally divided between daughter cells, allowing divisions to be counted in terms 
of the halving of fluorescence.
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Overall, the results presented in this chapter demonstrate that overexpression of 
different PKC family members in WEHI-231 alter the response of WEHI-231 cells 
to stimulation via the BCR. All isoforms studied provided protection from anti-lg 
induced growth arrest and apoptosis after 24 hours stimulation, most noticeably 
PKCe, as WEHI-231 PKCe-CAT cells actually demonstrated a dose dependent 
increase in proliferation in response to anti-lg, a response more suited to a 
mature B cell, not immature transitional B cells. However, by 48 hours, WEHI- 
231 cells expressing all PKC constructs examined appear to exhibit growth 
arrest. Examination of key cell cycle regulatory proteins failed to reveal a clear 
molecular basis for the alterations in response to anti-lg.
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Figure 4.1 Structure of constitutively active and dominant-negative mutants 
of specific isoforms of protein kinase C
Schematic diagrams of structures of PKC mutants. PKC-CAT constructs encode 
a truncated protein in which the catalytic domain is expressed but the entire 
regulatory domain has been deleted. PKC-KR constructs encode a full-length 
PKC with a point mutation that abolishes ATP binding ability.
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Figure 4.2 Effects of expression of PKCa mutants on anti-lg induced
growth arrest in WEHi-231 ceils
A WEHI-231 cells (1 x10* cells/well) containing the pcDNA3.1 vector, pcDNA3.1 
PKCa-CAT, or pcDNA3.1 PKCa-KR were cultured, in triplicate, in the presence 
of increasing concentrations of anti-lg antibodies (0.1, 1, 10 [xg/ml). Control cells 
were cultured in the presence of medium alone. Culture wells were pulsed with 
[^H]-thymidine (0.5 fxCi/well) for 4 hours prior to harvesting at 24 hours and pH]- 
incorporation was assessed by liquid scintillation counting. Data from individual 
experiments were normalised by expressing the mean [^H]-thymidine uptake 
values of anti-lg treated cells as a percentage of those obtained with control cell 
cultures. The normalised values from 3 independent experiments were then 
pooled and expressed as means ± sem.
B WEHI-231 cells (1 x10* cells/well) containing the pcDNA3.1 vector, pcDNA3.1 
PKCa-CAT, or pcDNA3.1 PKCa-KR were cultured, in triplicate, in the presence 
of increasing concentrations of anti-lg antibodies (0.1, 1, 10 jxg/ml). Control cells 
were cultured in the presence of medium alone. Culture wells were pulsed with 
[^H] -Thymidine (0.5 jxCi/well) for 4 hours prior to harvesting at 48 hours and fh ]-  
incorporation was assessed by liquid scintillation counting. Data from individual 
experiments were normalised by expressing the mean [^H]-thymidine uptake 
values of anti-lg treated cells as a percentage of those obtained with control cell 
cultures. The normalised values from 3 independent experiments were then 
pooled and expressed as means ± sem.
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Figure 4.3 Effects of expression of PKCa mutants on anti-lg induced
apoptosfs in WEHI-231 cells
WEHI-231 cells (5x10® cells/ml) containing the pcDNAS.I vector, pcDNAS.I 
PKCa-CAT, or pcDNAS.I PKCa-KR were cultured in the presence of anti-lg (10 
[xg/ml) or a combination of anti-lg and anti-CD40 (both 10 i^g/ml). Cells cultured 
in the presence of medium alone were included as a control. Levels of apoptosis 
and the proportion of cells in each cell cycle phase were determined by 
propidium iodide staining followed by FACS analysis to assess DNA content after 
24, 48 and 72 hours, as described in Materials and Methods. Data are 
representative of three independent experiments.
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Figure 4.4 Effects of expression of PKCa mutants on CD40-mediated
rescue of anti-lg induced growth arrest in WEHI-231 cells
WEHI-231 ceils (1 xIO* cells/well) containing the pcDNAS.I vector, pcDNAS.I 
PKCa-CAT, or pcDNAS.I PKCa-KR were cultured, in triplicate, in the presence 
of anti-lg (10 ^xg/mi) or a combination of anti-lg and anti-CD40 (both 10 pg/ml). 
Control cells were cultured in the presence of medium alone. Culture wells were 
pulsed with [®H] -Thymidine (0.5 jnCi/well) for 4 hours prior to harvesting at 48 
hours and [^H]-incorporation was assessed by liquid scintillation counting. Data 
from individual experiments were normalised by expressing the mean [^H]- 
thymidine uptake values of treated cells as a percentage of those obtained with 
control cell cultures. The normalised values from 4 independent experiments 
were then pooled and expressed as means ± sem.
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Figure 4.5 Effects of expression of PKCô mutants on anti-lg induced growth
arrest in WEHI-231 cells
A WEHI-231 cells (1 xIO* cells/well) containing the pcDNAS.I vector, pcDNAS.1 
PKCô-CAT, or pcDNAS.I PKCô-KR were cultured, in triplicate, in the presence of 
increasing concentrations of anti-lg antibodies (0.1,1, 10 pig/ml). Control cells 
were cultured in the presence of medium alone. Culture wells were pulsed with 
[^H] -Thymidine (0.5 jxCi/well) for 4 hours prior to harvesting at 24 hours and [®H]- 
incorporation was assessed by liquid scintillation counting. Data from individual 
experiments were normalised by expressing the mean [^H]-thymidine uptake 
values of anti-lg treated cells as a percentage of those obtained with control cell 
cultures. The normalised values from S independent experiments were then 
pooled and expressed as means ± sem.
B WEHI-231 cells (1 xIO* cells/well) containing the pcDNAS.I vector, pcDNAS.I 
PKCô-CAT, or pcDNAS.I PKCô-KR were cultured, in triplicate, in the presence of 
increasing concentrations of anti-lg antibodies (0.1,1, 10 fxg/ml). Control cells 
were cultured in the presence of medium alone. Culture wells were pulsed with 
[^H] -Thymidine (0.5 fxCi/well) for 4 hours prior to harvesting at 48 hours and [®H]- 
incorporation was assessed by liquid scintillation counting. Data from individual 
experiments were normalised by expressing the mean [^H]-thymidine uptake 
values of anti-lg treated cells as a percentage of those obtained with control cell 
cultures. The normalised values from S independent experiments were then 
pooled and expressed as means ± sem.
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Figure 4.6 Effects of expression of PKCô mutants on anti-lg induced
apoptosis in WEHI-231 cells
WEHI-231 cells (5x10® cells/ml) containing pcDNAS.I PKCô-CAT, pcDNAS.I 
PKCô-KR, or the pcDNAS.I vector were cultured in the presence of anti-lg (10 
jAg/ml). Cells cultured in the presence of medium alone were included as a 
control. Levels of apoptosis and the proportion of cells in each cell cycle phase 
were determined by propidium iodide staining followed by FACS analysis to 
assess DNA content after 24, 48 and 72 hours, as described in Materials and 
Methods. Data are representative of three independent experiments.
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Figure 4.7 Effects of expression of PKCô mutants on CD40-mediated rescue
of anti-lg induced growth arrest in WEHI-231 cells
WEHI-231 cells (1 X 1Q4 cells/well) containing pcDNAS.I PKCô-CAT, pcDNAS.I 
PKCô-KR, or the pcDNAS.I vector were cultured, in triplicate, in the presence of 
anti-lg (10 \ig/m\) or a combination of anti-lg and anti-CD40 (both 10 fig/ml). 
Control cells were cultured in the presence of medium alone. Culture wells were 
pulsed with [^Hj -Thymidine (0.5 fxCi/well) for 4 hours prior to harvesting at 48 
hours and [®H]-incorporation was assessed by liquid scintillation counting. Data 
from individual experiments were normalised by expressing the mean [®H]- 
thymidine uptake values of treated cells as a percentage of those obtained with 
control cell cultures. The normalised values from 4 independent experiments 
were then pooled and expressed as means ± sem.
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Figure 4.8 Effects of expression of PKCe mutants on anti-lg induced growth
arrest in WEHI-231 cells
A WEHI-231 cells (1x10* cells/well) containing the pcDNAS.I vector, pcDNAS.1 
PKCe-CAT, or pcDNAS.1 PKCe-KR were cultured, in triplicate, In the presence of 
increasing concentrations of anti-lg antibodies (0.1, 1, 10 |Lig/ml). Control cells 
were cultured in the presence of medium alone. Culture wells were pulsed with 
[®H] -Thymidine (0.5 jtCi/well) for 4 hours prior to harvesting at 24 hours and [®H]- 
incorporation was assessed by liquid scintillation counting. Data from individual 
experiments were normalised by expressing the mean [®H]-thymidine uptake 
values of anti-lg treated cells as a percentage of those obtained with control cell 
cultures. The normalised values from S independent experiments were then 
pooled and expressed as means ± sem.
B WEHI-231 cells (1 xIO* cells/well) containing the pcDNAS.I vector, pcDNAS.1 
PKCs-CAT, or pcDNAS.I PKCe-KR were cultured, in triplicate, in the presence of 
increasing concentrations of anti-lg antibodies (0.1, 1, 10 ^g/ml). Control cells 
were cultured in the presence of medium alone. Culture wells were pulsed with 
[®H] -Thymidine (0.5 fACi/well) for 4 hours prior to harvesting at 48 hours and [®H]- 
incorporation was assessed by liquid scintillation counting. Data from individual 
experiments were normalised by expressing the mean [®H]-thymidine uptake 
values of anti-lg treated cells as a percentage of those obtained with control cell 
cultures. The normalised values from 3 independent experiments were then 
pooled and expressed as means ± sem.
205
co
a
.■5E
Xeu
150-
100-
75-
pcDNA
PKCeCAT50-
PKCeKR
25
1010 0.1
Anti-lg (p,g/ml)
B
co
a
0 çy
1.c
Xeu
125-
100-
75-
50-
25-
pcDNA
PKCeCAT
PKCeKR
0.1
- I—
10
Anti-lg (^g/ml)
Figure 4.9 Effects of expression of PKCe mutants on anti-lg induced
apoptosis in WEHI-231 cells
WEHI-231 cells (5 x 10® cells/mi) containing pcDNAS.I PKCe-CAT, pcDNAS.I 
PKCe-KR, or the pcDNAS.I vector were cultured in the presence of anti-lg (10 
M-g/ml). Cells cultured in the presence of medium alone were included as a 
control. Levels of apoptosis and the proportion of cells in each cell cycle phase 
were determined by propidium iodide staining followed by FACS analysis to 
assess DNA content after 24, 48 and 72 hours, as described in Materials and 
Methods. Data are representative of three independent experiments.
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Figure 4.10 Effects of expression of PKCe mutants on CD40-mediated
rescue of anti-lg induced growth arrest and apoptosis in WEHI-231 cells
WEHI-231 cells (1 X  10  ^cells/well) containing pcDNAS.I PKCe-CAT, pcDNAS.I 
PKCe-KR, or the pcDNAS.I vector were cultured, in triplicate, in the presence of 
anti-lg (10 p.g/ml) or a combination of anti-lg and anti-CD40 (both 10 |xg/ml). 
Control cells were cultured in the presence of medium alone. Culture wells were 
pulsed with [®H] -Thymidine (0.5 p.Ci/well) for 4 hours prior to harvesting at 48 
hours and [^H]-incorporation was assessed by liquid scintillation counting. Data 
from individual experiments were normalised by expressing the mean f  H]- 
thymidine uptake values of treated cells as a percentage of those obtained with 
control cell cultures. The normalised values from 4 independent experiments 
were then pooled and expressed as means ± sem.
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Figure 4.11 Effects of expression of PKCÇ mutants on anti-lg induced
growth arrest in WEHI-231 cells
A WEHI-231 cells (1 xIO* cells/well) containing the pcDNAS.I vector, pcDNAS.1 
PKC^-CAT, or pcDNAS.I PKC^-KR were cultured, in triplicate, in the presence of 
increasing concentrations of anti-lg antibodies (0.1, 1, 10 ^g/ml). Control cells 
were cultured in the presence of medium alone. Culture wells were pulsed with 
[®H] -Thymidine (0.5 |xCi/well) for 4 hours prior to harvesting at 24 hours and [^H]- 
incorporation was assessed by liquid scintillation counting. Data from individual 
experiments were normalised by expressing the mean [^H]-thymidine uptake 
values of anti-lg treated cells as a percentage of those obtained with control cell 
cultures. The normalised values from 3 independent experiments were then 
pooled and expressed as means ± sem.
B WEHI-231 cells (1 x 10'* cells/well) containing the pcDNAS.I vector, pcDNAS.I 
PKC^-CAT, or pcDNAS.I PKC^-KR were cultured, in triplicate, in the presence of 
increasing concentrations of anti-lg antibodies (0.1, 1, 10 ^ig/ml). Control cells 
were cultured in the presence of medium alone. Culture wells were pulsed with 
[^H] -Thymidine (0.5 jxCi/well) for 4 hours prior to harvesting at 48 hours and f  H]- 
incorporation was assessed by liquid scintillation counting. Data from individual 
experiments were normalised by expressing the mean [^H]-thymidine uptake 
values of anti-lg treated cells as a percentage of those obtained with control cell 
cultures. The normalised values from S independent experiments were then 
pooled and expressed as means ± sem.
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Figure 4.12 Effects of expression of PKC^ mutants on anti-lg induced
apoptosis in WEHI-231 cells
WEHI-231 cells (5x10® ceils/ml) containing pcDNAS.I PKCÇ-CAT, pcDNAS.I 
PKCt”KR, or the pcDNAS.I vector were cultured in the presence of anti-lg (10 
fxg/ml). Cells cultured in the presence of medium alone were included as a 
control. Levels of apoptosis and the proportion of cells in each cell cycle phase 
were determined by propidium iodide staining followed by FACS analysis to 
assess DNA content after 24, 48 and 72 hours, as described in Materials and 
Methods. Data are representative of three independent experiments.
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Figure 4.13 Effects of expression of PKC  ^mutants on CD40-mediatect
rescue of anti-lg induced growth arrest and apoptosis in WEHI-231 cells
WEHI-231 cells (1 xIO* cells/well) containing pcDNAS.I PKC^-CAT, pcDNAS.I 
PKC^-KR, or the pcDNAS.I vector were cultured, in triplicate, in the presence of 
anti-lg (10 \igfm\) or a combination of anti-lg and anti-CD40 (both 10 ^g/ml). 
Control cells were cultured in the presence of medium alone. Culture wells were 
pulsed with [^H] -Thymidine (0.5 p,Ci/well) for 4 hours prior to harvesting at 48 
hours and pH]-incorporation was assessed by liquid scintillation counting. Data 
from individual experiments were normalised by expressing the mean [®H]- 
thymidine uptake values of treated cells as a percentage of those obtained with 
control cell cultures. The normalised values from 4 independent experiments 
were then pooled and expressed as means ± sem.
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Figure 4.14 Effects of the expression of PKC mutants on the expression of
p27*"'  ^ in WEHI-231 cells
WEHl-231 cells (1x10^ cells) containing the individual PKC constructs or the
empty pcDNAS.I vector were stimulated in the presence of anti-lg (10 jxg/ml) or 
anti-CD40 (10 p.g/m(), alone and in combination, for the times indicated. Cells 
incubated in the presence of medium alone were included as a control. Whole 
cell lysates were prepared and subjected to Western blot analysis with anti- 
p2?Kipi antibody.
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Figure 4.15 Effects of the expression of PKC mutants on the expression of
D-type cyclins in WEHI-231 cells
WEHI-231 cells (1 X  10  ^cells) containing the individual PKC constructs or the 
empty pcDNAS.I vector were stimulated in the presence of anti-lg (10 p.g/ml) or 
anti-CD40 (10 ng/ml), alone and in combination, for the times indicated. Cells 
incubated in the presence of medium alone were included as a control. Whole 
cell lysates were prepared and subjected to Western blot analysis with anti-cyclin 
DI/2 antibody.
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Figure 4.16 Effects of the expression of PKC mutants on the regulation of
the retinoblastoma protein, Rb, in WEHI-231 ceils
WEHI-231 cells (1 X  10  ^cells) containing the individual PKC constructs or the 
empty pcDNAS.I vector were stimulated in the presence of anti-lg (10 ^g/ml) or 
anti-CD40 (10 ^g/ml), alone and in combination, for the times indicated. Cells 
incubated in the presence of medium alone were included as a control. Whole 
cell lysates were prepared and subjected to Western blot analysis with anti- 
phospho-Rb (Ser®°^ ^®^ )^ antibody.
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Figure 4.17 Effects of the expression of PKC mutants on the regulation of
the cdc2 protein in WEHI-231 cells
WEHI-231 cells (1 x 10  ^cells) containing the individual PKC constructs or the 
empty pcDNAS.I vector were stimulated in the presence of anti-lg (10 \ig/m\) or 
anti-CD40 (10 |xg/ml), alone and in combination, for the times indicated. Cells 
incubated in the presence of medium alone were included as a control. Whole 
ceil lysates were prepared and subjected to Western blot analysis with anti- 
phospho-cdc2 (Tyr^ ®) antibody.
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Figure 4.18 Role of PKC family members in anti-lg induced growth arrest
and apoptosis, and CD40-mediated rescue, in WEHI-231 cells
The novel PKC, PKCe, abrogates anti-lg induced growth arrest in WEHI-231 
cells. PKCa seems to play a role in promoting CD40-mediated rescue of anti-lg 
induced growth arrest and apoptosis, whilst the novel PKC, PKCô, appears to 
negatively regulate CD40-mediated proliferation. The atypical PKC, PKCÇ, 
protects WEHI-231 cells from anti-lg induced growth arrest and apoptosis to a 
certain extent.
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Chapter 5 -  Regulation of BCR-mediated responses by 
the Erk-MAPKinase in mature B cells
5.1 Introduction
Regulation of the B cell response to antigen requires the maintenance of 
appropriate levels of signalling through the B cell antigen receptor (sIg/BCR). To 
maintain this control, B cells employ a variety of positive and negative co­
receptors such as CD19, CD22, CD72, and FcyRllb that modulate the signals 
that are transduced by the BCR. Signals generated by these molecules appear to 
alter the signalling threshold of the BCR either by facilitating the positive 
signalling or by down modulating its function. Furthermore, efficient 8 cell 
responses generally require interactions with helper T cells (T h) that are specific 
for the same antigen. Activated T cells can provide assistance to B cells via both 
membrane-bound molecules such as CD40-ligand (CD40L) and secreted 
molecules such as IL-4.
IL-4 was first described in 1982 as a cofactor in the proliferation of resting B cells 
stimulated through the cross-linking of their membrane IgM by anti-IgM (Howard 
and Paul, 1982). IL-4 is the hallmark of the Th2 subset of CD4^ helper T cells, 
though it can also be produced by activated mast cells and basophils, as well as 
some CD8^ T cells. IL-4 is secreted by T h2 cells directly towards the interacting B 
cell, ensuring that it acts selectively on the antigen-specific target B cell. IL-4 
exerts different effects on B cells at different stages of the cell cycle. For 
example, on resting B cells, IL-4 acts as an activating factor, inducing them to 
enlarge in size and increase class II MHC expression. Following activation by an 
antigen, IL-4 acts as a growth factor, driving DMA replication in the B cells. In the 
case of proliferating B cells, IL-4 acts as a differentiation factor by regulating 
class switching to IgE and IgGI isotypes. CD40L plays a crucial role in the 
regulation of the humoral immune response, including cell activation,
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proliferation, immunoglobulin isotype switching, formation of germinal centres 
and induction of memory B cells (Durie et a/., 1994).
The necessity for a balance of activation and inhibitory pathways has been 
highlighted by observations that a loss of suitable inhibitory signalling can lead to 
inappropriate stimulation and activation of B cells (O'Keefe etal., 1996), resulting 
in a variety of chronic inflammatory processes, including autoimmune disease.
5.1.1 FcyRllb modulation of BCR activated signalling pathways
Fc receptors (FcRs) provide a critical link between the humoral and cellular arms 
of the immune system by binding the Fc domain of antibodies. The FcyRs are 
specific for the Fc domain of IgG, and comprise a family of structurally 
homologous, yet distinct, receptors. The only FcyR found on B cells is the low 
affinity FcyRllb receptor, where it functions to Inhibit signalling through the BCR 
upon cross-linking of the two receptors by IgG containing immune complexes. 
This down regulation of the BCR response to antigen provides a valuable 
negative feedback mechanism under physiological conditions, whereby immune 
complex formation results in aggregation of FcyRllb with the BCR, leading to 
growth arrest and/or apoptosis. This may be of importance for preventing the 
appearance of autoreactive B cells in the periphery, in addition to the negative 
selection of immature B cells, by promoting the deletion of low affinity, self­
reactive B cells in germinal centres and by the induction of IgG-mediated 
peripheral B cell tolerance.
FcyRllb signalling appears to inhibit B cell activation by modulating three key 
signalling pathways activated by the BCR. These are the phospholipase C-y 
(PLC-y) pathway which is responsible for the hydrolysis of phosphatidylinositol
4.5-bisphosphate (Ptdlns-(4,5)P2 0r PIP2) to diacylglycerol (DAG) and inositol-
1.4.5-trisphosphate (lns(1,4,5)Psor IP3), the phosphatidylinositol 3-kinase (Pl-3- 
Kinase) pathway which is responsible for the generation of phosphatidylinositol-
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3,4,5-trisphosphate (Ptdlns-(3,4,5)P3 or PIP3), and the Ras/MAPKinase pathway. 
Signals derived from these pathways converge at the nucleus where they 
regulate key transcription factors that dictate the fate of the B cell.
The elevation of cytosolic calcium levels is a major downstream event of B cell 
activation via the BCR. This is the result of an initial release of calcium from 
intracellular stores followed by a lower, but sustained, rise in intracellular calcium 
that requires the presence of extracellular calcium. The generation of the second 
messenger IP3, by PLC-y, has been shown to be essential for the release of 
calcium by binding to IP3 receptors on the endoplasmic reticulum (Parekh and 
Penner, 1997). Emptying of the BCR-sensitive intracellular stores activates a 
plasma membrane calcium channel with L-type characterisitics, a phenomenon 
known as capacitative calcium entry (Grafton etal., 2003). In co-operation with 
DAG, the second PLC-y product, calcium regulates several key B cell signalling 
events including activation of some PKC isoforms and the nuclear localisation 
and activity of NF-kB (Berridge, 1993), The activation of PKC isoforms is one of 
the earliest events in the cascade, leading to a variety of cellular responses 
including gene expression and proliferation (Dekker and Parker, 1994; Nishizuka, 
1992). Induction of expression of genes such as c-fos seems to require both PKC 
activation and calcium mobilisation, whereas the induction oiegr~1 and c~myc 
appear to require only PKC activation. Furthermore, the induction of Ets-1 
requires calcium but is independent of PKC activation. PKC activation can also 
play a role in the regulation of the Erk-MAPK pathway, as PKCa is known to be a 
potent activator of Raf-1 (Schonwasser et a i, 1998).
Activation of PI-3-Kinase and the subsequent generation of PIP2 and PIP3 are 
known to be important for BCR-mediated proliferation, differentiation and survival 
(Campbell, 1999), The generation of PIP3 by PI-3-Kinase has been shown to 
activate the survival promoting factor Akt (also known as protein kinase B, PKB) 
via the recruitment of the protein serine/threonine kinases, PDK1 and PDK2 to 
the plasma membrane. PDK1 and PDK2 activate Akt by phosphorylating it, within
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its activation loop, on Thr °^® and Ser , respectively. Akt promotes survival by 
phosphorylating and compromising multiple components of the cell death 
pathway, including the pro-apoptotic Bcl-2 family member Bad (del Peso et af.,
1997) and the initiator caspase, caspase-9 (Cardone etal., 1998). In addition to 
regulating cell survival, Akt may regulate cell proliferation by phosphorylation of 
other target molecules. Recently, two separate reports demonstrated that Akt 
phosphorylates the cyclin dependent kinase inhibitor, p27^'^\ at threonine 157 in 
breast cancer cells. This residue lies within the nuclear localisation signal of 
p27^"^\ so as a result of this phosphorylation event nuclear import is inhibited, 
enabling the cdk2/cyclin E complex in the nucleus to become activated, inducing 
cell cycle progression (Liang etal., 2002; Shin etal., 2002).
The mitogen-activated protein kinases (MAPKs) are activated by a wide range of 
external stimuli, and as such are able to mediate a wide range of cellular 
responses from proliferation and activation to growth arrest and cell death. MAPK 
signalling cascades, consisting of an upstream serine/threonine kinase 
(MAPKKK), a middle dual-specificity kinase (MAPKK) and a downstream 
serine/threonine kinase (MAPK) (Dhanasekaran and Premkumar Reddy, 1998) 
are common to all eukaryotic cells, from yeast to mammals. Activation of the 
extracellular signal-regulated kinase (Erk) MAPK pathway has been shown to act 
on a wide range of downstream molecules and transcription factors controlling 
growth and differentiation. In B cells, initiation of this signalling cascade requires 
recruitment of the adaptor molecule, She, to the phosphorylated cytoplasmic tail 
of the activated BCR. The phosphorylation of She promotes its interaction with 
the adaptor molecule, Grb2, in an SH2 domain-dependent manner. Along with 
She, a recently identified adaptor protein that localises to lipid rafts, LAB (Linker 
for Activation of B cells), and the linker protein BLNK, appear to play key roles in 
the activation of the Erk-MAPKinase pathway via the recruitment of Grb2 to the 
BCR (Janssen etal., 2003) (Kelly and Chan, 2000). Grb2 is already associated 
with the Ras guanine nucleotide exchange factor (GEF), Sos, via SH3 domain 
interactions, bringing Sos into close proximity with Ras, promoting the conversion
219
of Ras from its GDP-bound inactive form into its active GTP-bound form 
(Henning and Cantrell, 1998; Li etal., 1993). Active Ras then recruits the 
serine/threonine kinase Raf-1, an upstream regulator of Erk-MAPKinase activity, 
to the plasma membrane, where it becomes phosphorylated. Phosphorylated 
Raf-1 then activates the dual specificity kinases MEK1 and MEK2 (MAPKinase 
Kinases 1 and 2), which go on to activate Erki (p44) and Erk2 (p42)
MAPKinases by phosphorylating key threonine and tyrosine residues. Activated 
Erk-MAPKinases proceed to phosphorylate and activate a number of cytoplasmic 
effectors, such as cytosolic phospholipase A2 (cPLAa), as well as translocating to 
the nucleus where it phosphorylates a number of transcription factors, including 
Elk-1 and Stat-3. The 90 kDa Ribosomal S6 kinase (p9QRSK) is also 
phosphorylated by active ErkMAPKinase and regulates gene expression through 
the phosphorylation of the Creb and c-fos transcription factors.
5.1.2 Mechanisms of FcyRllb negative regulation of BCR signalling
Following the discovery of the ITIM motif within the cytoplasmic domain of 
FcyRllb and other inhibitory receptors, distinct pathways of inhibition have been 
described (Gupta etal., 1997; Scharenberg and Kinet, 1998). The signalling 
pathways responsible involve the tyrosine phosphorylation of the ITIM by protein 
tyrosine kinases and the recruitment of SH2 domain-containing proteins to the 
phosphorylated ITIM. The protein tyrosine phosphatases, SHP-1 and SHP-2 
(Burshtyn etal., 1999) and the inositol 6' phosphatase, SHIP (Ono etal., 1996) 
have been shown to be the major proteins recruited by ITIM containing inhibitory 
receptors such as FcyRllb, CD22 and CD72 in B cells, CTLA-4 in T cells and the 
family of Leukocyte Inhibitory Receptors (LIRs) (Daeron, 1997; Unkeless and Jin, 
1997; Vely etal., 1997). These SH2-domain containing phosphatases act to 
dephosphorylate key signalling components downstream of the inhibiting 
receptors, thereby inhibiting normal cellular responses.
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Early in vitro studies on FcyRllb indicated that recruitment of the tyrosine 
phosphatases, SHP-1 and SHP-2, mediated the inhibitory effect of this receptor 
in B cells (D'Ambrosio et ai., 1995). SHP-2 has a broad expression profile and 
has been shown to mediate both positive and negative regulatory effects. Its 
association with the platelet-derived growth factor p (PDGF-(3) receptor, leads to 
the recruitment of the Grb-2-SoS complex and MAPKinase activation (Bennett et 
ai, 1994). However, in human B cells, SHP-2 is thought to mediate FcyRllb 
inhibition of the Ras/MAPKinase and PI3-kinase pathways by dephosphorylating 
its potential substrates SHIP and She (Koncz et a/., 1999). In contrast, SHP-1 
expression appears to be limited to cells of the haematopoietic lineage. SHP-1 is 
widely accepted to act as a negative regulator of many immunoreceptors, 
including the B cell receptor, CD22, CD72, and the natural killer cell inhibitory 
receptor (KIR) (Daeron, 1997; Vely etal., 1997).
The negative regulatory role of SHP-1 was highlighted in SHP-1 deficient 
motheaten (me) and motheaten viable (me^ mice. These mice, which are SHP-1 
null or express a catalytically inactive form of SHP-1, respectively (Tsui and Tsui, 
1994) display a phenotype of widespread autoimmunity as a result of multiple 
haematopoietic cell defects (Shultz et a!., 1997). in particular, B cells from me 
and me'' mice are hyper-responsive to stimulation via the BCR. This suggests 
that by removing SHP-1, the threshold of activation of B cells is substantially 
lowered, thus the threshold of apoptosis in immature B cells is similarly 
decreased. Hence, SHP-1 deficient mice possess a reduced number of bone 
marrow B220* progenitor B cells and a decreased resting B cell population. A 
high percentage of the residual peripheral B cells are also spontaneously 
activated with a skewing towards the B-1 subset As B-1 B cells are associated 
with autoantibody production and are often expanded under conditions of 
autoimmunity (Hayakawa and Hardy, 2000), this would explain the observation 
that these mice exhibit many autoreactive features such as hyper­
gammaglobulinemia, increased autoantibody titres and immune complex 
deposition.
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However, SHP-1 was shown to be dispensable for FcyRIlb-mediated inhibition of 
B cell antigen receptor activation (Nadler eta!., 1997). Thus, in vivo, FcyRllb 
does not necessarily recruit SHP-1 or SHP-2 but rather recruits the inositol 5’ 
phosphatase, SHIP (Liu etal., 1998; Ono etal., 1997). Interestingly, the binding 
of SHP-1 to the phosphorylated ITIM of FcyRllb seems to be correlated with the 
amount of receptor aggregation (Lesourne et al., 2001; Sato and Ochi, 1998). 
Thus, in conditions of low receptor aggregation SHIP appears to be preferentially 
utilised. However, when there are high levels of immune complexes and 
superclustering of receptors both SHIP and SHP-1 are recruited to FcyRllb.
Thus, FcyRI lb-associated SHP-1 activity may be involved in downregulating BCR 
signalling, for example by deactivating the Src-family PTK, Lyn. It is possible, 
therefore, that the conditions of BCR-FcyRllb co-ligation determine the selectivity 
of these phosphatases and that SHP-1 may act to enhance the downstream 
inhibitory effects of SHIP.
Studies with dominant negative SHIP mutants and knockout models have 
confirmed the inhibitory role of SHIP in mediating the FcyRllb negative signal 
(Gupta etal., 1997; Huberef a/.. 1998; Liu etal., 1998). SHIP is a 145 kDa, SH2- 
domain containing, 5’-inositol-polyphosphate phosphatase. The catalytic domain 
bears homology to several 5'-inositol phosphatases, whilst the c-termina! region 
contains several PTB (phospho-tyrosine binding) domains and a proline rich 
region. Post-translational C-terminal truncated forms of SHIP, 135-, 125- and 
110-kDa in size, have recently been identified (Damen etal., 1998). The 110 kDa 
form possesses the same inositol 5' phosphatase activity as the 145 kDa form. It 
is therefore possible that different forms of SHIP are generated in vivo and 
perform distinct functions within haematopoietic cells.
Recruitment of SHIP to the tyrosine-phosphorylated ITIM of FcyRllb, following co­
ligation with the BCR, leads to a drastic reduction in levels of phosphoinositide 
hydrolysis, influx of extracellular calcium, cellular proliferation and
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immunoglobulin secretion. FcyRllb abrogation of BCR activation by the hydrolysis 
of Ptdlns(3,4,5)P3 disrupts PH domain phosphoinosito! lipid interactions and 
prevents the association of Btk and PLC-y with the plasma membrane (Bolland et 
al., 1998). The deletion of SHIP increases Ptdlns(3,4,6)P3 levels, resulting in 
increased Btk membrane association and hyper-responsive BCR signalling. The 
negative effects of SHIP on Btk recruitment can also be overcome by the 
expression of Btk as a membrane-associated chimera. Thus, one key role of 
SHIP-1 is to inhibit the pathways leading to calcium mobilisation by interrupting 
PLC-y recruitment to the membrane. Another substrate of SHIP-1 is 
lns(1,3,4,5)P4, which is hydrolysed to lns(1,3,4)P3, a form of IP3 unable to bind to 
receptors in the endoplasmic reticulum, preventing release of calcium from 
intracellular stores (Scharenberg and Kinet, 1998), providing another mechanism 
for the abrogation of BCR-induced calcium signalling.
Through its catalytic phosphatase domain, SHIP-1 also results in the partial 
inhibition of the survival factor Akt/PKB by hydrolysis of Ptdlns(3,4,5)p3 (Aman et 
al., 1998). However, the hydrolysis product, Ptdlns(3,4)P2 has also been shown 
to be involved in the positive regulation of Akt activity (Downward, 1998). Thus, 
the inhibition of Akt may be as a result of upstream deregulation by the 
alternative inositol phosphatase, PTEN (Cantley and Neel, 1999), which is able 
to dephosphorylate the 3' position of its inositol substrates (Maehama and Dixon,
1998). Indeed, a study by Stambolic, 1998 confirmed that PTEN can negatively 
regulate Akt/PKB by dephosphorylating Ptdlns(3,4,5)P3. Furthermore, PTEN has 
also been shown to dephosphorylate Ptdlns(3,4)p2 suggesting that PTEN may 
directly counteract PI3-kinase activation of Akt/PKB (Haas-Kogan etal., 1998).
FcyRllb ligation also inhibits BCR-mediated activation of the RasMAPK pathway. 
However, there is a lack of consensus as to the mechanism underlying this 
downstream effect. There are currently three proposed models; the first concerns 
the GTPase exchange factors (GEFs), SOS and Vav. SOS and Vav interact with 
Ptdlns(3,4,5)P3 at the plasma membrane via PH domain interactions. As
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discussed above, by hydrolysing Ptdlns(3,4,5)P3, SHIP-1 may prevent Ras 
activation by preventing the translocation of PH-domain containing exchange 
factors to the plasma membrane (Bolland etal., 1998).
The second and most popular of the models involves the ability of SHIP-1 to also 
act as an adaptor protein and engage in PTB binding domain interactions. 
Phosphorylated SHIP-1 can recruit the adaptor molecules She (p52/46) and Grb- 
2 and the association of SHIP-1 with She is enhanced upon BCR-FcyRllb 
coligation (Chacko etal., 1996). Thus, SHIP may indirectly inhibit RasMAPK 
activation by competing with S0S/Grb2 complexes for She binding (Tridandapani 
et al., 1997). However, this interaction is not considered sufficient to mediate the 
inhibitory action of SHIP-1 on the RasMAPK pathway as multiple stimuli, 
including BCR aggregation and cytokine activation, can induce the association 
between SHIP and She, possibly via PTB binding domain interactions (Lamkin et 
al., 1997).
Thirdly, a Ras GTPase activating protein (RasGAP) has been shown to be 
recruited by the adaptor protein. p62’^ °’^ , in a SHIP-dependent manner following 
FcyRllb co-ligation with the BCR (Tamir etal., 2000). By activating RasGAP via 
p62Dok, FcyRllb may enhance the conversion of active Ras-GTP to inactive 
Ras-GDP, thus preventing activation of the ErkMAPK pathway.
Overall, the recruitment and activation of SHIP by FcyRllb results in the inhibition 
of multiple B cell signalling pathways and the modulation of both BCR-induced B 
cell activation and antigen internalisation (Figure 1.8). In addition, ligation of 
FcyRllb alone on B cells has been found to be capable of generating an apoptotic 
signal (Ashman etal., 1996; Ono etal., 1997). Studies in the B cell line, DT40, 
demonstrated that this response was independent of SHIP recruitment, 
suggesting that FcyRllb may directly couple to an apoptotic pathway in the 
absence of BCR-ligation. Additional work by Pearse, 1999 demonstrated that 
failure to recruit SHIP, either by deletion of SHIP or mutation of FcyRllb, resulted
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in enhanced FcyRI lb-triggered apoptosis. Further studies demonstrated that this 
SHIP-independent pathway led to the Btk-dependent activation of JNK. Overall, 
these studies suggest that aggregation of FcyRllb in B cells results in a stress 
response that leads to apoptosis and that SHIP recruitment following co-ligation 
with the BCR ‘rescues’ the cells from apoptosis. Interestingly, SHIP-1 may 
mediate this effect by recruiting the p85 subunit of PI3-kinase upon BCR-ligation 
and could act to regulate downstream events such as B cell activation-induced 
apoptosis (Gupta et al., 1999).
Another mechanism by which FcyRllb can negatively regulate BCR signalling is 
by disrupting its association with lipid rafts. In resting B cells the BCR is excluded 
from lipid rafts, but following cross-linking either by Ig-specific antibodies or 
antigen, the BCR associates with lipid rafts, and a number of components of the 
BCR signalling pathways are recruited to rafts (Cheng etal., 1999). The 
association of the BCR with rafts is one consequence of BCR ligation that can be 
regulated by both positive and negative co-receptors. The association of the BCR 
with lipid rafts is more stable and less transient when the CD19/CD21 co­
receptor complex is co-ligated to the BCR via the binding of C3d-tagged antigens 
(Cherukuri etal., 2001). In contrast, when co-ligated in mature B cells both the 
BCR and FcyRI I b1 associate with lipid rafts, where FcyRllbl recruits the inositol 
phosphatase SHIP and blocks BCR signalling (Aman etal., 2001). This results in 
a more transient association of the BCR with rafts.
6.2 Aims and Objectives
Effective B cell proliferation requires not only ligation of the BCR by antigen, but 
signals derived from helper T cells also, such as IL-4 and CD40-L. The signalling 
mechanisms activated immediately after BCR ligation are becoming well 
established, but the processes underlying sustained proliferation in response to 
BCR ligation are less well defined. This is similar to the role of FcyRllb in
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terminating a B celt response, as previous studies on FcyRllb signalling have 
focused on the early signalling events following BCR-FcyRllb co-ligation. 
However, recent studies have indicated that FcyRllb ligation can lead to distinct 
cellular responses of growth arrest and/or apoptosis in B cells, dependent on the 
levels and type of aggregation. This finding has important implications for the 
selection and modulation of B cell activity by immunocomplexes during B cell 
development.
This study aims to investigate the signalling mechanisms responsible for the 
initiation and, more importantly, the maintenance of proliferation, and for FcyRllb 
inhibition of BCR-mediated proliferative signalling in primary splenic B cells, and 
how these affect the key controllers of the cell cycle. In particular, it aims to 
address:
1. The kinetics of initiation and maintenance of proliferation in response to 
BCR ligation and T cell derived signals.
2. Identification of the signalling molecules involved, utilising specific 
inhibitors of key kinases.
3. The role of phosphodiesterases, particularly PDE4 and PDE7, in the B cell 
response to antigen, using specific PDE4 or PDE7 inhibitors.
4. The role of Erk-MAPKinase in BCR signalling, using the feedback 
inhibition mechanism provided by the FcyRllb receptor.
5. The effects of BCR ligation and FcyRllb inhibition on key ceil cycle 
regulatory molecules, and key regulators of apoptosis.
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5.3 Results
Efficient B cell responses generally require an interaction with helper T cells (Th) 
that are specific for the same antigen. Activated T cells can provide assistance to 
B cells via both membrane-bound molecules such as CD40-ligand (CD40L) and 
secreted molecules such as IL-4. In order to examine the signals involved in the 
ongoing responses of B cells to a variety of stimuli, it was first important to 
assess the activation of B cells in response to a variety of mitogenic factors.
5.3.1 The effects of mitogenic signalling on RNA synthesis in primary 
splenic B cells
Experimentally, F(ab’)2 fragments of anti-lg are used to stimulate B cells as they 
possess exactly the same binding characteristics as a whole antibody molecule, 
but are unable to interact with BCR co-receptors, allowing the BCR effects to be 
assayed directly. In contrast, intact antibodies that ligate the BCR are poor 
polyclonal B cell activators, in comparison to F(ab’)2 fragments, because the Fc 
portion of the intact antibody is able to interact with the inhibitory Fc receptor 
expressed by B cells, FcyRllb. One measure of activation of B cells is the level of 
RNA synthesis. Small, resting B cells do not require much in the way of RNA 
synthesis, as there is very little protein synthesis going on. Before any 
proliferation can occur, mitogenically stimulated B cells must first increase their 
size, therefore increase both their RNA and protein synthesis rates.
The effects of F(ab’)2 fragments of anti-lg, either alone or in combination with 
increasing concentrations of anti-CD40 or recombinant IL-4 on RNA synthesis in 
primary murine splenic B cells was investigated by means of the [^H]-uridine 
assay. Stimulation of primary murine splenic B cells for 24 hours with increasing 
concentrations of F(ab')2 fragments of anti-lg leads to a dose dependent increase 
in RNA synthesis, as measured by [^Hj-uridine incorporation (Figure 5.1 A). This 
is greatly enhanced by co-stimulation with anti-CD40, mimicking B cell - helper T
227
ceil interactions. The effects of anti-CD40 on F(ab’)2 fragment of anti-lg induced 
RNA synthesis are also dose dependent, with a maximal effect afforded by 10 
{uig/ml (Figure 5.1 B). Co-stimulation with IL-4, mimicking Th2 cytokine production, 
also enhances F(ab')2 anti-lg induced RNA synthesis, again in a dose dependent 
manner, with 10 U/ml IL-4 providing the maximum response (Figure 5.10),
5.3.2 The effects of mitogenic signalling on DMA synthesis in primary 
splenic B cells
Another measure of B cell activation is DNA synthesis, as activated mature B 
cells proliferate. It is well established that ligation of the murine BCR with F(ab')2 
fragments of anti-mouse Ig antibodies leads to B cell proliferation (Klaus etal., 
1985; Klaus et al., 1984). Using the [^H]-thymidine assay as a measure of DNA 
synthesis. Figure 5.2A shows that stimulation of murine splenic B cells via the 
BCR with F(ab’)2 fragments of anti-lg results in a dose-dependent increase in 
DNA synthesis. The effects of co-stimulation with F(ab’)2 fragments of anti-lg and 
either anti-CD40 or recombinant IL-4 on DNA synthesis in primary murine splenic 
B cells was also investigated by means of the [^H]-thymidine assay (Figure 5.2B 
and 5.20). Co-stimulation with anti-CD40 enhances F(ab')2 anti-lg induced 
proliferation in a dose dependent manner, again with 10 pg/ml providing the 
maximal enhancement. As with the induction of RNA synthesis, co-stimulation 
with IL-4 also enhances F(ab’)2 anti-lg induced proliferation, but to a lesser extent 
than co-stimulation with anti-CD40.
To assess the longevity of the proliferative response, the proliferation of murine 
splenic B cells was assessed over a period of 168 hours, by means of the f  Hj- 
thymidine incorporation assay, in response to F(ab’)2 fragments of anti-lg plus 
either anti-CD40 (Figure 5.3A) or IL-4 (Figure 5.3B). These data show that, 
upon stimulation with F(ab’)2 fragments of anti-lg alone, the proliferation of B cells 
peaks around 48 to 72 hours, then drops significantly. Upon co-stimulation with 
anti-CD40, the kinetics are altered slightly. The peak of proliferation (as assessed
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by f  H]-thymidine incorporation) shifts to 72 hours, and though the levels drop 
there is still considerable proliferation ongoing at 120 hours (Figure 5.3A). IL-4 
co-stimulation produces a more dramatic increase in proliferation at 120 hours, 
with the levels around the same as the levels exhibited at 72 hours (Figure 
5.3B) At 48 hours, the levels of proliferation are very similar whether cells are 
stimulated with F(ab’)2 fragments of anti-lg alone or co-sti mu lated via CD40 or 
with IL-4. This clearly demonstrates the importance of T cell derived signals in 
the sustained B cell response to antigen.
5.3.3 Effects of specific kinase inhibitors on BCR-mediated proliferation
Ligation of the BCR leads to activation of, amongst other molecules, three major 
signalling pathways, the PLC-y, PI3-Kinase, and Erk-MAPKinase pathways. As 
demonstrated in Chapter 3, the Erk-MAPKinase plays a key role in BCR- 
mediated signalling in immature and transitional B cells. To determine which 
signals are important for BCR-mediated proliferation in primary splenic B cells, 
specific kinase inhibitors were used.
Primary splenic B cells were incubated with the MEK inhibitor PD98059, another 
MEK inhibitor, U0126, the p38 inhibitor SB203580, or the PI-3-Kinase inhibitor 
LY294002 and stimulated with F(ab’)2 fragments of anti-lg. After 48 hours of 
stimulation proliferation was assessed by the [^H]-thymidine incorporation assay. 
Treatment of primary splenic B cells with F(ab’)2 fragments of anti-lg, in the 
absence of any inhibitor, induces proliferation (Figure 5.4). F(ab’)2 anti-lg 
induced proliferation is completely abrogated by treatment of the cells with either 
of the MEK inhibitors, PD98059 or U0126, suggesting that Erk-MAPKinase 
activity plays a major role in F(ab’)2 anti-lg induced proliferation. Inhibition of p38 
activity with the p38 inhibitor, SB203580, inhibits F(ab')2 anti-lg induced 
proliferation to a certain extent, but not as effectively as inhibition of MEK. 
Inhibition of PI-3-Kinase with the inhibitor LY294002 also reduces F(ab’)2 anti-lg 
induced proliferation, to a similar extent as inhibition of p38. These results
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suggest that Erk-MAPKinase plays a major role in the proliferative response of 
mature B cells to antigen, and that PI-3-Kinase, and to a lesser extent, p38, may 
play minor roles in the proliferation of mature B cells. It was decided to 
concentrate on the effects of Erk-MAPKinase on the mitogenic response of 
mature B cells in light of the results indicating the importance of Erk-MAPKinase 
in the WEHI-231 immature B cell line.
5.3.4 The effects of PDE7 inhibitors on B cell proliferative response to 
antigen
Another key signalling pathway that is involved in controlling a wide range of 
events In different cell types is the cyclic AMP (cAMP) pathway. Recently it has 
been demonstrated that the cAMP pathway and the Erk-MAPKinase pathway are 
interlinked at a number of distinct points (Houslay and Kolch, 2000). The effects 
elevated levels of cAMP have on Erk-MAPKinase activity vary between cell 
types, depending on which Raf isoform is expressed. Raf-1 can be inhibited by 
PKA, which is activated by elevated levels of cAMP. Conversely, B-Raf is 
activated in response to elevated levels of cAMP, hence leading to Erk- 
MAPKinase activation.
Cyclic nucleotide phosphodiesterases (PDEs) are responsible for regulating the 
cyclic nucleotide signalling system by converting adenosine-3’,5’-cyclic 
monophosphate (cAMP) into adenosine-5’-monophosphate (5 -AMP), switching 
off pathways downstream from cAMP. PDEs are a diverse and complex group of 
enzymes, with at least 10 isoforms described to date. They are responsible for 
the regulation of a wide variety of responses, from platelet aggregation to cardiac 
muscle inflammation. When T cell receptors are activated by antigen, cAMP 
levels drop and proliferation occurs. Previous studies in our laboratory had 
shown that PDE4 family members were activated following mitogenic stimulation 
via the BCR (Harnett, unpublished observations), and in WEHI-231 cells, 
stimulation via the BCR, which induces growth arrest, inhibits PDE4 activity,
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leading to an increase in cAMP (Gauld, 2001). Other PDE family members are 
known to play roles in regulation of proliferation in lymphocytes, for instance, it 
has been shown that PDE7 mRNA and protein levels are up-regulated when 
human T cells become activated, and that blocking the PDE7 induction blocked 
the activation of the cells (Li et a/., 1999). These results strongly suggest that 
suppressing levels of cAMP could enhance proliferation in lymphocytes. To 
determine if PDE7 is also important in B cell activation, PDE7 activity was 
inhibited with a variety of compounds.
Primary splenic B cells were stimulated, in the presence or absence of a variety 
of PDE7 inhibitors (10 ^M), with F(ab’)2 fragments of anti-lg, either alone or in 
combination with anti-CD40 or recombinant IL-4, or with LPS. Following 48 hours 
treatment proliferation was assessed by the pH]-thymidine uptake assay. As 
Figure 5.5 shows, B cells receiving no stimulation incorporate very little [^H]- 
thymidine as they are resting and not undergoing proliferation. In response to 
stimulation with F(ab’)2 fragments of anti-lg, cells receiving no PDE7 inhibitors 
display an increase in their thymidine incorporation, indicating increased 
proliferation in response to BCR ligation. B cells stimulated with F(ab’)2 fragments 
of anti-lg in the presence of the PDE7 inhibitor PD0329870 also demonstrate a 
massive increase in thymidine incorporation, indicating that this inhibitor has no 
effect on BCR-induced proliferation. Indeed, this inhibitor fails to alter the 
response of B cells to any of the stimuli used. In contrast to this, PD0322408 
inhibits B cell proliferation in response to all stimuli used, more effectively than 
the other inhibitors. This is most obvious in response to LPS, where the other 
inhibitors only marginally inhibit B cell proliferation, whilst PD0322408 reduces it 
by approximately 75%. The other 3 inhibitors all appear to have very similar 
effects on B cell proliferation, in that they inhibit anti-lg induced proliferation, even 
in the presence of IL-4, but not in the presence of anti~CD40.
PD0322408 and PD0326875 both have effects on B cell proliferation, so to 
further characterise these inhibitors, B cells were stimulated with either the
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combination of LPS and IL-4, or the combination of F(ab’)2 fragments of anti-lg, 
IL-4 and anti-CD40 in the presence of increasing concentrations of these two 
PDE7 inhibitors. The PDE4 specific inhibitor, rolipram, was also used to compare 
the effects of PDE7 and PDE4 inhibition on B cell responses. Proliferation was 
assessed after 48 hours by means of the [^H]-thymidine incorporation assay.
These data demonstrate that the effects of PD0322408 on LPS induced 
proliferation are reduced slightly by the presence of IL-4, as the levels of 
proliferation in response to LPS are reduced to about two thirds in the presence 
of 10 p.lVI PD0322408 (Figure 5.6). In contrast, the effects on anti-lg induced 
proliferation are not as striking in the presence of IL-4 and anti-CD40, again 
demonstrating the importance of T cell derived signals in B cell activation. The 
inhibitor PD326875 does not significantly alter the proliferative response to any of 
the stimuli used, nor indeed does rolipram. These results suggest that neither 
PDE4 or PDE7 play significant roles in mitogen induced proliferation.
5.3.5 The effects of PDE7 inhibitors on B cell apoptosis
The decrease in [^H]-thymidine incorporation induced by these PDE7 inhibitors 
could be due to non-specific cytotoxic effects, rather than as a specific result of 
PDE7 inhibition. To assess the effects of the various PDE7 inhibitors on B cell 
viability, primary splenic B cells were stimulated, in the presence or absence of a 
variety of PDE7 inhibitors (10 i^M), with F(ab')2 fragments of anti-lg, either alone 
or in combination with anti-CD40, or with LPS. Following 48 hours treatment,
DMA content was assessed by flow cytometry following propidium iodide 
staining. Figure 5.7 shows the percentage of cells in each cell cycle phase.
Reflecting their resting state, B cells receiving no inhibitor or agonists are mainly 
in Go/Gi phase, and treatment with an agonist induces an increase in the 
percentage of cells in either S phase or G2/M. Stimulation with F(ab’)2 fragments 
of anti-lg appears to induce a slight increase in the percentage of cells displaying
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a sub-diploid DNA content. The PDE7 inhibitor, PD0322408, induces a rather 
large increase in apoptosis in the absence of any agonist, and this is enhanced 
when cells are treated with the combination of inhibitor and F(ab')2 fragments of 
anti-lg. This could account for the decrease in proliferation demonstrated by cells 
treated with this inhibitor in the [^H]-thymidine incorporation assay (Figure 5.5). 
Treatment with LPS or the combination of F(ab’)2 fragments of anti-lg and anti- 
CD40 provide protection from apoptosis induced by PD0322408, though the 
inhibitor still manages to inhibit proliferation induced by these agonists, as there 
are fewer cells in S phase and G2/M compared to cells not treated with inhibitor.
Corroborating the results from the [^H]-thymidine incorporation assay, the 
inhibitor PD0323590 prevents anti-lg induced proliferation as there is a lower 
percentage of cells in S phase or G2/M in response to anti-lg compared to cells 
stimulated in the absence of inhibitor. This appears to be mostly due to an 
increase in apoptosis, rather than an increase in growth arrest, as there is a 
greater proportion of cells with a sub-diploid DNA content.
5.3.6 MEK inhibition blocks BCR-mediated Erk-MAPKinase activation
In the WEHI-231 immature B cell line, the kinetics of Erk-MAPKinase signalling 
determine the specific outcome. For example, ligation of the BCR with anti-lg 
leads to a transient Erk-MAPKinase activation that terminates within 4 hours, 
whilst CD40-mediated rescue of anti-lg induced growth arrest and apoptosis 
leads to a sustained, cyclical pattern of Erk-MAPKinase activation, with activity 
still detectable after 24 and 48 hours (Section 3.3.3) (Gauld et a i, 2002). In 
mature B cells, BCR ligation also leads to the activation of Erk-MAPKinase, 
within minutes of antigen binding (Campbell, 1999). The activity of Erk- 
MAPKinase in response to BCR ligation over a longer period of time remains to 
be fully elucidated. It seems highly likely that Erk-MAPKinase activity is required 
for B cell responses to antigen, as inhibition of Erk-MAPKinase with the specific 
MEK inhibitor PD98059 blocks F(ab’)2 anti-lg mediated proliferation (Figure 5.4).
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To assess the longer term effects of BCR ligation on Erk-MAPKinase 
phosphorylation, primary splenic B cells were stimulated with F(ab’)2 fragments of 
anti-lg in the presence or absence of the MEK inhibitor PD98069 for the times 
indicated. The presence of PD98059 abrogates the phosphorylation of Erk- 
MAPKinase at 6 hours, and dramatically reduces it at 17 and 20 hours (Figure 
5.8A). By 24 hours, PD98059 is still effective at blocking the BCR-mediated 
activation of Erk-MAPKinase (Figure 5.8B).
To assess the localisation of this phosphorylated Erk-MAPKinase, primary 
splenic B cells were stimulated for 16 hours with F(ab’)2 fragments of anti-lg in 
the presence or absence of the MEK inhibitor PD98059. Cells were adhered to 
slides, and the activity of Erk-MAPKinase assessed by staining with an anti- 
phospho Erk1/2 antibody, and staining visualised using the image analysis 
abilities of the LSC, as described in Section 2.12.3 The nucleus was visualised 
via DAP I staining. Stimulation via the BCR leads to phosphorylation of Erk- 
MAPKinase, even after 16 hours (Figure 5.8A). It appears as though this 
phospho-Erk localises to an area adjacent to the nucleus. Treatment of cells 
stimulated via the BCR with the MEK inhibitor, PD98059, abrogates this 
phosphorylation of Erk-MAPKinase.
5.3.7 FcyRilb ligation abrogates antigen receptor mediated B cell 
proliferation
The above data show that, upon mitogenic stimulation via the BCR, Erk- 
MAPKinase becomes activated, and that inhibition of this Erk-MAPKinase activity 
by specific inhibitors blocks BCR-induced proliferation. This is analogous to the 
physiological negative regulation of the BCR by the FcyRllb receptor, so it was 
decided to utilise the FcyRllb receptor to further investigate the role of Erk- 
MAPKinase in mature B cells under more physiologically relevant conditions.
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It is well established that ligation of the murine BCR with F(ab’)2 fragments of 
anti-mouse Ig antibodies leads to B cell proliferation, whilst BCR-FcyRllb co­
ligation using intact anti-lg antibodies inhibits BCR-mediated DNA synthesis 
(Klaus et al., 1985; Klaus et al., 1984). Using the [^H]-thymidine assay as a 
measure of DNA synthesis, Figure 5.9A shows that stimulation of murine splenic 
B cells via the BCR (F(ab’)2 anti-lg) results in a dose-dependent increase in DNA 
synthesis. Following stimulation with intact antibody alone over a range of similar 
concentrations, no DNA synthesis is detected (Figure 5.98). Co-ligation of the 
BCR with FcyRllb using a combination of F(ab’)2 fragments and intact anti-lg 
antibodies together results in a dose-dependent decrease in BCR-induced DNA 
synthesis (Figure 5.90) and provides an experimental model for negative 
feedback inhibition of ongoing B cell responses. Maximal inhibition of BCR- 
induced DNA synthesis was achieved using intact anti-lg antibodies at a 
concentration of 75 fxg/ml, i.e. at a concentration which is equimolar to the 
concentration of F(ab')2 fragments of anti-lg required for maximum DNA 
synthesis (Figure 5.90).
To confirm that co-ligation of the BCR with FcyRllb is required for the inhibitory 
effect of intact anti-lg antibody on BCR-mediated proliferation, an anti-FcyRII/RIII 
antibody (2.4G2) was used to block BCR-FcyRllb co-ligation (Figure 5.9D). Co­
stimulation of murine splenic B cells with F(ab’)2 fragments and intact anti-lg 
antibodies in the presence of 2.4G2 resulted in the almost total restoration of 
levels of DNA synthesis observed when cells were stimulated via the BCR alone, 
consistent with previously published observations (Unkeless, 1979). Together, 
these results confirm that FcyRllb co-ligation can reduce or prevent BCR- 
mediated proliferation of murine splenic B cells, demonstrating that this receptor 
plays a key role in negative feedback regulation of B cells.
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5.3.8 Ligation of FcyRIIB on splenic B cells induces apoptosis
The above results confirmed that co-ligation of the BCR with FcyRllb is able to 
inhibit BCR-induced DNA synthesis, a process that could be reversed by an anti- 
FcyRII/lll blocking antibody. To investigate whether the FcyRIlb-mediated 
inhibition of BCR-induced DNA synthesis was a result of growth arrest, or a 
consequence of apoptosis, cells were stimulated with F(ab’)2 fragments of anti-lg, 
intact anti-lg, alone and in combination. Unstimulated cells were used as a 
control. The DNA content of the cells was determined by flow cytometry analysis 
following propidium iodide staining (Figure 5.10). These results confirm the 
ability of BCR stimulation to promote the entry of murine splenic B cells into the S 
and G2/M phases of the cell cycle, consistent with the increased levels of DNA 
synthesis seen in Figure 5.9. Co-ligation of the BCR with FcyRllb resulted in an 
increase in the proportion of B cells arrested in G0/G1 phases of the cell cycle, 
and an increase in apoptosis (sub-diploid DNA content) compared to the basal 
level.
5.3.9 FcyRllb inhibits Erk-MAPKinase phosphorylation
Ligation of the BCR leads to activation of Erk-MAPKinase following the formation 
of adaptor protein scaffolds, which are recruited by protein tyrosine kinases 
(Campbell, 1999). Inhibition of Erk-MAPKinase activity with the specific MEK 
inhibitor PD98059 blocks BCR-mediated proliferation very effectively (Figure 
5.4), as does co-ligation of the BCR with FcyRllb (Figure 5.9). Ligation of FcyRllb 
results in the activation of the phosphatases SHIP and SHP-1, which are known 
to dephosphorylate and deactivate key BCR-coupled signalling molecules, 
abrogating BCR-induced proliferative signalling.
To investigate the effect of FcyRllb ligation on Erk-MAPKinase activation, primary 
splenic B cells were stimulated with F(ab’)2 fragments of anti-lg alone, or a 
combination of F(ab’)2 fragments and intact anti-lg antibodies. Unstimulated cells
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were used as a control. Whole cell lysates were prepared and probed for 
phospho-Erk expression using a phospho-Erk1/2 antibody. Unstimulated B cells 
exhibit no detectable Erk phosphorylation by Western blot analysis, reflecting the 
resting state of the cells (Figure 5.11) Stimulation of B cells via the BCR alone 
results in a rapid up regulation of Erk-MAPKinase phosphorylation, sustained for 
at least 30 minutes. Co-ligation of the BCR with FcyRllb results in a more 
transient increase in Erk-MAPKinase phosphorylation, which is terminated by 30 
minutes.
5.3.10 Localisation of active Erk-MAPkinase in response to BCR ligation 
and FcyRllb co-ligation
Immune receptors and components of their signalling cascades are spatially 
organised, and this spatial organisation plays a key role in the initiation and 
regulation of signalling. This spatial organisation is due to cholesterol- and 
sphingolipid-rich plasma membrane microdomains, or lipid rafts. Lipid rafts are 
known to be important for signalling via both the BCR and FcyRllb. The BCR 
associates with lipid rafts following antigen binding, and upon co-ligation with the 
BCR, FcyRllb also localises to lipid rafts, where it can recruit SHIP and abrogate 
BCR signalling. One of the key roles of lipid rafts is thought to be to enable the 
co-localisation of key signalling molecules.
To investigate the effects of BCR ligation and BCR and FcyRllb co-ligation on the 
localisation of active Erk, primary splenic B cells were stimulated with F(ab’)2 
fragments of anti-lg, or intact anti-lg, either alone or in combination, in the 
presence and absence of the MEK inhibitor PD98059. Lipid rafts were visualised 
by staining with a biotin labelled chlera toxin B subunit, which attaches to cells by 
binding to ganglioside Gmi, a ubiquitous glycolipid cell surface receptor that is a 
component of lipid rafts. Dually phosphorylated Erk-MAPKinase was detected 
with a monoclonal, phospho-specific antibody, whilst DNA was stained with
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DAP I, as described in Section 2.12.3. In Figure 5.12 lipid rafts are shown in red, 
the nucleus in blue, and phospho-Erk-MAPKinase as green.
Stimulation of primary splenic B cells via the BCR with F(ab’)2 fragments of anti- 
lg results in a dramatic increase in the presence of phospho-Erk, hence Erk- 
MAPKinase activity (Figure 5.12). This Erk-MAPKinase activity appears to be 
heavily polarised, with most cells displaying a single point of intense Erk- 
MAP Kinase activity, which appears to co-localise with lipid rafts at earlier time 
points. Co-ligation of the BCR with FcyRllb abrogates this Erk-MAP Kinase 
activity. Interestingly, on its own PD98069 does not appear to fully abrogate 
F(ab')2 anti-lg-induced Erk-MAP Kinase activation at 1 hour as there are still some 
cells displaying a low level of Erk-MAPKinase activity. However, when cells are 
stimulated with the combination of F(ab’)2 fragments and intact anti-lg antibodies, 
and treated simultaneously with PD98059, Erk-MAPKinase activity is completely 
abolished. After 20 hours of treatment with F(ab’)2 fragments of anti-lg and 
PD98059 Erk-MAPKinase activity is abolished completely. Treatment of cells 
with intact anti-lg antibodies alone for 20 hours appears to alter the integrity or 
composition of lipid rafts, as the staining appears more punctate compared to 
control cells at this time.
5.3.11 FcyRllb modulates the expression of key cell-cycie regulator proteins
The retinoblastoma protein,Rb, is a tumour suppressor protein that controls the 
progression of cells through the Gi restriction point, the key regulatory step prior 
to S phase entry. Rb inhibits progression into S phase by binding to and 
sequestering the E2F family of transcription factors, which are required for 
transcription of key genes involved in DNA synthesis and cell cycle progression. 
This interaction is abrogated by phosphorylation of Rb by Cdk4/6 and Cdk2 
complexes, allowing E2F to induce transcription of its target genes (Dyson,
1998). Both immature and mature B cells show BCR-induced increases in Cyclin 
D and Cdk4 levels, which are essential for early Gi phase progress and transition
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through the Gi restriction point. This may be due to Erk-MAP Kinase dependent 
activation of the Cyclin D gene via the transcription of MAP Kinase responsive 
genes.
Since FcyRllb signalling has been demonstrated to inhibit B cell Gi-S phase 
progression following co-ligation with the BCR the effect of FcyRllb recruitment 
on the expression of key cell-cycle regulator proteins was investigated. The 
expression profile of Rb was investigated in whole cell lysates of splenic B cells 
stimulated via the BCR or BCR-FcyRllb for 72 hours. The existence of multiple 
forms of Rb observed during Western blotting is indicative of Rb phosphorylation; 
with hyper-phosphorylated Rb exhibiting a greater apparent molecular weight in 
comparison to hypo- or unphosphorylated Rb. Figure 5.14A shows that Rb 
appears to be differentially phosphorylated in splenic B cells following BCR 
and/or FcyRllb stimulation. Correlating with entry into the S and Ga/M phases of 
the cell cycle, BCR stimulation over 72 hours results in the hyper-phosphorylation 
of Rb, as indicated by the predominance of the higher molecular weight form. In 
contrast, co-ligation of FcyRllb results in a Rb phosphorylation profile similar to 
that of basal cells, with a large percentage of cells demonstrating hypo- 
phosphorylated Rb. Thus, FcyRllb actively inhibits entry in the proliferative 
phases of the cell cycle by preventing the hyper-phosphorylation and 
deactivation of Rb.
Following mitogenic stimulation of cells, two events controlling the Gi/S transition 
are thought to occur. Firstly Cyclin D levels are increased and secondly, the 
levels of p27, a Cyclin-dependent kinases inhibitor (CKI), are reduced (Sherrand 
Roberts, 1999). Together with another CKI, p21, p27 inhibits Cyclin-E/Cdk2 
complexes whilst acting as an assembly factor for Cyclin D and Cdk4/6 (Cheng 
et al., 1999). By binding to the Cyclin/Cdk complexes, these CKIs lead to the 
inhibition of Cdk activity and thus prevent the phosphorylation of Rb and cell 
cycle progression. Whilst p27 is constitutively expressed, p21 levels are induced 
during periods of stress by p53.
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The tumour suppressor protein, p53, plays a major role in the cellular response 
to DNA damage and other genomic aberrations. Importantly, the activation of p53 
by MARK mediated phosphorylation on multiple residues, can either lead to cell 
cycle arrest and DNA repair, or apoptosis (Levine, 1997; Meek, 1994). p63 is 
normally held in an inactive complex with a negative regulator, MDM2. MDM2 
inhibits the accumulation of p53 by targeting it for ubiquination and proteasomal 
degradation (Chehab et al., 1999). DNA damage or apoptotic signals induce the 
phosphorylation of p53 at residues serine 15 and serine 20 . These 
phosphorylation events impair the MDM2-p53 interaction thus promoting both the 
accumulation and functional activation of p53.
To investigate whether p53 was functionally activated by FcyRllb ligation, whole 
cell lysates from BCR and/or FcyRllb co-stimulated splenic B cells were Western 
blotted for the expression of phospho-p53 Ser^ .^ Figure 5.14B clearly 
demonstrates that FcyRllb induces the phosphorylation of p53 on the critical 
serine residue over 72 hours, compared to control or BCR stimulated cells. Thus, 
the activation of p53 may represent an important pro-apoptotic mechanism 
initiated by FcyRllb following ligation on splenic B cells.
Cyclin dependent kinases (Cdks) play a major role in the phosphorylation of Rb 
during Gi (Zarkowska and Mittnacht, 1997). Cyclin D-Cdk4/6 complexes and 
Cyclin E-Cdk2 complexes contribute to the activation of Rb. As Cdk4 is required 
for the phosphorylation of Rb, the expression levels of Cdk4 were investigated in 
whole cell lysates of BCR and BCR-FcyRllb stimulated cells. Figure 5.140 
shows that BCR stimulation for 1 hour results in a downregulation in Cdk4 
expression levels followed by a return to basal levels over time. A similar pattern 
of slight Cdk4 suppression followed by a return to basal levels is shown following 
FcyRllb co-ligation with the BCR. The lack of significant modulation of Cdk4 
levels following stimulation may be due to the short stimulation times chosen and 
an investigation of later times in the cell cycle may highlight differential
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expression or activation of Cdk4 by FcyRllb and the BCR. However, consistent 
with our results, recent studies in murine B cells over 48 hours have shown that 
FcyRllb ligation does not inhibit the expression of Cdk4 but acts to block the 
assembly and stabilisation of Cyclin D-Cdk4/6 complexes (Tanguay ef a/., 1999).
5.3.12 FcyRllb modulates the expression of key cell-cycle regulatory genes
The transcription of a further group of cell cycle regulatory proteins was also 
assessed by means of the ribonuclease protection assay (RPA). The RPA is a 
highly sensitive and specific method for the detection and quantitation of mRNA 
species. The multi-probe system developed by Pharmingen allows the 
quantitation of several mRNA species in a single sample of total RNA due to the 
fact that each template is a distinct length and represents a sequence in distinct 
mRNA species. The multi-probe template set utilised here is shown in Table 5.1.
To investigate the mRNA levels of the key cell cycle regulatory genes purified B 
cells were stimulated with F(ab’)2 fragments of anti-lg, either alone or in 
combination with intact anti-lg antibodies. At the times indicated, whole RNA was 
isolated from each sample (1x10® cells) as described in Materials and Methods 
(Section 2.15), The assay was carried out as per the manufacturer’s instructions 
(see Section 2.16), and the RNA levels quantitated using a phosphorimager.
As Figure 5.14 shows, the levels of cyclin D2 did not alter much under any 
condition, and the same was true for levels of cdk2 mRNA, though these were 
slightly higher upon antibody stimulation that in the control cells. Somewhat 
surprisingly, the levels of cyclin D3 were increased by co-stimulation with F(ab’)2 
fragments and intact anti-lg, which normally does not lead to proliferation, but not 
by F(ab’)2 fragments alone, conditions which normally do lead to proliferation 
(Figure 5.9). A further surprising result was the increase in p27 '^^  ^ expression 
induced by F(ab’)2 fragments of anti-lg alone after 16 hours of stimulation. This is 
possibly the opposite of what would be expected as an increase in the levels of
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p27 protein is associated with Gi arrest, yet F(ab’)z fragments of anti-lg induce 
proliferation.
5.3.13 Ligation of FcyRI IB on splenic B cells induces a collapse of the 
mitochondrial membrane potential
The tumour suppressor protein p53 possesses two distinct functions, the ability 
to induce cell cycle arrest and the ability to induce apoptosis. These functions are 
separable, as evidenced by the isolation of structural p53 mutants that possess 
defects in apoptosis induction, but not cell cycle arrest (Ryan and Vousden,
1998). One of the mechanisms by which p53 is able to induce apoptosis is the 
modulation of mitochondrial function, perhaps as a result of its ability to 
translocate to the mitochondria (Marchenko eta!., 2000). An early indication of 
apoptosis is the reduction in mitochondrial membrane potential (Aipm), as this 
constitutes an early, obligatory step of apoptosis in lymphocytes (Zamzami et al., 
1995). This reduction in Aipm can be detected using DiOC6(3), a cationic lipophilic 
dye whose uptake by cells correlates with their Aipm- To investigate whether 
FcyRllb-induced apoptosis in murine splenic B cells correlated with a reduction in 
Ai|)m, cells were stimulated via the BCR alone, the FcyRllb alone, or by co-ligation 
of the two receptors. Unstimulated cells were included as a control. Mitochondrial 
membrane potential was analysed by flow cytometry following staining of the 
cells with DiOC6(3) (Figure 5.13). These data clearly show that co-ligation of the 
BCR and FcyRllb results in an increased percentage of primary splenic B cells 
with a low DiOC6(3) fluorescence intensity, indicating apoptosis (Figure 5.13). 
These results confirm that FcyRllb ligation on B cells can initiate mechanisms 
that lead to the disruption of mitochondrial stability.
5.3.14 FcyRllb modulates the expression of key apoptosis regulatory genes
Apoptosis is a highly regulated process, and as such a number of different 
molecules are involved in the control of apoptosis, from Bcl-2 family members to
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the caspases. in order to further investigate the induction of apoptosis by 
FcyRllb, the transcription of some apoptosis regulatory genes was also assessed 
by RPA. The protocol was exactly as described in Section 5.3.12, and the multi­
probe template set is shown in Table 5.1.
T h e  expression levels of p53, bax, and Bc I-X l were all assessed by means of the 
RPA (Figure 5.16). These results show that stimulation of B cells with the 
combination of F(ab’)2 fragments and intact anti-lg antibodies leads to an 
increase in the transcription of p53, as well as Bak, albeit to a lesser extent. This 
is unsurprising, as Bak is a known transcriptional target of p53, and we had 
previously shown that the p53 protein is activated in response to ligation of 
FcyRllb (Figure 5.13). Interestingly, co-ligation of the BCR with FcyRllb also led 
to the increased transcription of Bc I-X l, an anti-apoptotic member of the Bcl-2 
family, in the WEHI-231 immature B cell line, Bc I-Xl plays a key role in protecting 
the cells from anti-lg induced apoptosis (Choi eta!., 1995), so as co-ligation of 
the BCR with FcyRllb leads to apoptosis, it might be expected that Bc I-X l levels 
would fall.
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5.4 Discussion
Regulation of the B cell response to antigen requires the maintenance of 
appropriate levels of signalling through the B cell antigen receptor. The signalling 
mechanisms activated immediately after BCR ligation are becoming well 
established, but the processes underlying sustained proliferation in response to 
BCR ligation are less well defined. Experimental models have developed, 
however, which potentially allow dissection of the key regulatory events. For 
example, stimulation of the BCR with F(ab’)2 fragments of anti-lg antibodies 
results in B cell activation and proliferation. In contrast, by using intact anti-lg 
antibodies to mimic physiological antibody-antigen complexes, it is possible to 
co-ligate the BCR with FcyRllb, inhibiting the response to mitogenic F(ab’)2 anti- 
lg antibodies. Thus, BCR signalling and negative feedback regulation of BCR 
signalling by FcyRllb can be investigated in vitro. This study utilised this 
approach, in conjunction with the use of specific inhibitors of key kinases, to 
investigate the signalling mechanisms involved in the initiation and maintenance 
of BCR-mediated proliferation, and how these affect key cell cycle regulatory 
proteins.
In general, maximal B cell responses require an interaction with helper T cells 
(Th) that are specific for the same antigen. Such signals include the soluble 
cytokine IL-4, and a molecule on the T cell surface, CD40-ligand (CD40L), which 
interacts with CD40 on the surface of B cells. Experimentally, the CD40 -  CD40L 
interaction can be mimicked using anti-CD40 antibodies, which bind CD40 and 
activate the signalling pathways downstream of the receptor. The induction of 
RNA synthesis by B cells is maximal when the cells were stimulated with the 
combination of F(ab’)2 fragments of anti-lg and anti-CD40, with the level almost 
double that of the combination of F(ab’)2 anti-lg plus IL-4, and around five times 
that of F(ab’)2 anti-lg alone. This is also the case for DNA synthesis, with the 
combination of F(ab’)2 fragments of anti-lg and anti-CD40 inducing far more DNA
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synthesis than F(ab’)2 anti-lg alone or in combination with IL-4. This underlines 
the physiological importance of T cell derived signals in the activation of B cells.
Not only are T cell derived signals important for the induction of B cell activation, 
they also play a major role in the ongoing B cell response to antigen, as 
evidenced by the duration of proliferation when T cell derived signals are present 
Stimulation with F(ab’)2 fragments of anti-lg alone results in proliferation of B 
cells, but not to the same levels as when IL-4 or anti-CD40 are present, and the 
duration is greatly reduced in the absence of T cell derived signals. Even by 72 
hours, the response to F(ab’)2 fragments of anti-lg alone is diminishing, however, 
in the presence of IL-4, the response stays high until 120 hours, before falling by 
168 hours. Again, this underlines the importance of the help signals produced by 
T cells in the activation of B cells. It would be very interesting to assess the 
number of divisions B cells undergo over this period. This was attempted using 
the CFSE fluorescent molecule, which can be incorporated into cells prior to 
stimulation, and the decrease in fluorescence in successive cell divisions 
assessed by flow cytometry. This was attempted, but encountered difficulties due 
to cytotoxic effects of CFSE on B cells, as well as variable uptake of the dye by 
the cells prior to stimulation. The uptake conditions require optimisation for B 
cells to ensure minimal cytotoxicity, and it may also be useful to select a 
population of cells with a narrow range of fluorescence with a cell sorting 
machine prior to stimulation. This would help ensure that defined peaks can be 
observed after each subsequent division, as another of the difficulties arose from 
the lack of distinct peaks after stimulation, as there was a large range of 
fluorescence at the outset.
In order to identify the relative roles of the various signalling pathways involved in 
B cell proliferation, we used specific inhibitors to prevent activation of key 
kinases, then assessed the effects on B cell proliferation by means of the [^H]- 
thymidine incorporation assay. The MEK inhibitors, PD98059 and U0126, 
completely abrogated F(ab’)2 anti-lg induced proliferation of B cells,
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demonstrating the importance of Erk-MAPKinase signalling in the B cell 
proliferative response to antigen. Both the p38 inhibitor, SB203580, and the PI-3- 
Kinase inhibitor, LY294002, inhibited BCR induced proliferation to a certain 
extent, but not to anywhere near the level of the MEK inhibitors, further 
underscoring the importance of Erk-MAPKinase in B cell activation. The ability of 
the stimulation via BCR to induce sustained activation of Erk-MAPKinase activity 
strongly suggest that, as in WEHI-231 immature B cells, sustained Erk- 
MAPKinase activity plays a role in the proliferation of mature B cells. The 
apparent translocation of Erk-MAPKinase to an area adjacent to the nucleus 
upon sustained activation is rather intriguing, and is similar to findings in other 
systems whereby sustained activation of Erk-MAP Kinase is associated with 
translocation to the nucleus (Shah et al., 2003). However, in contrast with our 
findings that sustained Erk-MAPKinase activity is associated with proliferation, in 
a number of other systems transient Erk-MAPKinase activity usually leads to 
proliferation, whereas sustained Erk-MAPKinase activity often elicits 
differentiation (Kao eta!., 2001; Liang eta!., 2002; York eta!., 1998).
Erk-MAPKinase activity can be modulated by many signalling elements, including 
cyclic AMP (cAMP). cAMP is generated at the plasma membrane by adenylate 
cyclases, a large family of enzymes, and is degraded is through the action of 
various cyclic nucleotide phosphodiesterases (PDEs), of which several families 
also exist. The importance of PDEs in many cellular processes including the 
regulation of Erk-MAPKinase activity (Houslay and Kolch, 2000) has been 
reinforced recently with the emergence of inhibitors of these enzymes, 
particularly the PDE4 family, as having potential therapeutic value in treating a 
number of inflammatory diseases, such as asthma, as well as possessing anti­
depressant properties (Houslay and Baillie, 2003). Recently, it has been 
demonstrated that a novel PDE family member, PDE7, plays a key role in T cell 
activation, as PDE7 mRNA levels are up-regulated upon activation of human T 
cells, and blocking the induction of PDE7 abrogates activation of the cells (Li et 
a!., 1999). A role for PDE7 in B cells has been suggested due to the fact that
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PDE7 is expressed in human B cells, and is upregulated by elevation of 
intracellular cAMP levels (Lee et ai, 2002). Indeed, it appears as though PDE7 
may also play a role in regulating B cell proliferation, as F(ab’)2 anti-lg induced 
proliferation was reduced when cells were treated with PDE7 inhibitors. The 
inhibitors used in this study had widely different efficacies, with PD0322408 
producing the most dramatic effect (Figure 6.5), though only PD0329870 did not 
greatly inhibit BCR-mediated proliferation. This inhibition appears largely to be 
the result of the induction of apoptosis. Due to the highly variable efficacies of the 
inhibitors, however, it was decided not to follow up the role of PDE7 in regulating 
B cell proliferation by Erk-MAP Kinase signalling. Nevertheless, IL-4 was unable 
to overcome this inhibition, however, CD40-mediated signals did appear to 
provide some measure of protection. This suggests that some signalling pathway 
activated in response to CD40 ligation, but not ligation of the IL-4 receptor, 
provides a signal that can override inhibition of PDE7.
The low affinity receptor for IgG, FcyRllb, negatively regulates BCR-mediated 
proliferative signalling, and as such provides a negative feedback mechanism 
whereby co-crosslinking of FcyRllb with the BCR by antigen-antibody complexes 
inhibits antigen-driven responses and may act to prevent progression or 
induction of certain autoimmune diseases (Ravetch and Bolland, 2001). The 
understanding of the mechanisms underlying FcyRllb-mediated suppression of 
BCR signalling are beginning to be fairly well elucidated, at least in terms of the 
initial signalling events. How these events impinge on downstream targets, such 
as the cell cycle machinery, is less well understood. Experimentally this can be 
demonstrated by stimulating B cells with a combination of F(ab’>2 fragments of 
anti-lg and intact anti-lg antibodies to cross-link the BCR and FcyRllb, as the 
presence of intact anti-lg antibodies leads to inhibition of F(ab’)2 anti-lg-induced 
proliferation. One of the ways this is achieved is by the rapid inactivation of Erk- 
MAPKinase, as assessed by Western blotting using a phospho-Erk antibody.
This was further evidenced by imaging studies, where we demonstrate that co­
ligation of FcyRllb with the BCR produces an effect very similar to that induced
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by the MEK inhibitor PD98059 in that sustained Erk-MAPKinase signalling is 
abolished (Figure 5.12). FcyRllb recruitment of SHIP is proposed to disrupt 
Ras/MAPKinase mediated proliferative signalling by sequestering She, one of the 
adaptor molecules responsible for coupling the BCR to the Ras/MAPKinase 
pathway (Tridandapani et a!., 1997), and by the recruitment of the RasGAP 
binding protein p62‘^ “‘^ , to promote Inactivation of Ras (Tamir et al., 2000). It has 
also been recently demonstrated by this laboratory that FcyRllb recruits the 
nuclear phosphatase, Pac-1, which is capable of dephosphorylating and 
inactivating Erk-MAP Kinase (Brown etal., 2004). Thus, Fc '^RIIb utilises multiple 
mechanisms to abrogate Erk-MAPKinase activity, both by inhibiting the upstream 
activation of Erk and terminating any ongoing Erk-MAP Kinase activity (Figure 
5.17).
We investigated the effects of signalling via the BCR and/or FcyRllb on a number 
of potential downstream targets of Erk-MAP Kinase that might impact on growth 
arrest, such as cyclin D and p27^ '^ ^^ . The results of the ribonuclease protection 
assay (RPA) investigating the expression patterns of such key cell cycle 
regulators at the mRNA level at first appear very contradictory (Figure 5.14). 
Despite inducing proliferation, it appears as though stimulation with F(ab’)2 
fragments of anti-lg does not increase the expression of either cyclin D2 or cyclin 
D3, which is surprising as cyclin D2 has been reported to be essential for BCR- 
mediated proliferation in that cyclin D2 '^ ' B cells fail to proliferate in response to 
anti-lg stimulation (Solvason etal., 2000). Interestingly, development of 
conventional B cells in these mice was normal, however, their B-1 B cell 
compartment was significantly reduced, perhaps indicating a particular role for 
cyclin D2 in the development of this population of B cells, which are self- 
renewing (Solvason etal., 2000). The RPA only assesses mRNA levels, 
however, therefore the protein levels of cyclin D2 may increase without there 
being a detectable increase in the levels of the mRNA due to instability of the 
mRNA. Similarly, the apparent increase in p27*^ 'P^  expression in F(ab’)2 
stimulated cells after 16 hours also appears counter intuitive, as p27 '^^^
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accumulation is associated with Gi arrest. However, the regulation of p27 is 
highly complex, involving both translational control and regulation of the stability 
of the protein, so an increase in the transcription does not necessarily lead to an 
increase in the protein levels. Furthermore, although p27^ '"^  ^ is a potent inhibitor 
of cyclin E/Cdk2 complexes, it is also an essential assembly factor for cyclin 
D/CDK4 complexes, so this increase in expression could be required for the 
assembly of the cyclin D/CDK4 complex, allowing the initiation of phosphorylation 
of Rb. Further work would have to include the use of antibodies specific for key 
phosphorylated residues of Rb, such as Ser®°^  and Ser®^\ to assess fully the 
phosphorylation status of Rb in response to stimulation with F(ab’)2 fragments of 
anti-lg, both alone and in combination with intact anti-lg.
A key regulator of the mammalian cell cycle involved in the regulation of cyclin 
dependent kinase inhibitor expression and activity is the tumour suppressor 
protein, p53 (Levine, 1997). The observed activation of the p53 protein induced 
by ligation of FcyRllb (Figure 5.13B) suggests that one of the mechanisms by 
which FcyRllb induces growth arrest is via the p53 pathway. p53 plays a key role 
in cellular responses to many types of stress, including DNA damage and 
inappropriate proliferative signals, and has the ability to induce cell cycle arrest, 
DNA repair, or apoptosis, depending on a number of factors, including cell type 
(Bates and Vousden, 1996). This activation of p53 may play a role in the down­
regulation of Erk-MAPKinase activity, as it has recently been shown that the dual 
specificity protein phosphatase MKP1, which is capable of inactivating Erk- 
MAPKinase, is a transcriptional target of p53 (Li et a/., 2003). Another 
transcriptional target of p53 is the phosphatase, Pac-1, which is also capable of 
inactivating Erk-MAPKinase (Yin et a i, 2003), and which has recently been 
shown by this laboratory to be activated by FcyRllb, resulting in rapid 
dephosphorylation and inactivation of Erk-MAP Kinase, uncoupling Erk- 
MAPKinase activity from the BCR (Brown et al., 2004).
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Another functional outcome of p53 activation is apoptosis, which can also be 
induced by co-ligation of the BCR with FcyRllb. One of the earliest, non- 
reversible steps in apoptosis is the depolarisation of the mitochondrial membrane 
potential (AijJm), which can be detected using cationic lipophilic dyes such as 
DiOC(6)3 (Zamzami et a i, 1995). It appears as though the apoptosis induced by 
FcyRllb follows this mitochondrial pathway, as stimulation of B cells with intact 
antibody, either alone or in combination with F(ab’)2 fragments of anti-lg, leads to 
reduction in Ai|)m. This may be linked to the activation of p53, as p53 has been 
associated with mitochondrial function, as it has been shown to translocate to the 
mitochondria (Marchenko et a i, 2000), where it may induce a rise in oxidative 
species and degradation of mitochondrial components (Polyak et ai, 1997). p53 
is also capable of inducing the expression of Bax, a pro-apoptotic member of the 
Bcl-2 family (Miyashita and Reed, 1995), as well as negatively regulating the 
expression of Bcl-2, an anti-apoptotic member of the family (Miyashita et ai, 
1994). The results of the RPA assay investigating the expression of apoptotic 
regulators agrees with this, as p53 expression is greatly increased, and the 
western blotting studies show p53 is activated in response to FcyRllb ligation by 
phosphorylation on serine 15, abrogating the interaction between MDM2 and 
p53, presumably leading to the observed increase in the transcription of Bax 
(Figure 5.16). This strongly suggests that one mechanism by which FcyRllb 
induces apoptosis is by the activation of p53, which in turn leads to the increased 
expression of Bak which can then proceed to disrupt mitochondrial function 
(Figure 5.17).
Overall, the results obtained in this chapter further demonstrate the importance of 
T cell derived signals in the initiation and maintenance of a B cell response to 
antigen. The importance of sustained Erk-MAPKinase in promoting B cell 
proliferation is also underlined, both by studies utilising MEK inhibitors and 
studies using the FcyRllb receptor to inhibit BCR-mediated proliferation. Finally, 
the ability of FcyRllb to induce B cell energy, growth arrest and/or apoptosis can
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be explained, at least in part, by its modulation of BCR-activated cell cycle 
regulatory proteins and important apoptotic factors.
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Figure 5.1 Ligation of the BCR induces RNA synthesis in primary splenic B 
cells, and this is enhanced by helper T cell signals
Purified splenic B cells from Balb/c mice (2x10® cells/well) were stimulated for 
24 hours in the presence of the indicated agonists. Culture wells were pulsed 
with [®H]-uridine (1 (iCi/well) 4 hours prior to harvesting and [®H]-uridine 
incorporation was assessed by liquid scintillation counting. Data are the mean ± 
standard deviation of triplicate measurements from the same experiment, 
representative of at least two other independent experiments.
A Cells stimulated with increasing concentrations of F(ab’)2 fragments of goat 
anti-mouse IgM (^,-chain specific).
B Cells stimulated with increasing concentrations of F(ab’)2 fragments of goat 
anti-mouse IgM (jx-chain specific) in combination with increasing concentrations 
of anti-CD40 antibody (FGK45).
C Cells stimulated with increasing concentrations of F(ab’)2 fragments of goat 
anti-mouse IgM (n-chain specific) in combination with increasing concentrations 
of recombinant IL-4.
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Figure 5.2 BCR induced proliferation is enhanced by signals emanating
from helper T cells
Purified splenic B cells from Balb/c mice (2x10® cells/well) were stimulated for 
48 hours in the presence of the indicated agonists. Culture wells were pulsed 
with [®H]-thymidine (0.5 pCi/welt) 4 hours prior to harvesting and [^H]-thymldine 
incorporation was assessed by liquid scintillation counting. Data are the mean ± 
standard deviation of triplicate measurements from the same experiment, 
representative of at least two other independent experiments.
A Cells stimulated with increasing concentrations of F(ab’)2 fragments of goat 
anti-mouse IgM (fx-chain specific).
B Cells stimulated with increasing concentrations of F(ab’)2 fragments of goat 
anti-mouse IgM (|x-chain specific) in combination with increasing concentrations 
of anti-CD40 antibody (FGK45).
C Cells stimulated with increasing concentrations of F(ab')2 fragments of goat 
anti-mouse IgM (|x-chain specific) in combination with increasing concentrations 
of recombinant IL-4.
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Figure 5.3 BCR induced proliferation is sustained by signals emanating
from helper T cells
Purified splenic B cells from Balb/c mice (2x10® cells/well) were stimulated for 
up to 168 hours in the presence of the indicated agonists. Culture wells were 
pulsed with [®H]-thymidine (0.5 i^iCi/well) 4 hours prior to harvesting at 24, 48, 72, 
120 or 168 hours, and [®H]-thymidine incorporation was assessed by liquid 
scintillation counting. Data are the mean ± standard deviation of triplicate 
measurements from the same experiment, representative of at least two other 
independent experiments.
A Cells stimulated with P(ab’)2 fragments of goat anti-mouse IgM (p.-chain 
specific) (50 fxg/ml), anti-CD40 antibody (FGK45) (10 fig/ml), ora combination of 
both.
B Celts stimulated with F(ab’)2 fragments of goat anti-mouse IgM (p.-chain 
specific) (50 p.g/ml), recombinant IL-4 (10 U/ml), or a combination of both.
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Figure 5.4 Specific kinase inhibitors can abrogate BCR-mediated 
proliferation of murine primary splenic B cells
Purified splenic B cells from Balb/c mice (2x10^ cells/well) were stimulated with 
50 fig/ml F(ab')z fragments of goat anti-mouse IgM (fx-chain specific), either alone 
or in the presence of the MEK inhibitor PD98059 (10 jiM), the MEK inhibitor 
U0126 (1 \iM), the PI-3-Kinase inhibitor LY294002 (1 fiM), or the p38 inhibitor 
SB203580 (5 jxM), for 48 hours. Control cells were cultured in the presence of 
medium alone. Culture wells were pulsed with fH]-thymidine (0.5 jiCi/well) 4 
hours prior to harvesting and pH]-thymidine incorporation was assessed by liquid 
scintillation counting. Data are the mean ± standard deviation of triplicate 
measurements from the same experiment, representative of at least two other 
independent experiments.
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Figure 5.5 The effects of Inhibition of PDE7 on the proliferative response of
B cells to stimulation
Purified splenic B cells from Balb/c mice (2 x 10® cells/well) were stimulated for 
48 hours in the presence of the indicated agonists. The concentrations of the 
agonists were P(ab')2 fragments of goat anti-mouse IgM (50 ^g/ml), IL-4 (10 
U/ml), Anti-CD40 (10 p,g/ml), LPS (50 fxg/ml). Control cells were cultured in the 
presence of medium atone. In addition, cells were cultured in the presence of a 
variety of specific PDE7 inhibitors (10 p,M), as a control some cells received no 
PDE7 inhibitor. Culture wells were pulsed with [^H]-thymidine (0.5 pCi/well) 4 
hours prior to harvesting and [®H]-thymidine incorporation was assessed by liquid 
scintillation counting. Data are the mean ± standard deviation of triplicate 
measurements from a single experiment, representative of at least one other 
independent experiment.
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Figure 5.6 The effects of the PDE7 inhibitors PD0322408 and PD0326875 on 
the proliferative responses of B cells to stimulation
Purified splenic B cells from Balb/c mice (2 x 10® cells/well) were stimulated for 
48 hours in the presence of the indicated agonists. The concentrations of the 
agonists were P(ab’)2 fragments of goat anti-mouse IgM (50 fig/ml), IL-4 (10 
U/ml), Anti-CD40 (10 jxg/ml), LPS (50 fxg/ml). Control cells were cultured in the 
presence of medium alone. In addition, cells were cultured in the presence of a 
the specific PDE7 inhibitors PD0322408 or PD0326875 over a range of 
concentrations (0 .01 , 0.1, 1, and 10 p,M). As a control some cells received no 
PDE7 inhibitor, whilst others received the specific PDE4 inhibitor, rolipram (10 
|j,M). Culture wells were pulsed with [^H]-Thymidine (0.5 jxCi/well) 4 hours prior to 
harvesting and [^H]-incorporation was assessed by liquid scintillation counting. 
Data are the mean ± standard deviation of triplicate measurements from a single 
experiment, representative of at least one other independent experiment.
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Figure 6.7 The effects of inhibition of PDE7 on the viability of B cells in 
response to antigenic stimulation
Purified splenic B ceils from Balb/c mice (1 x 10® cells/well) were stimulated for 
48 hours with 50 fxg/ml F(ab’)2 fragments of goat anti-mouse IgM (ji-chain 
specific), either alone (2) or in combination with anti-CD40 (10 |xg/ml) (4), or with 
LPS alone (50fig/ml) (3), in the presence of various specific PDE7 inhibitors (10 
p,M). Control cells were cultured in the presence of medium alone (1). DNA 
content was determined by propidium iodide (PI) staining and FACS analysis, as 
described in Materials and Methods. Data represents each cell cycle stage 
expressed as a percentage of the total cells analysed from a single experiment, 
representative of at least one other independent experiment.
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Figure 5.8 Effect of prolonged BCR and PcyRIIb co-ligation and the MEK 
inhibitor PD98059 on the phosphorylation of Erk-MAPKinase
A Purified splenic B cells from Balb/c mice (2 x 10® cells/well) were stimulated in 
the presence of 50 }xg/ml F(ab’)2 fragments of goat anti-mouse IgM (fx-chain 
specific), in the presence or absence of the MEK inhibitor PD98059 (10 p-M), for 
the times indicated. Control cells were cultured in the presence of medium alone. 
Whole cell lysates were subjected to Western blot analysis with phospho-specific 
Erk-MAPKinase antibody.
B Purified splenic B cells from Balb/c mice (2 x 10® cells/well) were stimulated in 
the presence or absence of 50 fxg/ml F(ab')2 fragments of goat anti-mouse IgM 
(fx-chain specific), in the presence or absence of the MEK inhibitor PD98059 (10 
f.iM), for 24 hours. Control cells were cultured in the presence of medium alone. 
Whole cell lysates were subjected to Western blot analysis with phospho-specific 
Erk-MAPKinase antibody.
C Purified splenic B cells from Balb/c mice (2 x 10® cells/ml) were stimulated in 
the presence of 50 |xg/ml F(ab')2 fragments of goat anti-mouse IgM (^x-chain 
specific), in the presence or absence of the MEK inhibitor PD98059 (10 fxM), for 
16 hours. Control cells were cultured in the presence of medium alone. Cells 
were adhered to slides, fixed and permeabilised, then stained for phospho-Erk 
and the nucleus stained with DAPI, as described in Materials and Methods. 
Images were acquired using the LSC with Openlab 3.0.9 software (Improvision, 
Coventry, U.K.). Phospho-Erk appears as green, the nucleus appears as blue.
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Figure 5.9 FcyRlib co-ligation inhibits BCR-mediated B cell proliferation, 
which can be restored in the presence of a blocking anti-FcvRII/lll antibody
Purified splenic B cells from Balb/c mice (2 x 10® cells/well) were stimulated for 
48 hours in the presence of the indicated antibodies. Control cells were cultured 
in the presence of medium alone. Culture wells were pulsed with [®H]-thymidine 
(0.5 |xCi/welI) 4 hours prior to harvesting and [^H]-thymidine incorporation was 
assessed by liquid scintillation counting. Data are the mean ± standard deviation 
of triplicate measurements from a single experiment, representative of at least 
two other independent experiments.
A Cells stimulated with increasing concentrations of F(ab’)2 fragments of goat 
anti-mouse lgM([x-chain specific).
B Cells stimulated with increasing concentrations of intact rabbit anti-mouse 
IgG/lgM.
C Cells stimulated with increasing concentrations of F(ab’)2 fragments of goat 
anti-mouse IgM (jx-chain specific) in combination with increasing concentrations 
of intact rabbit anti-mouse IgG/lgM.
D Cells stimulated with 50 p,g/ml F(ab’)2 fragments of goat anti-mouse IgM or 75 
^ig/ml intact rabbit anti-mouse IgG/lgM or 50 ^g/ml anti-FcyRll/lll (2.4G2) 
antibody either alone, or in combination, as indicated.
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Figure 5.10 Effects of BCR and FcyRlib co-ligation on the DNA content of
splenic B cells from Balb/c mice
Purified splenic B cells from Balb/c mice (1 x 10® cells) were stimulated in the 
presence of 50 ^g/ml F(ab’)2 fragments of goat anti-mouse IgM (^-chain specific) 
or 75 [xg/ml intact rabbit anti-mouse IgG/lgM either alone, or in combination, for 
the times indicated. As a control, an aliquot of cells was removed prior to any 
stimulation to permit DNA content analysis of unstimulated cells. DNA content 
was determined by propidium iodide staining and FACS analysis, as described in 
Materials and Methods. Data represents each cell cycle stage expressed as a 
percentage of the total cells analysed from a single experiment, representative of 
at least two other independent experiments.
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Figure 5.11 Effect of BCR and FcyRlib co-ligation on the phosphorylation of
Erk-MAPKinase
Purified splenic B cells from Balb/c mice (1x10^ cells) were stimulated in the 
presence of 50 jxg/ml P(ab’)2 fragments of goat anti-mouse IgM (ji-chain specific), 
either alone or in combination with 75 p,g/ml intact rabbit anti-mouse IgG/lgM, for 
the times indicated. Cells stimulated in the presence of medium alone were 
included as a control. Whole cell lysates were subjected to Western blot analysis 
with phospho-specific Erk-MAPKinase antibody (upper panel). Blots were 
stripped and reprobed with total Erk-MAPKinase antibody (lower panel).
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Figure 5.12 Effect of BCR and FcyRlib co-ligation on the localisation of Erk-
MAPKinase
Purified splenic B cells from Balb/c mice (2 x 10® cells/ml) were stimulated in the 
presence of 50 jig/ml F(ab’)2 fragments of goat anti-mouse IgM (p,-chain specific), 
either alone or in combination with 75 \ig/m\ intact rabbit anti-mouse IgG/lgM, in 
the presence or absence of the MEK inhibitor PD98059 (10 jiM), for the times 
indicated. Control cells were cultured in the presence of medium alone. Cells 
were adhered to slides, fixed and permeabilised, then stained for ganglioside 
Gmi, phospho-Erk (with a monoclonal phospho-Erk antibody) and the nucleus 
stained with DAPI, as described in Materials and Methods. Images were acquired 
using the LSC with Openlab 3.0.9 software (Improvision, Coventry, U.K.). 
Ganglioside G m i appears as red, phospho-Erk appears as green, and the 
nucleus appears as blue.
i Unstimulated, no PD908059
ii F(ab')z fragments of anti-lg, no PD98059
iii F(ab’)2 fragments of anti-lg + Intact antibody, no PD98059
iv Unstimulated, plus PD908059
V F(ab’)2 fragments of anti-lg, plus PD98059
vi F(ab’)2 fragments of anti-lg + Intact antibody, plus PD98059
263
1 Hr
4 Hr
20 Hr
Figure 5.13 FcyRlib ligation modulates BCR-mediated phosphorylation of
Rb and p53.
Purified splenic B cells from Balb/c mice (1 x 10  ^cells) were stimulated in the 
presence of 50 fxg/m! F(ab')2 fragments of goat anti-mouse IgM (^-chain specific) 
or 75 }xg/ml intact rabbit anti-mouse IgG/lgM either alone, or in combination, for 
the times indicated. Cells stimulated in the presence of medium alone were 
included as a control.
A Whole cell lysates (50 ^g/lane) were subjected to Western blot analysis with an 
anti-Rb antibody.
B Anti-p53 immune precipitates were subjected to Western blot analysis with a 
monoclonal anti-phospho-p53 (ser15) antibody, stripped and reprobed with an 
anti-p53 antibody.
0 Whole cell lysates (50 |ig/lane) were subjected to Western blot analysis with an 
anti-Cdk4 antibody.
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Table 5.1 The multi-probe template set used In the RPA analysis
A list of the genes included in the mutli-probe template set used in the 
ribonuclease protection assay, including the size, in nucleotides, of the probe, 
and the size of the protected fragments after digestion.
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Gene Probe Protected
CDK1 459 430
CDK2 417 388
FasL 381 352
p53 345 316
BcI-Xl 299 272
Bak 231 202
Cyclin D2 210 181
Cyclin D3 189 160
p27 172 143
L32 141 112
GAPDH 125 97
Figure 5.14 Expression profiles of key cell cycle regulatory genes alter in
response to BCR ligation and co-ligation with FcyRllb
Purified splenic B cells from Ba!b/c mice (1x10^ cells) were stimulated in the 
presence of F(ab’)2 fragments of goat anti-mouse IgM (pi-chain specific) (50 
ji,g/ml), either alone or in combination with intact rabbit anti-mouse IgG/IgM (75 
^g/ml), for the times indicated. Cells stimulated in the presence of medium alone 
were included as a control. Total RNA was isolated from the cells at the times 
indicated, and the expression of key proteins assessed by means of the 
ribonuclease protection assay (RFA), as described in Materials and Methods 
(Section 2.16). The multi-probe template set used is shown in Table 5.1. Data 
were quantified using a Storm phosphorimager.
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Figure 5.15 FcyRllb-mediated mechanisms of B cell inhibition result in a 
decrease in mitochondrial membrane potential
Purified splenic B cells from Balb/c mice (1 x 10® cells) were stimulated in the 
presence of 50 ^g/ml F(ab’)2 fragments of goat anti-mouse IgM (fx-chain specific) 
or 75 fig/ml intact rabbit anti-mouse IgG/IgM alone, or in combination as 
indicated for 72 hours. Cells stimulated in the presence of medium alone were 
included as a control. The mitochondrial membrane potential was determined by 
DiOC6(3) staining and FACS analysis, as described in Materials and Methods. 
Data represents the DiOCeCS)^ ®'''' cell population, as determined on a logarithmic 
FL-1 axis, and expressed as a percentage of the total cells analysed of a single 
experiment and representative of at least two other independent experiments.
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Figure 5.16 Expression profiles of key apoptosis regulatory genes alter in
response to BCR ligation and co-ligation with FcyRllb
Purified splenic B cells from Balb/c mice (1x10^ cells) were stimulated in the 
presence of P(ab’)2 fragments of goat anti-mouse IgM (fx-chain specific) (50 
fxg/ml), either alone or in combination with intact rabbit anti-mouse IgG/IgM (75 
|xg/ml), for the times indicated. Cells stimulated in the presence of medium alone 
were included as a control. Total RNA was isolated from the cells at the times 
indicated, and the expression of key proteins assessed by means of the 
ribonuclease protection assay (RPA), as described in Materials and Methods 
(Section 2.16). The multi-probe template set used is shown in Table 5.1 Data 
were quantified using a Storm phosphorimager.
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Figure 5.17 Effect of BCR and FcyRllb co-ligation on the activity of p53 and 
Bak, and the consequences upon the mitochondria
Co-ligation of the BCR with FcyRllb results in the inhibition of BCR-induced Erk- 
MAPKinase activity (1), and an increase in the activity of the tumour suppressor 
protein p53 (2). The inhibition of BCR-induced Erk-MAPKinase activity is dual- 
pronged, with both the recruitment of p62 °^"  ^to inhibit Ras activity, and the 
induction of expression of a transcription target of p53, the phosphatase Pac-1, 
which dephosphorylates and inactivates Erk-MAPKinase directly. The increase in 
p53 activity may also lead to an increase in expression of the pro-apoptotic Bcl-2 
family member, Bak (3), and a concomitant decrease in mitochondria! membrane 
potential (4), an early, irreversible step in the apoptosis pathway.
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Chapter 6 - General Discussion
B ceils are the principal cellular mediators of the specific humoral response to 
infection by bacteria, viruses and parasites as they are the cells that produce 
antigen-specific antibodies. During B cell development, however, the response of 
B cells to antigen encounter changes drastically. Immature B cells generally 
respond to antigen by undergoing negative selection, whereas mature B cells are 
usually activated by antigen. Immature B cells do not always undergo negative 
selection, however, as in vivo the presence of other, extrinsic signals can lead to 
alternative fates. One of these signals is mediated through CD40, which can 
induce rescue from BCR-mediated growth arrest and apoptosis. This is most 
likely to occur in the periphery rather than the bone marrow, as B cells maintain 
the immature B cell phenotype for several days after exit into the periphery to 
ensure any B cells that are specific for self-antigens expressed in the periphery 
and not the bone marrow are negatively selected (Carsetti et al., 1995). The 
ability of CD40 to mediate rescue from BCR-induced growth arrest and apoptosis 
would allow for recruitment of antigen-specific immature B cells into an ongoing 
immune response where T cell help already exists (Monroe, 2000).
The work presented in this thesis has focused on identifying the important 
signalling mechanisms linking BCR ligation with regulation of the cell cycle and 
induction of apoptosis in immature and mature B lymphocytes. In particular, 
investigations in Chapter 3 focused on the role of the Erk-MAPKinase pathway in 
anti-lg induced growth arrest and apoptosis of immature B cells, and CD40- 
mediated rescue of these effects, by investigating the function of the small 
GTPase, Ras. Chapter 4 set out to ascertain the roles individual PKC isoforms, 
known to regulate Erk-MAPKinase activity in a number of systems, might play in 
the regulation of growth arrest and apoptosis in immature B lymphocytes, by 
utilising constitutively active or kinase dead mutants of individual PKC family 
members. Finally, in Chapter 5, the emphasis switched to mature B cells, and the 
signalling mechanisms important for the initiation and maintenance of a
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proliferative response in mature B cells, as well as the key signalling events 
involved in FcyRllb mediated inhibition of BCR-mediated proliferation and how 
these affect the key controllers of the cell cycle.
6.1 The role of the small GTPase Ras in WEHI-231 cells
The early signalling mechanisms activated upon ligation of the BCR under 
conditions leading to proliferation or apoptosis appear to be very similar, with 
phospholipase C, PI-3 kinase and Erk-MAPKinase all being activated under both 
circumstances. However, we have shown that although BCR ligation of WEHI- 
231 cells results in early stimulation of Erk-MAPKinase activity, in the long term it 
leads to down-regulation of Erk-MAPKinase activity. In contrast, co-stimulation 
with anti-lg and anti-CD40 re-establishes sustained, cycling Erk activity, driving 
proliferation of the cells. This temporal regulation of Erk-MAPKinase activity to 
induce differential responses is becoming evident in a number of other systems, 
for example in PC 12 cells transient activation of Erk-MAPKinase results in 
proliferation, whilst sustained MAPKinase activation induces differentiation (York 
et a/., 1998). Furthermore, the location of the Erk-MAPKinase activity is also 
thought to play a role in determining the outcome of the signal, though generally 
speaking this is linked to the duration of the signal as sustained activation is 
associated with translocation to the nucleus (Liang ef a/., 2002). It would be very 
interesting to ascertain the intracellular location of the both the transient Erk- 
MAPKinase activity and the sustained Erk-MAPKinase activity in WEHI-231 cells, 
in order to establish whether the location of the signal, as well as the duration, is 
playing a role in determining the outcome. As WEHI-231 cells are rather small, 
confocal microscopy would be a better method for determining this than LSC, as 
the resolution of confocal microscopy is much greater.
It is interesting to speculate as to the nature of the targets of Erk-MAPKinase 
activity in B cells under the differential functional outcomes of apoptosis versus 
prolfieration. The Erk-MAPKinase has been shown to promote proliferation by
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inducing the expression of cyclin D1 (Lavoie et a i, 1996). However, it has been 
suggested that cyclin D1 is not expressed in B cells, and that cyclin D2 is the 
major D type cyclin involved in the regulation of proliferation of B cells (Solvason 
et ai, 2000). Other proliferative targets for Erk-MAPKinase are numerous, and 
include both the RNA pol I and RNA pol III transcription machinery (Felton- 
Edkins et a i, 2003; Stefanovsky et ai, 2001). Transcription by RNA pol I and pol 
III have to be tightly linked, as ribosomes require an equimolar ratio of rRNAs, so 
it seems likely that Erk-MAPKinase plays a role in co-ordinating production of 
ribosomes, which are necessary for growth and cell cycle progression 
(Stefanovsky et a i, 2001). It would be interesting to assess ribosome production 
in both anti-lg and anti-lg plus anti-CD40 stimulated WEHI-231 cells, to 
determine if the different Erk-MAPKinase signals affect transcription by RNA pols 
I and III in different manners. Phosphorylation and concomitant activation of 
certain ribosomal S6 kinase isoforms (RSK1-3) by Erk-MAPKinase has also been 
postulated to be important for the regulation of translation (Frodin and 
Gammeltoft, 1999). Moreover, one substrate of RSK, and Erk-MAPKinase, is 
Sos, with phosphorylation of Sos leading to dissociation of the Grb2-Sos-Ras 
complex, perhaps a negative feedback loop. Investigation of the activation of 
RSK may also provide clues as to the differential targets of the transient and 
sustained Erk-MAPKinase activity, as anti-lg induced Erk-MAPKinase may 
activate RSK, leading to the down-regulation of Erk-MAPKinase activation by the 
dissociation of the Grb2-Sos-Ras complex. This does not appear to be the case 
in WEHI-231 cells, as results in this laboratory have demonstrated that BCR 
ligation abrogates Erk-MAPKinase activity not by affecting upstream regulators, 
but rather by activating phosphatases such as Pac-1, to inactivate Erk- 
MAPKinase directly (Gauld et a i, 2002).
The small GTPase Ras, a key regulator of Erk-MAPKinase and PI-3-kinase, also 
seems to play an important role in both anti-lg induced growth arrest and 
apoptosis, and CD40-mediated rescue. For example, a constitutively active Ras 
mutant, RasV12, appears to reduce anti-lg induced grov\4h arrest, enabling
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WEHI-231 cells to continue proliferating in the presence of anti-lg, presumably 
because it can restore, at least to a certain extent, sustained, cycling Erk- 
MAPKinase activity. Interestingly, a constitutively active mutant of Ras that can 
activate the PI-3-kinase pathway but not the Erk-MAPKinase pathway, RasV12- 
C40, also reduces anti-lg induced growth arrest. Interestingly, these cells also 
display sustained, cycling Erk-MAPKinase activity, suggesting that Erk- 
MAPKinase can be activated downstream of PI-3-Kinase, as reported elsewhere 
for B cells and other systems (Jacob et a/., 2002). One of the major substrates of 
PI-3-kinase is the serine/threonine protein kinase Akt (also known as PKB), 
which has been shown to be a powerful mediator of growth factor-induced 
survival and is capable of suppressing apoptosis induced by a wide range of 
stimuli (Datta eta!., 1997). PI-3-kinase activity has also been shown to be 
required for progression from Gi phase of the cell cycle to S phase in fibroblasts 
(Jones eta!., 1999), and previous studies in our laboratory suggest a positive 
role for PI-3-kinase in proliferation of unstimulated WEHI-231 cells, as inhibition 
of PI-3-kinase induces growth arrest (Gauld, 2001). This strongly suggests that 
the PI-3-kinase pathway plays a role in the proliferation and CD40-mediated 
survival of WEHI-231 cells.
The data presented in Chapter 3 showed that the Ras mutants only partially 
rescued anti-lg mediated growth arrest. This may simply reflect that although the 
Ras mutants generate constitutively active Ras signals, this was not reflected in 
terms of constitutive Erk-MAPKinase activity. However, sustained Erk- 
MAPKinase activation was partially restored (Cathona Ford, personal 
communication), thus it would be interesting to ascertain the kinetics of anti-lg 
induced effects, or lack thereof, in WEHI-231 cells expressing these RasV12 
mutants, in light of the observations that WEHI-231 cells transfected with PKC 
mutants exhibit different responses at 24 and 48 hours (Chapter 4). Indeed, 
preliminary experiments suggest that, at 24 hours, all three RasVI 2 mutants 
abrogate anti-lg induced growth arrest more efficiently than at 48 hours, as these 
cells exhibit similar levels of proliferation in the absence or presence of anti-lg.
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even at 10 [ig/ml (Figure 6.1). This suggests that the kinetics of anti-lg induced 
growth arrest are altered by expression of these constructs, as anti-lg does 
induce growth arrest in these cells at 48 hours, yet in cells containing the empty 
vector growth arrest is demonstrated as early as 24 hours. It would be interesting 
to study the proliferation of these cells at a number of time points between 24 
and 48 hours, as well as the number of divisions these cells undergo.
The down regulation of sustained, cycling Erk-MAPKinase activity by anti-lg 
stimulation of WEHI-231 cells does not seem to depend upon position of the cell 
in the cell cycle, as anti-lg can induce growth arrest and inhibit Erk activity 
following arrest and release of cells in either Gi or S phase. It would, however, 
be interesting to synchronise WEHI-231 cells transfected with the various 
RasVI2 constructs to further investigate whether the effects these molecules 
have on anti-lg mediated growth arrest and apoptosis are dependent upon cell 
cycle stage. In particular, it would be very interesting to determine if the cells can 
undergo apoptosis from any cell cycle phase, or if they have to transit to Gi in 
order to apoptose. For example, when B cells are infected with the protozoan 
apicomplexan parasite, Theileria, they require parasite survival for the observed 
oncogenic transformation. Thus, when the parasite is killed, the cells apoptose, 
but they can only do so from Gi, whereas T cells in the same circumstances can 
undergo apoptosis at any stage of the cell cycle (Gordon Langsley, Institut 
Pasteur, Paris, personal communication). It would also be interesting to 
determine whether the cellular localisation of p27 differs as the cells proliferate, 
as the localisation of p27 determines its function. In the cytoplasm, p27 interacts 
with cyclin D/CDK complexes, acting as an essential assembly factor, whereas in 
the nucleus, p27 interacts with cyclin E/CDK2, inhibiting the kinase activity and 
blocking cell cycle progression. It has recently been proposed that Akt, a major 
effector of PI-3-kinase, impairs nuclear import of p27, thus abrogating the ability 
of p27 to induce Gi arrest (Liang et al., 2002).
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Thus, this study has demonstrated a key role for the Erk-MAPKinase in anti-lg 
induced growth arrest and apoptosis, as well as CD40-mediated rescue of anti-lg 
induced effects in WEHI-231 cells. It has also established the ability of 
constitutively active Ras mutants to alter the normal biological response of 
WEHI-231 cells to antigen, as well as indicating a role for PI-3-kinase in CD40- 
mediated rescue of anti-lg induced apoptosis. This study has also suggested that 
the 5’ inositol phosphatase, SHIP, does not play a significant role in the 
regulation of anti-lg induced effects in WEHI-231 cells, unlike in mature B cells 
where SHIP is thought to be a major negative regulator of anti-lg induced 
proliferation.
6.2 The role of PKC isoforms in WEHI-231 cells
Upon ligation with antigen the B cell receptor activates a number of signalling 
pathways to mediate a response. One of the first pathways shown to be activated 
by the BCR was phospholipase Gy, which results in the generation of the second 
messenger DAG, a key regulator of both the conventional PKCs and the novel 
PKCs. This suggests a key role for PKC family members in BCR signalling. 
Indeed, BCR cross-linking on mature B cells leads to strong activation of PKCs, 
whereas ligation of the BCR on immature B cells does not, providing a possible 
explanation for the differential responses to BCR cross-linking in mature and 
immature B cells (Sarthou et ai, 1989). As a consequence, it has been proposed 
that BCR uncoupling from PKC activation may be a major factor in anti-lg 
induced growth arrest and apoptosis in immature B ceils. This is consistent with 
the finding that treatment of WEHI-231 cells with PMA, a potent activator of most 
PKC isoforms, protects them from anti-lg induced growth arrest and apoptosis 
(Gold and DeFranco, 1987).
The activation of PKCs is also linked to the upstream activity of PI-3-kinase, as 
Pl-3-kinase activity produces PIP3, which recruits Btk to the plasma membrane 
where it can proceed to activate PLCy, resulting in the production of DAG, which
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is required for activation of the conventional and novel PKCs. The importance of 
PI-3-kînase and Btk in PLCy2 activation are evidenced by the similarity in 
phenotype of p1100-deficient mice (the major PI-3-kinase catalytic subunit found 
in B cells), PLCy2 deficient mice and xid im mu nodeficient mice, which have a 
mutation in the PIP3 binding domain of Btk, preventing its recruitment and 
concomitant activation of PLCy (Okkenhaug e/a/., 2002; Rawlings e/a/., 1993; 
Wang et a/., 2000). The downstream targets of PKC isoforms are manifold, and 
include the Erk-MAPKinase pathway, via both Raf, which is upstream of MEK 
(Cacace et a/., 1996), and the Grb-2/Sos adaptor complex, which is involved in 
Ras activation (Kawakami e/a/., 2003).
Expression of most of the PKC isoforms In WEHI-231 B cells led to an Increase 
in phosphorylation of Erk-MAPKinase. A recently isolated member of the CDC25 
family of Ras GEFs, RasGRPS, which is also recruited to the plasma membrane 
by DAG, is preferentially expressed in B cells, and has been proposed to be a 
downstream target of PKC isoforms (Teixeira e/a/., 2003). It would be interesting 
to investigate the role of RasGRPS in WEHI-231 cells transfected with these PKC 
constructs, as one of the major roles of RasGRP3 is to activate Ras. Indeed,
PKC inhibitors that block phosphorylation of RasGRPS also attenuate Ras/Erk- 
MAPKinase signalling in Ramos B cells (Teixeira e/a/., 2003).
With reference to the individual PKC isoforms, PKCa has been proposed to play 
a positive role in proliferation and an anti-apoptotic role in a number of cell types. 
Thus, overexpression of a catalytically active PKCa in NIH-3T3 cells results in 
increased expression of cyclins D1 and E and a concomitant increase in 
proliferation (Soh and Weinstein, 2003). However, it has been reported that 
cyclin D1 is not expressed in B lymphocytes, cyclin D2 being the predominant 
isoform in B cells (Solvason et a/., 1996), yet there was no evidence of an 
increase in cyclin D2 expression in WEHI-231 cells expressing a constitutively 
active PKCa mutant (Figure 3.16). It has recently been reported, however, that 
cyclin D2 ^  mice display normal conventional B cell development, suggesting
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perhaps that cyclin D3 is more important than cyclin D2 for B cell development, 
or can at least fulfil the role of cyclin D2 in the absence of cyclin D2 (Solvason et 
a!., 2000). It would be interesting to investigate the expression patterns of cyclin 
D3 in WEHI-231 cells.
The results obtained did not highlight a clear cut unifying role for a particular 
element in the regulation of immature B cell apoptosis and proliferation.
However, a number of PKC isofbrms have been implicated in the regulation of 
NF-kB, a key regulator of survival in B lymphocytes (Gerondakis and Strasser, 
2003). Therefore, it would be interesting to assess the ability of WEHI-231 cells 
expressing PKC mutants to activate NF-xB-mediated transcription, as anti-lg 
Induced apoptosis involves down-regulation of NF-kB activity, whilst one 
mechanism by which CD40 mediates survival is through the induction of NF-kB 
activity (Schauer etaL, 1996). It must be noted, however, that the results 
obtained in this study do not fully support the hypothesis that the differential 
responses of immature and mature B cells are a result of uncoupling of the BCR 
from PKC activation in immature B cells, though expression of most of these 
PKC constructs did provide a level of protection from anti-lg induced growth 
arrest at 24 hours.
6.3 Maintenance of activation of mature B cells
Mature B cells generally respond quite differently to BCR ligation than immature 
B cells. Upon ligation of the BCR on mature B cells, they undergo proliferation, 
which can lead to differentiation to effector memory or plasma cells. Under 
physiological conditions, an optimal B ceil response generally requires signals 
from helper T cells, such as IL-4 and CD40L, which provide positive signals to 
the cell to enhance proliferation. In contrast, there are also factors that negatively 
regulate B cell proliferation, such as those signals emanating from the FcyRllb 
receptor, a low affinity IgG receptor. Co-ligation of the BCR and FcyRllb leads to 
the inhibition of BCR-triggered B cell activation and cell cycle arrest. This
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mechanism is important for quenching a specific B cell response at an 
appropriate time. Thus, the immune system Is capable of terminating a response 
once the pathogenic agent has been cleared.
Besides the key roles Erk-MAPKinase plays in the responses of immature B cells 
to antigen, as evidenced by its importance in the WEHI-231 cell line, Erk- 
MAPKinase also plays a major role in the response of mature B cells to antigen, 
despite the fact that these two responses are very different. The fact that 
inhibition of MEK abrogates F(ab')z induced proliferation strongly suggests that 
Erk-MAPKinase is a major player in initiation and maintenance of proliferation in 
these cells. The importance of Erk-MAPKinase in BCR-induced proliferation in 
mature B cells is further underlined by the actions of the FcyRllb receptor, which 
negatively regulates BCR-mediated proliferative signalling. One of the 
mechanisms by which FcyRllb achieves this is the rapid inactivation of Erk- 
MAPKinase activity. Not only is the initial inactivation of Erk-MAPKinase activity 
rapid, it is prolonged, with Erk-MAPKinase activity remaining undetectable after 
20 hours. In contrast, cells stimulated with F(ab’)2 fragments of anti-lg antibodies 
exhibit a sustained activation of Erk-MAPKinase activity, in much the same way 
that proliferating WEHI-231 cells exhibit sustained activation of Erk-MAPKinase. 
Indeed, when WEHI-231 cells are stimulated with anti-lg, which induces growth 
arrest, the sustained nature of the Erk-MAPKinase activation is lost, comparable 
to co-ligation of the BCR with the FcyRllb in mature B cells, demonstrating a key 
role for sustained Erk-MAPKinase activity in promoting B cell survival and 
proliferation in both immature and mature B cells. It would be interesting to 
further study the localisation of this sustained Erk-MAPKinase activity in mature 
B cells, to determine whether, as in HEK293 cells, sustained activation of Erk- 
MAPKinase is associated with translocation of Erk to the nucleus (Shah et al., 
2003). The LSC is not the ideal instrument for this, as the resolution is not as 
good as that afforded by confocal microscopy, and mature B cells are very small 
in size, so high resolution is required for an accurate assessment of intracellular 
localisation of proteins.
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The effects that BCR ligation and co-ligation of the BCR with FcyRllb have on the 
expression patterns of key cell cycle regulatory proteins potentially downstream 
of Erk-MAPKinase signalling are very interesting. Thus, the pattern of Rb 
phosphorylation correlates with the observed biological responses of the cells at 
each time point, with BCR ligation seemingly inducing hyper-phosphorylation of 
Rb, which is required for proliferation. On the other hand, cells that have their 
BCRs co-ligated with FcyRllb, which results in inhibition of B cell proliferation, 
possess hypo-phosphorylated Rb, which correlates with growth arrest. It also 
appears that co-ligation of the BCR with FcyRllb results in the activation of the 
tumour suppressor protein p53, which is known to possess both apoptotic and 
growth inhibitory functions. These results suggest that Rb and p53 may play key 
roles in the mechanisms by which FcyRllb exerts its growth arrest and apoptotic 
effects.
Another key regulator of the cell cycle is the CKI, p27, which induces Gi arrest by 
inhibiting the cyclin E/CDK2 complex. The role of p27 in regulating B cell 
responses appears to be non-classical, however. Thus, stimulation of B cells with 
F(ab’)2 fragments of anti-lg, which induces proliferation, also induces a strong 
increase in the transcription of the p27‘^ *^  ^ gene. As stated above, the regulation 
of p27 expression is highly complex, and involves both translational control and 
regulation of the stability of the protein. The translation of p27 is negatively 
regulated by Rho (Vidal et al., 2002), and the stability of the protein is regulated 
by both ubiquitin-dependent degradation by the proteasome (Montagnoli et al., 
1999) and degradation by calpain (Patel and Lane, 2000). Thus, an increase in 
the translation of the mRNA may not necessarily lead to an increase in the levels 
of protein, therefore one future experiment would be to assess the levels of the 
p27 protein. If the protein levels also show an increase, it could be that in B cells 
p27 plays an important role in the assembly of cyclin D/CDK4 complexes, as 
opposed to the inhibition of cyclin E/CDK2 complexes. As mentioned previously, 
the subcellular localisation of p27 also regulates its activity, therefore if the
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protein levels do show a rise, it would be important to assess the location within 
the cell, either by western blotting of specific subcellular fractions, or by confocal 
microscopy.
It seems highly likely that p53 plays a role in FcyRllb mediated apoptosis of 
mature B cells, as not only is it strongly upregulated at the mRNA level, but it is 
also activated by phosphorylation on serine 15, a key indication of activation, in 
response to ligation of FcyRllb. Moreover, transcription of one of its downstream 
targets, the pro-apoptotic Bcl2 family member Bak, is also induced. This 
suggests that one mechanism utilised by FcyRllb to initiate apoptosis is the 
activation of p53, and the subsequent increase in the levels of Bak. This 
proceeds to induce a drop in the mitochondrial membrane potential, and 
subsequently apoptosis.
Though interesting, the RPA results require a degree of validation, as they 
represent a single experiment. This would preferably be repeated, and perhaps 
also supported with western blotting analysis to assess protein levels, as mRNA 
need not necessarily directly reflect the amount of protein, particularly of key celt 
cycle regulatory proteins which are strictly regulated at the mRNA level as well as 
protein stability, such as p27 (Montagnoli etaL, 1999; Vidal e/a/., 2002).
Overall, this study has further demonstrated the importance of T cell derived 
signals in the initiation and maintenance of a B cell response to antigen. The 
importance of the Erk-MAPKinase in mature B cells, as well as immature B cells, 
is also underlined, as proliferation of both immature and mature B cells is 
associated with sustained activation of Erk-MAPKinase. It has also suggested a 
link between FcyRllb, p53, Bak and apoptosis.
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6.4 Concluding remarks
This project has examined the differential roles of Erk-MAPKinase signalling in 
immature and mature B cells. In particular, the roles of differential Ras signals 
and the impact of specific PKC isoforms on these pathways have been 
investigated in the response of immature transitional B cells to BCR ligation and 
CD40 mediated rescue of BCR-induced growth arrest and apoptosis. These 
studies demonstrated that the differential regulation of Ras signals by the BCR 
and CD40 is important for determining the functional biological outcome of 
ligation of these receptors. For example, the Ras effector, PI-3-Kinase, appears 
to play a major role in B cell proliferation and survival, perhaps through its 
modulation of p27 activity. A key role for sustained, cycling Erk-MAPKinase 
activity in the proliferation of immature B cells was also demonstrated. Consistent 
with this, the study also highlighted a key role for sustained Erk-MAPKinase 
activity in the proliferation of mature B cells, along with downstream roles for the 
tumour suppressor proteins Rb and p53 in the regulation of proliferation and 
survival of mature B cells, particularly with respect to FcyRllb-mediated negative 
feedback inhibition of BCR signalling.
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Figure 6.1 Effects of overexpression of RasVI2 mutants on anti-lg-induced
growth arrest in WEHI-231 cells
WEHI-231 cells (1 X 10* cells/well) transfected with either pcDNA3.1.RasVI2, 
pcDNA3.1, RasVI 2-S35, pcDNA3.1.RasVI2-C40 or the pcDNAS.1 vector were 
cultured, in triplicate, in the presence of increasing concentrations of anti-lg 
(0.01, 0.1, 1, 10 jixg/ml), for 24 hours. Control cells were cultured in the presence 
of medium alone. Culture wells were pulsed with pH]-thymidine (0.5 pCi/well) 4 
hours prior to harvesting and pH]-incorporation was assessed by liquid 
scintillation counting. Data from individual experiments were normalised by 
expressing the mean [^H]-thymidine uptake values of anti-lg treated cells as a 
percentage of those obtained with control cell cultures. The normalised values 
from at least 2 independent experiments were then pooled and expressed as 
means ± sem.
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Figure 6.2 Integrated signalling mechanisms responsible for the induction
of apoptosis and growth arrest, and CD40-mediated rescue, in WEHI-231
cells
The differential responses of immature B cells to BCR ligation in the presence 
and absence of T cell derived signals are mediated by a complex network of 
signalling pathways enabling the growth arrest and apoptosis, or proliferation and 
survival decision of WEHI-231 cells to be carefully regulated. Stimulation via the 
BCR leads to a strong, but transient activation of Erk-MAPKinase followed by 
desensitisation of sustained, cycling Erk-MAPKinase activity, possibly due to the 
induction of the phosphatase Pac-1, which results in growth arrest and apoptosis. 
Expression of PKCô or PKC^ appear to enable stimulation via the BCR alone to 
lead to sustained activation of Erk-MAPKinase, which normally leads to 
proliferation (1). Constitutive activation of the small GTPase Ras can provide 
some measure of protection from anti-lg induced growth arrest, mediated, at 
least in part, by PI-3-Kinase and the subsequent induction of the anti-apoptotic 
Bcl-2 family member, BcI-Xl. Interestingly, constitutive activation of Ras does not 
result in constitutive activation of Erk-MAPKinase, possibly as a consequence of 
the actions of phosphatases, including Pac-1, which can deactivate Erk- 
MAPKinase by removing key phosphoryl residues.
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Figure 6.3 Inhibition of BCR induced proliferation by FcyRllb mediated 
signals
Ligation of the BCR on mature B cells leads to sustained activation of the Erk- 
MAPKinase, concomitant with increased phosphorylation of the retinoblastoma 
protein, Rb, and proliferation. Co-ligation of the BCR with the inhibitory FcyRllb 
receptor abrogates this sustained activation of Erk-MAPKinase, in part by 
inducing the interaction between Erk and the nuclear phosphatase, Pac-1. The 
phosphorylation of the retinoblastoma protein is also abrogated by co-ligation of 
the BCR with FcyRllb. The tumour suppressor protein, p53, is activated in 
response to BCR and FcyRllb co-ligation, and this is concomitant with increased 
expression of Bak, a collapse in the mitochondrial membrane potential and 
apoptosis.
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Appendix -  Modulation of B cell responses by parasitic 
products
A.1 Introduction
Filarial nematodes are a large group of arthropod-transmitted vertebrate 
parasites that mediate lifelong infection. Moreover, individual parasites are 
capable of surviving in the host for in excess of five years. They are known to 
cause a range of debilitating diseases known collectively as filariasis, which 
includes lymphatic filariasis and onchocerciasis. Clinical manifestations of the 
disease can include blindness, swollen limbs, and severe damage to the kidneys 
and lymphatic system, much of this pathology resulting as a consequence of the 
host immune response. The general success of the parasites, however, reflects 
the fact that the majority of infected individuals exhibit much less severe 
symptoms as a consequence of their ability to modulate or suppress the host 
immune response. Indeed, filarial infection has been demonstrated to modulate 
both parasite-specific and general immune cell mediated responses (King and 
Nutman, 1991).
It is reasonable to postulate that the longevity of parasitic nematodes is 
dependent on molecular secretions that interact with the host immune system. 
Consistent with this, studies have shown that the rodent filarial nematode 
Acanthocheilonema viteae secretes a protein, ES-62 (Harnett et al., 1989) that 
possesses many immunomodulatory properties (Harnett and Harnett, 2001). For 
example, ES-62 is found to reduce murine lymphocyte proliferation and polarise 
immune responses towards an anti-inflammatory phenotype. For example, 
exposure to ES-62 not only renders B and T cells anergic to subsequent 
stimulation via the antigen receptors but also polarises immune responses to a 
Th2 phenotype by inhibiting pro-inflammatory cytokine production and driving 
differentiation of DCs to a DC2, TH2-promoting phenotype (Harnett and Harnett, 
1999).
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Extensive studies In lymphocytes have shown that ES-62 mediates its anti­
proliferative effects by uncoupling the antigen receptors from key downstream 
proliferative signalling pathways. In particular, by selectively downregulating 
certain PKC isoforms and by desensitising protein tyrosine kinase-dependent 
coupling of the antigen receptors to Pl-3-kinase and the Ras/ErkMAPKinase 
signalling cascades (Figure A.1). Thus, this uncoupling results in a novel 
mechanism by which ES-62 can inhibit antigen receptor-mediated proliferative 
responses and subvert the normal immune response of the host.
Similarities between the inhibitory signalling mechanisms of ES-62 and FcyRllb 
on B cells suggested that they could share similar effector pathways. Specifically, 
ES-62 has been shown to desensitise the BCR-mediated activation of ErkMAPK 
by the recruitment of the tyrosine phosphatase SHP-1 and the MAPKinase 
phosphatase, Pac-1 (Deehan ei a i, 2001) (Figure A.2). Moreover, the ability of 
ES-62 to initiate a polarised Th2 response may represent a novel therapeutic 
strategy for the treatment of inflammatory-type autoimmune diseases, since the 
generation of a Tnl-type immune response by collagen-specific CD4^ T cells, is 
crucial for the development of arthritis in the collagen induced arthritis model in 
mice. Thus, the ability of ES-62 to suppress B cell activation and antibody 
production was of interest when investigating the role of FcyRllb in the regulation 
of CIA.
It has also been shown that ES-62 contains a post-translational modification, the 
covalent addition of phosphorylcholine (PC) to an N-type glycan (Harnett and 
Harnett, 2001 ). This PC group provides a major contribution to the 
immunomodulatory properties of ES-62 (Harnett and Harnett, 1999; Harnett and 
Harnett, 2001). The addition of PC to carbohydrate appears to be a feature of the 
nematode phylum, extending to a number of proteins and, in addition, some 
glycosphingolipids (Lochnit eta!., 2000). The immunomodulatory properties of 
these latter molecules are largely unexplored but two PC-containing 
glycosphingolipids ot Ascaris suum that induce secretion of TNF-a, IL-1 and IL-6
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from human peripheral blood mononuclear cells have recently been described 
(Lochnit et al., 1998a). This activity was shown to be due to PC as the removal of 
PC from the molecules eliminates this activity.
A.2 Aims and objectives
Previous studies in this laboratory have investigated the mechanisms by which 
ES-62 modulates the proliferative response of lymphocytes to antigen, in order to 
identify key pathways involved in both the positive and negative regulation of 
proliferation. The aim of this study was to further investigate the 
immunomodulatory properties of the PC-containing glycosphingolipids produced 
by the filarial nematode Ascaris suum, specifically repeating a number of the 
experiments previously undertaken in this laboratory to examine ES-62, with the 
aim of further elucidating the mechanisms utilised by filarial nematodes to 
regulate the host immune response.
In particular, this study aims to address:
1. The effects these molecules have on the proliferative response of B cells 
upon stimulation via the BCR.
2. The specific role the PC moiety plays, if any, in the modulation of B cell 
responses.
3. The ability of synthetically produced mimetics to induce the same effects 
as the natural products on B cell responses.
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A 3 Results
A.3.1 Modulation of the B cell proliferative response by Ascaris suum 
glycosphingolipids
To investigate the effects of the PC-containing glycosphingolipids produced by 
Ascaris suum on B cells, B cell responses to a number of stimuli were 
investigated in the presence and absence of these molecules. Primary splenic B 
cells were incubated with native Ascaris suum glycosphingolipids or Ascaris 
suum glycosphingolipids that had had the PC moiety chemically removed, and 
stimulated with either F(ab’)2 fragments of anti-lg (60 (xg/ml), or LPS (50 fig/ml). 
Unstimulated cells were included as a control. After 48 hours stimulation 
proliferation was assessed by means of the fH]-thymidine incorporation assay. 
As expected, in the absence of Ascaris suum glycosphingolipids both LPS and 
F(ab')z induced a substantial increase in proliferation of the mature B cell (Figure 
A 3) The presence of the Ascaris suum glycosphingolipids (10 fxg/ml) 
significantly reduces proliferation induced by either of these stimuli. In the case of 
F(ab’)2 anti-lg induced proliferation, the glycosphingolipid induced reduction is 
not dependent on the PC moiety, as F(ab’)2 anti-lg induced proliferation is 
reduced by a similar amount by PC-free glycosphingolipid and whole 
glycosphingolipid. However, LPS induced proliferation is dependent upon the PC 
moiety as PC-free glycosphingolipid is unable to inhibit LPS induced proliferation.
A.3.2 Modulation of the B cell proliferative response by synthetic mimetics 
of Ascaris suum glycosphingolipids
To dissect the mechanism by which these Ascaris suum glycosphingolipids 
modulate the B cell proliferative response, and to attempt to establish the nature 
of the non-PC immunomodulatory moiety within the molecules, a number of 
chemically synthesised homologues were produced. A native form of the whole 
glycosphingolipid molecule, a PC-free molecule, and a ceramide free molecule 
were all generated (Dr Rudi Geyer and Dr Gunther Lochnit, Giessen, Germany). 
To assess the effectiveness of these synthetic molecules as immunomodulators,
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primary splenic B cells were incubated with each of them individually, or the 
ceramide component alone, or a p120 glycoprotein containing demethylamino 
ethanol instead of PC from L  carinii (all at 10 fxg/ml), and stimulated with either 
P(ab')2 fragments of anti-lg or LPS (both 50 i^g/ml). Proliferation was assessed 
after 48 hours by means of the f^HJ-thymidine incorporation assay.
Of the molecules tested, the ceramide component has by far the greatest effect 
on the B cell response to LPS (Figure A 4) However, this is likely due to 
cytotoxicity rather than specific effects on the response to LPS, as ceramide 
abolishes proliferation in the absence of any other stimuli. We have previously 
shown that ceramide induces apoptosis in the WEHI-231 immature B cell line 
(Katz et a/., 2001). Of the other molecules, none have any significant effect on 
LPS-induced proliferation of B cells except for the PC-free molecule, which 
slightly inhibits LPS-induced proliferation of primary splenic B cells (p value 
<0.05). In terms of the effect of these molecules on anti-lg-induced proliferation, 
again ceramide produced the largest effect, due to its cytotoxicity. Of the other 
molecules studied, none produced any significant effects on anti-lg-induced 
proliferation. Taken together, these results suggest that the synthetically 
produced molecules do not accurately mimic the effects of the molecules 
produced by Ascaris suum. ‘Natural’ Ascaris suum glycosphingolipids can inhibit 
anti-lg-induced proliferation of primary splenic B cells in a PC-independent 
manner, whereas the inhibition of LPS-induced proliferation is entirely dependent 
upon PC. However, the chemically synthesised molecules have no effect on anti- 
lg-induced proliferation, whilst the PC-free molecule inhibits LPS-induced 
proliferation. As for the Lcarinii molecule, it appears that this has no effect on the 
proliferation of B cells in response to either LPS or anti-lg.
A.3.3 Ascaris suum glycosphingolipids inhibit anti-lg-induced B cell 
proliferation by inducing an increase in apoptosis
The above results showed that the glycosphingolipids from Ascaris suum are 
capable of inhibiting anti-lg induced B cell proliferation in a PC-independent
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manner. To investigate whether this was a result of growth arrest or an increase 
in apoptosis, the DNA content of the cells was analysed by propidium iodide 
staining. B cells were stimulated with F(ab’)2 fragments of anti-lg in the presence 
or absence of Ascaris glycosphingolipids for 48 hours, and the DNA content 
assessed by flow cytometry following propidium iodide staining (Figure A.5). Co­
stimulation of B cells with F(ab’)2 anti-lg and Ascaris glycosphingolipids results in 
a substantial increase in the proportion of cells with a sub-diploid DNA content, 
compared to unstimulated cells, and cells stimulated with F(ab’)2 fragments of 
anti-lg or glyco-sphingolipid alone. As expected, this increase in the proportion of 
sub-diploid cells is accompanied by a decrease in the proportion of cells either in 
S phase or G2/M. On the other hand, B cells stimulated with F(ab’)2 anti-lg atone 
demonstrate an increase in the proportion of cells in S phase, consistent with the 
[^H]-thymidine incorporation data that showed that F(ab’)2 stimulated cells 
increase their proliferation (Figure A 3)
To corroborate the above findings that co-stimulation of B cells with F(ab’)2 
fragments of anti-lg and Ascaris glycosphingolipids induces apoptosis, the 
mitochondrial membrane potential was assessed. Primary splenic B cells were 
stimulated with F(ab’)2 fragments of anti-lg in the presence or absence of Ascaris 
glycosphingolipids for 20 hours, and the mitochondrial potential assessed by flow 
cytometry following DiOC6(3) staining. Co-stimulation of B cells with F(ab')2 
fragments of anti-lg and Ascaris glyco-sphingolipids induces a substantial 
increase in the proportion of cells displaying a shift to low DiOC6(3) uptake, 
hence a reduction in mitochondria! membrane potential (Figure A.6). F(ab’)2 
fragments of anti-lg or glycosphingolipid alone do not induce a collapse of 
mitochondrial membrane potential, consistent with the DNA content analysis 
data. These data strongly suggest that one mechanism by which Ascaris suum 
glycosphingolipids inhibit anti-lg induced B cell proliferation is by increasing the 
level of apoptosis.
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A.4 Discussion
Previous work in our laboratory has shown that two PC-containing “molecules”, 
the filarial nematode glycoprotein ES-62 (reviewed in Harnett and Harnett, 2001) 
and a glycosphingolipid fraction of A. suum (Lochnit et a i, 1998a), possess 
immunomodulatory properties. The latter were found by bioassay to induce 
release of the proinflammatory cytokines, IL-1, IL-6 and TNF-a when co-cultured 
with human peripheral blood mononuclear cells. That this effect was likely to be 
due to the PC moiety was revealed when the selected glycosphingolipids lost 
their biological activity following removal of PC by HF treatment (Lochnit et al., 
1998b). Whereas these experiments targetting human PBMC represent our only 
investigation of the immunomodulatory properties of the glycosphingolipids to 
date, ES-62 has been subject to analysis for almost a decade (reviewed in 
Harnett and Harnett, 2001). Based mainly on studies on mice, it has been shown 
to affect a number of cells of the immune system, with an overall tendency to 
suppress pro-inflammatory immune reactivity and hence produce a phenotype 
that is essentially anti-inflammatory. Although only one study has been 
conducted on PC-depleted ES-62 (on how removal of PC influences antibody 
responses to other epitopes present on this molecule (Houston etal., 2000)), 
many of ES-62 s effects can be mimicked by PC alone or conjugated to BSA 
(reviewed in Harnett and Harnett, 1999). Taking all of this into account, it was 
assumed that the glycosphingolipids would mirror ES-62 with respect to their 
immunomodulatory properties and hence we set out to test the PC-containing 
Ascaris glycosphingolipids in some of the assays in which ES-62 had previously 
been tested.
As predicted, PC-containing Ascaris glycosphingolipids were found to inhibit 
activation of resting splenic B cells induced via the antigen receptor. This form of 
immunomodulation represents the first ever observed with ES-62 and was 
considered to be due to PC as it could be mimicked by PC-conjugated to BSA or 
even PC alone (Harnett and Harnett, 1993). it was therefore a surprise to find
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that inhibition of anti-lg-mediated B cell proliferation could also be inhibited by 
PC-free glycosphingolipids (Figure A.3). This result indicates that the 
glycosphingolipids contain a non-PC immunomodulatory component. Additionally 
of interest, however, was the finding that the PC-depleted glycosphingolipids 
inhibited B cell proliferation at least as well as the native Ascaris material. This 
result suggests that either the PC component of the glycosphingolipids is not 
active in this system or that the two immunomodulatory components are active in 
a way that is not additive.
Previous studies in our laboratory have shown that the ability of ES-62 to inhibit 
anti-lg-mediated B cell proliferation is not due to apoptosis (M. Harnett, personal 
communication). The results shown here indicate that the inhibitory effect 
induced by the glycosphingolipids was however associated with increased 
apoptosis (Figure A.5 and Figure A.6). This result underscores the idea initially 
invoked by the difference in PC-dependence, that ES-62 and the Ascaris suum 
glycosphingolipids inhibit B cell proliferation by different mechanisms. Of the two 
non-PC components of glycosphingolipids - carbohydrate and ceramide, the 
latter is perhaps more likely to be the immunomodulatory moiety. This is because 
ceramide has been shown to be an apoptotic agent in many cell types, including, 
B cells (Katz et al., 2001 ). The finding that treatment with Ascaris suum 
glycosphingolipids on their own does not induce apoptosis but that it requires 
costimulation with anti-lg, however, suggests that crosstalk between signals 
elicited by the ceramide moiety and the BCR are required for induction of cell 
death, presumably via an activation-induced cell death mechanism.
The PC-containing Ascaris glycosphingolipids were also found to inhibit LPS- 
induced activation of B cells, and this effect appears to be PC-dependent (Figure 
A 3) This would suggest that the inhibitory effect results from either PC 
targetting the LPS receptor or from cross talk following ligation of the LPS and 
PC receptors. BiaCore and Far Western analysis has indicated that ES-62 binds 
to lymphocyte and monocyte membrane fractions with receptor-like affinity in a 
PC-dependent manner (M. Harnett, personal communication). This binding could
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reflect the PC-receptor previously identified on B cells (Bach etal., 1983). 
Alternatively, as PC has been conserved by pathogens throughout evolution and 
can be detected in a wide range of prokaryotic and eukaryotic pathogens 
(Harnett and Harnett, 1999), it is possible that PC-containing pathogen products 
are recognised via binding of PC to pattern-recognition receptors, such as the 
recently identified Toll-like receptors (TLRs). TLRs have been proposed to initiate 
and direct innate and adaptive immune responses by recognising conserved 
“Danger signals” such as LPS on pathogens (Kaisho and Akira, 2000). It would 
prove very interesting to study the effects of these glycosphingolipid molecules in 
mice deficient in members of the TLR family.
Overall, these results show that the glycosphingolipid molecules produced by 
Ascaris suum are able to modulate the response of B cells to both anti-lg and 
LPS. These effects are not both due to the PC moiety, as modulation of anti-lg 
induced proliferation occurred in the absence of the PC moiety, whereas 
inhibition of LPS-induced proliferation proved tp be PC-dependent. This inhibitory 
effect can be partly explained by an induction of apoptosis. This apoptosis- 
inducing effect is not necessarily an intrinsic property of these molecules, as 
alone they do not induce apoptosis, only when anti-lg is also present.
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Figure A.1 ES-62 desensitises coupling of the BCR to key proliferative 
signalling cascades.
Exposure of murine B cells to ES-62 selectively desensitises BCR-mediated 
proliferation by targeting key proliferative signalling pathways. Whilst, early slg- 
coupled mediators such as the PTKs Lyn, Syk and BIk are relatively unaffected 
the subsequent PTK-mediated activation of downstream PI3-K and Ras-MAPK 
pathways is targeted. The nematode product also modulates the activity of 
certain PKC isoforms. The BCR is uncoupled from those pathways represented 
to the right of the arrow.
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Figure A.2 ES-62 uncouples the BCR from Erk-MAPKinase activation by 
priming B cells for BCR-mediated recruitment of SHP-1 and Pac-1.
ES-62 uncouples the BCR from Erk-MAPKinase by (1) promoting the BCR 
recruitment of Lyn-SHP-1 protein tyrosine phosphatase complexes. (2) the 
dephosphorylation of Ig-p, preventing the recruitment of Shc-SOS complexes. (3) 
the formation of Erk-MAPK/Pac-1 complexes.
295
Grb2
ErkMAPK
Nuc eus ErkMAPK
Figure A.3 Ascaris glycosphingolipids inhibit anti-ig- and LPS-induced 
proliferation of primary splenic B cells
A Purified splenic B cells from Balb/c mice (2 x 10® cells/well) were stimulated for 
48 hours with 50 |ig/ml F(ab’)2 fragments of goat anti-mouse IgM (p,-chain 
specific), in the presence or absence of native (GSL) or PC-free (GSL-PC) 
Ascaris suum glycosphingolipids at the indicated concentrations. Control cells 
were cultured in the presence of medium alone. Culture wells were pulsed with 
[®H]-thymidine (0.5 ^Ci/well) 4 hours prior to harvesting and [®H]-incorporation 
was assessed by liquid scintillation counting. Data are the mean ± standard 
deviation of triplicate measurements from a single experiment, representative of 
at least two other independent experiments.
B Purified splenic B cells from Balb/c mice (2 x 10® cells/well) were stimulated for 
48 hours with LPS (50 jAg/ml), in the presence or absence of native or PC-free 
Ascaris suum glycosphingolipids at the indicated concentrations. Control cells 
were cultured in the presence of medium alone. Culture wells were pulsed with 
[^H]-thymidine (0.5 jiCi/well) 4 hours prior to harvesting and [®H]-thymidine 
incorporation was assessed by liquid scintillation counting. Data are the mean ± 
standard deviation of triplicate measurements from a single experiment, 
representative of at least two other independent experiments.
296
25000-
20000-
S- 15000-
10000-
5000-
n  None
□  GSL (1 fig/ml)
B  GSL(10^g/ml)
□  GSL-PC (1 ng/ml)
□  GSL-PC (10 ng/ml)
Control F(ab’ ) 2
B
30000
2 20000
E 10000
D None
□  GSL (1 ng/ml)
B  GSL (10 pig/ml)
□  GSL-PC (1 ng/ml) 
B  GSL-PC (10 ng/ml)
Control LPS
Figure A.4 Synthetic mimetics of Ascaris suum glycosphingolipids fail to 
exert the same effect on anti-lg- and LPS-induced proliferation of primary 
splenic B cells
A Purified splenic B cells from Balb/c mice (2x10® cells/well) were cultured for 
48 hours in the presence of three chemically synthesised components of Ascaris 
suum glycosphingolipids (10 |xg/ml) (GSL1, GSL2, GSL3), the ceramide 
component (10 jig/ml), or natural L  cann// glycosphingolipids (10 jxg/ml). Control 
cells were cultured in the presence of medium alone. Culture wells were pulsed 
with [^H]“thymidine (0.5 p,Ci/well) 4 hours prior to harvesting and [®H]-thymidine 
incorporation was assessed by liquid scintillation counting. Data are the mean ± 
standard deviation of triplicate measurements from a single experiment, 
representative of at least two other independent experiments.
B Purified splenic B cells from Balb/c mice (2 x 10® cells/well) were stimulated for 
48 hours with LPS (50 ng/m\) in the presence or absence of glycosphingolipid 
components, and DNA synthesis assessed as above.
0 Purified splenic B cells from Balb/c mice (2 x 10® cells/well) were stimulated for 
48 hours with P(ab’)2 fragments of goat anti-mouse IgM (^-chain specific) (50 
fig/ml) in the presence or absence of glycosphingolipid components, and DNA 
synthesis assessed as above.
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Figure A.5 Ascaris suum glycosphingolipids inhibit anti-lg-induced B cell 
proliferation by inducing an increase in apoptosis
Purified splenic B cells from Balb/c mice (1 x 10® cells) were stimulated with 50 
Jig/ml P(ab’)2 fragments of goat anti-mouse IgM ((x-chain specific) in the presence 
or absence of ES-62 (2 jig/ml) or native Ascaris suum glycosphingolipid (GSL) (5 
(xg/ml). Cells incubated in the presence of medium alone were included as a 
control. DNA content was determined by propidium iodide (PI) staining and 
FACS analysis, as described in Materials and Methods. Data represents each 
cell cycle stage expressed as a percentage of the total cells analysed from a 
single experiment, representative of at least one other independent experiment.
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Figure A.6 Ascaris suum glycosphingolipld-mediated increase in apoptosis 
involves a collapse of the mitochondrial membrane potential
Purified splenic B cells from Balb/c mice (1 x 10® cells) were stimulated for 20 
hours with F(ab')2 fragments of goat anti-mouse IgM (^-chain specific) (50 jxg/ml) 
in the presence or absence of ES-62 (2 ^g/ml) or native Ascaris suum 
glycosphingolipid (GSL) (5 jig/ml). Cells incubated in the presence of medium 
alone were included as a control. The mitochondrial membrane potential was 
determined by DiOCe(3) staining and FACS analysis, as described in Materials 
and Methods. Data represents the DiOCe(3) high (non-apoptotic) or DiOCe(3) low 
(apoptotic) cell populations, as determined on a logarithmic FL-1 axis, and 
expressed as a percentage of the total cells analysed in a single experiment, and 
representative of at least two other independent experiments.
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